Clinical trial NCT03761056
Conditions: B-cell Lymphoma
Sponsor: Kite, A Gilead Company
Start date: 2019-01-29; Completion date: 2023-10-12
Enrollment: 42 participants; Allocation: NA; Intervention model: SINGLE_GROUP

Brief summary:
The primary objective of this study is to estimate the efficacy of axicabtagene ciloleucel in participants with high-risk large B-cell lymphoma.

After the end of KTE-C19-112 (ZUMA-12), participants who received an infusion of axicabtagene ciloleucel will complete the remainder of the 15-year follow-up assessments in a separate long-term follow-up study, KT-US-982-5968.

Detailed description:

Arms: arm 1: Participants will receive cyclophosphamide 500 mg/m\^2/day intravenously (IV) and fludarabine 30 mg/m\^2/day IV conditioning chemotherapy for 3 days followed by axicabtagene ciloleucel administered as a single IV infusion at a target dose of 2 x 10\^6 anti-cluster of differentiation (CD)19 chimeric antigen receptor (CAR) transduced autologous T cells/kg on Day 0. For participants weighing ≥ 100 kg, a maximum flat dose of axicabtagene ciloleucel at 2 x 10\^8 anti-CD19 CAR T cells will be administered.

Participants who achieve partial response or complete response and subsequently experience disease progression will have an option to receive second course of conditioning chemotherapy therapy and axicabtagene ciloleucel. Participants will receive the same axicabtagene ciloleucel regimen as the original target dose anytime during the study.
Interventions: intervention 1: Axicabtagene Ciloleucel intervention 2: Fludarabine intervention 3: Cyclophosphamide
Intervention descriptions: intervention 1: A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells intervention 2: Administered according to package insert intervention 3: Administered according to package insert

Protocol documents:
SAP_002.pdf: 
TRANSLATIONAL STATISTICAL ANALYSIS PLAN
KTE-C19-112 TRANSLATIONAL PRIMARY ANALYSIS (PA)
Sponsor:
Kite Pharma, Inc.
2400 Broadway
Santa Monica, CA 90404
United States of America
Product Name:
Axicabtagene ciloleucel
Protocol:
A Phase 2 Multicenter Study Evaluating the Efficacy and 
Safety of Axicabtagene Ciloleucel as First-Line Therapy in 
Subjects with High-Risk Large B-Cell Lymphoma (ZUMA-
12)
Protocol Version:
Amendment 1, 14 August 2019 
TSAP Release Date:
25 February 2021
Replaces Previous 
Version(s):
CONFIDENTIALITY NOTICE
This document contains confidential information of Kite Pharma Inc. This Document must not 
be disclosed to anyone other than the site research staff and members of the institutional 
review board/independent ethics committee, a scientific review board or an equivalent. The 
information in this document cannot be used for any purpose other than the conduct of the 
clinical investigation without the prior written consent of Kite Pharma Inc. Questions 
regarding how this document should be used or the conduct of the clinical trial should be 
directed to the key sponsor contacts.


KTE-C19 
Translational Statistical Analysis Plan 
KTE-C19-l 12 (ZUMA-12) 
TABLE OF CONTENTS 
Kite Pha1ma, Inc. 
Final 
TRANSLATIONAL STATISTICAL ANALYSIS PLAN ............................................................................................. 1 
TABLE OF CONTENTS ................................................................................................................................................ 2 
LIST OF IN-TEXT TABLES ......................................................................................................................................... 2 
LIST OF ABBREVIATIONS ......................................................................................................................................... 3 
1. 
INTRODUCTION ................................................................................................................................................. .4 
2. 
OBJECTIVES ......................................................................................................................................................... 5 
2.1. 
Objectives .................................................................................................................................................. 5 
2.2. 
Hypothesis ................................................................................................................................................. 5 
3. 
ENDPOINTS, SUBGROUPS AND COVARIATES ............................................................................................ 6 
3 .1. 
Biomarker datasets .................................................................................................................................... 6 
3.2. 
Endpoints ................................................................................................................................................... 7 
3.3. 
Outcomes, Subgroup, and Key Covariates ................................................................................................ 7 
4. 
DEFINITION ......................................................................................................................................................... 9 
4.1. 
General ...................................................................................................................................................... 9 
4.2. 
Key Measmements of Phannacokinetics: Anti-CD19 CAR+ T Cell ........................................................ 9 
4.3. 
Key Measmements of Phannacodynamics: Senun Cytokines, Chemokines, and Other Blood 
Biomarkers ................................................................................................................................................ 9 
4.4. 
Product Characteristics ............................................................................................................................ 10 
5. 
ANALYSIS SETS ................................................................................................................................................ 11 
5 .1. 
Safety Analysis Set .................................................................................................................................. 11 
5.2. 
Response Evaluable Analysis Set ............................................................................................................ 11 
5.3. 
Safety Re-treatinent Analysis Set ............................................................................................................ 11 
6. 
STATISTICALANALYSIS ................................................................................................................................ 12 
6.1. 
General Methods ..................................................................................................................................... 12 
6.2. 
Analysis ................................................................................................................................................... 12 
6.2.1. 
6.2.1 Characterize the anti-CD 19 CART cell expansion (PK) and senun 
.......................... 12 
--
I 
7. 
REFERENCE ....................................................................................................................................................... 16 
8. 
APPENDICES ...................................................................................................................................................... 17 
Table 3-1. 
Table 6-1. 
CONFIDENTIAL 
LIST OF IN-TEXT TABLES 
Data ove1view on assay methods and biomarker lists ............................................................... 6 
Non-parameti'ic Compai'isons .................................................................................................. 14 
Page2 
25 Febrna1y 2021 


KTE-C19
Kite Pharma, Inc.
Translational Statistical Analysis Plan
KTE-C19-112 (ZUMA-12)
Final
CONFIDENTIAL
Page 3
25 February 2021
LIST OF ABBREVIATIONS
Abbreviation
Definition
AUC
area under the curve
CAR
chimeric antigen receptor
CCR7
C-C motif chemokine receptor 7
CR
complete response
CRP
C-reactive protein
CRS
cytokine release syndrome
CSF
cerebrospinal fluid
IPI
International Prognostic Index
NE
neurologic event
OR
objective response
ORR
objective response rate
PA
primary analysis
PBMC
peripheral blood mononuclear cell
PD
progressive disease
PK
pharmacokinetics
PR
partial response
SD
stable disease
TNF
tumor necrosis factor
TSAP
translational statistical analysis plan


KTE-C19
Kite Pharma, Inc.
Translational Statistical Analysis Plan
KTE-C19-112 (ZUMA-12)
Final
CONFIDENTIAL
Page 4
25 February 2021
1.
INTRODUCTION
This translational statistical analysis plan (TSAP) outlines the primary analyses (PA) to be 
conducted for translational data within protocol KTE-C19-112 Amendment 1 titled “A Phase 2 
Multicenter Study Evaluating the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line 
Therapy in Subjects with High-Risk Large B-Cell Lymphoma”, dated on 14 August 2019.


KTE-C19
Kite Pharma, Inc.
Translational Statistical Analysis Plan
KTE-C19-112 (ZUMA-12)
Final
CONFIDENTIAL
Page 5
25 February 2021
2.
OBJECTIVES
2.1.
Objectives

Characterize the presence, expansion, persistence and clearance of anti-CD19 chimeric 
antigen receptor (CAR) T cell in blood (cells/µL) (pharmacokinetics [PK]), and serum 
cytokine (pharmacodynamics) profiles

Explore associations between anti-CD19 CAR T cell PK/pharmacodynamics and clinical 
efficacy and safety outcomes

Characterize levels of serum cytokines at baseline, after conditioning chemotherapy, and 
prior to and after infusion of KTE-C19

Explore association between serum cytokine profile (e.g. peak, area under the curve [AUC]) 
versus safety outcomes

Characterize the key KTE-C19 product attributes

Explore association between key product attributes and anti-CD19 CAR T cell PK, clinical 
efficacy, and safety outcomes
2.2.
Hypothesis
The analyses outlined in this TSAP are descriptive summaries, and no formal prespecified 
hypothesis will be tested.


KTE-C19
Kite Pharma, Inc.
Translational Statistical Analysis Plan
KTE-C19-112 (ZUMA-12)
Final
CONFIDENTIAL
Page 6
25 February 2021
3.
ENDPOINTS, SUBGROUPS AND COVARIATES
3.1.
Biomarker datasets
Table 3-1.
Data overview on assay methods and biomarker lists
Data type
Assay method/
Sample type
Biomarker set
Time points of 
scheduled 
assessment
PK data (Anti-CD19 
CAR T cell levels in 
blood)
qPCR/PBMC
Number of CAR T cells (cells/μL) 
Outlined in 
Appendix 1
Pharmacodynamic 
data (levels of 
cytokines in serum)
Cytokine assay/serum 
sample
Homeostatic, pro-inflammatory and 
immune modulating cytokines IL-2, 
IL-6, IL-10, IL-12p40/p70, IL-15, 
IL-17a, TNF-α, IFN-γ and GM-CSF
acute phase reactants, such as CRP
chemokines IL-8, MCP-1 and MIP-
1α and IP-10
HLH related markers ferritin and IL-
2Rα
Outlined in 
Appendix 2
Product characteristics
Flow 
cytometry/investigational 
products
Total number of T cells
Total number of CAR T cells
CD4/CD8 ratio
% Tnaive 
% T central memory
% T effector memory
% T effector cells
(% Tnaive + % T central memory)/
(% T effector memory + % T 
effector cells)
IFN-gamma level (pg/ml)
% CD4
% CD8
Viability
% transduction rate
Vector copy number
CCR7
Abbreviations: CAR, chimeric antigen receptor; CCR, C-C chemokine receptor; CD, cluster of differentiation; GM-CSF, 
granulocyte-macrophage colony-stimulating factor; HLH, hemophagocytic lymphohistiocytosis; IFN, interferon; IL, interleukin; 
IL-2Rα, interleukin-2 receptor α; IP, interferon gamma-induced protein; MCP, monocyte chemoattractant protein; MIP, 
macrophage inflammatory protein; PBMC, peripheral blood mononuclear cells; PK, pharmacokinetics; qPCR, quantitative 
polymerase chain reaction; TNF, tumor necrosis factor.


KTE-C19
Kite Pharma, Inc.
Translational Statistical Analysis Plan
KTE-C19-112 (ZUMA-12)
Final
CONFIDENTIAL
Page 7
25 February 2021
3.2.
Endpoints
All definitions are generally applied to PK and/or pharmacodynamics endpoints. Detailed 
definitions can be found in Section 4.

Peak

Time to peak

AUC

Fold change from baseline at Day X

Fold change from Day 0 at Day X
All measurable biomarker values at each visit will be used in calculating endpoints for all 
biomarkers listed in Table 3-1 as follows:

Levels of anti-CD19 CAR T cells in blood samples measured as number of CAR T cells in 
blood (cells/µL) by visit, peak value, Day 0-28 AUC, and time to peak (details for the 
derivations are included in Section 4, the definition section)

Levels of cytokines in serum by scheduled visit, fold change from baseline, fold change from 
Day 0, peak value, Day 0-28 AUC, and time to peak

Product attributes measurements after product manufacturing and prior to dosing
3.3.
Outcomes, Subgroup, and Key Covariates
All of the covariates from clinical Statistical Analysis Plan will be investigated if applicable to 
translational data analysis, including:

Worst neurologic event (NE) grade: Grade 3 or higher versus Grade 2 or lower

Worst NE grade: Grade 2 or higher versus Grade 1 or lower

Worst cytokine release syndrome (CRS) grade: Grade 3 or higher versus Grade 2 or lower

Worst CRS grade: Grade 2 or higher versus Grade 1 or lower

Complete response (CR) vs. non-CR (partial response [PR] + stable disease [SD] + 
progressive disease [PD]) per study investigator assessment

Objective response (OR; CR + PR) vs. nonresponder (SD + PD) per study investigator 
assessment


KTE-C19
Kite Pharma, Inc.
Translational Statistical Analysis Plan
KTE-C19-112 (ZUMA-12)
Final
CONFIDENTIAL
Page 8
25 February 2021

Ongoing response (ongoing vs. relapsed vs. nonresponder) by data cutoff date

Baseline covariates
Age at baseline (< 65 years, ≥ 65 years)
Sex (male, female)
Race (categories may be collapsed or expanded based on accrual)

Tocilizumab use (Yes, No)

Systemic Steroids used
Yes vs. No
Steroids alone, Tocilizumab alone, Both Steroids and Tocilizumab, Neither Steroids nor 
Tocilizumab

Diagnosis category per central lab (Double-/Triple-hit Lymphomas, Double-/Triple-hit with 
International Prognostic Index (IPI) score ≥ 3, Double-/Triple-hit with IPI score < 3, Non-
double-/triple-hit with IPI score ≥ 3, Overall)

Diagnosis category per study investigator assessment (Double-/Triple-hit Lymphomas, 
Double-/Triple-hit with IPI score ≥ 3, Double-/Triple-hit with IPI score < 3, Non-double-
/triple-hit with IPI score ≥ 3, Overall)

Baseline tumor burden (sum of product of diameters in mm2 by median or quartiles)

CD19 immunohistochemistry (IHC) test H-Score at baseline (≤ 5 vs. > 5) by central 
pathology

Other baseline covariates if applicable


KTE-C19
Kite Pharma, Inc.
Translational Statistical Analysis Plan
KTE-C19-112 (ZUMA-12)
Final
CONFIDENTIAL
Page 9
25 February 2021
4.
DEFINITION
4.1.
General
All definitions are generally applied to PK and pharmacodynamics endpoints and analyses.
Study Day 0 is defined as the day the subject received the first axicabtagene ciloleucel infusion. 
The day prior to Study Day 0 will be Study Day -1. Any days after enrollment and prior to Study 
Day -1 will be sequential and negative integer valued.
4.2.
Key Measurements of Pharmacokinetics: Anti-CD19 CAR+ T Cell
The presence, expansion, persistence of anti-CD19 CAR T cells in peripheral blood will be 
measured by quantitative polymerase chain reaction (qPCR) analysis.
Scheduled blood draw for anti-CD19 CAR T cells: Enrollment/Leukapheresis, Day 7, Week 2 
(Day 14 ± 3 days), Week 4 (Day 28 ± 3 days), Month 3 (Day 90 ± 1 week), Month 6, Month 9, 
Month 12, and Month 24. This TSAP will focus on blood anti-CD19 CAR T cell PK data 
collected per planned assessment. The analytic visit window is defined in Appendix 1.
Number of anti-CD19 CAR T (cells/µL) derivation:
𝑊ℎ𝑖𝑡𝑒 𝐵𝑙𝑜𝑜𝑑 𝐶𝑒𝑙𝑙 𝑐𝑜𝑢𝑛𝑡𝑠 (/µ𝐿) × (𝑀𝑜𝑛𝑜𝑐𝑦𝑡𝑒𝑠(%) + 𝐿𝑦𝑚𝑝ℎ𝑜𝑐𝑦𝑡𝑒𝑠(%)) ×  𝑃𝐵𝑀𝐶𝑠(%)
Baseline anti-CD19 CAR T (cells/µL) is defined as 0 since KTE-C19 is infused on Day 0.
Peak anti-CD19 CAR T cell (cells/µL) is defined as the maximum absolute number of CAR T 
cells in blood attained after Day 0.
Time to Peak of anti-CD19 CAR T cells (days) is defined as “Peak date – KTE-C19 dosing date 
+1”.
AUC of anti-CD19 CAR T cell (cells/ mL*Days) from Day 0 to Day 28 is defined as the area 
under the curve in a plot of levels of anti-CD19 CAR T cells against scheduled visits from Day 0 
to Day 28. This AUC measures the total levels of anti-CD19 CAR T cells over time. Given that 
anti-CD19 CAR T cells are measured at certain discrete time points, the trapezoidal rule (see 
Appendix 3) will be used to estimate the AUC.
4.3.
Key Measurements of Pharmacodynamics: Serum Cytokines, Chemokines, 
and Other Blood Biomarkers
Scheduled blood draws for cytokines: Enrollment/Leukapheresis, Day 0, Day 1, Day 3, Day 7, 
Week 2 (Day 14 ± 3 days), and Week 4 (Day 28 ± 3 days). This TSAP will focus on the cytokine 
data collected from baseline to Day 28. The analytic visit window is defined in Appendix 2.
Baseline is defined as the last value measured prior to conditioning chemotherapy.


KTE-C19
Kite Pharma, Inc.
Translational Statistical Analysis Plan
KTE-C19-112 (ZUMA-12)
Final
CONFIDENTIAL
Page 10
25 February 2021
Fold change from baseline at Day X is defined as
Cytokine level at Day X
Cytokine level at baseline
Fold change from Day 0 at Day X is defined as 
Cytokine level at Day X
Cytokine level at Day 0
Change from baseline at Day X is defined as
Analyte level at Day X – Analyte level at baseline
Peak post baseline is defined as the maximum level of analytes in serum attained after baseline 
up to Day 28.
Time to peak of serum biomarker is defined as the number of days from Day 0 to the day when 
the peak level was attained, “Peak date – KTE-C19 dosing date + 1”.
AUC from baseline to Day 28 is defined as the area under the curve in a plot of levels of serum 
analytes against scheduled visits from baseline to Day 28. This AUC measures the total levels of 
serum analytes overtime. Given the measurements are made at certain discrete time points, the 
trapezoidal rule will be used to estimate the AUC (see Appendix 3).
4.4.
Product Characteristics

All product characteristics as defined in Table 3-1 will be summarized individually and also 
for the correlative analysis with anti-CD19 CAR T levels and clinical outcome endpoints.

Two additional covariates will be derived for exploration:
CD4/CD8 ratio is defined as: 
CD4 Cells (%)
CD8 Cells (%) 
CCR7+ in (%) or (#) is defined as naïve (%) or (#) + central memory (%) or (#), 
respectively


KTE-C19
Kite Pharma, Inc.
Translational Statistical Analysis Plan
KTE-C19-112 (ZUMA-12)
Final
CONFIDENTIAL
Page 11
25 February 2021
5.
ANALYSIS SETS
5.1.
Safety Analysis Set
The safety analysis set is defined as all subjects treated with any dose of axicabtagene ciloleucel. 
The safety analysis set will be used to summarize translational data and association analysis 
between translational data and safety outcomes.
5.2.
Response Evaluable Analysis Set
The response evaluable analysis set will consist of the subjects who are enrolled and treated with 
axicabtagene ciloleucel at a dose of at least 1 x 106 anti-CD19 CAR T cells/kg and centrally 
confirmed disease type (double-/triple- hit lymphomas) or IPI score ≥ 3. This analysis set will be 
used for all association analysis between translational data and efficacy outcomes including CR 
rate, objective response rate (ORR), and ongoing response.
5.3.
Safety Re-treatment Analysis Set
The safety retreatment analysis set will consist of all subjects who undergo retreatment with 
axicabtagene ciloleucel. This set will be used to summarize translational data in the retreatment 
period.


KTE-C19
Kite Pharma, Inc.
Translational Statistical Analysis Plan
KTE-C19-112 (ZUMA-12)
Final
CONFIDENTIAL
Page 12
25 February 2021
6.
STATISTICAL ANALYSIS
6.1.
General Methods
The following methods will be applied to the data analysis when applicable.

Summary statistics
Summary statistics refers to number of subjects, median, first quartile (Q1), third quartile (Q3), 
minimum and maximum for continuous measurements by appropriate subgroups and covariates, 
and summary analysis in quartile range ( [Min , Q1), [Q1, Median), [Median, Q3), [Q3, Max] ) 
by appropriate subgroup and covariates.

Simple Linear Regression
Simple Linear Regression (SLR) may be conducted to explore relationships between biomarkers 
and continuous numbers (Gelman and Hill, 2006). The estimated slope and its 95% confidence 
interval with the unadjusted p-value will be reported.

Non-parametric Wilcoxon rank sum tests
Non-parametric Wilcoxon rank sum tests (Wilcoxon, 1945; Siegel, 1956) will be utilized to 
explore the associations between PK/pharmacodynamics, product characteristics, and outcomes. 
Unadjusted p-values will be reported. The multiplicity adjustment (Holm-Bonferroni step-down 
method, Holm 1979; Hommel 1988) may be implemented when further characterizations of 
potential association are identified, and adjusted p-values will be reported. Median fold change 
will be utilized to describe the differences in the outcome.

Non-parametric Kruskal-Wallis test
Non-parametric Kruskal-Wallis test (Kruskal; Wallis, 1952) will be conducted for 3 or more 
group comparison followed by pairwise comparisons using Dunn’s test with Holm’s adjustment 
method (Dunn, 1964).
6.2.
Analysis
6.2.1.
6.2.1 Characterize the anti-CD19 CAR T cell expansion (PK) and serum 
cytokine (pharmacodynamics) profile

Safety Analysis Sets will be used

The Median Line plot over time with interquartile range (IQR) will be produced

Anti-CD19 CAR T cell profile (PK) over time will be summarized using summary statistics 
described in section 6.1 by subgroup and baseline covariates specified in section 3.3.


KTE-C19 
Translational Statistical Analysis Plan 
KTE-C19-l 12 (ZUMA-12) 
Kite Pha1ma, Inc. 
Final 
• 
Similarly, phaimacodynamics profile as measured by sernm cytokine levels over time will be 
summarized by subgroup and baseline covariates using sUIIllnaiy statistics described in 
section 6.1. 
-
Pre-selected key analytes as listed in Table 3-1 will be presented in the Clinical 
Phaimacology repo1t 
-
Number(%) of subjects with a 2-fold or higher change from baseline at peak and week 4 
will be summarized. 
-
I 
I 
I 
I 
-
I 
I 
I 
CONFIDENTIAL 
Page 13 
25 Febrna1y 2021 


KTE-C19 
Translational Statistical Analysis Plan 
KTE-C19-l 12 (ZUMA-12) 
6.2.4. 
6.2.4 Characterize product attributes 
• 
Safety analysis set will be used 
I 
I 
I 
I 
I 
I 
CONFIDENTIAL 
Page 14 
Kite Pha1ma, Inc. 
Final 
25 Febrna1y 2021 


KTE-C19 
Translational Statistical Analysis Plan 
KTE-C19-l 12 (ZUMA-12) 
I 
CONFIDENTIAL 
Kite Pha1ma, Inc. 
Final 
Page 15 
25 Febrna1y 2021 


KTE-C19
Kite Pharma, Inc.
Translational Statistical Analysis Plan
KTE-C19-112 (ZUMA-12)
Final
CONFIDENTIAL
Page 16
25 February 2021
7.
REFERENCE
Andrew Gelman and Jennifer Hill. "Data Analysis Using Regression and Multilevel/Hierarchical 
Models". Cambridge University Press, 2006. ISBN 978-0-521-68689-1
Kochenderfer JN, Feldman SA, Zhao Y, et al. Construction and preclinical evaluation of an anti-
CD19 chimeric antigen receptor. J Immunother. 2009; 32(7):689-702.
Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy 
along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-
antigen-receptor-transduced T cells. Blood. 2012; 119:2709-2720.
Kochenderfer JN, et al. Anti-CD19 CAR T Cells Administered after Low-Dose Chemotherapy 
Can Induce Remissions of Chemotherapy-Refractory Diffuse Large B-Cell 
Lymphoma. ASH 2014.
Kochenderfer JN, et al. Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent 
B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells 
Expressing an Anti-CD19 Chimeric Antigen Receptor. J Clin Oncol. 2015; 
33(6):540-549.
Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, et al. T 
cells expressing CD19 chimeric antigen receptors for acute lymphoblastic 
leukemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 
2015; 385:517–528.
Perez A, et al. Pharmacodynamic Profile and Clinical Response in Patients with B-Cell 
Malignancies of Anti-CD19 CAR T Cell Therapy. ASH 2015.
Dinno, A. Package “dunn.test.” 2015.


KTE-C19
Kite Pharma, Inc.
Translational Statistical Analysis Plan
KTE-C19-112 (ZUMA-12)
Final
CONFIDENTIAL
Page 17
25 February 2021
8.
APPENDICES
Appendix 1.
Definition of Analytic Visit Windows for CAR T Cells in Blood 
Measurements
To define the analytic visit for scheduled measurements of CAR T cell in blood, given the real 
lab data, for each analytic visit, say ‘Day 7’, search through the records with lab day in window 
of Day [1, 10], then assign analytic visit ‘Day 7’ to the record whose lab day is closest to ‘Target 
Day’, ie, Day 7. If there are 2 records being same closest to target day, choose the earlier one.
Analytic 
Visit
Baseline
Day 7
Week 2
Week 4
Month 
3
Month 
6
Month 
9
Month 
12
Month 
24
Target Day
0
7
14
28
90
180
270
360
720
Lab 
Window
≤ 0
[1, 10]
[11, 21]
[22, 59]
[60, 
135]
[136, 
225]
[226, 
314]
[315, 
540]
>=541
Appendix 2.
Definition of Analytic Visit Windows for Cytokines in Serum 
Measurements
To define the analytic visit for scheduled measurements of cytokines in serum, given the real lab 
data, for each analytic visit, say ‘Day 7’, search through the records with lab day in window of 
Day [5, 10], then assign analytic visit ‘Day 7’ to the record whose lab day is closest to ‘Target 
Day’, ie, Day 7. If there are 2 records being same closest to target day, choose the earlier one.
Analytic Visit
Baseline
Day 0
Day 1
Day 3
Day 7
Week 2
Week 4
Target Day
-5
0
1
3
7
14
28
Lab Window
≤ -5
0
1
[2, 4]
[5, 10]
[11, 21]
[22, 59]
Appendix 3.
Trapezoidal Rule to Approximate the Area Under the Curve
AUC ≈
1
2(𝑦0 + 𝑦1) ∙Δ𝑥+ 1
2(𝑦1 + 𝑦2) ∙Δ𝑥+ 1
2(𝑦2 + 𝑦3) ∙Δ𝑥+ …
I 
I 
I 
I 
Yo 
Y1 Y2 Y3 Y4 Ys 
Ax Ax Ax Ax Ax 


KTE_C19_112_TSAP
ELECTRONIC SIGNATURES
Signed by
Meaning of Signature
Server Date
(dd-MMM-
yyyy hh:mm:ss)
Biostatistics eSigned
21-Jun-2021
18:24:11
PPD

Prot_003.pdf: 
  
CLINICAL STUDY PROTOCOL
Protocol Title:
A Phase 2 Multicenter Study Evaluating the Efficacy and 
Safety of Axicabtagene Ciloleucel as First-Line Therapy in 
Subjects with High-Risk Large B-Cell Lymphoma 
(ZUMA-12)
Protocol Number:
KTE-C19-112
Indication:
First-line treatment of adult subjects with high-risk large 
B-cell lymphoma, including either high-grade B-cell 
lymphoma (HGBL) with MYC and BCL2 and/or BCL6 
translocations, or large B-cell lymphoma with a high 
intermediate/high risk International Prognostic Index (IPI) 
score of ≥ 3; all subjects must have positive positron 
emission tomography after 2 cycles (PET2+) of 
chemoimmunotherapy.
Kite Investigational Product:
Axicabtagene ciloleucel
Company Code:
KTE-C19
IND Number:
016278
EudraCT Number:
2019‐002291‐13
Clinical Trials.gov Identifier:
NCT03761056
Sponsor:
Kite Pharma, Inc.
2400 Broadway
Santa Monica, CA 90404
Contact Information:
The medical monitor name and contact information is 
provided on the Key Study Team Contact List.
Original Protocol Date:
26 June 2018
Amendment 1:
14 August 2019
Amendment 2:
25 March 2022
Amendment 3:
14 June 2022
CONFIDENTIALITY NOTICE
This document contains confidential information of Kite Pharma, Inc., a wholly owned 
subsidiary of Gilead Sciences Inc. This document must not be disclosed to anyone other than the 
study site research staff, collaborators, and members of the Institutional Review 
Board/Independent Ethics Committee, a scientific review board, or an equivalent. The 
information in this document cannot be used for any purpose other than the conduct of the 
clinical investigation without the prior written consent of Kite Pharma, Inc.


Axicabtagene Ciloleucel 
Kite Pharma, Inc. 
Clinical Protocol 
 
KTE-C19-112 (ZUMA-12) 
 
CONFIDENTIAL 
Page 2 
 
14 JUN 2022 
Sponsor and Investigator Signature Page 
KITE PHARMA, INC. 
2400 BROADWAY 
SANTA MONICA, CA 90404 
 
STUDY ACKNOWLEDGMENT 
 
A Phase 2 Multicenter Study Evaluating the Efficacy and Safety of Axicabtagene Ciloleucel as 
First-Line Therapy in Subjects with High-Risk Large B-Cell Lymphoma (ZUMA-12) 
Amendment 3.0, 14 June 2022 
This protocol has been approved by Kite Pharma, Inc. The following signature documents this 
approval. 
 
Kite Medical Monitor Name (Printed)
Date
 
INVESTIGATOR STATEMENT 
I have read the protocol, including all appendices, and I agree that it contains all necessary 
details for me and my staff to conduct this study as described. I will conduct this study as 
outlined herein and will make a reasonable effort to complete the study within the time 
designated. 
I agree to comply with the International Council for Harmonisation of Technical Requirements 
for Pharmaceuticals for Human Use Harmonised Tripartite Guideline on Good Clinical Practice 
and applicable national or regional regulations and guidelines. I will provide all study personnel 
under my supervision copies of the protocol and access to all information provided by Kite 
Pharma, Inc. I will discuss this material with them to ensure that they are fully informed about 
the investigational product and study. 
I agree and will ensure that financial disclosure statements will be completed by: 
 Me (including, if applicable, my spouse, legal partner, and dependent children) 
 Sub investigators (including, if applicable, their spouse, legal partner, and dependent 
children) at the start of the study and for up to 1 year after the study is completed. 
I agree to ensure that the confidential information contained in this document will not be used for 
any purpose other than the conduct of the clinical investigation without prior written consent 
from Kite Pharma, Inc. 
Principal Investigator Name (Printed)
Signature
Date
Study Site Number
DocuSign Envelope ID: 7221257E-AECF-4BA3-89FD-152ACD70DA2F
15-Jun-2022
PPD
PPD


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 3
14 JUN 2022
PROTOCOL SYNOPSIS
Title:
A Phase 2 Multicenter Study Evaluating the Efficacy and Safety 
of Axicabtagene Ciloleucel as First-Line Therapy in Subjects with 
High-Risk Large B-Cell Lymphoma (ZUMA-12)
Indication:
The indication is for the first-line treatment of adult subjects with 
high-risk large B-cell lymphoma, including either high-grade B-cell 
lymphoma (HGBL) with MYC and BCL2 and/or BCL6 translocations 
(hereafter referred to as double-hit or triple-hit lymphomas), or large 
B-cell lymphoma with a high intermediate/ high risk International 
Prognostic Index [IPI] score of ≥ 3; all subjects must have positive 
positron emission tomography after 2 cycles (PET2+) of 
chemoimmunotherapy.
Study Design:
Approximately 40 subjects with high-risk large B-cell lymphoma 
(either double-/triple-hit lymphomas, or high-risk large B-cell 
lymphoma with IPI score ≥3) will be enrolled and treated with 
cyclophosphamide and fludarabine conditioning chemotherapy, 
followed by a target dose of 2 x 106 anti-CD19 chimeric antigen 
receptor (CAR) T cells/kg body weight.
Each subject with a positive interim positron emission 
tomography-computed tomography (PET-CT) per the Lugano 
Classification {Cheson 2014} (Deauville 5-point scale PET score of 
4 or 5) after 2 cycles (PET2+) of chemoimmunotherapy will proceed 
through the following study periods:

Screening

Enrollment/Leukapheresis


Conditioning chemotherapy period

Investigational product treatment period

Post-treatment assessment period

Long-term follow-up (LTFU) period
Following at least 36 months of assessments, subjects who received 
an infusion of axicabtagene ciloleucel will complete the remainder of 
the 15-year follow-up assessments in the separate LTFU study, 
KT-US-982-5968.
For study requirements assigned to each study period, refer to 
Section 7 for details.
A study schema is provided at the end of the protocol synopsis 
section.
CCI


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 4
14 JUN 2022
Study Objectives:
The primary objective of the study is to estimate the efficacy of 
axicabtagene ciloleucel, as measured by complete response (CR) rate, 
in subjects with high-risk large B-cell lymphoma. Secondary 
objectives will include assessing the safety of axicabtagene ciloleucel 
and additional efficacy endpoints.
Hypothesis:
No formal hypothesis will be tested in this study. The study is 
designed to estimate the CR rate in subjects with high-risk large 
B-cell lymphoma treated with axicabtagene ciloleucel as first-line 
therapy.
Primary Endpoints:
CR rate: CR rate is defined as the incidence of a CR per the Lugano 
Classification {Cheson 2014} as determined by study investigators. 
All evaluable subjects who do not meet the criteria for a CR by the 
analysis data cutoff date will be considered nonresponders.
Secondary 
Endpoints:

Objective response rate (ORR): ORR is defined as the incidence 
of either a CR or a partial response per the Lugano Classification 
{Cheson 2014} as determined by study investigators

Duration of response (DOR)

Event-free survival (EFS)

Progression-free survival (PFS)

Overall survival (OS)

Incidence of adverse events (AEs) and clinical significant 
changes in safety laboratory values

Relapse with central nervous system (CNS) disease
Additional Secondary Endpoints:

Pharmacokinetics (levels of anti-CD19 CAR T cells in blood)

Pharmacodynamics (levels of cytokines in serum)
Sample Size:
Approximately 40 enrolled and treated subjects
Study Eligibility:
Refer to Section 5 for a complete and detailed list of inclusion and 
exclusion criteria.


Axicabtagene Ciloleucel 
Clinical Protocol 
KTE-C19-l 12 (ZUMA-12) 
Kite Phruma, Inc. 
Treatment: Investigational Product: 
• 
Axicabtagene ciloleucel treatment consists of a single infusion of 
CAR transduced autologous T cells administered intravenously at 
a target dose of 2 x 106 anti-CD19 CART cells/kg. For subjects 
weighing 2::: 100 kg, a maximum flat dose of 2 x 108 anti-CD19 
CAR T cells will be administered. 
I 
I 
Procedures: At specific time points as outlined in the schedule of assessments, 
subjects will undergo the following assessments/procedures: 
collection of info1med consent, general medical histo1y including 
previous treatments for large B-cell lymphoma, physical exam 
including vital signs and Eastern Cooperative Oncology Group 
perfonnance status, neurologic examinations, blood draws for 
complete blood count, cheinistiy panels, cytokines, C-reactive 
protein, lymphocyte subsets, replication-competent retrovims and 
anti-CD 19 CAR T-cell analysis. 
CONFIDENTIAL 
Subjects will also undergo a baseline electrocardiogram, 
echocardiogram, PET-CT, and leukapheresis. Subjects may also need 
bone maiTow aspirate/biopsy, brain magnetic resonance image, and 
lumbar puncture. 
Routinely throughout the conduct of the study, subjects will be asked 
to repo1i concoinitant medications and AEs and will have their 
disease assessed. 
Page5 
14 JUN 2022 


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 6
14 JUN 2022
Data Safety 
Monitoring Board:
An independent Data Safety Monitoring Board (DSMB) will be 
chartered to meet and review the serious adverse events (SAEs) and 
suspected unexpected serious adverse reactions (SUSARs) on a semi-
annual basis after the first subject has been treated with axicabtagene 
ciloleucel up through the primary analysis. Kite Pharma, Inc., or 
delegate, will submit SAEs and SUSARs to the DSMB on a regular 
basis throughout the study up through the primary analysis. The 
DSMB will also meet to review safety data after 15 subjects have 
been enrolled and treated with axicabtagene ciloleucel and have had 
an opportunity to be followed for 3 months after axicabtagene 
ciloleucel infusion. The DSMB will make trial conduct 
recommendations on an ongoing basis based on an analysis of risk 
versus benefit. The DSMB may request additional safety data for 
review or recommend modifications to the study conduct if safety 
concerns are identified.
The DSMB may meet more often as needed. Refer to Section 9.10.
Statistical 
Considerations:
No formal hypothesis test will be performed. Analyses will be 
descriptive.
One planned interim analysis will be performed.

Interim Analysis 1 will be conducted after 15 subjects have been 
enrolled and treated with axicabtagene ciloleucel and have had an 
opportunity to be followed for 3 months after axicabtagene 
ciloleucel infusion. This analysis will be for efficacy and safety.
The primary endpoint for the study is CR rate per the Lugano 
Classification {Cheson 2014} as determined by study investigators.
The primary analysis will occur after all subjects treated with 
axicabtagene ciloleucel have an opportunity to be assessed for 
response 6 months after the Week 4 disease assessment.
The final analysis will occur when all subjects have had the 
opportunity to be followed for at least 36 months. Subjects treated 
with axicabtagene ciloleucel will be transitioned to the KT-US-982-
5968 study for the remainder of the 15-year LTFU period. 
Descriptive estimates of key efficacy and safety analyses may be 
updated to assess the overall treatment profile.


Axicabtagene Ciloleucel 
Clinical Protocol 
KTE-C19-l 12 (ZUMA-12) 
Kite Pha1ma, Inc. 
Figure 1. 
Study Schema 
Treatment Period: Axicabtagene Ciloleucel 
'"O 
0 
u 
Treatment 
·c 
.,, 
., 
>-.. 
'"O 
V) 
0.. 
Q) 
0 
..... 
/1., 
. .... 
V) 
ro 
1--< 
Q) 
tu 
..... 
Q) 
t 
i:: 
/1., 
..i:::: 
Q) 
..c: 
..... 
Subjects will receive a single infusion of axicabtagene 
E 
0.. 
Of) 
0.. 
0 
;:::l 
ro 
i= 
ciloleucel administered intravenously at a target dose of 
V) 
I 
C: 
3 
Q) 
V) 
·a 
Q) 
----. 
----. 
----. 
..i:::: 
2 x 106 anti-CD19 CART cells/kg on treatment Day 0. 
V) 
0 
Q) 
Q) 
u 
----. 
----. 
V) ----. -
ts 
<I:'. 
-
Q) 
0 
1--< 
Of) 
0 
..... 
µ.... 
1/J 
5 
.!: 
Subjects will receive axicabtagene ciloleucel in a 
i:: 
§ 
i:: 
Q) 
.§ 
0 
healthcare facility followed by a minimum 7-day 
i= 
:.a 
.p 
2 
0 
obse1vation pe1iod. 
ro 
I 
cl 
'"O 
Q) 
Of) 
i:: 
.p 
C: 
0 
I 
0 
..... 
u 
V) 
....:I 
0 
/1., 
Approximately 40 subjects who are either double hit/tdple hit or have IPI 2: 3 will be enrolled and treated. 
En.-ollment/Leukapheresis: Subjects who have a positive interim PET per the Lugano Classification {Cheson 2014} (Deauville PET score of 
4 or 5) after 2 cycles (PET2+) of an anti-CD20 monoclonal antibody and anthracycline-containing regimen per local standard of care 
b 
C 
d 
(eg, DA-EPOCH-R) if double hit/triple hit, or an anti-CD20 monoclonal antibody and anthracycline-containing regimen per local standard of 
care (eg, R-CHOP) iflarge B-cell lymphoma with IPI score c::: 3. 
Conditioning Chemotherapy: Subjects will receive a 3-day conditioning chemotherapy regimen consisting of fludarabine 30 mg/m2/day and 
cyclophosphamide 500 mg/m2/day (Day - 5 to Day -3) followed by 2 rest days (Day -2 and Day - 1). 
Long-term Follow-up Pe1iod: After the end of ZUMA-12, subjects who received an infusion of axicabtagene ciloleucel will complete the 
remainder of the 15-year follow-up assessments in a separate long-te1m follow-up study, KT-US-982-5968. 
CONFIDENTIAL 
Page7 
14 JUN 2022 


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 8
14 JUN 2022
TABLE OF CONTENTS
CLINICAL STUDY PROTOCOL..................................................................................................................................1
PROTOCOL SYNOPSIS................................................................................................................................................3
TABLE OF CONTENTS................................................................................................................................................8
LIST OF TABLES........................................................................................................................................................10
LIST OF FIGURES ......................................................................................................................................................10
LIST OF ABBREVIATIONS.......................................................................................................................................11
1.
OBJECTIVES.......................................................................................................................................................13
1.1.
Primary Objective....................................................................................................................................13
1.2.
Secondary Objective(s) ...........................................................................................................................13
1.3.
.........................................................................................................................13
2.
DISEASE BACKGROUND ................................................................................................................................14
2.1.
Disease Background ................................................................................................................................14
2.2.
Standard First-line Therapy.....................................................................................................................16
2.3.
Axicabtagene Ciloleucel..........................................................................................................................16
2.4.
Prior Anti-CD19 CAR T-cell Study Designs and Results.......................................................................17
3.
STUDY DESIGN AND RATIONALE................................................................................................................18
3.1.
General Study Design..............................................................................................................................18
3.2.
Study Design Rationale ...........................................................................................................................19
3.2.1.
Rationale for Conditioning Chemotherapy ...........................................................................20
3.2.2.
Rationale for Axicabtagene Ciloleucel Dose ........................................................................20
3.3.
Participating Sites....................................................................................................................................21
3.4.
Number of Subjects .................................................................................................................................21
3.5.
Replacement of Subjects .........................................................................................................................21
3.6.
Study Duration.........................................................................................................................................21
3.6.1.
Study Duration for Individual Subjects.................................................................................21
3.6.2.
Completion of Study..............................................................................................................22
4.
SUBJECT IDENTIFICATION ASSIGNMENT .................................................................................................23
5.
SUBJECT ELIGIBILITY.....................................................................................................................................24
5.1.
Inclusion Criteria.....................................................................................................................................24
5.2.
Exclusion Criteria....................................................................................................................................25
6.
PROTOCOL TREATMENT................................................................................................................................28
6.1.
Study Treatment ......................................................................................................................................28
6.1.1.
Leukapheresis........................................................................................................................28
6.1.3.
Conditioning Chemotherapy .................................................................................................29
6.1.4.
Axicabtagene Ciloleucel........................................................................................................30
6.1.5.
Concomitant Therapy ............................................................................................................30
6.1.6.
Excluded Medications ...........................................................................................................31
6.1.7.
Subsequent Therapy ..............................................................................................................32
6.1.8.
Toxicity Management............................................................................................................32
7.
STUDY PROCEDURES......................................................................................................................................33
7.1.
Informed Consent ....................................................................................................................................33
CCI
CCI-


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 9
14 JUN 2022
7.2.
Screening .................................................................................................................................................33
7.2.1.
Rescreening ...........................................................................................................................34
7.3.
Demographic Data...................................................................................................................................34
7.4.
Medical and Treatment History...............................................................................................................34
7.5.
Conditioning Chemotherapy and Axicabtagene Ciloleucel Infusion......................................................34
7.5.1.
Requirements for Initiating Conditioning Chemotherapy.....................................................35
7.5.2.
Requirements for Initiating Axicabtagene Ciloleucel Infusion.............................................36
7.5.3.
Requirements to Work-up Potential Infectious and/or Inflammatory States ........................37
7.5.4.
Conditioning Chemotherapy Administration (Day –5 Through Day –3 
Prior to Axicabtagene Ciloleucel Infusion)...........................................................................38
7.6.
Physical Exam, Vital Signs, and Performance Status .............................................................................38
7.7.
Cardiac Function .....................................................................................................................................39
7.8.
Neurological Examination.......................................................................................................................39
7.9.
Disease Assessment.................................................................................................................................39
7.9.1.
Imaging..................................................................................................................................39
7.9.2.
Determination of Bone Marrow Involvement .......................................................................40
7.10.
Cell Collection and Axicabtagene Ciloleucel Study Treatment Schedule and Administration ..............41
7.10.1.
Leukapheresis........................................................................................................................41
7.10.3.
Axicabtagene Ciloleucel Treatment Period...........................................................................42
7.11.
Laboratory ...............................................................................................................................................44
7.11.1.
Local Laboratory Analysis ....................................................................................................44
7.11.2.
Central Laboratory Analyses.................................................................................................45
7.12.
Post-treatment Assessment Period ..........................................................................................................47
7.13.
Long-term Follow-up Period...................................................................................................................48
7.14.
Summary of Scheduled Assessments ......................................................................................................48
8.
SUBJECT WITHDRAWAL ................................................................................................................................54
8.1.
Reasons for Removal from Treatment ....................................................................................................54
8.2.
Reasons for Removal from Study............................................................................................................55
9.
SAFETY REPORTING........................................................................................................................................56
9.1.
Adverse Events........................................................................................................................................56
9.2.
Reporting of Adverse Events...................................................................................................................56
9.2.1.
Reporting Abnormal Laboratory Findings ............................................................................57
9.3.
Definition of Serious Adverse Events .....................................................................................................58
9.4.
Reporting of Serious Adverse Events......................................................................................................58
9.5.
Reporting Deaths.....................................................................................................................................59
9.6.
Diagnosis Versus Signs and Symptoms ..................................................................................................59
9.7.
Pregnancy and Lactation .........................................................................................................................60
9.8.
Hospitalization and Prolonged Hospitalization.......................................................................................60
9.9.
Abnormal Vital Sign Values ...................................................................................................................61
9.10.
Data Safety Monitoring Board ................................................................................................................61
10.
STATISTICAL CONSIDERATIONS.................................................................................................................62
10.1.
Hypothesis ...............................................................................................................................................62
10.2.
Study Endpoints.......................................................................................................................................62
10.2.1.
Primary Endpoint...................................................................................................................62
10.2.2.
Secondary Endpoints.............................................................................................................62
10.2.3.
...........................................................................................................63
10.2.4.
Covariates and Subgroups .....................................................................................................63
10.3.
Sample Size Considerations ....................................................................................................................64
10.4.
Access to Individual Subject Treatment Assignments ............................................................................64
10.5.
Interim Analysis and Early Stopping Guidelines ....................................................................................64
CCI
CCI
1111 


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 10
14 JUN 2022
10.6.
Analysis Subsets......................................................................................................................................65
10.7.
Planned Method of Analysis ...................................................................................................................65
10.7.1.
CR Rate .................................................................................................................................65
10.7.2.
ORR.......................................................................................................................................65
10.7.3.
DOR.......................................................................................................................................66
10.7.4.
EFS ........................................................................................................................................66
10.7.5.
PFS ........................................................................................................................................66
10.7.6.
OS..........................................................................................................................................66
10.7.7.
Relapse with CNS Disease ....................................................................................................66
10.7.8.
Safety.....................................................................................................................................67
10.7.9.
Pharmacokinetic Analysis .....................................................................................................67
10.7.10.
Pharmacodynamics Analyses ................................................................................................67
10.7.11.
...........................................................................................67
11.
REGULATORY OBLIGATIONS.......................................................................................................................68
11.1.
Independent Review Board/Independent Ethics Committee...................................................................68
11.2.
Subject Confidentiality............................................................................................................................68
11.3.
Investigator Signatory Obligations..........................................................................................................69
12.
PROTOCOL AMENDMENTS AND TERMINATION .....................................................................................70
13.
STUDY DOCUMENTATION AND ARCHIVING............................................................................................71
14.
STUDY MONITORING AND DATA COLLECTION......................................................................................72
15.
PUBLICATION ...................................................................................................................................................73
16.
COMPENSATION...............................................................................................................................................74
17.
REFERENCES.....................................................................................................................................................75
18.
APPENDICES......................................................................................................................................................80
Appendix 1.
Lugano Classification {Cheson 2014} ....................................................................................81
Appendix 2.
International Prognostic Index in Aggressive Lymphomas.....................................................85
Appendix 3.
Country-Specific Regulatory Agency Requirements ..............................................................86
Appendix 4.
Birth Control Methods Which May Be Considered as Highly Effective................................87
LIST OF TABLES
Table 2.
Clinical Laboratory Parameters...............................................................................................44
Table 3.
Schedule of Assessments.........................................................................................................49
Table 4.
Long-term Follow-up Assessments.........................................................................................52
Table 5.
Lower and Upper Limits of 80%/95% CIs for CR Rates from 60% to 100% for a 
Sample of 40 Subjects .............................................................................................................64
LIST OF FIGURES
Figure 1.
Study Schema ............................................................................................................................7
Figure 2.
International Prognostic Index in Aggressive Lymphomas.....................................................15
CCI
CCI-


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 11
14 JUN 2022
LIST OF ABBREVIATIONS
Abbreviation 
Definition
5PS
5-point scale
ABC
activated B-cell
AE
adverse event
BP
blood pressure
CAR
chimeric antigen receptor 
CBC
complete blood count
CD
cluster of differentiation
CHOP
cyclophosphamide, doxorubicin, vincristine, prednisone 
CI
confidence interval
CNS
central nervous system
CR
complete response
CRF
case report form
CRP
C-reactive protein
CRS
cytokine release syndrome
CSF
cerebrospinal fluid
CSR
clinical study report
CT
computed tomography
CTCAE
Common Terminology Criteria For Adverse Events 
DA-EPOCH-R
dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, 
rituximab
DH
double-hit
DLBCL
diffuse large B-cell lymphoma
DOR
duration of response 
DORR
duration of retreatment response
DSMB
Data Safety Monitoring Board
ECHO
echocardiogram
ECOG
Eastern Cooperative Oncology Group
eCRF
electronic case report form
EFS
event-free survival
FDA
Food and Drug Administration
FDG
fluorodeoxyglucose 
GCB
germinal center B-cell
GCP
Good Clinical Practice
GELA
Groupe d’Etude des Lymphomes de l’Adulte
HIV
human immunodeficiency virus
HDMP
high-dose methylprednisolone
HEENT
head, eyes, ears, nose, and throat
HGBL
high-grade B-cell lymphoma
HR
heart rate


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 12
14 JUN 2022
IB
Investigator’s Brochure  
ID
identification
ICF
informed consent form
ICH
International Conference on Harmonisation
IEC
independent ethics committee
IL
interleukin 
IPI
International Prognostic Index
IPM
investigational product manual
IRB
institutional review board
IRC
independent review committee
IV
intravenous
IWG
international working group
LDi
longest transverse diameter
LTFU
long-term follow-up
MCP
monocyte chemoattractant protein
NCI
National Cancer Institute
NHL
non-Hodgkin lymphoma
NOS
not otherwise specified
ORR
objective response rate 
OS
overall survival
PBMC
peripheral blood mononuclear cell
PCR
polymerase chain reaction
PD
progressive disease
PET-CT
positron emission tomography–computed tomography
PFS
progression-free survival
PK
pharmacokinetic
PMBCL
primary mediastinal B-cell lymphoma 
PMD
progressive metabolic disease 
PR
partial response
PFS
progression-free survival
R-CHOP
rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone
R-ACVBP
rituximab, doxorubicin, cyclophosphamide, vindesine, bleomycin, prednisone
RCR 
replication-competent retrovirus
SAE
serious adverse event
SCT
stem cell transplant
SDi
shortest transverse diameter
SOA
schedule of assessments
SUSAR
suspected unexpected serious adverse reactions
ULN
upper limit of normal
WBC
white blood cell
WHO
World Health Organization


Axicabtagene Ciloleucel 
Clinical Protocol 
KTE-C19-l 12 (ZUMA-12) 
L 
OBJECTIVES 
1.1. 
Primary Objective 
Kite Phruma, Inc. 
• 
To estimate the efficacy of axicabtagene ciloleucel, as measured by complete response (CR) 
rate, in subjects with high-risk large B-cell lymphoma, as detennined by study investigators 
1.2. 
Secondary Objective(s) 
• 
To characterize the safety profile, and to further characterize efficacy with secondaiy 
endpoints; fmther secondaiy objectives will include phaim acokinetic/phaim acodynamic 
endpoints 
1.3. 
CONFIDENTIAL 
Page 13 
14 JUN 2022 


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 14
14 JUN 2022
2.
DISEASE BACKGROUND
2.1.
Disease Background
Non-Hodgkin lymphoma (NHL) comprises a heterogeneous group of cancers originating 
primarily in B lymphocytes, and to a lesser extent, in T lymphocytes and natural killer cells. 
NHL is the most prevalent hematological malignancy and is the seventh most common new 
cancer among men and women, accounting for 4% of all new cancer cases and 3% of 
cancer-related deaths {Howlader 2015}. Diffuse large B-cell lymphoma (DLBCL) is the most 
common subtype of B-cell NHL, accounting for approximately 30% to 40% of all cases across 
regions {Chaganti 2016, Morton 2006, Sehn 2015, Tilly 2012}. DLBCL can be further divided 
into subtypes based on factors including cytology, site of origin, and clinical background. 
Nevertheless, most cases are classified as DLBCL-not otherwise specified (NOS). The 2016 
revision of the World Health Organization (WHO) classification of lymphomas included 2 new 
subcategories of DLBCL-NOS by cell of origin: activated B-cell (ABC) and germinal center 
B-cell (GCB). Per the new classification system, DLBCL-NOS also includes those with MYC or 
BCL-2 protein overexpression, which has been suggested to confer worse outcome in patients 
treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) 
as first-line therapy {Swerdlow 2016}.
The 2016 revision of the WHO classification for lymphomas also included a new category, 
high-grade B-cell lymph oma (HGBL), which accounts for < 10% of DLBCL cases and is now 
considered distinct from DLBCL {Friedberg 2017, Swerdlow 2016}. HGBL includes 
2 subcategories, the first of which is characterized by gene rearrangements of MYC and BCL-2 
and/or BCL-6 (ie, double- or triple-hit lymphomas, depending on the number of rearrangements 
present). The second category lacks these rearrangements and is characterized by the presence of 
Ki67 protein (HGBL-NOS) {Broyde 2009, Swerdlow 2016}. Double- and triple-hit lymphomas 
typically do not respond to rituximab-based chemoimmunotherapy and are more likely to involve 
the central nervous system (CNS) {Friedberg 2017}. Only 40% and 41% of patients with MYC 
translocations and with double-hit lymphoma, respectively, were alive 2 years following 
first-line treatment {de Jonge 2016, Oki 2014}. Retrospective studies suggest a benefit of 
aggressive induction regimens, and consideration is even given for consolidation with high-dose 
therapy and transplant in select cases {Chen 2017, Friedberg 2017}.
The International Prognostic Index (IPI) is widely used for risk stratification of patients with 
aggressive B-cell lymphoma. In the original study of 2031 patients of all ages, the prognostic 
model, based on age, tumor stage, serum lactate dehydrogenase concentration, performance 
status, and number of extranodal disease sites, identified 4 risk groups of low, low-intermediate, 
high-intermediate, and high with predicted 5-year survival rates of 73%, 51%, 43%, and 26%, 
respectively {International Non-Hodgkin's Lymphoma Prognostic Factors Project 1993} 
(Figure 2). The IPI also remains a valid predictor of outcome in the rituximab era, independent of 
double-hit status and cell of origin (eg, GCB and ABC subtypes) {Staiger 2017, Ziepert 2010}.


Axicabtagene Ciloleucel 
Clinical Protocol 
KTE-C19-l 12 (ZUMA-12) 
Kite Phruma, Inc. 
Figure 2. 
International Prognostic Index in Aggressive Lymphomas 
(/J -
C 
:.:; 
«' 
a. -
0 
-::R. 
0 
0 
0 
2 
Overall Survival 
4 
L 
LI 
----HI 
H 
6 
8 
Death Rate per Year 
10 
2 
4 
6 
8 
10 
Year 
Prognostic factors: age > 60 years; pe1fo1mance status:;:: 2; lactate dehydrogenase > I x nonnal; extranodal sites> I; Stage III or 
IV 
Risk category (number of factors): Low (L: 0 or I) I Low-intermediate (LI; 2); High-intenuediate (HI; 3); High (H; 4 or 5) 
[Intemational NHL Prognostic Factors Project. N Engl J Med. 1993;329:987-94] 
A number of recent studies have assessed the role of early PET-CT using visual analysis by 
Deauville criteria {Banington 2014} to further predict patients with large B-cell lymphoma 
treated with rituximab-containing regimens who may be at higher risk. An international 
retrospective conf111nato1y study reported that early positive PET-CT after 2 induction cycles 
(PET2+) had prognostic value in DLBCL when there is no change in therapy: the 3-year PFS 
estimate was 59% in PET2+ patients versus 81 % in PET2-negative (PET2- ) patients (P = 0.003) 
{Itti 2013}. A meta-analysis of 11 studies revealed higher CR rates in the early ( after 2 to 
4 induction cycles) PET-negative group compared with the early PET-positive group (relative 
risk: 5.5, 95% confidence interval [CI]: 2.59 to 11.80) {Zhu 2015}. A prospective study in 
DLBCL patients assessed PET2 by central review, and found a 2-year EFS rate of 48% for 
PET2+ patients and 74% for PET2- patients (P = 0.004) {Mamot 2015}. Another prospective 
study in DLBCL patients revealed PET2 results to be prognostic for PFS based on cell of origin, 
with a 30-month PFS of 60% for PET2+ patients vs. 100% for PET2- patients with GCB 
DLBCL (P = 0.001) {de Oliveira Costa 2016}. Based on the results of these studies, patients 
with large B-cell lymphoma who are PET2+ based on Deauville criteria appear to have a worse 
prognosis compared with patients who are PET2- and represent a subgroup with a high unmet 
medical need. 
This study will emoll patients with high-risk large B-cell lymphoma, defined as either 
double-/triple-hit lymphoma or large B-cell lymphoma with high-intennediate and high risk 
(IPI 
3). All study subjects must also be PET2+. Given the poor outcomes observed with 
cmTently available therapies, this group has a high need for more effective treatment. 
CONFIDENTIAL 
Page 15 
14 JUN 2022 


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 16
14 JUN 2022
2.2.
Standard First-line Therapy
Since the 1970s, chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone 
(CHOP) had been standard-of-care first-line therapy for patients with DLBCL. More intensive 
combinations failed to show additional survival benefit. The current standard of care for first-line 
treatment is CHOP in combination with the anti-CD20 monoclonal antibody rituximab 
(R-CHOP, rituximab-based chemoimmunotherapy) {Flowers 2010}. In the seminal study by the 
Groupe d’Etude des Lymphomes de l’Adulte (GELA), first-line R-CHOP was superior to CHOP, 
with 10-year overall survival (OS) and progression-free survival (PFS) of 43.5% vs 27.6% and 
36.5% vs 20.1%, respectively {Coiffier 2010}. Thus, while more effective than chemotherapy 
alone, first-line R-CHOP still only results in long-term disease remission in < 40% of subjects. 
Recently a Phase 3 trial of first-line R-CHOP versus dose-adjusted etoposide, prednisone, 
vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-EPOCH-R) demonstrated no 
difference in event-free survival (EFS) or OS between the regimens {Wilson 2016}.
Patients with double- and triple-hit lymphomas have been shown to have a poor prognosis with 
R-CHOP chemoimmunotherapy, and there is no established standard of care {Green 2012, 
NCCN 2016}. In a large retrospective study of patients with double-hit lymphoma, there was no 
apparent benefit with the more aggressive induction regimen DA-EPOCH-R, compared with 
standard R-CHOP, with a median OS of 30 months and 34 months, respectively {Petrich 2014}. 
In the GELA randomized Phase 2 study, which evaluated the efficacy of rituximab, doxorubicin, 
cyclophosphamide, vindesine, bleomycin, and prednisone (R-ACVBP) or R-CHOP-14 induction 
using IWG (International Working Group) 2007 criteria in young patients with high-risk 
DLBCL, the primary objective of achieving a higher than 50% CR rate after 4 cycles of 
induction regimen was not met in either randomization group {Casasnovas 2017}.
Unfortunately, there are no published prospective trials in the setting of double- or triple-hit 
lymphoma. These patients represent the greatest unmet clinical need in DLBCL according to a 
recent clinical trials planning meeting from the National Cancer Institute National Clinical Trials 
Network, and prospective randomized trials are currently being developed for double-hit 
lymphoma {Nowakowski 2016}.
2.3.
Axicabtagene Ciloleucel
On 18 October 2017, the Food and Drug Administration (FDA) granted regulatory approval to 
axicabtagene ciloleucel for the treatment of adult patients with relapsed or refractory large B-cell 
lymphoma after 2 or more lines of systemic therapy, including DLBCL-NOS, primary 
mediastinal large B-cell lymphoma (PMBCL), HGBL, and DLBCL arising from follicular 
lymphoma {YESCARTA 2019}.
Axicabtagene ciloleucel is a chimeric antigen receptor (CAR) T-cell immunotherapy. It consists 
of autologous T cells that are genetically modified to produce a CAR protein, allowing the 
T cells to identify and eliminate CD19-expressing normal and malignant cells. CD19 is expressed 
by most B-cell malignancies {Johnson 2009, Leonard 2001, Olejniczak 2006, Rodriguez 1994, 
Uckun 1988} as well as all normal B lymphocytes in peripheral blood and spleen, but not by 
granulocytes, monocytes, platelets, erythrocytes, and T lymphocytes {Uckun 1988}. Briefly, the 


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 17
14 JUN 2022
anti-CD19 CAR comprises the following domains: an anti-human CD19 single-chain variable 
region fragment derived from the murine monoclonal antibody FMC63; the partial extracellular 
domain and complete transmembrane and intracellular signaling domains of human CD28, a 
lymphocyte costimulatory receptor that plays an important role in optimizing T-cell survival and 
function; and the cytoplasmic portion, including the signaling domain, of human CD3ζ, a 
component of the T-cell receptor complex {Nicholson 1997}. Following CAR engagement with 
CD19+ target cells, the CD3ζ domain activates a downstream signaling cascade that leads to 
T-cell activation, proliferation, and acquisition of effector function.
Approval was based on ZUMA-1, a single-arm multicenter trial of 101 adult patients with 
aggressive B-cell NHL. Eligible patients had refractory disease to the most recent therapy or 
relapse within 1 year after autologous hematopoietic stem cell transplantation. Patients received 
a single infusion of axicabtagene ciloleucel following completion of conditioning chemotherapy. 
Efficacy was established on the basis of an objective response rate (ORR) of 72% with a CR rate 
of 51%, as determined by an independent review committee (IRC) per {Cheson 2007, 
YESCARTA 2019}. In addition, the median duration of response (DOR) by IRC assessment per 
{Cheson 2007} was 9.2 months. The DOR was longer in patients with a best overall response of 
CR, as compared to a best overall response of partial remission {YESCARTA 2019}.
The most common Grade 3 or higher adverse reactions (incidence of 10% or greater) include 
febrile neutropenia, fever, cytokine release syndrome (CRS), encephalopathy, infections-
pathogen unspecified, hypotension, hypoxia, and lung infections. Serious adverse reactions 
occurred in 52% of patients and the most common serious adverse reactions (> 2%) included 
encephalopathy, fever, lung infection, febrile neutropenia, cardiac arrhythmia, cardiac failure, 
urinary tract infection, renal insufficiency, aphasia, cardiac arrest, Clostridium difficile infection, 
delirium, hypotension, and hypoxia. Fatal cases of CRS and neurologic toxicity occurred. The 
FDA approved axicabtagene ciloleucel with a Risk Evaluation and Mitigation Strategy 
{YESCARTA 2019}.
The dose of axicabtagene ciloleucel is a single intravenous (IV) infusion with a target of 
2 x 106 CAR-positive viable T cells per kg body weight (maximum 2 x 108 CAR-positive viable 
T cells per kg body weight), preceded by fludarabine and cyclophosphamide conditioning 
chemotherapy. Axicabtagene ciloleucel is not indicated for the treatment of patients with primary 
CNS lymphoma. Additional details regarding the mechanism of action and clinical results of 
axicabtagene ciloleucel can be found in the Investigator’s Brochure (IB).
2.4.
Prior Anti-CD19 CAR T-cell Study Designs and Results
Refer to the current axicabtagene ciloleucel IB for the most current anti-CD19 CAR T-cell 
nonclinical and clinical information.


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 18
14 JUN 2022
3.
STUDY DESIGN AND RATIONALE
3.1.
General Study Design
Study KTE-C19-112 (ZUMA-12) is a Phase 2 multicenter, open-label study evaluating the 
efficacy and safety of axicabtagene ciloleucel as first-line therapy in adult subjects with high-risk 
large B-cell lymphoma, including either HGBL with MYC and BCL2 and/or BCL6 translocations 
(double-/triple-hit lymphomas) or large B-cell lymphomas with high-intermediate-/high-risk IPI 
scores (≥ 3). Approximately 40 subjects will be enrolled upon a positive interim PET per the 
Lugano Classification {Cheson 2014} (Deauville 5-point scale [5PS] PET score of 4 or 5) after 
2 cycles (PET2+) of standard-of-care chemoimmunotherapy.
Subjects will proceed through the following study periods:

Screening

Enrollment/Leukapheresis


Conditioning chemotherapy period

Investigational product treatment period

Post-treatment assessment period

Long-term follow-up (LTFU) period
At the end of ZUMA-12, subjects who received an infusion of axicabtagene ciloleucel will 
complete the remainder of the 15-year follow-up assessments in a separate LTFU study, 
KT-US-982-5968.
An independent Data Safety Monitoring Board (DSMB) will be chartered to meet and review the 
serious adverse events (SAEs) and suspected unexpected serious adverse reactions (SUSARs) on 
a semi-annual basis after the first subject has been treated with axicabtagene ciloleucel up 
through the primary analysis. Kite Pharma, Inc. (hereafter referred to as Kite or Kite Pharma), or 
delegate, will submit SAEs and SUSARs to the DSMB on a regular basis throughout the study 
up through the primary analysis. The DSMB will also meet to review safety data after 
15 subjects have been enrolled and treated with axicabtagene ciloleucel and have had an 
opportunity to be followed for 3 months after axicabtagene ciloleucel infusion. The DSMB will 
make trial conduct recommendations on an ongoing basis based on an analysis of risk versus 
benefit. The DSMB may request additional safety data for review or recommend modifications 
to the study conduct if safety concerns are identified. Refer to Section 9.10 for further details. 
For study requirements assigned to each study period, refer to the schedule of assessments 
(SOA) (Table 3) and Section 7 for details.
A study schema is described in Figure 1.
CCI


Axicabtagene Ciloleucel 
Clinical Protocol 
KTE-C19-l 12 (ZUMA-12) 
3.2. 
Study Design Rationale 
Kite Phruma, Inc. 
ZUMA-12 is an open-label, single-aim study evaluating the efficacy and safety of axicabtagene 
ciloleucel as first-line therapy in adult subjects with high-risk lai·ge B-cell lymphoma (ie, 
double-/triple-hit lymphomas or large B-cell lymphoma with IPI scores 2::. 3). 
Immunotherapy, which is based on the enhancement of an immune response against the tumor, is 
a promising approach to treating many cancer types. T cells play an important role in destrnying 
diseased cells throughout the body. Studies with immune checkpoint inhibitors and bi-specific 
T-cell engagers have demonstrated the potential of T cells to treat cancer. T cells need to possess 
the appropriate specificity for a tumor, be present in sufficient numbers, and overcome any local 
immunosuppressive factors to be effective. CAR-engineered T cells may address these issues 
and ai·e an approach for cancer therapy. 
Axicabtagene ciloleucel is an engineered autologous T-cell immunotherapy in which a patient's 
own T cells ai·e collected and subsequently genetically altered to recognize CD 19. CD 19 is 
expressed on the cell surface ofB-cell malignancies and nonnal B cells. In the pivotal ZUMA-I 
Phase 1/2 trial, the safety and efficacy of axicabtagene ciloleucel were evaluated in patients with 
refracto1y DLBCL, primaiy mediastinal B-cell lymphoma (PMBCL), and transfo1med folliculai· 
lymphoma. In ZUMA-I, the ORR was 72% with a CR rate of 51 %, as dete1mined by an IRC 
IWG 2007 criteria Cheson 2007 and met the rimai end oint YESCARTA 2019 . 
CONFIDENTIAL 
Page 19 
14 JUN 2022 


Axicabtagene Ciloleucel 
Clinical Protocol 
KTE-C19-l 12 (ZUMA-12) 
Axicabtagene ciloleucel may also have improved efficacy and tolerabili 
chemo-refracto1 disease or in atients with lower disease burden. 
Kite Phruma, Inc. 
Patients with double-/triple-hit lymphoma or high-inte1mediate-/high-risk IPI (IPI score ~ 3) 
have a high unmet medical need. Therefore, axicabtagene ciloleucel will be assessed as first-line 
treatment in these high-risk large B-cell lymphoma patients who are also PET positive after 
2 cycles (PET2+) of standard-of-care chemoimmunotherapy. 
3.2.1. 
Rationale for Conditioning Chemotherapy 
Increasing levels of conditioning chemotherapy coITelates with clinical responses to adoptive cell 
therapy {Dudley 2008}. Specifically, there appears to be a link between adequate 
lymphodepletion and adoptively transfe1Ted T-cell expansion and function in preclinical models, 
which demonstrate that the depth and duration of lymphodepletion coITelates with anti tumor 
activity of the adoptively transfe1Ted tumor-specific ens+ T cells { Gattinoni 2005}. 
Lymphodepletion may function by eradicating cytokine sinks for the transfe1Ted cells, 
eliminating T regulato1y cells, or enhancing antigen presenting cell activation {Klebanoff 2005}. 
The cyclophosphamide and fludarabine combination is a potent conditioning chemotherapy 
regimen. Cyclophosphamide (500 mg/m2/day) and fludarabine (30 mg/m2/day) are both given for 
3 consecutive days. This combination has been studied in subjects with B-cell malignancies and 
was tolerated by this population {Kochenderfer 2017, O'Brien 2001}. The low-dose conditioning 
chemotherapy regimens used in these studies could not directly induce durable remissions. 
Low-dose cyclophosphamide and fludarabine alone increases interleukin (IL )-15, IL-7 and 
monocyte chemoattractant protein (MCP)-1 sernm levels, which increased IL-15 sernm levels is 
associated with efficacy of anti-CD19 CART cells {Kochenderfer 2017}. This low-dose 
cyclophosphamide and fludarabine conditioning chemotherapy was also used in the pivotal 
ZUMA-I {Locke 2017, Neelapu 2017} 
3.2.2. 
Rationale for Axicabtagene Ciloleucel Dose 
The rationale for the axicabtagene ciloleucel dose in this study is based on the aggregate safety 
and efficacy data compiled from ZUMA-I as outlined in the IB. Based on the favorable 
benefit/risk ratio seen in ZUMA-I and FDA approval for the treatment of adult patients with 
relapsed or refracto1y large B-cell lymphoma after 2 or more lines of systemic therapy, 
axicabtagene ciloleucel will be administered at a target dose of 2 x 106 anti-CD19 
CART cells/kg but subjects may be dosed at a minimum of 1 x 106 anti-CD19 CART cells/kg. 
For subjects weighing~ 100 kg, a maximum flat dose of axicabtagene ciloleucel at 
2 x 108 anti-CD19 CART cells will be administered. 
CONFIDENTIAL 
Page 20 
14 JUN 2022 


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 21
14 JUN 2022
A positive risk benefit ratio is further supported by the expectation that subjects in this study will 
have a lower disease burden at the time of axicabtagene ciloleucel administration as they are 
receiving the dose earlier in their disease course compared to subjects in ZUMA-1 {Locke 
2018}. In ZUMA-1, the observed response rates were consistent when comparing subsets with 
high versus lower tumor burden based on medians (ZUMA-1 clinical study report [CSR]; 
Section 11.1.1.3).
3.3.
Participating Sites
Approximately 10 centers located in North America and the European Union will participate in 
this study and other regions may be considered. During the conduct of the study, additional 
regions, countries, or sites may be added as necessary.
3.4.
Number of Subjects
Participants in this trial will be referred to as “subjects.” It is anticipated that approximately 
40 subjects will be enrolled and treated into this study.
3.5.
Replacement of Subjects
Subjects may continue to be enrolled until the specified number of subjects are dosed with 
axicabtagene ciloleucel. Subjects who have not received axicabtagene ciloleucel will be retained 
in the analyses of disposition and safety, where appropriate (see Section 10.6).
3.6.
Study Duration
3.6.1.
Study Duration for Individual Subjects
The duration of the study for individual subjects will be up to approximately 15 years. The 
duration of participation for individual subjects will vary depending on a subject’s screening 
requirements, response to treatment, survival, and timing of transition to the separate Kite LTFU 
study, KT-US-982-5968 (discussed in Section 7.13).
Following at least 36 months of assessments in the ZUMA-12 protocol, subjects who received an 
infusion of axicabtagene ciloleucel will complete the remainder of the 15-year follow-up 
assessments in the separate LTFU study, KT-US-982-5968. 
For a subject who completes participation in this study and also completes the LTFU period in 
the separate LTFU study, the entire duration of a subject’s participation in both studies will be up 
to approximately 15 years after the initial infusion of axicabtagene ciloleucel. The need for 
prolonged follow-up is based on the potential persistence of gene transfer vectors in treated 
subjects and need to understand and mitigate the potential risks of delayed onset adverse events 
(AEs) that could be the potential consequence of this emerging technology.


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 22
14 JUN 2022
3.6.2.
Completion of Study
Completion of the study is defined as the time at which the last subject completes at least 
36 months of assessments, is lost to follow-up, withdraws consent, or dies. Upon activation of 
the LTFU study, KT-US-982-5968 at the subject’s study site, the subject will be offered the 
opportunity to complete LTFU assessments under the KT-US-982-5968 protocol.


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 23
14 JUN 2022
4.
SUBJECT IDENTIFICATION ASSIGNMENT
Each subject who enters the screening period, which starts when the subject signs the informed 
consent form (ICF), will receive a unique subject identification (ID) number. This number will 
be used to identify the subject throughout the study and must be used on all study documentation 
related to the subject. The subject identification number will never be changed even if the subject 
is rescreened.


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 24
14 JUN 2022
5.
SUBJECT ELIGIBILITY
5.1.
Inclusion Criteria
101)
Large B-cell lymphoma with one or more of the following features:
a) HGBL with MYC and BCL2 and/or BCL6 translocations (double-hit or triple-hit) as 
determined by investigator by fluorescent in situ hybridization 
OR
b) Other histologically confirmed large B-cell lymphoma defined by WHO 2016 
{Swerdlow 2016} with an IPI score of ≥ 3 at initial diagnosis or anytime between 
initial diagnosis and enrollment, including the following lymphoma types:
i)
DLBCL-NOS, including GCB type and ABC type
ii) Intravascular large B-cell lymphoma
iii) T-cell/histiocyte-rich large B-cell lymphoma
iv) DLBCL associated with chronic inflammation
v) Epstein-Barr virus + DLBCL-NOS
vi) HGBL-NOS
102)
Subjects must have a positive interim PET per the Lugano Classification {Cheson 
2014}(Deauville PET score of 4 or 5) after 2 cycles (PET2+) of chemoimmunotherapy as 
follows:
a) 2 cycles of an anti-CD20 monoclonal antibody (unless investigator determines that 
tumor is CD20 negative) and anthracycline-containing regimen (eg, DA-EPOCH-R), 
with or without intrathecal chemotherapy, at the discretion of the investigator per 
local standard of care for double-hit or triple-hit lymphoma
OR
b) 2 cycles of an anti-CD20 monoclonal antibody (unless investigator determines that 
tumor is CD20 negative) and anthracycline-containing regimen (eg, R-CHOP) at the 
discretion of the investigator per local standard of care for large B-cell lymphoma 
with IPI score of ≥ 3
103)
At least 2 weeks must have elapsed since any prior systemic therapy at the time the 
subject is planned for leukapheresis


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 25
14 JUN 2022
104)
No evidence, suspicion, and/or history of CNS involvement of lymphoma
105)
Toxicities due to prior therapy must be stable and recovered to Grade 1 or less (except for 
clinically nonsignificant toxicities such as alopecia)
106)
Age 18 or older
107)
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
108)
Adequate bone marrow, renal, hepatic, pulmonary, and cardiac function defined as:
a) Absolute neutrophil count ≥ 1000/μL
b) Platelet count ≥ 75,000/μL
c) Absolute lymphocyte count ≥ 100/μL
d) Creatinine clearance (as estimated by Cockcroft Gault) ≥ 60 mL/min
e) Serum alanine aminotransferase and aspartate aminotransferase ≤ 2.5 upper limit of 
normal (ULN)
f)
Total bilirubin ≤ 1.5 mg/dL, except in subjects with Gilbert’s syndrome
g) Cardiac ejection fraction ≥ 50%, no evidence of pericardial effusion (except trace or 
physiological) as determined by an echocardiogram (ECHO), and no clinically 
significant electrocardiogram findings 
h) No clinically significant pleural effusion
i)
Baseline oxygen saturation > 92% on room air
109)
Females of childbearing potential must have a negative serum or urine pregnancy test 
(females who have undergone surgical sterilization or who have been postmenopausal for 
at least 2 years are not considered to be of childbearing potential).
5.2.
Exclusion Criteria
201)
History of malignancy other than nonmelanoma skin cancer or carcinoma in situ 
(eg, cervix, bladder, breast) unless disease free for at least 3 years
202)
History of Richter’s transformation of chronic lymphocytic leukemia or PMBCL
203)
History of autologous or allogeneic SCT
204)
Prior CD19-targeted therapy
205)
Prior CAR therapy or other genetically modified T-cell therapy


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 26
14 JUN 2022
206)
History of severe, immediate hypersensitivity reaction attributed to aminoglycosides
207)
Presence or suspicion of fungal, bacterial, viral, or other infection that is uncontrolled or 
requiring IV antimicrobials for management; simple urinary tract infection and 
uncomplicated bacterial pharyngitis are permitted if responding to active treatment and 
after consultation with the sponsor’s medical monitor
208)
History of human immunodeficiency virus (HIV) infection or acute or chronic active 
hepatitis B or C infection; subjects with history of hepatitis infection must have cleared 
their infection as determined by standard serological and genetic testing per current 
Infectious Diseases Society of America guidelines or applicable country guidelines
209)
Presence of any indwelling line or drain (eg, percutaneous nephrostomy tube, indwelling 
Foley catheter, biliary drain, or pleural/peritoneal/pericardial catheter); dedicated central 
venous access catheters, such as a Port-A-Cath® or Hickman® catheter, are permitted
210)
Subjects with detectable cerebrospinal fluid malignant cells, brain metastases, or active 
CNS lymphoma
211)
History or presence of CNS disorder, such as seizure disorder, cerebrovascular 
ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS 
involvement
212)
Subjects with cardiac atrial or cardiac ventricular lymphoma involvement
213)
History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or 
other clinically significant cardiac disease within 12 months of enrollment
214)
Requirement for urgent therapy due to tumor mass effects (eg, blood vessel compression, 
bowel obstruction, or transmural gastric involvement)
215)
Primary immunodeficiency
216)
History of autoimmune disease (eg, Crohns, rheumatoid arthritis, systemic lupus) 
resulting in end organ injury or requiring systemic immunosuppression/systemic disease 
modifying agents within the last 2 years
217)
History of symptomatic deep vein thrombosis or pulmonary embolism within 6 months of 
enrollment
218)
Any medical condition likely to interfere with assessment of safety or efficacy of study 
treatment
219)
History of severe immediate hypersensitivity reaction to any of the agents used in this 
study
220)
Live vaccine ≤ 6 weeks prior to planned start of conditioning regimen


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 27
14 JUN 2022
221)
Women of childbearing potential who are pregnant or breastfeeding because of the 
potentially dangerous effects of the preparative chemotherapy on the fetus or infant. 
Females who have undergone surgical sterilization or who have been postmenopausal for 
at least 2 years are not considered to be of childbearing potential
222)
Subjects of either sex who are not willing to practice birth control from the time of 
consent through 6 months after the completion of conditioning chemotherapy or 
axicabtagene ciloleucel infusion, whichever is longer
223)
In the investigator’s judgment, the subject is unlikely to complete all protocol-required 
study visits or procedures, including follow-up visits, or comply with the study 
requirements for participation


Axicabtagene Ciloleucel 
Clinical Protocol 
KTE-C19-l 12 (ZUMA-12) 
6_ 
6.1. 
6.1.1. 
PROTOCOL TREATMENT 
Study Treatment 
Leukapheresis 
Kite Phruma, Inc. 
Leukapheresis refers to the procedure for collecting peripheral blood mononuclear cells 
(PBMCs) that are used to manufacture axicabtagene ciloleucel. 
Subjects will undergo leukapheresis to obtain T cells for the manufacturing of axicabtagene 
ciloleucel. Leukapheresed cells obtained at paiiicipating centers will be shipped to the sponsor's 
manufacturing facility as described in the Investigational Product Manual (1PM). 
At least 2 weeks must have elapsed since any prior systemic therapy at the time the subject is 
planned for leukapheresis. 
-
CONFIDENTIAL 
Page 28 
14 JUN 2022 


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 29
14 JUN 2022
6.1.3.
Conditioning Chemotherapy
Conditioning chemotherapy refers to fludarabine and cyclophosphamide used for 
lymphodepletion prior to administration of axicabtagene ciloleucel.
Conditioning chemotherapy will be supplied by the investigative site unless otherwise noted.
Refer to the current product label for guidance on packaging, storage, preparation, administration, 
and toxicity management associated with the administration of chemotherapy agents.
6.1.3.1.
Fludarabine
Fludarabine phosphate is a synthetic purine nucleoside that differs from physiologic nucleosides 
in that the sugar moiety is arabinose instead of ribose or deoxyribose. Fludarabine is a purine 
antagonist antimetabolite.
Refer to the most recent version of the package insert for specific details surrounding the 
administration of fludarabine.
6.1.3.2.
Cyclophosphamide
Cyclophosphamide is a nitrogen mustard-derivative that acts as an alkylating agent following 
conversion to active metabolites in the liver and has potent immunosuppressive activity. The 
serum half-life after IV administration ranges from 3 to 12 hours; the drug and/or its metabolites 
can be detected in the serum for up to 72 hours after administration.
Refer to the most recent version of the package insert for specific details surrounding the 
administration of cyclophosphamide.
CCI


Axicabtagene Ciloleucel 
Clinical Protocol 
KTE-C19-l 12 (ZUMA-12) 
6.1.3.3. 
Mesna 
Kite Phruma, Inc. 
Mesna is a detoxifying agent used to inhibit the hemonhagic cystitis induced by chemotherapy. 
The active ingredient in mesna is a synthetic sulfhychy l compound designated as 
sodium-2-mercaptoethane sulfonate with a molecular fo1mula of C2H5NaO3S2. 
Mesna should be achninistered per institutional guidelines. Refer to the most recent version of the 
package insert for specific details smTounding the achninistration of mesna. 
6.1.4. 
Axicabtagene Ciloleucel 
Axicabtagene ciloleucel is the investigational product for this study. 
There have been no instances of accidental overdose of subjects in this program to date. In case 
of accidental overdose, treatment should be suppo1tive. Co1ticosteroid therapy may be 
considered if any dose is associated with severe toxicity. 
roblems related to the use of axicabta ene ciloleucel 
research staff should report the problem per the instructions in the IPM. 
Refer to the cmTent version of the IB for more details regarding axicabtagene ciloleucel. 
6.1.5. 
Concomitant Therapy 
Concomitant therapy refers to ti·eatment that subjects receive during the conduct of the study. 
During the course of the study, investigators may prescribe any concomitant therapies deemed 
necessaiy to provide adequate suppo1tive cai·e except those medications listed in Section 6.1.6. 
CONFIDENTIAL 
Page 30 
14 JUN 2022 


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 31
14 JUN 2022
All concomitant therapies, including medications, intubation, dialysis, oxygen, and blood 
products, will be recorded.
For subjects who receive axicabtagene ciloleucel treatment:

Concomitant therapies will be recorded from the date of the informed consent until 3 months 
after completing treatment with axicabtagene ciloleucel.

After this 3-month follow-up period, targeted concomitant therapies will be recorded for 
either 24 months after axicabtagene ciloleucel infusion or until disease progression, 
whichever occurs first. Targeted concomitant therapies include gammaglobulin, 
immunosuppressive drugs, anti-infective drugs, and vaccinations.
For subjects who are enrolled, but not dosed with axicabtagene ciloleucel, concomitant therapies 
will be recorded from the date of the informed consent until 30 days after the last study-specific 
procedure has occurred (eg, leukapheresis, conditioning chemotherapy) or until the initiation of 
new antilymphoma therapy, whichever occurs first.
For subjects who are not enrolled (eg, screen failure), only concomitant therapies related to any 
SAE[s] will be recorded.
Specific concomitant therapy collection requirements and instructions are included in the case 
report form (CRF) completion guidelines.
6.1.6.
Excluded Medications
Excluded medications refer to treatment that is not to be administered, unless otherwise 
specified, during the conduct of the study.
Corticosteroid therapy at a pharmacologic dose (≥ 5 mg/day of prednisone or equivalent doses of 
other corticosteroids) and other immunosuppressive drugs must be avoided for 7 days prior to 
leukapheresis and 5 days prior to axicabtagene ciloleucel administration.
Systemic corticosteroids may not be administered as premedication to subjects for whom 
CT scans with contrast are contraindicated (ie, subjects with contrast allergy or impaired renal 
clearance). Such subjects should undergo noncontrast CT scans instead.
Corticosteroids and other immunosuppressive drugs should also be avoided for 3 months after 
axicabtagene ciloleucel administration unless used to manage axicabtagene ciloleucel-related 
toxicities. Other medications that might interfere with the evaluation of axicabtagene ciloleucel, 
such as nonsteroidal anti-inflammatory agents, should also be avoided for the same period unless 
medically necessary.
Therapeutic doses of systemic anticoagulants, such as unfractionated heparin and low-molecular 
weight heparin, should be avoided when possible anytime subjects are at risk of bleeding due to 
thrombocytopenia.


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 32
14 JUN 2022
Treatments for lymphoma, such as chemotherapy, immunotherapy, targeted agents, radiation, 
and high-dose corticosteroids (other than those defined/allowed in this protocol) and other 
investigational agents, are prohibited, except as needed for treatment of disease progression after 
axicabtagene ciloleucel.
If permissibility of a specific medication/treatment is in question, contact the sponsor’s medical 
monitor.
6.1.7.
Subsequent Therapy
Subsequent therapy refers to treatment administered after axicabtagene ciloleucel that is 
necessary to treat a subject’s disease.
Subsequent therapy administered after axicabtagene ciloleucel that is necessary to treat a 
subject’s disease, such as non-study specified chemotherapy, immunotherapy, targeted agents, 
SCT, or radiation therapy, will be recorded for subjects until one of the following happens: the 
subject transitions to the LTFU study KT-US-982-5968, is considered lost to follow-up, 
withdraws consent, or dies.
For subjects who are enrolled, but do not receive axicabtagene ciloleucel infusion, any additional 
anti-lymphoma therapy will also be collected until the subject completes their participation in the 
current study, is considered lost to follow-up, withdraws consent, or dies, whichever occurs first.
6.1.8.
Toxicity Management
To date, the following risks have been identified with axicabtagene ciloleucel: CRS, neurologic 
events, infections, cytopenias, and hypogammaglobulinemia. Refer to Section 6 of the current IB 
for details regarding these events and management guidance.
As the safety experience with axicabtagene ciloleucel increases, the management guidance may 
be updated. Therefore, it is important to always refer to the most current version of the 
axicabtagene ciloleucel IB for guidance regarding managing axicabtagene ciloleucel-related 
toxicities. Additional information and management recommendations can also be found in the IB 
regarding important potential risks associated with axicabtagene ciloleucel, as well as possible 
complications associated with malignancy and cancer treatment.
Refer to the SOA (Table 3) for the timing of evaluations for CRS-related symptoms.


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 33
14 JUN 2022
7.
STUDY PROCEDURES
Research staff should refer to the SOA (Table 3) for an outline of the procedures required.
The visit schedule is calculated from axicabtagene ciloleucel infusion on Day 0.
The visit schedule for disease assessments is also calculated from axicabtagene ciloleucel 
infusion on Day 0, including CT scans, PET scans, bone marrow biopsy, physical exams needed 
to assess disease, and collection of subsequent antilymphoma therapy.
An overview of study assessments/procedures is outlined below. Refer to the CRF completion 
guidelines for data collection requirements and best practices for documentation of study procedures.
7.1.
Informed Consent
Before a subject participates in the clinical study, the investigator is responsible for obtaining 
written informed consent from the subject after adequately explaining the study design, anticipated 
benefits, and potential risks. Subjects should sign the most current institutional Review Board 
(IRB)/Independent Ethics Committee (IEC)-approved ICF before any nonstandard-of-care 
study-specific activity or procedure is performed.
The consent process and the subject’s agreement or refusal to participate in the study must be 
documented in the subject’s medical records. If the subject agrees to participate, the ICF must be 
signed and dated by both the subject and the person who conducted the informed consent 
discussion. The original signed ICF will be retained in accordance with institution policy and 
IRB/IEC requirements, and a copy of the ICF will be provided to the subject.
All subjects who are enrolled into the study should be reconsented with any updated version of 
the IRB/IEC-approved ICF if the new version is relevant to their participation.
7.2.
Screening
Investigative sites will maintain a log of all screened subjects who were reviewed and evaluated 
for study participation. Information collected in the screening log should include limited 
information, such as the date of screening, date the subject was enrolled, or the reason for why 
the subject failed screening.
The screening period begins on the date the subject signs the IRB/IEC-approved ICF and 
continues through confirmation of eligibility into the study. Informed consent must be obtained 
before completion of any nonstandard-of-care study-specific procedures. Procedures that are part 
of standard of care are not considered study-specific and, therefore, may be performed prior to 
obtaining consent and used to confirm eligibility provided they occur within the time allowance 
outlined below and in the SOA.
After written informed consent has been obtained, Kite will assign a unique subject ID number to 
the subject.


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 34
14 JUN 2022
See Section 7.2.1 for the study procedures for subjects who rescreen into the study. Only subjects 
who meet the eligibility criteria listed in Section 5 will be enrolled into the study. If at any time 
prior to enrollment the subject fails to meet the eligibility criteria, the subject should be 
designated as a screen failure within the subject’s screening log, and the reasons for failing 
screening should also be recorded.
Refer to the SOA for a listing of study procedures to be completed during the screening period.
7.2.1.
Rescreening
Subjects who are unable to complete or meet the eligibility criteria during the 28-day screening 
period will be permitted to rescreen 1 time. Subjects will retain the same subject ID number 
assigned at the original screening. If rescreening occurs within 28 days of the signing of the 
original informed consent, it is only necessary to perform the procedure(s)/assessment(s) that did 
not originally meet the eligibility criteria; all other initial screening procedures/assessments do 
not need to be repeated. If rescreening occurs after more than 28 days, or leukapheresis is 
delayed more than 28 days from the signing of the original informed consent, subjects must be 
reconsented and repeat all screening procedures/assessments.
7.3.
Demographic Data
Demographic data will be collected as per country and local regulations and guidelines. Where 
applicable, demographic data will include sex, year of birth, race, ethnicity, and country of 
enrollment to study a possible association between these variables and subject safety and 
treatment effectiveness.
7.4.
Medical and Treatment History
Relevant medical history prior to the start of AE reporting will be collected. Relevant medical 
history is defined as data on the subject’s current medical condition that would be typically 
shared in a referral letter. In addition to the medical history, all history related to the subject’s 
disease, treatment, and response to treatment will be collected and must date back to the original 
diagnosis. All findings will be recorded on the CRFs.
For subjects who are being referred from another clinic or institution to the participating research 
center, copies from the subject’s chart should be obtained.
7.5.
Conditioning Chemotherapy and Axicabtagene Ciloleucel Infusion
Administration of CAR T cells to subjects with ongoing infection or inflammation, even if such 
processes are asymptomatic, increases the risk of high-grade and fatal toxicity. All efforts should 
be made to rule out such conditions prior to cell infusion. Signs, symptoms, or abnormal 
laboratory results attributed to the malignancy tumor fever and elevated C-reactive protein (CRP) 
are diagnoses of exclusion that require a documented workup to establish. Conditioning 
chemotherapy and axicabtagene ciloleucel infusion should be initiated only once it is reasonably 
assured that cell infusion can safely proceed.


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 35
14 JUN 2022
Refer to Section 7.5.3 for requirements for workup of potential infectious and/or inflammatory 
states.
7.5.1.
Requirements for Initiating Conditioning Chemotherapy
If any of the following criteria are met prior to the initiation of conditioning chemotherapy, then 
the workup listed in Section 7.5.3 must be performed to determine the potential cause if there is 
no identified source of infection.

Temperature > 38°C within 72 hours of conditioning chemotherapy

CRP > 100 mg/L anytime between enrollment to start of conditioning chemotherapy

White blood cell (WBC) count or WBC differential concerning for infectious process 
between enrollment to start of conditioning chemotherapy WBC > 20,000, rapidly increasing 
WBC, or differential with high percentage of segs/bands)
Additionally:

If any screening assessments or procedures are repeated between confirmation of eligibility 
and the start of conditioning chemotherapy and results are outside the eligibility criteria listed 
in Section 5, then the condition must resolve prior to proceeding with conditioning 
chemotherapy.

Complete history and physical exam including head, eyes, ears, nose, and throat (HEENT), 
and cardiac, vascular, respiratory, gastrointestinal, integumentary, and neurological systems 
must not reveal evidence of infection/inflammation.

The subject must not have received systemic antimicrobials for the treatment of a known or 
suspected infection within 48 hours before conditioning chemotherapy (prophylactic use of 
antimicrobials is allowed).

The treatment course of any antimicrobials given for known or suspected antecedent 
infection should be complete as per infectious disease consult (if applicable) 
recommendation before stopping or switching to prophylactic antimicrobials.

If a subject is confirmed to have an infectious process for which antimicrobials are not 
available (eg, viral pneumonia), the infection must be clinically resolved as determined by 
the investigator in consultation with the infectious disease service (if applicable).

Most recently collected blood, urine, or other body fluid cultures must show no growth for at 
least 48 hours, and any other infectious workup performed (bacterial, viral serologies, 
polymerase chain reaction (PCR), stool studies, imaging studies) must be negative. If clinical 
suspicion is for an infection for which cultures are unlikely to be positive within 48 hours 
(eg, fungal infection), adequate time must be allowed for cultures to become positive.
Once the above criteria are met, then the subject can proceed with conditioning chemotherapy.


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 36
14 JUN 2022
7.5.2.
Requirements for Initiating Axicabtagene Ciloleucel Infusion
If any of the following criteria are met prior to the initiation of axicabtagene ciloleucel infusion, 
then the workup listed in Section 7.5.3 must be performed to determine the potential cause if 
there is no identified source of infection.

Temperature > 38°C within 72 hours of axicabtagene ciloleucel infusion

CRP > 100 mg/L anytime between enrollment to start of axicabtagene ciloleucel infusion

WBC count or WBC differential concerning for infectious process between enrollment to 
start of axicabtagene ciloleucel infusion WBC > 20,000, rapidly increasing WBC, or 
differential with high percentage of segs/bands)
Additionally:

If any screening assessments or procedures are repeated between confirmation of eligibility 
and the start of axicabtagene ciloleucel infusion and results are outside the eligibility criteria 
listed in Section 5, then the condition must resolve prior to proceeding with axicabtagene 
ciloleucel infusion (except for peripheral blood cell counts that have been impacted by 
conditioning chemotherapy).

Complete history and physical exam including HEENT, and cardiac, vascular, respiratory, 
gastrointestinal, integumentary, and neurological systems must not reveal evidence of 
infection/inflammation.

The subject must not have received systemic antimicrobials for the treatment of a known or 
suspected infection within 48 hours before axicabtagene ciloleucel (prophylactic use of 
antimicrobials is allowed).

The treatment course of any antimicrobials given for known or suspected antecedent 
infection should be complete as per infectious disease consult (if applicable) 
recommendation before stopping or switching to prophylactic antimicrobials.

If a subject is confirmed to have an infectious process for which antimicrobials are not 
available (eg, viral pneumonia), the infection must be clinically resolved as determined by 
the investigator in consultation with the infectious disease service (if applicable).

Most recently collected blood, urine, or other body fluid cultures must show no growth for at 
least 48 hours, and any other infectious workup performed (bacterial, viral serologies, PCR, 
stool studies, imaging studies) must be negative. If clinical suspicion is for an infection for 
which cultures are unlikely to be positive within 48 hours (eg, fungal infection), adequate 
time must be allowed for cultures to become positive.
Once the above criteria are met, then the subject can proceed with administration of axicabtagene 
ciloleucel.
If the axicabtagene ciloleucel infusion is delayed > 2 weeks, protocol-specified conditioning 
chemotherapy must be repeated.


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 37
14 JUN 2022
7.5.3.
Requirements to Work-up Potential Infectious and/or Inflammatory States
In the absence of an identified source of infection (eg, line infection, pneumonia on chest x-ray), 
the minimum workup to be performed prior to administration of conditioning chemotherapy 
and/or axicabtagene ciloleucel consists of:

Call Kite medical monitor

Infectious disease service consult

CT imaging of the chest, abdomen, and pelvis with IV contrast. If there is a medical 
contraindication to contrast, then noncontrast CT is allowed.

The following must be performed (prior to the initiation of antimicrobials if clinically 
feasible):
Blood cultures (aerobic and anaerobic x 2 bottles each) and urinalysis and urine culture. 
Deep/induced sputum culture if clinically indicated
All indwelling lines, such as central venous catheters, should be examined for any signs 
of infection and additional cultures should be drawn from the line.
Nasopharyngeal-throat swab or equivalent assay for viral infection, such as influenza A/B 
(including H1N1), parainfluenza 1/2/3, adenovirus, respiratory syncytial virus, 
coronavirus, metapneumovirus
Collection of fungal cultures and markers as appropriate (galactomannan, Fungitell®)
Collection of appropriate serum viral studies (eg, cytomegalovirus)

If a CNS process is suspected, appropriate brain imaging and subsequent lumbar puncture 
with cytology, culture, Gram stain, and viral PCR should be performed.

Any additional sign or symptom-directed investigation should be performed as clinically 
indicated.
Prior to proceeding with conditioning chemotherapy or axicabtagene ciloleucel infusion, the 
above workup must not suggest the presence of an active infection and all requirements for 
conditioning chemotherapy and axicabtagene ciloleucel infusion must be satisfied.
If the above workup was triggered due to CRP > 100 mg/L, testing for CRP should be repeated, 
and if CRP continues to increase significantly, evaluation should be performed for any other 
potential infectious or inflammatory condition not previously evaluated.


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 38
14 JUN 2022
7.5.4.
Conditioning Chemotherapy Administration (Day –5 Through Day –3 Prior 
to Axicabtagene Ciloleucel Infusion)
Subjects will receive a conditioning chemotherapy regimen consisting of cyclophosphamide and 
fludarabine. The first dose of conditioning chemotherapy will be designated as Day –5. Subjects 
will initiate conditioning chemotherapy with cyclophosphamide and fludarabine beginning on 
Day –5 and through Day –3, with 2 rest days (Day –2 and Day –1) before receiving axicabtagene 
ciloleucel. The 3-day conditioning chemotherapy regimen will be administered in an outpatient 
setting.
The 3-day conditioning regimen of fludarabine and cyclophosphamide will be administered in 
accordance with the following daily dosing instructions:

IV hydration with a balanced crystalloid according to institutional guidelines prior to 
administration of cyclophosphamide on the day of infusion

Cyclophosphamide 500 mg/m2 IV over approximately 60 minutes or per institutional 
guidelines

Fludarabine 30 mg/m2 IV over approximately 30 minutes or per institutional guidelines

Additional IV hydration with a balanced crystalloid according to institutional guidelines to be 
administered upon completion of the cyclophosphamide infusion

Mesna to be administered per institutional guidelines
Subjects should be instructed to drink plenty of liquids during chemotherapy and throughout the 
24-hour period following chemotherapy (approximately 2 L/24 hours). In general, subjects 
should be kept well hydrated but closely monitored to prevent fluid overload. 
Refer to the SOA Table 3 for a listing of study procedures to be completed during the 
axicabtagene ciloleucel conditioning chemotherapy period.
7.6.
Physical Exam, Vital Signs, and Performance Status
Physical exams will be performed during screening and at times noted in the SOA. All physical 
exam changes noted in subsequent exams when compared to the baseline exam will be reported 
as AEs.
Vital signs, including blood pressure (BP), heart rate, respiratory rate, oxygen saturation, and 
temperature, will be monitored and recorded at screening and at times outlined in the SOA. In 
addition to the time points outlined in the SOA, it is recommended that vital signs are monitored 
during and after study treatment (see Section 6) and as clinically indicated.
Performance status as measured by the ECOG scale will be performed to quantify the subject’s 
general well-being and ability to perform activities of daily life.


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 39
14 JUN 2022
7.7.
Cardiac Function
Each subject’s cardiac function, as measured by left ventricular ejection fraction, will be 
assessed during the screening period to confirm study eligibility. No evidence of pericardial 
effusion will also be confirmed, per study eligibility criteria. Both the left ventricular ejection 
fraction and pericardial effusion will be assessed prior to study entrance by an ECHO. An ECHO 
that was performed after the subject’s last chemoimmunotherapy treatment may also be used to 
confirm eligibility, provided that it occurred ≤ 28 days prior to signing the consent.
To establish a baseline, a 12-lead electrocardiogram will also be performed during the screening 
period.
7.8.
Neurological Examination
A neurological examination will be performed, and any of the following abnormalities will be 
recorded: level of consciousness, orientation, vision, cranial nerves and brain stem functions, 
pyramidal and extra pyramidal motor system, reflexes, muscle tone and trophic findings, 
coordination, sensory system, and neuropsychological findings (eg, speech, cognition, and 
emotion).
A neurological examination should be done prior to axicabtagene ciloleucel infusion on 
treatment Day 0, then on Day 1, Day 3, Day 5, and Day 7 during the observation period, which 
must last a minimum of 7 days.
For new onset of neurologic symptoms suspected to be related to axicabtagene ciloleucel 
treatment, refer to Section 6.1.8. Subjects will be specifically asked about changes in 
neurological status since the previous neurological examination, as noted in the SOA 
(see Table 3).
7.9.
Disease Assessment
Subjects will be evaluated for disease response by the site investigator at times indicated in the 
SOA. Disease assessments will be evaluated per the Lugano Classification {Cheson 2014} 
(see Appendix 1). Flow cytometric, molecular, or cytogenetic studies will not be used to 
determine response.
7.9.1.
Imaging
7.9.1.1.
Pre-treatment Disease Assessment
A fluorodeoxyglucose (FDG)-PET from skull base to mid-thighs and a diagnostic quality 
contrast-enhanced (unless contraindicated) CT from skull base through lesser trochanters 
(PET-CT), along with the appropriate imaging of all other sites of disease must be performed 
within 28 days prior to enrollment/leukapheresis.


Axicabtagene Ciloleucel 
Clinical Protocol 
KTE-C19-l 12 (ZUMA-12) 
Kite Phruma, Inc. 
If a PET-CT cannot be perfonned as standard of care following 2 cycles of 
chemoimmunotherapy, a subject may have the PET-CT perfonned on study after infonned 
consent is obtained. 
7.9.1.2. 
Post-ti·eatment Response Assessment 
Post-ti·eatment PET-CT response assessments will begin at Day 28 and continue at time points 
outlined in the SOA (Table 3). If there was evidence of baseline bone maITow involvement and 
no PET-CT is available or if there are unexplained cytopenias or suspicion of bone maITow 
involvement, then a bone maiTow aspirate and biopsy will be perfo1med in subjects who are 
being assessed for CR. To confnm a CR, the bone man ow aspirate and biopsy must show no 
evidence of disease by m01phology, or, if indetenninate by mo1phology, must be negative by 
immunohistochemistiy. 
PET-CTs will continue through Month 24 or until disease progression, whichever comes first. If 
the subject's disease has not progressed by Month 24, disease assessments can then be perfo1med 
at standai·d-of-cai·e intervals. Subjects with symptoms suggestive of disease progression should 
be evaluated for progression at the time symptoms occur even if this requires an unscheduled 
visit. If the subject has sta1ted subsequent antilymphoma therapy, then imaging assessments will 
no longer be required per protocol. PET-CT can be perfonned at any time disease progression is 
suspected. FDG-PET assessment takes precedence over CT assessment for time points when 
both are available. If only CT is available for a paiticulai· time point, then the CT assessment 
should include a comparison with and may be affected by the PET-CT assessment at the prior 
time point. Please refer to the imaging manual for finther details. 
Bone maiTow aspirate/biopsy should also be considered to evaluate hemophagocytic 
lymphohistiocytosis as indicated. Refer to the IB for additional infonnation. 
7.9.1.3. 
Response Evaluation to Reti·eatment 
For the pmpose of dete1mining response to reti·eatment with axicabtagene ciloleucel, the last 
scan prior to reu-eatment will be considered the baseline. 
7.9.2. 
Determination of Bone Marrow Involvement 
A subject's bone maiTow involvement should be confnmed by PET-CT or bone maITow biopsy 
and aspirate prior to enrollment. Confinnation of man ow involvement from dete1mination at 
initial diagnosis or between diagnosis and screening is acceptable. 
CONFIDENTIAL 
Page40 
14 JUN 2022 


Axicabtagene Ciloleucel 
Clinical Protocol 
KTE-C19-l 12 (ZUMA-12) 
Kite Phruma, Inc. 
7.10. 
Cell Collection and Axicabtagene Ciloleucel Study Treatment Schedule and 
Administration 
7.10.1. 
Leukapheresis 
Subjects must remain eligible per the eligibility criteria outlined in Section 5 prior to the sta1t of 
leukapheresis. 
If any screening assessments or procedures are repeated between confinnation of eligibility and 
the strut of leukapheresis and results m·e outside the eligibility criteria listed in Section 5, conta.ct 
the sponsor's medical monitor prior to proceeding with leukapheresis. 
Before leukapheresis commences, the following criteria must be met: 
• 
No evidence or suspicion of an infection 
• 
Co1ticosteroid therapy at a phmmacologic dose (~ 5 mg/day of prednisone or equivalent 
doses of other c01ticosteroids) and other immunosuppressive diugs must be avoided for 
7 days prior to leukapheresis 
The leukapheresis visit should occur within approximately 5 days of eligibility confnmation. 
After a subject commences leukapheresis, the subject will be considered emolled into the study. 
If criteria m·e not met, leukapheresis must be delayed until the event resolves. If leukapheresis is 
delayed more than 5 days after eligibility confnmation, baseline complete blood count (CBC) 
with differential and chemistry panel must be repeated. If results are outside the eligibility 
criteria listed in Section 5, contact the medical monitor prior to proceeding with leukapheresis. 
After the above criteria m·e met, mononuclem· cells will be obtained by leukapheresis 
(12 to 15 L) with a goal to tm·get approximately 5 to 10 x 109 mononuclem· cells. The 
leukapheresed cells m·e then packaged for expedited shipment to the manufacturing facility as 
described in the IPM. 
Refer to the SOA Table 3 for a listing of study procedures to be completed on the leukapheresis 
collection day and as outlined in the SOA. 
-
CONFIDENTIAL 
Page 41 
14 JUN 2022 


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 42
14 JUN 2022
7.10.3.
Axicabtagene Ciloleucel Treatment Period
7.10.3.1.
Axicabtagene Ciloleucel Premedication Dosing
The following pre-axicabtagene ciloleucel infusion medications should be administered 
approximately 1 hour prior to infusion:

Acetaminophen 500 to 1000 mg taken orally or equivalent

Diphenhydramine 12.5 to 25 mg administered either orally or via IV or equivalent
7.10.3.2.
Axicabtagene Ciloleucel Administration Day 0
All subjects will receive axicabtagene ciloleucel infusion at a healthcare facility, followed by 
daily monitoring at a healthcare facility for ≥ 7 days to monitor for signs and symptoms of CRS 
and neurologic events. Alternatively, subjects may be hospitalized to receive their axicabtagene 
ciloleucel infusion and be observed for CRS and neurologic events in the hospital setting, if 
deemed appropriate by the investigator. Post-infusion monitoring of subjects must be for a 
minimum of 7 days unless otherwise required by country regulatory agencies (refer to 
Appendix 3).
If subjects are hospitalized, subjects should not be discharged from the hospital until all 
axicabtagene ciloleucel-related non-hematological toxicities resolve to Grade 1 or lower, or 
return to baseline. Subjects may be discharged with noncritical and clinically stable or improving 
toxicities (eg, renal insufficiency) even if higher than Grade 1, if deemed appropriate by the 
investigator. Subjects should remain in a hospital for ongoing axicabtagene ciloleucel-related 
fever, hypotension, hypoxia, or ongoing neurologic events higher than Grade 1, or if deemed 
necessary by the investigator.
Subjects should be instructed to remain within proximity of the clinical study site for at least 
4 weeks following axicabtagene ciloleucel infusion. Subjects should be advised to refrain from 
driving and engaging in hazardous occupations or activities, such as or operating heavy or 
potentially dangerous machinery, for at least 8 weeks following axicabtagene ciloleucel infusion. 
Subjects and their family members/caregivers should be educated on potential CRS and 
neurologic symptoms, such as fever, dyspnea, confusion, aphasia, dysphasia, somnolence, 
encephalopathy, ataxia, or tremor. Subjects or their family members/caregivers should be 
instructed to immediately contact the treating investigator or seek immediate medical attention if 
any of these symptoms develop.
Refer to the SOA for a listing of study procedures to be completed during the axicabtagene 
ciloleucel treatment period.
Central venous access, such as a port or a peripherally inserted central catheter, is required for 
the administration of axicabtagene ciloleucel. Catheter care, per institutional guidelines, should 
be followed. Materials and instructions for the thawing, timing, and administering of 
axicabtagene ciloleucel are outlined in the IPM. Vital signs should be measured during and after 
axicabtagene ciloleucel treatment (see Section 7.6).
Research sites should follow institutional guidelines for the infusion of cell products.


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 43
14 JUN 2022
7.10.3.3.
Axicabtagene Ciloleucel Retreatment
Subjects who achieve a partial response (PR) or CR and subsequently experience disease 
progression may have an option to receive a second course of conditioning chemotherapy and 
axicabtagene ciloleucel. If subject is eligible, retreatment must occur within 24 months after the 
initial axicabtagene ciloleucel infusion.
The following criteria must be met prior to being considered for a repeat course of therapy:

Subject had a PR or CR at any time after axicabtagene ciloleucel therapy and then 
subsequently progressed with CD19 tumor expression confirmed centrally by biopsy after 
disease progression and prior to retreatment

Subject continues to meet the original study eligibility criteria with the exception of prior 
axicabtagene ciloleucel use in this study; screening assessments and procedures should be 
repeated if clinically indicated (eg, ECHO)

Subject has not received subsequent therapy (see Section 6.1.7) for the treatment of 
lymphoma

Subject did not experience a life-threatening toxicity related to axicabtagene ciloleucel 
during the original course of treatment 

Toxicities related to conditioning chemotherapy (fludarabine and cyclophosphamide), with 
the exception of alopecia, have resolved to Grade 1 or lower, or returned to baseline prior to 
retreatment
Sites are required to collect a biopsy confirming disease progression and CD19 expression and to 
submit the biopsied tissue to the central laboratory before initiating retreatment.
The decision to retreat should be made in consultation with the sponsor’s medical monitor. In 
addition, before performing any study-related procedures or treatment, it is necessary to 
1) discuss the risks and benefits of retreatment with the subject, and 2) confirm with the subject 
how the second dose will be manufactured. The second dose could be manufactured at the same 
time that the first axicabtagene ciloleucel dose is made with existing cryopreserved PBMCs. 
Alternatively, the subject may need to undergo a second leukapheresis and should be informed of 
this possibility. These conversations should also be recorded in the subject’s source document.
A maximum of 1 retreatment course may occur per subject. Subjects who are retreated will 
follow the same treatment schedule and procedural requirements per the initial treatment.
Allowance for retreatment is based on clinical experience in ZUMA-1, where a total of 
10 subjects were retreated with axicabtagene ciloleucel (1 subject in Phase 1 and 9 subjects in 
Phase 2), and in ZUMA-7, where 9 subjects received retreatment with axicabtagene ciloleucel 
and were included in the retreatment analysis set. 
Overall, in ZUMA-1, six of 10 retreated subjects had a PR or CR to the retreatment. The subject 
retreated in Phase 1 achieved a PR at Month 1 after retreatment. Among the 9 subjects retreated 


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 44
14 JUN 2022
in Phase 2, five subjects responded (2 CR and 3 PR) at Month 1. Analysis of duration of 
retreatment response (DORR) among the retreated subjects in Phase 2 showed a median DORR 
of 3.5 months.
In ZUMA-7, nine subjects were retreated with axicabtagene ciloleucel. After retreatment, 
5 subjects had a response per central assessment, with all 5 subjects achieving a CR. Using the 
investigator assessment of response, 6 subjects had a response and 4 subjects had a CR.
After a subject is deemed eligible for retreatment and the means by which the second dose of 
axicabtagene ciloleucel has been confirmed (which will include determining whether a second 
leukapheresis is required), the subject will follow the study procedure requirements of the current 
IRB-approved protocol.
Re-treated subjects will be eligible for rollover to the LTFU study after completion of at least 
36 months of assessments from the initial IP treatment.
7.11.
Laboratory
7.11.1.
Local Laboratory Analysis
Assessments listed in Table 2 will be performed at the local laboratory at the time points 
indicated in the SOA.
Table 2.
Clinical Laboratory Parameters
Serum Chemistries
Hematology
Other
Albumin
Alanine aminotransferase
Alkaline phosphatase
Aspartate aminotransferase
Bicarbonate total
Bilirubin total
BUN or ureaa 
Calcium total
Chloride
Creatinine
Glucose
Lactate dehydrogenase
Magnesium total
Potassium
Sodium
Uric acidb 
CBC with differentialc
C-reactive protein
Ferritin
Pregnancy test
Viral testingd
Abbreviations: BUN, blood urea nitrogen; CBC, complete blood count; EU, European Union.
a
If BUN test cannot be analyzed by the local laboratory, urea should be analyzed. 
b
Per institutional guidelines. 


Axicabtagene Ciloleucel 
Clinical Protocol 
KTE-C19-l 12 (ZUMA-12) 
Kite Phruma, Inc. 
c 
At the following phannacokinetic time points, CBC with differential will be analyzed centrally: prior to leukapheresis, 
Day 7, Weeks 2 and 4, and Months 3, 6, 9, 12, and 24. 
d 
For EU sites only, serologic tests (eg, human innnunodeficiency vims, hepatitis B, hepatitis C, syphilis) may be can-ied out 
per institution guidelines and EU regulations 
7.11.2. 
Central Laboratory Analyses 
Assessment of CBC with differential will be submitted for central analysis at the following 
phannacokinetic (PK) time points: prior to leukapheresis, Day 7, Weeks 2 and 4, and Months 3, 
6, 9, 12, and 24. 
Clinical biospecimens (eg, tumor, maiTow, blood, cerebral spinal fluid [CSF], or other tissues) 
will be sent from clinical study centers to the centrnl laborato1y for sample processing, 
accessioning, and distribution to specialty laboratories. 
• 
Biospecimens are obtained at the times indicated in the SOA and instructions regai·ding 
sainple submission to centr·al laboratories ai·e provided in the Centr·al Laborato1y Manual. 
• 
Biospecimens to be collected by study sites: 
-
Archival tumor tissue (biopsy or slides) or fresh tumor sainple if archive tissue is not 
available 
-
Bone maiTow biopsy and aspirate, at baseline and/or post-tr·eatment as needed, for 
confinnation of diagnosis and genetic analyses related specifically to lai·ge B-cell 
lymphoma 
-
Blood for phannacokinetics (levels of anti-CD19 CART cells), replication-competent 
retrovims (RCR), and minimal residual disease (MRD) testing 
-
Semm for phannacodynainics (levels of sennn cytokines) 
-
CSF, if applicable, for phannacokinetics and phannacodynainics 
Multiple specialty laboratories may be employed for specific analyses. Refer to the Central 
Laborato1y Manual for instructions regarding submitting such samples to the appropriate 
laborato1y. 
CONFIDENTIAL 
Page45 
14 JUN 2022 


Axicabtagene Ciloleucel 
Clinical Protocol 
KTE-C19-l 12 (ZUMA-12) 
7.11.2.1. 
Central Confinnation of Diagnosis 
Kite Phruma, Inc. 
Local diagnosis of large B-cell lymphoma for detennination of study eligibility will be made by 
the investigator at each site. Diagnosis will be confnmed retrospectively by a centrnlized 
specialty laborato1y (see Central Laborato1y Manual) using tumor tissue in the fo1m of an 
archival fonnalin-fixed paraffin-embedded block, unstained pre-cut slides, or fresh tumor tissue 
from an on-study baseline (prior to conditioning chemotherapy) biopsy, along with a pathology 
repo1i. 
This confnmation of diagnosis will include the following: 
• 
Assessment of expression of other indication specific markers by immunohistochemistry or 
fluorescence in situ hybridization as needed for central confnmation of disease histology 
• 
Mo1phological evaluation by hematoxylin and eosin staining 
• 
Anatomical location of the biopsy 
• 
Central review of local pathology report 
If the central laborato1y pathologist's diagnosis is discordant with local laborato1y diagnosis, an 
additional pathologist will review the case for adjudication. If the inte1pretation remains 
discordant with the local laborato1y diagnosis, the sponsor will be consulted to detennine if the 
con ect tissue block or slides was received. If the con ect sample was received, the original slides 
used for local diagnosis will be requested for central review. If results are still discordant, the 
central laborato1y's pathologist and the sponsor's medical monitor will review the 
documentation and images. The central diagnosis will be used in cases where adjudication fails 
to reach a concordant result with the local diagnosis. Additional details will be specified in the 
cha1ier for the central specialty laborato1y. 
7.11.2.2. 
I 
I 
I 
Com lete details concerning these analyses will be provided in separate documents-
CONFIDENTIAL 
Page46 
14 JUN 2022 


Axicabtagene Ciloleucel 
Clinical Protocol 
KTE-C19-l 12 (ZUMA-12) 
7.11.2.3. 
Phaimacokinetics and Phannacodynamics 
7.11.2.4. 
Product Characteristics 
Kite Phruma, Inc. 
Sainples of leukapheresis material or final product will be retained and tested by the sponsor or 
specialty laborato1y for the pmpose of understanding the mechanism of action and safety profile 
of axicabtagene ciloleucel. 
7.11.2.5. 
Replication-competent Retrovirns Testing 
Axicabtagene ciloleucel comprises T cells transduced with a y-retroviral vector; hence, there is a 
theoretical risk for RCR developing in exposed subjects. Additional info1mation is provided in 
the IB. The timing of blood draws for detennination of the presence of RCR is specified in the 
SOA or may be done as clinically indicated. 
RCR testing will occur at leukapheresis and at Months 3, 6, and 12. If a subject tests positive for 
RCR at any time point within the first yeai·, samples will continue to be collected and tested 
yearly for up 15 years or as clinically indicated. 
7.12. 
Post-treatment Assessment Period 
After completing study treatment, all subjects will return to the clinic for post-treatment 
follow-up visits. 
If a subject does not respond to treatment at any time during the post-treatment assessment 
period, then the subject will continue to undergo the post-treatment follow-up procedures per the 
SOA, and then be followed for survival and disease outcomes in the LTFU portion of the study 
staiiing with the Month 6 visit (Table 4). 
CONFIDENTIAL 
Page 47 
14 JUN 2022 


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 48
14 JUN 2022
Refer to the SOA (Table 3) for a listing of study procedures and disease assessments to be 
completed during the post-treatment follow-up period.
7.13.
Long-term Follow-up Period
All enrolled subjects will be followed in the LTFU for safety analysis and survival and disease 
status for up to 15 years, if applicable. Subjects will begin the LTFU period beginning at the 
Month 6 visit. After completion of at least 36 months of assessments in the current protocol, 
subjects will transition to the LTFU study, KT-US-982-5968, after providing signed informed 
consent. Subjects who did not respond to treatment may receive off-protocol therapy but will 
continue to be followed for disease assessments (if progression was not documented), subsequent 
antilymphoma therapy, and survival.
Subjects may also be contacted by telephone to confirm survival status and subsequent 
antilymphoma therapy use. If the subject fails to return to the clinic for a scheduled 
protocol-specific visit, sites will need to make 2 attempts, using both the telephone and either 
mail or email to contact the subject. Sites must document both attempts to contact the subject. If 
a subject does not respond within 1 month after the second contact, then the subject will be 
considered lost to follow-up, and no additional contact will be required.
Refer to the SOA (Table 4) for a listing of study procedures and disease assessments to be 
completed during the LTFU period.
Subjects who are enrolled but did not receive the investigational product will be followed only 
until the end of this study and will undergo the following assessments at the time points outlined 
in the SOA:

Subsequent therapy for the treatment of NHL

Survival status 

Disease assessment per protocol
All subjects who received an infusion of axicabtagene ciloleucel will transition to the LTFU 
study KT-US-982-5968, where they will be monitored for occurrence of late-onset targeted 
AEs/SAEs suspected to be possibly related to axicabtagene ciloleucel as defined in Protocol 
KT-US-982-5968 and presence of RCR for up to 15 years from the time of axicabtagene 
ciloleucel infusion (also refer to Section 7.14).
In the LTFU study, KT-US-982-5968, subjects will continue assessments at timepoints 
contiguous with the LTFU timepoints in this study.
7.14.
Summary of Scheduled Assessments
The SOA and the LTFU assessments are provided in Table 3 and Table 4, respectively.


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 49
14 JUN 2022
Table 3.
Schedule of Assessments
Procedure
Screening
Enrollment/ 
Leukapheresis
Conditioning Chemotherapy
Axicabtagene 
Ciloleucel 
Administration
Post-treatment Follow-up
(each visit calculated from Day 0)
Visit
Within 
28 days of 
enrollment
Within approx.  
5 days of 
eligibility 
confirmation
D-5
D-4
D-3
D-2
D-1
D0
D1 to 7a
Week 2
(± 3 
days)
Week 4
(± 3 
days)
Month 2
(± 1 
week)
Month 3
(± 1 
week)
Medical history 
X
Physical examinationb
X
X
X
X
X
X
X
X
X
Neurological examinationc
X
X
QOD
X
X
Weight (plus height at 
screening)
X
X
Vital signs (BP, HR,RR, O2 
saturation, temperature)
Xd
X
X
X
X
X
X
X
X
X
X
ECOG performance status
X
Electrocardiogram
X
X
ECHOe
X
PET-CT disease assessmentf
Xd
X
X
Archival /Fresh tumor sampleg
X
D7-14
Pregnancy test (serum or urine)
X
Xh
Xh
X
Blood draw for chemistry panel
X
X
X
X
X
X
X
X
X
X
Blood draw for CBC with 
differentiali
X
X
X
X
X
X
X
X
X
X
Blood draw for serology (EU 
sites)j
X
X
Blood draw for LDH
X
Blood draw for MRD
X
X


Axicabtagene Ciloleucel 
Clinical Protocol 
KTE-C19- l 12 (ZUMA-12) 
I 
Procedure 
Visit 
Lumbar puncture'< 
-
Blood draw for CRP/ferritin 
Blood draw for RCR analysisn 
Blood draw for cytokines0 
Leukapheresis 
Fludarabine/Cyclophosphamide 
Axicabtagene ciloleucel 
intravenous infusion 
Adverse events/Concomitant 
therapy!' 
Screening 
Within 
28 days of 
enrollment 
X 
X 
Kite Pha1ma, Inc. 
Axicabtagene 
Em·ollment/ 
Ciloleucel 
Post-tr·eatment Follow-up 
Leukapheresis 
Conditioning Chemotherapy 
Administr·ation 
(each visit calculated from Day 0) 
Within approx. 
Week2 
Week4 
Month 2 
5 days of 
eligibility 
(± 3 
(± 3 
(± 1 
confirmation 
D-5 
D-4 
D-3 
D-2 
D-1 
DO 
Dl to 7• 
days) 
days) 
week) 
--------------------------------------------
--------------------------------------------
X 
X 
X 
Dl , D3, 
D7 
X 
X 
--------------------------------------------
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Month 3 
(± 1 
week) 
X 
X 
Abbreviations: BP, blood presstu·e; CAR, chimeric antigen receptor; CBC, complete blood count; CNS, central nervous system; CRP, C-reactive protein; CRS, cytokine release 
syndrome; D, day; ECHO, echocardiogram; ECOG, Eastern Cooperative Oncology Group; EU, European Union; HR, heart rate; LDH, lactate dehydrogenase; MRD, minimal 
residual disease; MRI, magnetic resonance imaging; PET-CT, positron emission tomography-computed tomography; PK, phannacokinetics; QOD, eve1y other day; RCR, 
replication-competent retrovims; RR, respirato1y rate. 
a 
Axicabtagene ciloleucel administration period, refer to Appendix 3 for requirements by countiy regulatory agencies. 
b 
Subjects with new onset symptoms related to CRS should undergo physical examination at least daily until symptoms resolve to baseline. Subjects with symptoms of CNS 
malignancy, such as new onset severe headaches, neck stiffness, seizures, encephalopathy, cranial nerve deficits, or any focal netu·ologic findings on physical exam, will have 
a brain MRI and lumbar puncture for examination of cerebral spinal fluid. A physical exam is required prior to the start of conditioning chemotherapy and prior to 
axicabtagene ciloleucel infusion. 
CONFIDENTIAL 
Page 50 
14 JUN 2022 


Axicabtagene Ciloleucel 
Clinical Protocol 
KTE-C19- l 12 (ZUMA-12) 
Kite Pha1ma, Inc. 
C 
d 
e 
f 
g 
h 
k 
1 I 
Nem·ologic assessment: A neurological assessment should be done prior to axicabtagene ciloleucel infusion on treatment Day 0, on treatment Day 1, Day 3, Day 5, and Day 7 
dtuing the minimum 7-day observation period. For new onset of neurologic symptoms or if neurologic symptoms persist, neurologic examination will be performed at least 
daily until symptoms resolve to baseline. 
In addition to the time points outlined in the SOA, it is recommended that vital signs are monitored during and after study treatment (see Section 6) and as clinically indicated. 
ECHO will be performed following the subject's last chemotherapy treatment and within 28 days prior to signing the consent may be used for confinnation of eligibility. 
PET-CT w-ill be performed within 28 days prior to enrollment. If bone marrow involvement was not evaluated within 28 days of enrolhuent, a PET-CT or a bone marrow 
biopsy will be performed to establish a baseline. PET-CT shall be pe1fo1med at any time disease progression is suspected. If there is evidence of baseline bone ma1l'Ow 
involvement, or if there are unexplained cytopenias, or suspicion of bone marrow involvement. a bone ma1l'Ow as irate and bio 
will be e1fon11ed in sub· ects who are 
being assessed for CR in order to confirm complete response. 
-
~-embedded tumor block or 30 unstained slides will be re uired. If an archived ttuuor sam le is not available a fresh ttuuor sam le is re uired 
iii
. t 
tat of chemotherapy to continue on study. 
Archived and fresh tumor samples (if app 1c 
e w1 
e su rmtte to a centra a orato1y a er e 1gi 1 1ty as een con lffile an pnor to sta1t o con 1tiomng 
a . Slides that have been reviousl stained with antibodies or other reagents are not acceptable. Screen failed subjects' archived samples should not be submitted. 
regnancy test serum or m,ne : 
o y: test to e comp ete w1 Ill days prior to both leukapheresis and conditioning chemotherapy for females of childbea1ing potential. 
At the following time points, CBC with differential will be analyzed centi·ally: prior to leukapheresis, Day 7, Weeks 2 and 4, and Month 3. 
For EU sites, serologic test (eg, HIV, hepatitis B, hepatitis C, syphilis) will be carried out per institutional guidelines and EU regulations. This may be done within 30 days 
prior to leukapheresis or on the day of leukapheresis. 
Subjects w-ith symptoms of CNS malignancy ( eg, new onset severe headaches, neck stiffness, or focal neurological fill dings) will have lumbar puncture pe1fon11ed at 
screening to assess cerebral spinal fluid for possible CNS involvement. Subjects with new onset Grade 2 or higher neurologic symptoms after axicabtagene ciloleucel infusion 
will have lumbar puncture pe1fo1med to assess cerebral spinal fluid when feasible. Measuring the opening pressure should be done, if possible, with recording of the results in 
the sub· ect site chart. 
n 
B oo 
·aws or RCR w1 
e co ecte pnor to et ap eres1s an at Mont 1s 3, 6, an 12 en collect yearly for up to 15 years. Yearly samples will only be collected/analyzed 
if positive at Month 3, 6, or 12. Blood and senun samples may also be used for fiuiher RCR evaluation as clinically indicated. 
o 
Blood draws for cytokines will be collected prior to leukapheresis, on Day 0 prior to administi·ation of axicabtagene ciloleucel, on Days 1, 3, 7, and Weeks 2 and 4. If a 
subject who was admitted to the hospital within the 7-day observation period is discharged and then subsequently re-admitted to the hospital with any axicabtagene ciloleucel-
related adverse events, blood samples for cytokines will be collected on the day of hospital re-admission and then weekly tlu·ough and including the day of discharge. Blood 
samples for cytokines will also be collected at the time of disease progression prior to starting any subsequent antilymphoma therapy. If the subject experiences a Grade 3 or 
higher axicabtagene ciloleucel-related toxicity, such as a Grade 3 CRS or neurologic event, 1 additional blood draw for cytokines will be taken at the time of the Grade 3 or 
higher axicabtagene ciloleucel-related toxicity and upon resolution of the event. 
p 
Adverse events will be recorded from the date of enrollment tmtil 3 months after completing treatment with axicabtagene ciloleucel. Concomitant therapies will be recorded 
from the date of info1med consent tmtil 3 months after completing treatment with axicabtagene ciloleucel. 
CONFIDENTIAL 
Page 51 
14 JUN 2022 


Axicabtagene Ciloleucel 
Clinical Protocol 
KTE-C19-l 12 (ZUMA-12) 
Table 4. 
Long-term Follow-up Assessments 
Procedure 
Visit 
Month 
Month 
Month 
Month 
Month 
frequency 
6 
9 
12 
15 
18 
Physical 
examination 
(with 
X 
X 
X 
X 
X 
neurological 
examination? 
PET-CT 
disease 
X 
X 
X 
X 
X 
assessment" 
Survival status 
X 
X 
X 
X 
X 
Blood draw for 
CBC with 
X 
X 
X 
X 
X 
differentiald 
CONFIDENTIAL 
Kite Pha1ma, Inc. 
Long-term Follow-up Period 
Each visit calculated from Day 0 
(all visits have± 28 day window) 
Month 72 
and 
Month 
Month 
Month 
Month 
Month 
Month 
Month 
Annually 
24 
30 
36 3 
42 
48 
54 
60 
Thereafter 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Page 52 
14 JUN 2022 


Axicabtagene Ciloleucel 
Clinical Protocol 
KTE-C19-l 12 (ZUMA-12) 
Kite Pha1ma, Inc. 
Long-term Follow-up Period 
Each visit calculated from Day 0 
Procedure 
(all visits have ± 28 day window) 
Month 72 
and 
Visit 
Month 
Month 
Month 
Month 
Month 
Month 
Month 
Month 
Month 
Month 
Month 
Month 
Annually 
frequency 
6 
9 
12 
15 
18 
24 
30 
36• 
42 
48 
54 
60 
Thereafter 
Targeted 
X 
X 
X 
X 
X 
X 
AEs/SAEsg 
Targeted 
concomitant 
X 
X 
X 
X 
X 
X 
medicationsh 
Subsequent 
therapy for 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
NHLi 
Abbreviations: AE, adverse event; CAR, chimenc antigen receptor; CBC, complete blood count; CT, computed tomography; NHL, non-Hodgkin lymphoma; PET-CT, positron enuss1on 
tomography-computed tomography; MRD, minimal residual disease; RCR, replication-competent retrovirus; SAE, serious adverse event. 
a 
After completion of at least 36 months of assessments in ZUMA-12, subjects who received an infusion of axicabtagene ciloleucel will transition to the L TFU study KT-US-982-5968 
after providing signed informed consent, to complete the remainder of the 15-year LTFU period. 
b 
Physical exams will continue through Month 24. 
c 
PET-CT/disease assessments will continue through Month 24 or until disease progression, whichever comes first. If subject's disease has not progressed by Month 24, disease 
assessments will continue to be performed per standard of care. 
g 
h 
Blood draw for CBC with differentials will continue throu 
Month 24 or until disease 
o ession, whichever comes first. 
aws or RCR ana ys1s w 
continue 
u 
Mon 
yzed if positive at Month 3, 6, or 12. Blood and serum saniples may also be 
used for further RCR evaluation as clinically indicated. 
After 3 months, only targeted AEs/SAEs will be reported. Targeted AEs/SAEs are defined as infections; neurological, hematological, and autoinlmune disorders; and secondary 
malignancies that occur up to 15 years after axicabtagene ciloleucel infusion or until disease progression (whichever occurs first). 
Targeted concomitant medications will be collected for 24 months or until disease progression (whichever occurs first). 
Subsequent therapy refers to therapy administered after axicabtagene ciloleucel infusion for a subject's disease, such as non-study-specified chemotherapy, inlmunotherapy, target 
agents, as well as stem cell transplant and radiation therapy, which must be collected until the subject completes the LTFU period, is considered lost to follow-up, withdraws consent, or 
dies. Subjects may be contacted by telephone to collect information about subsequent therapy for NHL and to assess survival status. 
CONFIDENTIAL 
Page 53 
14 JUN 2022 


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 54
14 JUN 2022
8.
SUBJECT WITHDRAWAL
Subjects have the right to withdraw from the study at any time and for any reason without 
prejudice to their future medical care by the physician or at the institution.
Subjects can decline to continue to receive study-required treatment and/or other 
protocol-required procedures at any time during the study while continuing to participate in the 
study. This is referred to as partial withdrawal of consent.
If partial withdrawal of consent occurs, the investigator must discuss with the subject the 
appropriate process for discontinuation from the investigational product, study treatment, or 
other protocol-required therapies and must also discuss options for continued participation, 
completion of procedures, and the associated data collection as outlined in the SOA. The level of 
follow-up and method of communication should also be discussed between the research staff and 
the subject and documented in the source documents.
Withdrawal of full consent from a study means that the subject does not wish to receive further 
protocol-required therapy, undergo procedures, and continue participating in study follow-up. 
Subject data collected up until withdrawal of consent will be retained and included in the 
analysis of the study. Publicly available data (death records) can be included after withdrawal of 
consent if local regulations permit. The investigator is to discuss with the subject appropriate 
procedures for withdrawal from the study.
As part of the study, sites may be asked to conduct searches of public records, such as those 
establishing survival status, if available, to obtain survival data for any subject for whom the 
survival status is not known. Sites may be asked to also retrieve autopsy reports to confirm status 
of disease at the time of death.
The investigator and/or sponsor can also decide to withdraw a subject from the investigational 
product and/or other protocol-required therapies, protocol procedures, or the study as a whole at 
any time prior to study completion.
8.1.
Reasons for Removal from Treatment
Reasons for removal from protocol-required investigational products or procedures include any 
of the following:

AEs

Subject request

Product not available

Lost to follow-up

Death

Decision by sponsor


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 55
14 JUN 2022
8.2.
Reasons for Removal from Study
Reasons for removal of a subject from the study are as follows:

Subject withdrawal of consent from further follow-up

Investigator decision

Lost to follow-up

Death


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 56
14 JUN 2022
9.
SAFETY REPORTING
9.1.
Adverse Events
An AE is defined as any untoward medical occurrence in a clinical trial subject. The event does 
not necessarily have a relationship with study treatment. The investigator is responsible for 
ensuring that any AEs observed by the investigator or reported by the subject are recorded in the 
subject’s medical record. The definition of AEs includes worsening of a pre-existing medical 
condition. Worsening indicates that the pre-existing medical condition has increased in severity, 
frequency, and/or duration or has an association with a worse outcome. When recording such 
events, provide descriptions that the pre-existing condition has changed (eg, more frequent 
headaches for a subject with pre-existing headaches or BP has increased in a subject with 
pre-existing hypertension).
A pre-existing condition that has not worsened during the study or involves an intervention, such 
as elective cosmetic surgery or a medical procedure while on study, is not considered an AE.
Interventions for pretreatment conditions (such as elective cosmetic surgery) or medical procedures 
that were planned before study participation are not considered AEs. Hospitalization for study-
treatment infusions or precautionary measures per institutional policy are not considered AEs.
The term “disease progression,” as assessed by measurement of malignant lesions on radiographs 
or other methods, should not be reported as AEs. Death due to disease progression in the absence 
of signs and symptoms should be reported under the primary tumor type (eg, B-cell lymphoma).
When an AE or SAE is due to the disease under investigation, it is necessary to report the signs 
and symptoms. Worsening of signs and symptoms of the malignancy under study should also be 
reported as AEs in the appropriate section of the CRF.
The investigator’s clinical judgment is used to determine whether a subject is to be removed 
from treatment due to an AE. If a subject requests to withdraw from protocol-required therapies 
or the study because of an AE, then the subject should undergo the procedures outlined in the 
Month 3 visit of the SOA.
9.2.
Reporting of Adverse Events
The investigator is responsible for reporting all AEs observed by the investigator or reported by 
the subject that occur after enrollment (ie, commencement of leukapheresis) through 3 months 
after treatment with axicabtagene ciloleucel infusion.
After 3 months, targeted AEs (eg, infections, neurological, hematological, and autoimmune 
disorders, and secondary malignancies) will be monitored and reported for 15 years after 
treatment with axicabtagene ciloleucel or until disease progression, whichever occurs first.
For subjects who are enrolled, but do not receive axicabtagene ciloleucel, the AE reporting 
period ends 30 days after the last study-specific procedure (eg, leukapheresis, conditioning 
chemotherapy).


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 57
14 JUN 2022
The investigator must provide the information listed below regarding the AEs being reported:

AE diagnosis or syndrome (if not known, signs or symptoms)

Dates of onset and resolution

Severity

Assessment of relatedness to axicabtagene ciloleucel, conditioning chemotherapy, or study 
procedures

Action taken
The AE grading scale used will be the National Cancer Institute (NCI) Common Terminology 
Criteria for Adverse Events (CTCAE) version 5.0. A copy of the grading scale can be 
downloaded from the Cancer Therapy Evaluation Program home page (http://ctep.cancer.gov). 
CRS events will be reported using the grading scale outlined in the IB.
In reviewing AEs, investigators must assess whether the AE is possibly related to 
1) axicabtagene ciloleucel, 2) conditioning chemotherapy, 3) any protocol-required study 
procedure or treatment, 4) disease progression, 5) concurrent disease, 6) concomitant medication, 
or 7) other. The relationship is indicated by a Yes or No response and entered into the CRF. A 
Yes response should indicate that there is evidence to suggest a causal relationship between the 
study treatment or procedure and the AE. Additional relevant data with respect to describing the 
AE will be collected in the CRFs.
The investigator is expected to follow reported AEs until stabilization or resolution. If a subject 
begins a new antilymphoma therapy, the AE reporting period for non-SAEs ends at the time the 
new treatment is started.
9.2.1.
Reporting Abnormal Laboratory Findings
The investigator is responsible for reviewing laboratory test results and determining whether an 
abnormal value in an individual study subject represents a clinically significant change from the 
subject’s baseline values. In general, abnormal laboratory findings without clinical significance 
(based on the investigator’s judgment) are not to be recorded as AEs. However, abnormal 
laboratory findings that result in new or worsening clinical sequelae, or that require therapy or 
adjustment in current therapy, are considered AEs. Where applicable, clinical sequelae (not the 
laboratory abnormality) are to be recorded as the AE.
An abnormal laboratory test result must be reported as an AE if it is a change from baseline and 
meets any of the following criteria:

Is associated with clinical symptoms

Results in a medical intervention (eg, potassium supplementation for hypokalemia or iron 
replacement therapy for anemia) or a change in concomitant therapy

Is clinically significant in the investigator’s judgment


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 58
14 JUN 2022
9.3.
Definition of Serious Adverse Events
An SAE is defined as an AE that meets at least 1 of the following serious criteria:

Fatal

Life-threatening (places the subject at immediate risk of death)

Requires inpatient hospitalization or prolongation of existing hospitalization

Results in persistent or significant disability/incapacity

Congenital anomaly/birth defect

Other medically important event
An AE would meet the criterion of “requires hospitalization” if the event necessitated an 
admission to a healthcare facility (eg, overnight stay).
Events that require an escalation of care when the subject is already hospitalized should be 
recorded as an SAE. Examples of such events include movement from routine care in the 
hospital to the intensive care unit or if that event resulted in a prolongation of the existing 
planned hospitalization.
If an investigator considers an event to be clinically important, but it does not meet any of the 
serious criteria, the event could be classified as an SAE with the criterion of “other medically 
important serious event.”
The terms “severe” and “serious” are not synonymous. Severity refers to the intensity of an AE 
according to NCI CTCAE criteria; the event itself may be of relatively minor medical 
significance and, therefore, may not meet the seriousness criteria. Severity and seriousness need 
to be independently assessed for each AE recorded on the electronic CRF (eCRF).
9.4.
Reporting of Serious Adverse Events 
The investigator is responsible for reporting all SAEs observed by the investigator or reported by 
the subject that occur after signing of the informed consent through 3 months after the 
axicabtagene ciloleucel infusion or until the initiation of another antilymphoma therapy, 
whichever occurs first. After 3 months, only targeted SAEs will be reported. Targeted SAEs are 
defined as and include infections; neurological, hematological, and autoimmune disorders; and 
secondary malignancies that occur up to 15 years after axicabtagene ciloleucel infusion or until 
disease progression, whichever occurs first.
SAEs, which the investigator assesses as related to axicabtagene ciloleucel, should be reported 
regardless of the time period.


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 59
14 JUN 2022
For subjects who screen fail or are enrolled but do not receive axicabtagene ciloleucel, the 
reporting period for SAEs ends 30 days after the last study-specific procedure (eg, screening 
procedure, leukapheresis, conditioning chemotherapy).
All SAEs must be submitted to Kite via the electronic SAE system within 24 hours of the 
investigator’s knowledge of the event. If the electronic SAE system is unavailable (eg, system 
outage), then the SAE must be submitted using the SAE Report Form and emailed to the SAE 
Reporting mailbox: safety_fc@gilead.com.
Following completion of ZUMA-12, any relevant information on ongoing SAEs must be 
submitted to Kite Pharma within 24 hours of the investigator’s knowledge of the event using the 
paper SAE Report Form and sent via e-mail to the SAE Reporting mailbox: 
safety_fc@gilead.com.
Subsequently, all SAEs will be reported to the health authorities per local reporting guidelines.
Disease progression of the malignancy is not considered an AE. However, signs and symptoms 
of disease progression may be recorded on the CRF as AEs or SAEs and indicated as being due 
to disease progression. If the malignancy has a fatal outcome before the end of the SAE reporting 
period, then the event leading to the death must be recorded as an SAE with the outcome being 
fatal.
Death must be reported if it occurs during the SAE reporting period, irrespective of any 
intervening treatment.
Any death occurring after the first dose of chemotherapy, for the purpose of pre-conditioning, 
and within 3 months of axicabtagene ciloleucel infusion, regardless of attribution to treatment, 
requires expedited reporting within 24 hours. Any death occurring after the SAE reporting period 
requires expedited reporting within 24 hours only if it is considered related to treatment.
9.5.
Reporting Deaths
Deaths that occur during the protocol-specified AE reporting period that are attributed by the 
investigator solely to progression of underlying lymphoma should be recorded as SAEs with the 
preferred term “B-cell lymphoma” and must be reported immediately to the sponsor. Death is an 
outcome and not a distinct event. The event or condition that caused or contributed to the fatal 
outcome should be recorded on the AE form. However, every effort should be made to capture 
the established cause of death, which may become available later on (eg, after autopsy). Refer to 
the CRF completion guidelines for detailed instructions.
9.6.
Diagnosis Versus Signs and Symptoms
For AEs, a diagnosis (if known) rather than individual signs and symptoms should be recorded 
on the AE form. The exception is for CRS where both the diagnosis and the signs and symptoms 
will be captured on the AE form. For signs and symptoms of the underlying cancer, the signs and 
symptoms should be captured. However, on the AE form, the investigator should state that these 
signs and symptoms are due to the underlying disease.


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 60
14 JUN 2022
9.7.
Pregnancy and Lactation
There is no relevant clinical experience with axicabtagene ciloleucel in pregnant or lactating 
women, and animal reproductive studies have not been performed. Women of childbearing 
potential must have a negative pregnancy test prior to enrollment because of the potentially 
dangerous effects of the preparative chemotherapy on the fetus. Women of childbearing potential 
should be monitored according to local and country-specific regulations. This experimental 
therapy should not be administered to pregnant women or women who are breastfeeding.
Female subjects and female partners of male subjects are recommended to use highly effective 
contraception (method must achieve an annual failure rate of < 1%) for at least 6 months after 
conditioning chemotherapy dosing or the administration of axicabtagene ciloleucel, whichever is 
longer. Male subjects are recommended to not father a child for at least 6 months after the 
conditioning chemotherapy dosing or the administration of axicabtagene ciloleucel, whichever is 
longer. Refer to Appendix 4 for a complete list of highly effective contraception methods.
If a pregnancy occurs in either a female subject enrolled into the study or a female partner of a 
male subject within 6 months of completing conditioning chemotherapy or the administration of 
axicabtagene ciloleucel, whichever is longer, the pregnancy must be reported to the sponsor. 
Information regarding the pregnancy and/or the outcome may be requested by the sponsor.
The pregnancy should be reported to the sponsor within 24 hours of the investigator’s knowledge 
of the pregnancy event by using the pregnancy report form and emailing it to: 
safety_fc@gilead.com.
The pregnancy outcome should be reported to the sponsor using the pregnancy outcome report 
form and emailing it to: safety_fc@gilead.com.
Lactation cases occurring in female patients taking protocol-required therapies (PRT) and up to 
6 months after PRT should be reported to safety_fc@gilead.com within 24 hours of awareness 
using the lactation reporting form.
9.8.
Hospitalization and Prolonged Hospitalization
Any AE that results in hospitalization or prolonged hospitalization should be documented and 
reported as an SAE as described in Section 9.4.
The following hospitalization scenarios are not considered to be SAEs:

Hospitalization for palliative care or hospice care

Planned hospitalization required by the protocol (eg, for monitoring of the subject or to 
perform an efficacy measurement for the study)

Planned hospitalization for a pre-existing condition

Hospitalization due to progression of the underlying cancer


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 61
14 JUN 2022
9.9.
Abnormal Vital Sign Values
Not all vital sign abnormalities qualify as an AE. A vital sign result must be reported as an AE if 
it is a change from baseline and meets any of the following criteria:

Accompanied by clinical symptoms

Results in a medical intervention or a change in concomitant therapy

Clinically significant in the investigator’s judgment
It is the investigator’s responsibility to review all vital sign findings. Medical and scientific 
judgment should be exercised in deciding if an isolated vital sign abnormality should be 
classified as an AE. However, if a clinically significant vital sign abnormality is a sign of a 
disease or syndrome (eg, high BP), only the diagnosis (ie, hypertension) should be recorded on 
the CRF.
9.10.
Data Safety Monitoring Board 
An independent DSMB will be chartered to meet and review the SAEs and SUSARs on a semi-
annual basis after the first subject has been treated with axicabtagene ciloleucel up through the 
primary analysis. Kite Pharma, or delegate, will submit SAEs and SUSARs to the DSMB on a 
regular basis throughout the study up through the primary analysis. The DSMB will also meet to 
review safety data after 15 subjects have been enrolled and treated with axicabtagene ciloleucel 
and have had an opportunity to be followed for 3 months after axicabtagene ciloleucel infusion. 
The DSMB will make trial conduct recommendations on an ongoing basis based on an analysis 
of risk vs benefit. The DSMB may request additional safety data for review or recommend 
modifications to the study conduct if safety concerns are identified. The DSMB may meet more 
often as needed.
The sponsor may request additional reviews by the DSMB. Data submitted to the DSMB may be 
monitored or unmonitored to facilitate timely DSMB review. At the time of expedited reporting 
of SUSARs to the FDA, Kite Pharma (or designee) will concurrently submit these reports to the 
DSMB chair.


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 62
14 JUN 2022
10.
STATISTICAL CONSIDERATIONS
10.1.
Hypothesis
No formal hypothesis will be tested. This study is designed to estimate the CR rate in subjects 
with high-risk large B-cell lymphoma. The CR rate targeted in this study is 60%.
10.2.
Study Endpoints
10.2.1.
Primary Endpoint
CR rate is defined as the incidence of a CR per the Lugano Classification {Cheson 2014} as 
determined by study investigators. All evaluable subjects who do not meet the criteria for a CR 
by the analysis data cutoff date will be considered non-responders.
The final analysis will be performed on subjects in this study after at least 36 months of follow-
up. Subjects will be transitioned to the KT-US-982-5968 study for the remainder of the 15-year 
LTFU period. Descriptive estimates of key efficacy and safety analyses may be updated to assess 
the overall treatment profile.
10.2.2.
Secondary Endpoints
ORR is defined as the incidence of either a CR or a PR per the Lugano Classification {Cheson 
2014} as determined by the study investigators. All evaluable subjects who do not meet the 
criteria for an objective response by the analysis cutoff date will be considered non-responders.
DOR is defined only for subjects who experience an objective response after axicabtagene 
ciloleucel infusion and is the time from the first objective response to disease progression per the 
Lugano Classification {Cheson 2014} or death from any cause. Subjects not meeting the criteria 
for disease progression or death from any cause by the analysis data cutoff date will be censored 
at their last evaluable disease assessment date. Subjects who receive any subsequent new 
antilymphoma therapy, including SCT in the absence of documented disease progression or 
death, will be censored at the last evaluable disease assessment prior to the subsequent new 
antilymphoma therapy.
EFS is defined as the time from the axicabtagene ciloleucel infusion date to the earliest date of 
disease progression per the Lugano Classification {Cheson 2014}, commencement of subsequent 
new antilymphoma therapy including SCT, or death from any cause. Subjects alive, in response, 
and with no new antilymphoma therapy including SCT will be censored at the last evaluable 
disease assessment.
PFS is defined as the time from the axicabtagene ciloleucel infusion date to the date of disease 
progression per the Lugano Classification {Cheson 2014} or death from any cause. Subjects not 
meeting the criteria for disease progression or death from any cause by the analysis data cutoff 
date will be censored at the last evaluable disease assessment. Subjects who receive any 
subsequent new antilymphoma therapy including SCT in the absence of documented disease 
progression or death will be censored at the last evaluable disease assessment prior to the 
subsequent new antilymphoma therapy.


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 63
14 JUN 2022
OS is defined as the time from axicabtagene ciloleucel infusion to the date of death from any 
cause. Subjects who are alive will be censored at their last date known to be alive or the data 
cutoff date, whichever is earlier. Subjects who die after the data cutoff date will be censored at 
the data cutoff date.
Relapse with CNS disease is defined as the time from the axicabtagene ciloleucel infusion date 
to the earliest date of CNS involvement with lymphoma, as determined by typical symptoms, 
CSF evaluation, and/or diagnostic imaging.
Incidence of AEs (including Grade 3 or higher, serious, fatal, and AEs of interest) and clinically 
significant changes in safety laboratory values. Additional secondary endpoints include PK and 
pharmacodynamic endpoints, such as the evaluation of anti-CD19 CAR T-cell levels in the blood 
and cytokine levels in the serum in relationship with clinical outcome.
10.2.3.
10.2.4.
Covariates and Subgroups
The following covariates at screening/baseline may be used in efficacy and safety analyses:

Age (< 65, ≥ 65 years)

Gender

Race

Ethnicity

ECOG status 

IPI score

Diagnosis category (double-hit lymphomas versus triple-hit lymphomas versus 
non-double-/triple-hit with IPI score ≥ 3)

Levels of cytokines

Levels of CAR T cells

CR achieved on the study
Additional associative analyses of covariates with subject outcomes will be specified in the 
statistical analysis plan.
CCI
CCI


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 64
14 JUN 2022
10.3.
Sample Size Considerations
In the GELA randomized Phase 2 study evaluating the efficacy of R-ACVBP or R-CHOP-14 
induction, using IWF 2007 criteria in young patients with high-risk DLBCL, the primary 
objective of achieving a higher than 50% CR rate after 4 cycles of induction regimen was not 
met in both randomization groups (47% in R-ACVBP and 39% in R-CHOP-14) {Casasnovas 
2017}. Accordingly, it is postulated that a CR rate of 60% would represent a clinically 
meaningful improvement over standard chemoimmunotherapy in a high-risk large B-cell 
lymphoma patient population. Although there is no formal hypothesis testing, the sample size 
has been determined in part with descriptive analysis described below.
The trial uses a single-arm design to estimate the CR rate in subjects with high-risk large B-cell 
lymphoma treated with axicabtagene ciloleucel. A CR rate of 60% with axicabtagene ciloleucel 
treatment is targeted. With a total sample size of 40 subjects, an observed CR rate of 60% will 
yield an 80% CI for the response rate with a maximum half-width of less than or equal to 11%, 
corresponding to a lower limit of at least 48.6%. This target CR rate, and the lower limit of the 
80% CI for the CR rate, is meaningful because it would represent a significant improvement in 
the response rate for the subjects with high-risk large B-cell lymphoma and would likely offer an 
improvement over existing therapies in patients with high-risk large B-cell lymphoma.
Table 5 provides the estimated CR rate and the lower and upper limits of 80%/95% CI based on 
the Clopper-Pearson method for a range of possible CR rates for a sample of 40 subjects. 
Table 5.
Lower and Upper Limits of 80%/95% CIs for CR Rates from 60% to 
100% for a Sample of 40 Subjects
Number (%) of CRs
24 (60)
28 (70)
32 (80)
36 (90)
40 (100)
Lower and upper limits 
of 80% CI (%, %)
48.6, 70.6
58.8, 79.5
69.6, 88.0
81.0, 95.6
94.4, 100
Lower and upper limits 
of 95% CI (%, %)
43.3, 75.1
53.5, 83.4
64.4, 90.9
76.3, 97.2
91.2, 100
Abbreviations: CI, confidence interval; CR, complete response.
10.4.
Access to Individual Subject Treatment Assignments
This is a single-arm, open-label study, and subjects and investigators will be aware of treatment 
received. Data-handling procedures for the study will be devised to reduce potential sources of 
bias and maintain the validity and credibility of the study. These procedures will be outlined in 
the study statistical plan, DSMB charter, and trial integrity document.
10.5.
Interim Analysis and Early Stopping Guidelines
The DSMB will meet and review SAEs and SUSARs on a semi-annual basis after the first 
subject has been dosed. The DSMB may request additional safety data.


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 65
14 JUN 2022
One planned interim analysis will be performed. Interim Analysis 1 will be conducted after 
15 subjects have been enrolled and treated with axicabtagene ciloleucel and have had an 
opportunity to be followed for 3 months after axicabtagene ciloleucel infusion. This analysis will 
be for efficacy and safety and will be descriptive.
10.6.
Analysis Subsets
In this study, subjects are to be dosed at a target of 2 x 106 (1.0 x 106 to 2.4 x 106) anti-CD19 
CAR T cells/kg. A minimum dose of 1 x 106 anti-CD19 CAR T cells/kg may be administered. 
For subjects weighing ≥ 100 kg, a maximum flat dose of 2 x 108 anti-CD19 CAR T cells will be 
administered. Subjects are considered to have received the target dose if they receive at least 
1 x 106 anti-CD19 CAR T cells/kg.
The safety analysis set is defined as all subjects treated with any dose of axicabtagene ciloleucel. 
This analysis set will be used for all safety data analyses.
The full analysis set will consist of all enrolled/leukapheresed subjects and will be used for the 
summary of subject disposition and the listing of deaths.
The response evaluable analysis set will consist of the subjects who are enrolled and treated with 
axicabtagene ciloleucel at a dose of at least 1 x 106 anti-CD19 CAR T cells/kg and have a 
centrally confirmed disease type (double-/triple-hit lymphomas) or large B-cell lymphoma with 
an IPI score ≥ 3. This analysis set will be used for all efficacy data analyses including CR rate, 
ORR, endpoints based on response (DOR, EFS, and PFS), relapse with CNS, and OS.
10.7.
Planned Method of Analysis
The primary analysis will occur after all treated subjects have an opportunity to be assessed for 
response 6 months after the Week 4 disease assessment. The CSR will be written based on the 
data collected and analyzed from this primary analysis. The final analysis will occur after all 
subjects complete at least 36 months of follow-up.
The primary analysis of CR rate will be based on the investigator’s review of disease 
assessments in the response evaluable analysis set.
10.7.1.
CR Rate
The subject incidence of CR will be calculated. The 2-sided 80%/90%/95% CIs will be provided 
about the CR rate, calculated with the Clopper-Pearson method.
10.7.2.
ORR
The subject incidence of objective response will be calculated. The 2-sided 80%/90%/95% CIs 
will be provided about the ORR, calculated with the Clopper-Pearson method.
The incidence of subjects with CR, PR, stable disease, PD, not done, and not evaluable, as best 
overall response to treatment, and exact 2-sided 80%/90%/95% CIs about the incidence will be 
generated.


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 66
14 JUN 2022
10.7.3.
DOR
Kaplan-Meier plots, estimates, and 2-sided 80%/90%/95% CIs will be generated for DOR among 
the subjects who achieve an objective response. Kaplan-Meier estimates of the proportion of 
subjects alive and PFS at 3-month intervals will be provided. The number of subjects censored or 
having events and the reasons for censoring or type of events (PD or death) will be summarized.
A sensitivity analysis of DOR will be conducted in which disease assessments obtained after 
SCT (for subjects who undergo SCT while in an axicabtagene ciloleucel-induced response) will 
be used in the derivation of DOR.
DOR may be evaluated in subgroups defined by the covariates described in Section 10.2.4.
10.7.4.
EFS
Kaplan-Meier plots, estimates, and 2-sided 80%/90%/95% CIs will be generated for EFS. 
Kaplan-Meier estimates of the proportion of subjects alive and event-free at 3-month intervals 
will be provided. The number of subjects censored or having events, and the reasons for 
censoring or type of events (PD, subsequent new antilymphoma therapy, or death) will be 
summarized.
EFS may be evaluated in subgroups defined by the covariates described in Section 10.2.4.
10.7.5.
PFS
Kaplan-Meier plots, estimates, and 2-sided 80%/90%/95% CIs will be generated for PFS. 
Kaplan-Meier estimates of the proportion of subjects alive and progression-free at 3-month 
intervals will be provided. The number of subjects censored or having events, and the reasons for 
censoring or type of events (PD or death) will be summarized. 
PFS may be evaluated in subgroups defined by the covariates described in Section 10.2.4.
10.7.6.
OS
Kaplan-Meier plots, estimates, and 2-sided 80%/90%/95% CIs will be generated for OS. 
Estimates of the proportion of subjects alive at 3-month intervals will be provided through 
2 years after the final subject has been enrolled and then annually through the completion of the 
study. The number of subjects censored or having events, and the reasons for censoring or type 
of events (death) will be summarized. 
OS may be evaluated in subgroups defined by the covariates described in Section 10.2.4.
10.7.7.
Relapse with CNS Disease
The number of subjects with CNS relapse and time to relapse with CNS disease among the 
subjects who experience CNS relapse will be summarized.
Relapse with CNS disease may be evaluated in subgroups defined by the covariates described in 
Section 10.2.4.


Axicabtagene Ciloleucel 
Clinical Protocol 
KTE-C19-l 12 (ZUMA-12) 
10.7.8. 
Safety 
Kite Phruma, Inc. 
Subject incidence rates of AEs, including all, serious, fatal, CTCAE Grade 3 or higher, 
treatment-related AEs, and AEs of interest repo1ted throughout the conduct of the study, will be 
tabulated by system organ class and prefened tenns or prefened te1ms only, coded with the 
Medical Dictiona1y for Regulato1y Activities. Changes in laborato1y values and vital signs will 
be summarized with descriptive statistics. 
The incidence of concomitant medications will be summarized. 
Tables and/or nairntives of deaths through the LTFU and treatment-related SAEs will be 
provided. 
The incidence, prevalence, duration, and reversibility of identified risks, RCR, and secondaiy 
malignancies will be summai·ized. 
10.7.9. 
Pharmacokinetic Analysis 
The levels of anti-CD19 CART cells measured in peripheral blood at Day 7 after axicabtagene 
ciloleucel infusion will be summarized with descriptive statistics. 
10.7.10. 
Pharmacodynamics Analyses 
The levels of cytokines in sernm will be summai·ized with descriptive statistics. 
10.7.11. 
will be 
CONFIDENTIAL 
Page 67 
14 JUN 2022 


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 68
14 JUN 2022
11.
REGULATORY OBLIGATIONS
This study will be conducted in accordance with the protocol and with the following:

Consensus ethical principles derived from international guidelines including the Declaration 
of Helsinki

Applicable International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) 
Guidelines

Applicable local laws and regulations
11.1.
Independent Review Board/Independent Ethics Committee
A copy of the protocol, ICF, and any additional subject or trial information, such as subject 
recruitment materials, must be submitted to each site’s respective IRB/IEC for approval. After 
approval is obtained from the IRB/IEC, all documents must be provided to the key sponsor 
contact before subject recruitment can begin.
The investigator must also receive IRB/IEC approval for all protocol and ICF changes or 
amendments. Investigators must ensure that ongoing/continuous IRB/IEC approval (ie, annual 
approval) is provided throughout the conduct of the study. Copies of IRB/IEC approval are to be 
forwarded to the key sponsor contact for archiving.
During the course of the study, investigators will submit site-specific and study SAEs (provided 
to the site by the key sponsor contact) along with any protocol deviations to their IRB/IEC in 
accordance with their respective IRB/IEC policies. 
11.2.
Subject Confidentiality
Subject confidentiality must be maintained within all material that is submitted to the key 
sponsor contact. The following rules are to be applied.

Subjects will be identified by a unique ID number

Year of birth/age at time of enrollment will be reported according with local laws and 
regulations
For the reporting of SAEs, subjects will be identified by their respective subject ID number, 
initials, and year of birth (as per their local reporting requirements for both initials and year of 
birth).


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 69
14 JUN 2022
Per country-specific regulations and ICH/GCP guidelines, investigators and institutions are 
required to permit authorization to the sponsor, contract research organization, IRB/IEC, and 
regulatory agencies to subject’s original source documents for verification of study data. The 
investigator is responsible for informing potential subjects that such individuals will have access 
to their medical records, which includes personal information.
11.3.
Investigator Signatory Obligations
Each CSR will be signed by the coordinating investigator. The coordinating investigator will be 
identified by Kite under the following criteria:

Is a recognized expert in the disease setting

Provided significant contributions to the design or analysis of study data

Participated in the study and enrolled a high number of eligible subjects


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 70
14 JUN 2022
12.
PROTOCOL AMENDMENTS AND TERMINATION
If the protocol is amended, the investigator’s agreement with the amendment and the IRB/IEC 
approval of the amendment must be obtained. Documentation acknowledging approval from 
both parties are to be submitted to the key sponsor contact.
Both Kite Pharma and the investigator reserve the right to terminate the investigator’s 
participation in the study as per the terms of the agreement in the study contract. The investigator 
is to provide written communication to the IRB/IEC regarding either the trial completion or early 
termination and provide the contract research organization with a copy of the correspondence.
Kite Pharma reserves the unilateral right, at its sole discretion, to determine whether to 
manufacture axicabtagene ciloleucel and provide it to sites and subjects after the completion of 
the study.


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 71
14 JUN 2022
13.
STUDY DOCUMENTATION AND ARCHIVING
The investigator will maintain a list of qualified staff to whom study responsibilities have been 
delegated. The individuals authorized to fulfil these responsibilities should be outlined and 
included in the Delegation of Authority Form.
Source documents are original documents, data, and records for which the study data are 
collected and verified. Examples of such source documents may include, but are not limited to, 
hospital records and patient charts; laboratory, pharmacy, and radiology records; subject diaries; 
microfiches; correspondence; and death registries. CRF entries may be considered as source data 
if the site of the original data collection is not available. However, the use of the CRFs as source 
documentation is not recommended as a routine practice.
The investigator and study staff are responsible for maintaining a comprehensive and centralized 
filing system of all subject records that are readily retrieved to be monitored and or audited at 
any time by the key sponsor contact, health authorities, and IRB/IECs. The filing system will 
include at a minimum:

Subject content including ICFs and subject ID lists

Protocols and protocol amendments, IB, copies of pre-study documentation, and all IRB/IEC 
and sponsor communication

Proof of receipt, experimental treatment flow records, and experimental product-related 
correspondence
Original source documents supporting entries into CRFs must be maintained at the site and 
readily available upon request. No study documents should be discarded without prior written 
agreement between Kite and the investigator. If storage is no longer available to archive source 
documents, or if source documents must be moved to an alternative location, the research staff 
should notify the key sponsor contact prior to shipping the documents.


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 72
14 JUN 2022
14.
STUDY MONITORING AND DATA COLLECTION
The key sponsor contact, monitors, auditors, or regulatory inspectors are responsible for 
contacting, and visiting the investigator for the purpose of inspecting the facilities and verifying 
source documents and records must also assure that subject confidentially is respected.
The monitor is responsible for source document verification of CRF data at regular intervals 
during the study. Protocol adherence and accuracy and consistency of study conduct and data 
collection with respect to local regulations will be confirmed. Monitors will have access to 
subject records as identified in Section 13.
By signing the investigator’s agreement, the investigator agrees to cooperate with the monitor to 
address and resolve issues identified during monitoring visits.
In accordance with ICH/GCP and the audit plan, a site may be chosen for a site audit. A site 
audit would include, but is not limited to, an inspection of the facility(ies), review of subject- and 
study-related records, and compliance with protocol requirements as well as ICH/GCP and 
applicable regulatory policies.
All data will be collected in an electronic CRF system. All entries must be completed in English 
and concomitant therapies should be identified by tradenames. For further details surrounding 
the completion of CRFs, please refer to the CRF completion guidelines.


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 73
14 JUN 2022
15.
PUBLICATION
Authorship of publications from data generated in study KTE-C19-112 (ZUMA-12) will be 
determined based on the uniform requirements for manuscripts submitted to biomedical journals 
(as outlined in the International Committee of Medical Journal Editors December 2013), which 
states that authorship should be based on:

Substantial contributions to the conception or design of the work, acquisition of data, 
analysis, or interpretation of data for the work; and

Drafting the article or revising it critically for important intellectual content; and

Final approval of the version to be published; and

Agreement to be accountable for all aspects of the work in ensuring that questions related to 
the accuracy or integrity of any part of the work are appropriately investigated or resolved
When a large, multicenter group has conducted the work, the group should identify the 
individuals who accept direct responsibility for the manuscript. This individual should fully meet 
the criteria for authorship defined above.
Funding, collection of data, or general supervision of the research alone or in combination does 
not qualify an individual for authorship.
Any publication, in any form, that is derived from this study must be submitted to Kite for 
review and approval. The study contract among the institution, principal investigator, and Kite or 
its delegate will outline the requirements for publication review.


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 74
14 JUN 2022
16.
COMPENSATION
Kite will provide compensation for study-related illness or injury pursuant to the information 
outlined in the injury section of the ICF.


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 75
14 JUN 2022
17.
REFERENCES
Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Mueller SP, et al. Role 
of imaging in the staging and response assessment of lymphoma: consensus of the 
International Conference on Malignant Lymphomas Imaging Working Group. J 
Clin Oncol 2014;32 (27):3048-58.
Broyde A, Boycov O, Strenov Y, Okon E, Shpilberg O, Bairey O. Role and Prognostic 
Significance of the Ki-67 Index in Non-Hodgkin's Lymphoma. Am J Hematol 
2009;84 (6):338-43.
Casasnovas RO, Ysebaert L, Thieblemont C, Bachy E, Feugier P, Delmer A, et al. FDG-PET-
driven consolidation strategy in diffuse large B-cell lymphoma: final results of a 
randomized phase 2 study. Blood 2017;130 (11):1315-26.
Castro JE, James DF, Sandoval-Sus JD, Jain S, Bole J, Rassenti L, et al. Rituximab in 
combination with high-dose methylprednisolone for the treatment of chronic 
lymphocytic leukemia. Leukemia 2009;23 (10):1779-89.
Chaganti S, Illidge T, Barrington S, McKay P, Linton K, Cwynarski K, et al. Guidelines for the 
management of diffuse large B-cell lymphoma. Br J Haematol 2016;174 (1):43-
56.
Chen AI, Leonard JT, Okada CY, Gay ND, Chansky K, Fan G, et al. Outcomes of DA-EPOCH-
R induction plus autologous transplant consolidation for double hit lymphoma. 
Leuk Lymphoma 2017:1-6.
Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. 
Recommendations for initial evaluation, staging, and response assessment of 
Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 
2014;32 (27):3059-68.
Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised 
response criteria for malignant lymphoma. J Clin Oncol 2007;25 (5):579-86.
Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, et al. Long-term 
outcome of patients in the LNH-98.5 trial, the first randomized study comparing 
rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by 
the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 2010;116 (12):2040-5.
de Jonge AV, Roosma TJ, Houtenbos I, Vasmel WL, van de Hem K, de Boer JP, et al. Diffuse 
large B-cell lymphoma with MYC gene rearrangements: Current perspective on 
treatment of diffuse large B-cell lymphoma with MYC gene rearrangements; case 
series and review of the literature. Eur J Cancer 2016;55:140-6.


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 76
14 JUN 2022
de Oliveira Costa R, Hallack Neto A, Siqueira S, Lage LA, de Paula HM, Coutinho AM, et al. 
Interim Fluorine-18 Fluorodeoxyglucose PET-Computed Tomography and Cell of 
Origin By Immunohistochemistry Predicts Progression-Free and Overall Survival 
in Diffuse Large B-Cell Lymphoma Patients in the Rituximab Era. Nucl Med 
Commun 2016;37 (10):1095-101.
Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, et al. Adoptive cell therapy 
for patients with metastatic melanoma: evaluation of intensive myeloablative 
chemoradiation preparative regimens. J Clin Oncol 2008;26 (32):5233-9.
Flowers CR, Sinha R, Vose JM. Improving outcomes for patients with diffuse large B-cell 
lymphoma. CA Cancer J Clin 2010;60 (6):393-408.
Friedberg JW. How I treat double-hit lymphoma. Blood 2017;130 (5):590-6.
Gattinoni L, Finkelstein SE, Klebanoff CA, Antony PA, Palmer DC, Spiess PJ, et al. Removal of 
homeostatic cytokine sinks by lymphodepletion enhances the efficacy of 
adoptively transferred tumor-specific CD8+ T cells. J Exp Med 2005;202 (7):907-
12.
Green TM, Young KH, Visco C, Xu-Monette ZY, Orazi A, Go RS, et al. Immunohistochemical 
double-hit score is a strong predictor of outcome in patients with diffuse large B-
cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, 
vincristine, and prednisone. J Clin Oncol 2012;30 (28):3460-7.
Howlader N, Noone A, Krapcho M, Miller D, Bishop K, Altekruse S, et al. SEER Cancer 
Statistics Review, 1975-2013. National Cancer Institute. Bethesda, MD, 
http://seer.cancer.gov/csr/1975_2013/, based on November 2015 SEER data 
submission, posted to the SEER web site, April 2016. 2015.
International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for 
aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329 (14):987-94.
Itti E, Meignan M, Berriolo-Riedinger A, Biggi A, Cashen AF, Vera P, et al. An International 
Confirmatory Study of the Prognostic Value of Early PET/CT in Diffuse Large B-
cell Lymphoma: Comparison between Deauville Criteria and DeltaSUVmax. Eur 
J Nucl Med Mol Imaging 2013;40 (9):1312-20.
Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, et al. Gene therapy 
with human and mouse T-cell receptors mediates cancer regression and targets 
normal tissues expressing cognate antigen. Blood 2009;114 (3):535-46.
Klebanoff CA, Khong HT, Antony PA, Palmer DC, Restifo NP. Sinks, suppressors and antigen 
presenters: how lymphodepletion enhances T cell-mediated tumor 
immunotherapy. Trends Immunol 2005;26 (2):111-7.


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 77
14 JUN 2022
Kochenderfer JN, Somerville RPT, Lu T, Shi V, Bot A, Rossi J, et al. Lymphoma Remissions 
Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With 
High Serum Interleukin-15 Levels. J Clin Oncol 2017;35 (16):1803-13.
Leonard JP, Schattner EJ, Coleman M. Biology and management of mantle cell lymphoma. Curr 
Opin Oncol 2001;13 (5):342-7.
Locke F, Ghobadi A, Lekakis L, Miklos D, Jacobson C, E. J, et al. Outcomes by prior lines of 
therapy (LoT) in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel 
(Axi-Cel) in patients (Pts) with refractory large B cell lymphoma. J Clin Oncol 
2018;Abstract # 3039.
Locke FL, Neelapu SS, Bartlett NL, Lekakis LJ, Miklos D, Jacobson CA, et al. Primary Results 
From ZUMA-1: A Pivotal Trial of Axicabtagene Ciloleucel (Axi-cel; KTE-C19) 
in Patients With Refractory Aggressive Non-Hodgkin Lymphoma (NHL). 
American Association for Cancer Research (AACR) 2017;Abstract #CT019.
Mamot C, Klingbiel D, Hitz F, Renner C, Pabst T, Driessen C, et al. Final Results of a 
Prospective Evaluation of the Predictive Value of Interim Positron Emission 
Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-
CHOP-14 (SAKK 38/07). J Clin Oncol 2015;33 (23):2523-9.
Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma 
incidence patterns by WHO subtype in the United States, 1992-2001. Blood 
2006;107 (1):265-76.
NCCN. Clinical Practice Guidelines in Oncology; Non-Hodgkin's Lymphomas, Version 3. 2016.
Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene 
Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J 
Med 2017;377 (26):2531-44.
Nicholson IC, Lenton KA, Little DJ, Decorso T, Lee FT, Scott AM, et al. Construction and 
characterisation of a functional CD19 specific single chain Fv fragment for 
immunotherapy of B lineage leukaemia and lymphoma. Mol Immunol 1997;34 
(16-17):1157-65.
Nowakowski GS, Blum KA, Kahl BS, Friedberg JW, Baizer L, Little RF, et al. Beyond RCHOP: 
A Blueprint for Diffuse Large B Cell Lymphoma Research. J Natl Cancer Inst 
2016;108 (12).
O'Brien SM, Kantarjian HM, Cortes J, Beran M, Koller CA, Giles FJ, et al. Results of the 
fludarabine and cyclophosphamide combination regimen in chronic lymphocytic 
leukemia. J Clin Oncol 2001;19 (5):1414-20.


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 78
14 JUN 2022
Oki Y, Noorani M, Lin P, Davis RE, Neelapu SS, Ma L, et al. Double hit lymphoma: the MD 
Anderson Cancer Center clinical experience. Br J Haematol 2014;166 (6):891-
901.
Olejniczak SH, Stewart CC, Donohue K, Czuczman MS. A quantitative exploration of surface 
antigen expression in common B-cell malignancies using flow cytometry. 
Immunol Invest 2006;35 (1):93-114.
Petrich AM, Gandhi M, Jovanovic B, Castillo JJ, Rajguru S, Yang DT, et al. Impact of induction 
regimen and stem cell transplantation on outcomes in double-hit lymphoma: a 
multicenter retrospective analysis. Blood 2014;124 (15):2354-61.
Rodriguez J, Pugh WC, Romaguera JE, Cabanillas F. Primary mediastinal large cell lymphoma. 
Hematological Oncology 1994;12 (4):175-84.
Sehn LH, Gascoyne RD. Diffuse large B-cell lymphoma: optimizing outcome in the context of 
clinical and biologic heterogeneity. Blood 2015;125 (1):22-32.
Staiger AM, Ziepert M, Horn H, Scott DW, Barth TFE, Bernd HW, et al. Clinical Impact of the 
Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in 
Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of 
the German High-Grade Non-Hodgkin's Lymphoma Study Group. J Clin Oncol 
2017;35 (22):2515-26.
Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the 
World Health Organization classification of lymphoid neoplasms. Blood 
2016;127 (20):2375-90.
Tilly H, Vitolo U, Walewski J, da Silva MG, Shpilberg O, Andre M, et al. Diffuse large B-cell 
lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment 
and follow-up. Ann Oncol 2012;23 Suppl 7:vii78-82.
Uckun FM, Jaszcz W, Ambrus JL, Fauci AS, Gajl-Peczalska K, Song CW, et al. Detailed Studies 
on Expression and Function of CD19 Surface Determinant by Using B43 
Monoclonal Antibody and the Clinical Potential of Anti-CD19 Immunotoxins. 
Blood 1988;71 (1):13-29.
Wilson WH, sin-Ho J, N. PB, Hsi ED, Friedberg J, Cheson B, et al. Phase III Randomized Study 
of R-CHOP Versus DA-EPOCH-R and Molecular Analysis of Untreated Diffuse 
Large B-Cell Lymphoma: CALGB/Alliance 50303. Blood (ASH Annual Meeting 
Abstracts) 2016:Abstract #469 
YESCARTA, Kite Pharma Inc. YESCARTA® (axicabtagene ciloleucel) Suspension for 
Intravenous Infusion. U. S. Prescribing Information. Santa Monica, CA. Revised: 
May.  2019:


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 79
14 JUN 2022
Zhu D, Xu XL, Fang C, Ji M, Wu J, Wu CP, et al. Prognostic Value of Interim (18)F-FDG-PET 
in Diffuse Large B Cell Lymphoma Treated with Rituximab-Based Immune-
Chemotherapy: A Systematic Review and Meta-Analysis. Int J Clin Exp Med 
2015;8 (9):15340-50.
Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, Pfreundschuh M, et al. Standard 
International prognostic index remains a valid predictor of outcome for patients 
with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol 
2010;28 (14):2373-80.


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 80
14 JUN 2022
18.
APPENDICES
Appendix 1.
Lugano Classification {Cheson 2014}
Appendix 2.
International Prognostic Index in Aggressive Lymphomas
Appendix 3.
Country-Specific Regulatory Agency Requirements
Appendix 4.
Birth Control Methods Which May Be Considered as Highly Effective


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 81
14 JUN 2022
Appendix 1.
Lugano Classification {Cheson 2014}
Please refer to {Cheson 2014} for details of assessment.
Deauville 5-Point Scale (5PS) {Barrington 2014}
Score
Description 
1 
No uptake above background 
2 
Uptake ≤ mediastinum 
3 
Uptake > mediastinum but ≤ liver 
4 
Uptake moderately higher than liver 
5 
Uptake markedly higher than liver and/or new lesions
X 
New areas of uptake unlikely to be related to lymphoma  
Complete Remission:
Complete Metabolic Response for Positron Emission Tomography–Computed Tomography-
Based Response
The designation of complete metabolic response requires all of the following:

A 5PS (5-point scale) score of 1, 2 or 3, with or without a residual mass 
In Waldeyer’s ring or extranodal sites with high physiologic uptake or with activation 
within spleen or marrow, uptake may be greater than normal in the mediastinum and/or 
liver. In this circumstance, complete metabolic response may be inferred if uptake at sites 
of initial involvement is no greater than surrounding normal tissue even if the tissue has 
high physiologic uptake.

No new sites of disease should be observed 

No evidence of fluorodeoxyglucose (FDG)-avid disease in bone marrow
Complete Radiologic Response for Computed Tomography-Based Response 
The designation of complete radiologic response requires all of the following:

Target nodes/nodal masses must regress to ≤ 1.5 cm in longest transverse diameter (LDi) of a 
lesion

No extralymphatic sites of disease

Absent nonmeasured lesion


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 82
14 JUN 2022

Organ enlargement regress to normal

No new sites of disease should be observed

Bone marrow normal by morphology; if indeterminate, immunohistochemistry negative
Partial Remission: 
Partial Metabolic Response for Positron Emission Tomography–Computed Tomography-Based 
Response
The designation of partial metabolic response requires all of the following:

A 5PS score of 4 or 5, with reduced uptake compared to baseline (screening), and residual 
mass(es) of any size 
Note:
At interim, these findings suggest responding disease 
At end of treatment, these findings suggest residual disease 

No new sites of disease should be observed 

Residual uptake is higher than uptake in normal bone marrow but reduced compared with 
baseline (diffuse uptake is compatible with reactive changes from chemotherapy allowed)
If there are persistent focal changes in the marrow in the context of a nodal response, 
consideration should be given to further evaluation with magnetic resonance image or biopsy or 
an interval scan.
Partial Radiologic Response for Computed Tomography-Based Response 
The designation of partial radiologic response requires all of the following:

≥ 50% decrease in sum of the product of the perpendicular diameters of up to 6 target 
measurable nodes and extranodal sites 
When a lesion is too small to measure on a computed tomography scan, assign 5 mm x 
5 mm as the default value
When no longer visible, 0 x 0 mm
For a node > 5 mm x 5 mm, but smaller than normal, use actual measurement for 
calculation 

Absent/normal, regressed, but no increase of nonmeasured lesions

Spleen must have regressed by > 50% in length beyond normal 

No new sites of disease should be observed


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 83
14 JUN 2022
Stable Disease:
No Metabolic Response for Positron Emission Tomography–Computed Tomography-Based 
Response 
The designation of no metabolic response requires all of the following:

A 5PS score of 4 or 5, with no significant change in FDG uptake compared to baseline 
(screening) at an interim time point or end of treatment 

No new sites of disease should be observed 

No change from baseline in bone marrow
Stable Radiologic Disease for Computed Tomography-Based Response
The designation of stable radiologic disease requires all of the following:

< 50% decrease from baseline in the sum of the product of the perpendicular diameters of up 
to 6 dominant, measurable nodes and extranodal sites; no criteria for progressive disease are 
met

No increase consistent with progression in nonmeasured lesion and organ enlargement 

No new sites of disease should be observed 
Progressive Disease:
Progressive Metabolic Disease for Positron Emission Tomography–Computed 
Tomography-Based Response 
The designation of progressive metabolic disease requires at least 1 of the following:

A 5PS score 4 or 5 with an increase in intensity of uptake from baseline and/or

New FDG-avid foci consistent with lymphoma at interim or end of treatment assessment 

New FDG-avid foci consistent with lymphoma rather than another etiology (eg, infection, 
inflammation). If uncertain regarding etiology of new lesions, biopsy or interval scan may be 
considered

New or recurrent FDG-avid foci in bone marrow 


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 84
14 JUN 2022
Progressive Radiologic Disease for Computed Tomography-Based Response 
The designation of progressive radiologic disease requires at least one of the following:

An individual node/lesion must be abnormal with:
LDi > 1.5 cm and 
Increase by ≥ 50% from cross product of LDi and perpendicular diameter nadir and
An increase in LDi or SDi, shortest axis perpendicular to the LDi, (SDi) from nadir 
■
0.5 cm for lesions ≤ 2 cm
■
1.0 cm for lesions > 2 cm
In the setting of splenomegaly, the splenic length must increase by > 50% of the extent of 
its prior increase beyond baseline (eg, a 15-cm spleen must increase to > 16 cm). If no 
prior splenomegaly, spleen must increase by at least 2 cm from baseline 
New or recurrent splenomegaly

New or clear progression of pre-existing nonmeasured lesions

New lesion
Regrowth of previously resolved lesions
A new node > 1.5 cm in any axis
A new extranodal site > 1.0 cm in any axis; if < 1.0 cm in any axis, its presence must be 
unequivocal and must be attributable to lymphoma
Assessable disease of any size unequivocally attributable to lymphoma

New or recurrent bone marrow involvement


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 85
14 JUN 2022
Appendix 2.
International Prognostic Index in Aggressive Lymphomas
The International Prognostic Index (IPI) score is calculated by adding the number of prognostic 
factors:

Age > 60 years

Performance status ≥ 2

Lactate dehydrogenase > 1 x normal

Extranodal sites > 1

Stage III or IV
The IPI risk level is determined based on the IPI score: 
Risk Level
IPI Score
Low (L)
0 or 1
Low-intermediate (LI)
2
High-intermediate (HI)
3
High (H)
4 or 5


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 86
14 JUN 2022
Appendix 3.
Country-Specific Regulatory Agency Requirements 
France
The post-infusion monitoring of subjects, described in Section 7.10.3.2 of this protocol, will be 
extended by monitoring on Day 8, Day 9, and Day 10, according to procedures outlined in 
Table 3, column “Axicabtagene Ciloleucel Administration Period, D1 to 7.” The subject may 
stay hospitalized or return to the clinic daily for this extended monitoring at the discretion of the 
investigator.
The daily monitoring will include vital signs (see Section 7.6), blood draw for chemistry panel 
with C-reactive protein, blood draw for complete blood count with differential, and neurological 
examination (see Section 7.8). Any observed toxicity will be managed according to Section 6.1.8 
of this protocol.


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 87
14 JUN 2022
Appendix 4.
Birth Control Methods Which May Be Considered as Highly Effective
For the purpose of this guidance, methods that can achieve a failure rate of < 1% per year when 
used consistently and correctly are considered as highly effective birth control methods. Such 
methods include:

Combined (estrogen and progesterone containing) hormonal contraception associated with 
inhibition of ovulation1:
Oral
Intravaginal
Transdermal

Progestogen-only hormonal contraception associated with inhibition of ovulation2:
Oral 
Injectable
Implantable2

Intrauterine device2

Intrauterine hormone-releasing system2

Bilateral tubal occlusion2

Vasectomized partner2,3

Sexual abstinence4
1 Hormonal contraception may be susceptible to interaction with the investigational product, which may reduce the 
efficacy of the contraception method.
2 Contraception methods that in the context of this guidance are considered to have low user dependency.
3 Vasectomized partner is a highly effective birth control method provided that partner is the sole sexual partner of 
the woman of childbearing potential trial subject and that the vasectomized partner has received medical assessment 
of the surgical success.
4 In the context of this guidance sexual abstinence is considered a highly effective method only if defined as 
refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. The 
reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred 
and usual lifestyle of the subject.

Prot_000.pdf: 
CLINICAL STUDY PROTOCOL 
Protocol Title: A Phase 2 Multicenter Study Evaluating the Efficacy and 
Safety of Axicabtagene Ciloleucel as First-Line Therapy in 
Subjects with High-Risk Large B-Cell Lymphoma 
(ZUMA-12) 
Protocol Number: KTE-C19-112 
Indication: First-line ti·eatment of adult subjects with high-risk large 
B-cell lymphoma, including either high-grade B-cell 
lymphoma (HGBL) with MYC and BCL2 and/or BCL6 
ti·anslocations -, or large B-cell lymphoma with a high 
intennediate/high risk International Prognostic Index (IPI) 
score of::::: 3; all subjects must have positive positi·on 
emission tomography after 2 cycles (PET2+) of 
chemoimmunotherapy. 
Kite Investi2ational Product: Axicabtagene ciloleucel 
Company Code: KTE-C19 
IND Number: 016278 
EudraCT Number: 2019-002291-13 
Clinical Trials.2:ov Identifier: NCT03761056 
Sponsor: Kite Phanna, Inc. 
2400 Broadway 
Santa Monica, CA 90404 
Key Sponsor Contacts: fPD 
I 
Executive Director, Medical Affairs 
Kite Phanna, Inc. 
2400 Broadway 
Santa Monica, CA 90404 
Phone:PPD 
emailjPPD 
PPD 
I 
Clinical Program Manager, Clinical Operations 
Kite Phanna, Inc. 
2400 Broadway, Santa Monica, CA 90404 
Phone:PPD 
I 
Email JP PD 
I 
Ori2inal Protocol Date: 26 June 2018 
Amendment 1 14 August 2019 
Amendment 2: 25 March 2022 


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 2
25 March 2022
CONFIDENTIALITY NOTICE
This document contains confidential information of Kite Pharma, Inc., a wholly owned 
subsidiary of Gilead Sciences Inc. This document must not be disclosed to anyone other than the 
study site research staff, collaborators, and members of the Institutional Review 
Board/Independent Ethics Committee, a scientific review board, or an equivalent. The 
information in this document cannot be used for any purpose other than the conduct of the 
clinical investigation without the prior written consent of Kite Pharma, Inc.


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 3
25 March 2022
Sponsor and Investigator Signature Page
KITE PHARMA, INC.
2400 BROADWAY
SANTA MONICA, CA 90404
STUDY ACKNOWLEDGMENT
A Phase 2 Multicenter Study Evaluating the Efficacy and Safety of Axicabtagene Ciloleucel as 
First-Line Therapy in Subjects with High-Risk Large B-Cell Lymphoma (ZUMA 12)
Amendment 2.0, 25March 2022
This protocol has been approved by Kite Pharma, Inc. The following signature documents this 
approval.
Kite Medical Monitor Name (Printed) 
Signature
Date
INVESTIGATOR STATEMENT
I have read the protocol, including all appendices, and I agree that it contains all necessary 
details for me and my staff to conduct this study as described. I will conduct this study as 
outlined herein and will make a reasonable effort to complete the study within the time 
designated.
I agree to comply with the International Council for Harmonisation of Technical Requirements 
for Pharmaceuticals for Human Use  Harmonised Tripartite Guideline on Good Clinical Practice 
and applicable national or regional regulations and guidelines. I will provide all study personnel 
under my supervision copies of the protocol and access to all information provided by Kite 
Pharma, Inc. I will discuss this material with them to ensure that they are fully informed about 
the investigational product and study.
I agree and will ensure that financial disclosure statements will be completed by:

Me (including, if applicable, my spouse, legal partner, and dependent children)

Sub investigators (including, if applicable, their spouse, legal partner, and dependent 
children) at the start of the study and for up to 1 year after the study is completed.
I agree to ensure that the confidential information contained in this document will not be used for 
any purpose other than the conduct of the clinical investigation without prior written consent 
from Kite Pharma, Inc.
Principal Investigator Name (Printed)
Signature
Date
Study Site Number
PPD


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 4
25 March 2022
PROTOCOL SYNOPSIS
Title:
A Phase 2 Multicenter Study Evaluating the Efficacy and Safety 
of Axicabtagene Ciloleucel as First-Line Therapy in Subjects with 
High-Risk Large B-Cell Lymphoma (ZUMA-12)
Indication:
The indication is for the first-line treatment of adult subjects with 
high-risk large B-cell lymphoma, including either high-grade B-cell 
lymphoma (HGBL) with MYC and BCL2 and/or BCL6 translocations 
(hereafter referred to as double-hit or triple-hit lymphomas), or large 
B-cell lymphoma with a high intermediate/ high risk International 
Prognostic Index [IPI] score of ≥ 3; all subjects must have positive 
positron emission tomography after 2 cycles (PET2+) of 
chemoimmunotherapy.
Study Design:
Approximately 40 subjects with high-risk large B-cell lymphoma 
(either double-/triple-hit lymphomas, or high-risk large B-cell 
lymphoma with IPI score ≥3) will be enrolled and treated with 
cyclophosphamide and fludarabine conditioning chemotherapy, 
followed by a target dose of 2 x 106 anti-CD19 chimeric antigen 
receptor (CAR) T cells/kg body weight.
Each subject with a positive interim positron emission 
tomography-computed tomography (PET-CT) per the Lugano 
Classification {Cheson 2014} (Deauville 5-point scale PET score of 
4 or 5) after 2 cycles (PET2+) of chemoimmunotherapy will proceed 
through the following study periods:

Screening

Enrollment/Leukapheresis

Conditioning chemotherapy period

Investigational product treatment period

Post-treatment assessment period

Long-term follow-up (LTFU) period
Following at least 36 months of assessments, subjects who received 
an infusion of axicabtagene ciloleucel will complete the remainder of 
the 15-year follow-up assessments in the separate LTFU study, 
KT-US-982-5968.
For study requirements assigned to each study period, refer to 
Section 7 for details.
CCI


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 5
25 March 2022
A study schema is provided at the end of the protocol synopsis 
section.
Study Objectives:
The primary objective of the study is to estimate the efficacy of 
axicabtagene ciloleucel, as measured by complete response (CR) rate, 
in subjects with high-risk large B-cell lymphoma. Secondary 
objectives will include assessing the safety of axicabtagene ciloleucel 
and additional efficacy endpoints.
Hypothesis:
No formal hypothesis will be tested in this study. The study is 
designed to estimate the CR rate in subjects with high-risk large 
B-cell lymphoma treated with axicabtagene ciloleucel as first-line 
therapy.
Primary Endpoints:
CR rate: CR rate is defined as the incidence of a CR per the Lugano 
Classification {Cheson 2014} as determined by study investigators. 
All evaluable subjects who do not meet the criteria for a CR by the 
analysis data cutoff date will be considered nonresponders.
Secondary 
Endpoints:

Objective response rate (ORR): ORR is defined as the incidence 
of either a CR or a partial response per the Lugano Classification 
{Cheson 2014} as determined by study investigators

Duration of response (DOR)

Event-free survival (EFS)

Progression-free survival (PFS)

Overall survival (OS)

Incidence of adverse events (AEs) and clinical significant 
changes in safety laboratory values

Relapse with central nervous system (CNS) disease
Additional Secondary Endpoints

Pharmacokinetics (levels of anti-CD19 CAR T cells in blood)

Pharmacodynamics (levels of cytokines in serum)
Sample Size:
Approximately 40 enrolled and treated subjects
Study Eligibility:
Refer to Section 5 for a complete and detailed list of inclusion and 
exclusion criteria.


Axicabtagene Ciloleucel 
Clinical Protocol 
KTE-C19-l 12 (ZUMA-12) 
Kite Phruma, Inc. 
Treatment: Investigational Product: 
• 
Axicabtagene ciloleucel treatment consists of a single infusion of 
CAR transduced autologous T cells administered intravenously at 
a target dose of 2 x 106 anti-CD19 CART cells/kg. For subjects 
weighing 2::: 100 kg, a maximum flat dose of 2 x 108 anti-CD19 
CAR T cells will be administered. 
I 
I 
Procedures: At specific time points as outlined in the schedule of assessments, 
subjects will undergo the following assessments/procedures: 
collection of info1med consent, general medical histo1y including 
previous treatments for large B-cell lymphoma, physical exam 
including vital signs and Eastern Cooperative Oncology Group 
perfonnance status, neurologic examinations, blood draws for 
complete blood count, cheinistiy panels, cytokines, C-reactive 
protein, lymphocyte subsets, replication-competent retrovims and 
anti-CD 19 CAR T-cell analysis. 
CONFIDENTIAL 
Subjects will also undergo a baseline electrocardiogram, 
echocardiogram, PET-CT, and leukapheresis. Subjects may also need 
bone maiTow aspirate/biopsy, brain magnetic resonance image, and 
lumbar puncture. 
Routinely throughout the conduct of the study, subjects will be asked 
to repo1i concoinitant medications and AEs and will have their 
disease assessed. 
Page6 
25 Mru·ch 2022 


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 7
25 March 2022
Data Safety 
Monitoring  Board:
An independent Data Safety Monitoring Board (DSMB) will be 
chartered to meet and review the serious adverse events (SAEs) and 
suspected unexpected serious adverse reactions (SUSARs) on a semi-
annual basis after the first subject has been treated with axicabtagene 
ciloleucel up through the primary analysis. Kite Pharma, Inc., or 
delegate, will submit SAEs and SUSARs to the DSMB on a regular 
basis throughout the study up through the primary analysis. The 
DSMB will also meet to review safety data after 15 subjects have 
been enrolled and treated with axicabtagene ciloleucel and have had 
an opportunity to be followed for 3 months after axicabtagene 
ciloleucel infusion. The DSMB will make trial conduct 
recommendations on an ongoing basis based on an analysis of risk 
versus benefit. The DSMB may request additional safety data for 
review or recommend modifications to the study conduct if safety 
concerns are identified.
The DSMB may meet more often as needed. Refer to Section 9.10.
Statistical 
Considerations:
No formal hypothesis test will be performed. Analyses will be 
descriptive.
One planned interim analysis will be performed.

Interim Analysis 1 will be conducted after 15 subjects have been 
enrolled and treated with axicabtagene ciloleucel and have had an 
opportunity to be followed for 3 months after axicabtagene 
ciloleucel infusion. This analysis will be for efficacy and safety.
The primary endpoint for the study is CR rate per the Lugano 
Classification {Cheson 2014} as determined by study investigators.
The primary analysis will occur after all subjects treated with 
axicabtagene ciloleucel have an opportunity to be assessed for 
response 6 months after the Week 4 disease assessment.
The final analysis will occur when all subjects have had the 
opportunity to be followed for at least 36 months. Subjects treated 
with axicabtagene ciloleucel will be transitioned to the KT-US-982-
5968 study for the remainder of the 15-year LTFU period. 
Descriptive estimates of key efficacy and safety analyses may be 
updated to assess the overall treatment profile.


Axicabtagene Ciloleucel 
Clinical Protocol 
KTE-C19-l 12 (ZUMA-12) 
Kite Pha1ma, Inc. 
Figure 1. 
Study Schema 
Treatment Period: Axicabtagene Ciloleucel 
'"O 
0 
u 
Treatment 
·c 
.,, 
., 
>-.. 
'"O 
V) 
0.. 
Q) 
0 
..... 
/1., 
. .... 
V) 
ro 
1--< 
Q) 
tu 
..... 
Q) 
t 
i:: 
/1., 
..i:::: 
Q) 
..c: 
..... 
Subjects will receive a single infusion of axicabtagene 
E 
0.. 
Of) 
0.. 
0 
;:::l 
ro 
i= 
ciloleucel administered intravenously at a target dose of 
V) 
I 
C: 
3 
Q) 
V) 
·a 
Q) 
----. 
----. 
----. 
..i:::: 
2 x 106 anti-CD19 CART cells/kg on treatment Day 0. 
V) 
0 
Q) 
Q) 
u 
----. 
----. 
V) ----. -
ts 
<I:'. 
-
Q) 
0 
1--< 
Of) 
0 
..... 
µ.... 
1/J 
5 
.!: 
Subjects will receive axicabtagene ciloleucel in a 
i:: 
§ 
i:: 
Q) 
.§ 
0 
healthcare facility followed by a minimum 7-day 
i= 
:.a 
.p 
2 
0 
obse1vation pe1iod. 
ro 
I 
cl 
'"O 
Q) 
Of) 
i:: 
.p 
C: 
0 
I 
0 
..... 
u 
V) 
....:I 
0 
/1., 
Approximately 40 subjects who are either double hit/tdple hit or have IPI 2: 3 will be enrolled and treated. 
En.-ollment/Leukapheresis: Subjects who have a positive interim PET per the Lugano Classification {Cheson 2014} (Deauville PET score of 
4 or 5) after 2 cycles (PET2+) of an anti-CD20 monoclonal antibody and anthracycline-containing regimen per local standard of care 
I 
C 
d 
(eg, DA-EPOCH-R) if double hit/triple hit, or an anti-CD20 monoclonal antibody and anthracycline-containing regimen per local standard of 
care (eg, R-CHOP) iflarge B-cell lymphoma with IPI score c::: 3. 
Conditioning Chemotherapy: Subjects will receive a 3-day conditioning chemotherapy regimen consisting of fludarabine 30 mg/m2/day and 
cyclophosphamide 500 mg/m2/day (Day - 5 to Day -3) followed by 2 rest days (Day -2 and Day - 1). 
Long-term Follow-up Pe1iod: After the end of ZUMA-12, subjects who received an infusion of axicabtagene ciloleucel will complete the 
remainder of the 15-year follow-up assessments in a separate long-te1m follow-up study, KT-US-982-5968. 
CONFIDENTIAL 
Page8 
25 March 2022 


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 9
25 March 2022
TABLE OF CONTENTS
CLINICAL STUDY PROTOCOL..................................................................................................................................1
PROTOCOL SYNOPSIS................................................................................................................................................4
TABLE OF CONTENTS................................................................................................................................................9
LIST OF TABLES........................................................................................................................................................11
LIST OF FIGURES ......................................................................................................................................................11
LIST OF ABBREVIATIONS.......................................................................................................................................12
1.
OBJECTIVES.......................................................................................................................................................14
1.1.
Primary Objective....................................................................................................................................14
1.2.
Secondary Objective(s) ...........................................................................................................................14
2.
DISEASE BACKGROUND ................................................................................................................................15
2.1.
Disease Background ................................................................................................................................15
2.2.
Standard First-line Therapy.....................................................................................................................17
2.3.
Axicabtagene Ciloleucel..........................................................................................................................17
2.4.
Prior Anti-CD19 CAR T-cell Study Designs and Results.......................................................................18
3.
STUDY DESIGN AND RATIONALE................................................................................................................19
3.1.
General Study Design..............................................................................................................................19
3.2.
Study Design Rationale ...........................................................................................................................20
3.2.1.
Rationale for Conditioning Chemotherapy ...........................................................................21
3.2.2.
Rationale for Axicabtagene Ciloleucel Dose ........................................................................21
3.3.
Participating Sites....................................................................................................................................22
3.4.
Number of Subjects .................................................................................................................................22
3.5.
Replacement of Subjects .........................................................................................................................22
3.6.
Study Duration.........................................................................................................................................22
3.6.1.
Study Duration for Individual Subjects.................................................................................22
3.6.2.
Completion of Study..............................................................................................................23
4.
SUBJECT IDENTIFICATION ASSIGNMENT .................................................................................................24
5.
SUBJECT ELIGIBILITY.....................................................................................................................................25
5.1.
Inclusion Criteria.....................................................................................................................................25
5.2.
Exclusion Criteria....................................................................................................................................26
6.
PROTOCOL TREATMENT................................................................................................................................29
6.1.
Study Treatment ......................................................................................................................................29
6.1.1.
Leukapheresis........................................................................................................................29
6.1.3.
Conditioning Chemotherapy .................................................................................................30
6.1.4.
Axicabtagene Ciloleucel........................................................................................................31
6.1.5.
Concomitant Therapy ............................................................................................................31
6.1.6.
Excluded Medications ...........................................................................................................32
6.1.7.
Subsequent Therapy ..............................................................................................................33
6.1.8.
Toxicity Management............................................................................................................33
7.
STUDY PROCEDURES......................................................................................................................................34
7.1.
Informed Consent ....................................................................................................................................34
CCI
CCI


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 10
25 March 2022
7.2.
Screening .................................................................................................................................................34
7.2.1.
Rescreening ...........................................................................................................................35
7.3.
Demographic Data...................................................................................................................................35
7.4.
Medical and Treatment History...............................................................................................................35
7.5.
Conditioning Chemotherapy and Axicabtagene Ciloleucel Infusion......................................................35
7.5.1.
Requirements for Initiating Conditioning Chemotherapy.....................................................36
7.5.2.
Requirements for Initiating Axicabtagene Ciloleucel Infusion.............................................37
7.5.3.
Requirements to Work-up Potential Infectious and/or Inflammatory States ........................38
7.5.4.
Conditioning Chemotherapy Administration (Day –5 Through Day –3 
Prior to Axicabtagene Ciloleucel Infusion)...........................................................................39
7.6.
Physical Exam, Vital Signs, and Performance Status .............................................................................39
7.7.
Cardiac Function .....................................................................................................................................40
7.8.
Neurological Examination.......................................................................................................................40
7.9.
Disease Assessment.................................................................................................................................40
7.9.1.
Imaging..................................................................................................................................40
7.9.2.
Determination of Bone Marrow Involvement .......................................................................41
7.10.
Cell Collection and Axicabtagene Ciloleucel Study Treatment Schedule and Administration ..............42
7.10.1.
Leukapheresis........................................................................................................................42
7.10.3.
Axicabtagene Ciloleucel Treatment Period...........................................................................43
7.11.
Laboratory ...............................................................................................................................................45
7.11.1.
Local Laboratory Analysis ....................................................................................................45
7.11.2.
Central Laboratory Analyses.................................................................................................45
7.12.
Post-treatment Assessment Period ..........................................................................................................48
7.13.
Long-term Follow-up Period...................................................................................................................49
7.14.
Summary of Scheduled Assessments ......................................................................................................49
8.
SUBJECT WITHDRAWAL ................................................................................................................................55
8.1.
Reasons for Removal from Treatment ....................................................................................................55
8.2.
Reasons for Removal from Study............................................................................................................56
9.
SAFETY REPORTING........................................................................................................................................57
9.1.
Adverse Events........................................................................................................................................57
9.2.
Reporting of Adverse Events...................................................................................................................57
9.2.1.
Reporting Abnormal Laboratory Findings ............................................................................58
9.3.
Definition of Serious Adverse Events .....................................................................................................59
9.4.
Reporting of Serious Adverse Events......................................................................................................60
9.5.
Reporting Deaths.....................................................................................................................................60
9.6.
Diagnosis Versus Signs and Symptoms ..................................................................................................61
9.7.
Pregnancy and Lactation .........................................................................................................................61
9.8.
Hospitalization and Prolonged Hospitalization.......................................................................................62
9.9.
Abnormal Vital Sign Values ...................................................................................................................62
9.10.
Data Safety Monitoring Board ................................................................................................................62
10.
STATISTICAL CONSIDERATIONS.................................................................................................................64
10.1.
Hypothesis ...............................................................................................................................................64
10.2.
Study Endpoints.......................................................................................................................................64
10.2.1.
Primary Endpoint...................................................................................................................64
10.2.2.
Secondary Endpoints.............................................................................................................64
10.2.4.
Covariates and Subgroups .....................................................................................................65
10.3.
Sample Size Considerations ....................................................................................................................66
10.4.
Access to Individual Subject Treatment Assignments ............................................................................66
10.5.
Interim Analysis and Early Stopping Guidelines ....................................................................................66
CCI
CCI


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 11
25 March 2022
10.6.
Analysis Subsets......................................................................................................................................67
10.7.
Planned Method of Analysis ...................................................................................................................67
10.7.1.
CR Rate .................................................................................................................................67
10.7.2.
ORR.......................................................................................................................................67
10.7.3.
DOR.......................................................................................................................................68
10.7.4.
EFS ........................................................................................................................................68
10.7.5.
PFS ........................................................................................................................................68
10.7.6.
OS..........................................................................................................................................68
10.7.7.
Relapse with CNS Disease ....................................................................................................68
10.7.8.
Safety.....................................................................................................................................69
10.7.9.
Pharmacokinetic Analysis .....................................................................................................69
10.7.10.
Pharmacodynamics Analyses ................................................................................................69
11.
REGULATORY OBLIGATIONS.......................................................................................................................70
11.1.
Independent Review Board/Independent Ethics Committee...................................................................70
11.2.
Subject Confidentiality............................................................................................................................70
11.3.
Investigator Signatory Obligations..........................................................................................................71
12.
PROTOCOL AMENDMENTS AND TERMINATION .....................................................................................72
13.
STUDY DOCUMENTATION AND ARCHIVING............................................................................................73
14.
STUDY MONITORING AND DATA COLLECTION......................................................................................74
15.
PUBLICATION ...................................................................................................................................................75
16.
COMPENSATION...............................................................................................................................................76
17.
REFERENCES.....................................................................................................................................................77
18.
APPENDICES......................................................................................................................................................82
Appendix 1.
Lugano Classification {Cheson 2014} ....................................................................................83
Appendix 2.
International Prognostic Index in Aggressive Lymphomas.....................................................87
Appendix 3.
Country-Specific Regulatory Agency Requirements ..............................................................88
Appendix 4.
Birth Control Methods Which May Be Considered as Highly Effective................................89
LIST OF TABLES
Table 2.
Clinical Laboratory Parameters...............................................................................................45
Table 3.
Schedule of Assessments.........................................................................................................50
Table 4.
Long-term Follow-up Assessments.........................................................................................53
Table 5.
Lower and Upper Limits of 80%/95% CIs for CR Rates from 60% to 100% for a 
Sample of 40 Subjects .............................................................................................................66
LIST OF FIGURES
Figure 1.
Study Schema ............................................................................................................................8
Figure 2.
International Prognostic Index in Aggressive Lymphomas.....................................................16
CCI
CCI


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 12
25 March 2022
LIST OF ABBREVIATIONS
Abbreviation 
Definition
5PS
5-point scale
ABC
activated B-cell
AE
adverse event
BP
blood pressure
CAR
chimeric antigen receptor 
CBC
complete blood count
CD
cluster of differentiation
CHOP
cyclophosphamide, doxorubicin, vincristine, prednisone 
CI
confidence interval
CNS
central nervous system
CR
complete response
CRF
case report form
CRP
C-reactive protein
CRS
cytokine release syndrome
CSF
cerebrospinal fluid
CSR
clinical study report
CT
computed tomography
CTCAE
Common Terminology Criteria For Adverse Events 
DA-EPOCH-R
dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, 
rituximab
DH
double-hit
DLBCL
diffuse large B-cell lymphoma
DOR
duration of response 
DSMB
Data Safety Monitoring Board
ECHO
echocardiogram
ECOG
Eastern Cooperative Oncology Group
eCRF
electronic case report form
EFS
event-free survival
FDA
Food and Drug Administration
FDG
fluorodeoxyglucose 
GCB
germinal center B-cell
GCP
Good Clinical Practice
GELA
Groupe d’Etude des Lymphomes de l’Adulte
HIV
human immunodeficiency virus
HDMP
high-dose methylprednisolone
HEENT
head, eyes, ears, nose, and throat
HGBL
high-grade B-cell lymphoma
HR
heart rate
IB
Investigator’s Brochure  


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 13
25 March 2022
ID
identification
ICF
informed consent form
ICH
International Conference on Harmonisation
IEC
independent ethics committee
IL
interleukin 
IPI
International Prognostic Index
IPM
investigational product manual
IRB
institutional review board
IRC
independent review committee
IV
intravenous
IWG
international working group
LDi
longest transverse diameter
LTFU
long-term follow-up
MCP
monocyte chemoattractant protein
NCI
National Cancer Institute
NHL
non-Hodgkin lymphoma
NOS
not otherwise specified
ORR
objective response rate 
OS
overall survival
PBMC
peripheral blood mononuclear cell
PCR
polymerase chain reaction
PD
progressive disease
PET-CT
positron emission tomography–computed tomography
PFS
progression-free survival
PK
pharmacokinetic
PMBCL
primary mediastinal B-cell lymphoma 
PMD
progressive metabolic disease 
PR
partial response
PFS
progression-free survival
R-CHOP
rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone
R-ACVBP
rituximab, doxorubicin, cyclophosphamide, vindesine, bleomycin, prednisone
RCR 
replication-competent retrovirus
SAE
serious adverse event
SCT
stem cell transplant
SDi
shortest transverse diameter
SOA
schedule of assessments
SUSAR
suspected unexpected serious adverse reactions
ULN
upper limit of normal
WBC
white blood cell
WHO
World Health Organization


Axicabtagene Ciloleucel 
Clinical Protocol 
KTE-C19-l 12 (ZUMA-12) 
L 
OBJECTIVES 
1.1. 
Primary Objective 
Kite Phruma, Inc. 
• 
To estimate the efficacy of axicabtagene ciloleucel, as measured by CR rate, in subjects with 
high-risk large B-cell lymphoma, as determined by study investigators 
1.2. 
Secondary Objective(s) 
• 
To characterize the safety profile, and to further characterize efficacy with secondaiy 
endpoints; fmther secondaiy objectives will include phaimacokinetic/phaim acodynamic 
endpoints 
I 
CONFIDENTIAL 
Page 14 
25 Mru·ch 2022 


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 15
25 March 2022
2.
DISEASE BACKGROUND
2.1.
Disease Background
Non-Hodgkin lymphoma (NHL) comprises a heterogeneous group of cancers originating 
primarily in B lymphocytes, and to a lesser extent, in T lymphocytes and natural killer cells. 
NHL is the most prevalent hematological malignancy and is the seventh most common new 
cancer among men and women, accounting for 4% of all new cancer cases and 3% of 
cancer-related deaths {Howlader 2015}. Diffuse large B-cell lymphoma (DLBCL) is the most 
common subtype of B-cell NHL, accounting for approximately 30% to 40% of all cases across 
regions {Chaganti 2016, Morton 2006, Sehn 2015, Tilly 2012}. DLBCL can be further divided 
into subtypes based on factors including cytology, site of origin, and clinical background. 
Nevertheless, most cases are classified as DLBCL-not otherwise specified (NOS). The 2016 
revision of the World Health Organization (WHO) classification of lymphomas included 2 new 
subcategories of DLBCL-NOS by cell of origin: activated B-cell (ABC) and germinal center 
B-cell (GCB). Per the new classification system, DLBCL-NOS also includes those with MYC or 
BCL-2 protein overexpression, which has been suggested to confer worse outcome in patients 
treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) 
as first-line therapy {Swerdlow 2016}.
The 2016 revision of the WHO classification for lymphomas also included a new category, 
high-grade B-cell lymphoma (HGBL), which accounts for < 10% of DLBCL cases and is now 
considered distinct from DLBCL {Friedberg 2017, Swerdlow 2016}. HGBL includes 
2 subcategories, the first of which is characterized by gene rearrangements of MYC and BCL-2 
and/or BCL-6 (ie, double- or triple-hit lymphomas, depending on the number of rearrangements 
present). The second category lacks these rearrangements and is characterized by the presence of 
Ki67 protein (HGBL-NOS) {Broyde 2009, Swerdlow 2016}. Double- and triple-hit lymphomas 
typically do not respond to rituximab-based chemoimmunotherapy and are more likely to involve 
the central nervous system (CNS) {Friedberg 2017}. Only 40% and 41% of patients with MYC 
translocations and with double-hit lymphoma, respectively, were alive 2 years following 
first-line treatment {de Jonge 2016, Oki 2014}. Retrospective studies suggest a benefit of 
aggressive induction regimens, and consideration is even given for consolidation with high-dose 
therapy and transplant in select cases {Chen 2017, Friedberg 2017}.
The International Prognostic Index (IPI) is widely used for risk stratification of patients with 
aggressive B-cell lymphoma. In the original study of 2031 patients of all ages, the prognostic 
model, based on age, tumor stage, serum lactate dehydrogenase concentration, performance 
status, and number of extranodal disease sites, identified 4 risk groups of low, low-intermediate, 
high-intermediate, and high with predicted 5-year survival rates of 73%, 51%, 43%, and 26%, 
respectively {International Non-Hodgkin's Lymphoma Prognostic Factors Project 1993} 
(Figure 2). The IPI also remains a valid predictor of outcome in the rituximab era, independent of 
double-hit status and cell of origin (eg, GCB and ABC subtypes) {Staiger 2017, Ziepert 2010}.


Axicabtagene Ciloleucel 
Clinical Protocol 
KTE-C19-l 12 (ZUMA-12) 
Kite Phruma, Inc. 
Figure 2. 
International Prognostic Index in Aggressive Lymphomas 
(/J -
C 
:.:; 
«' 
a. -
0 
-::R. 
0 
0 
0 
2 
Overall Survival 
4 
L 
LI 
----HI 
H 
6 
8 
Death Rate per Year 
10 
2 
4 
6 
8 
10 
Year 
Prognostic factors: age > 60 years; pe1fo1mance status:;:: 2; lactate dehydrogenase > I x nonnal; extranodal sites> I; Stage III or 
IV 
Risk category (number of factors): Low (L: 0 or I) I Low-intermediate (LI; 2); High-intenuediate (HI; 3); High (H; 4 or 5) 
[Intemational NHL Prognostic Factors Project. N Engl J Med. 1993;329:987-94] 
A number of recent studies have assessed the role of early PET-CT using visual analysis by 
Deauville criteria {Banington 2014} to further predict patients with large B-cell lymphoma 
treated with rituximab-containing regimens who may be at higher risk. An international 
retrospective conf111nato1y study reported that early positive PET-CT after 2 induction cycles 
(PET2+) had prognostic value in DLBCL when there is no change in therapy: the 3-year PFS 
estimate was 59% in PET2+ patients versus 81 % in PET2-negative (PET2- ) patients (P = 0.003) 
{Itti 2013}. A meta-analysis of 11 studies revealed higher CR rates in the early ( after 2 to 
4 induction cycles) PET-negative group compared with the early PET-positive group (relative 
risk: 5.5, 95% confidence interval [CI]: 2.59 to 11.80) {Zhu 2015}. A prospective study in 
DLBCL patients assessed PET2 by central review, and found a 2-year EFS rate of 48% for 
PET2+ patients and 74% for PET2- patients (P = 0.004) {Mamot 2015}. Another prospective 
study in DLBCL patients revealed PET2 results to be prognostic for PFS based on cell of origin, 
with a 30-month PFS of 60% for PET2+ patients vs. 100% for PET2- patients with GCB 
DLBCL (P = 0.001) {de Oliveira Costa 2016}. Based on the results of these studies, patients 
with large B-cell lymphoma who are PET2+ based on Deauville criteria appear to have a worse 
prognosis compared with patients who are PET2- and represent a subgroup with a high unmet 
medical need. 
This study will emoll patients with high-risk large B-cell lymphoma, defined as either 
double-/triple-hit lymphoma or large B-cell lymphoma with high-intennediate and high risk 
(IPI 
3). All study subjects must also be PET2+. Given the poor outcomes observed with 
cmTently available therapies, this group has a high need for more effective treatment. 
CONFIDENTIAL 
Page 16 
25 Mru·ch 2022 


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 17
25 March 2022
2.2.
Standard First-line Therapy
Since the 1970s, chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone 
(CHOP) had been standard-of-care first-line therapy for patients with DLBCL. More intensive 
combinations failed to show additional survival benefit. The current standard of care for first-line 
treatment is CHOP in combination with the anti-CD20 monoclonal antibody rituximab 
(R-CHOP, rituximab-based chemoimmunotherapy) {Flowers 2010}. In the seminal study by the 
Groupe d’Etude des Lymphomes de l’Adulte (GELA), first-line R-CHOP was superior to CHOP, 
with 10-year overall survival (OS) and progression-free survival (PFS) of 43.5% vs 27.6% and 
36.5% vs 20.1%, respectively {Coiffier 2010}. Thus, while more effective than chemotherapy 
alone, first-line R-CHOP still only results in long-term disease remission in < 40% of subjects. 
Recently a Phase 3 trial of first-line R-CHOP versus dose-adjusted etoposide, prednisone, 
vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-EPOCH-R) demonstrated no 
difference in event-free survival (EFS) or OS between the regimens {Wilson 2016}.
Patients with double- and triple-hit lymphomas have been shown to have a poor prognosis with 
R-CHOP chemoimmunotherapy, and there is no established standard of care {Green 2012, 
NCCN 2016}. In a large retrospective study of patients with double-hit lymphoma, there was no 
apparent benefit with the more aggressive induction regimen DA-EPOCH-R, compared with 
standard R-CHOP, with a median OS of 30 months and 34 months, respectively {Petrich 2014}. 
In the GELA randomized Phase 2 study, which evaluated the efficacy of rituximab, doxorubicin, 
cyclophosphamide, vindesine, bleomycin, and prednisone (R-ACVBP) or R-CHOP-14 induction 
using IWG (International Working Group) 2007 criteria in young patients with high-risk 
DLBCL, the primary objective of achieving a higher than 50% CR rate after 4 cycles of 
induction regimen was not met in either randomization group {Casasnovas 2017}.
Unfortunately, there are no published prospective trials in the setting of double- or triple-hit 
lymphoma. These patients represent the greatest unmet clinical need in DLBCL according to a 
recent clinical trials planning meeting from the National Cancer Institute National Clinical Trials 
Network, and prospective randomized trials are currently being developed for double-hit 
lymphoma {Nowakowski 2016}.
2.3.
Axicabtagene Ciloleucel
On 18 October 2017, the Food and Drug Administration (FDA) granted regulatory approval to 
axicabtagene ciloleucel for the treatment of adult patients with relapsed or refractory large B-cell 
lymphoma after 2 or more lines of systemic therapy, including DLBCL-NOS, primary 
mediastinal large B-cell lymphoma (PMBCL), HGBL, and DLBCL arising from follicular 
lymphoma {YESCARTA 2019}.
Axicabtagene ciloleucel is a chimeric antigen receptor (CAR) T-cell immunotherapy. It consists 
of autologous T cells that are genetically modified to produce a CAR protein, allowing the 
T cells to identify and eliminate CD19-expressing normal and malignant cells. CD19 is expressed 
by most B-cell malignancies {Johnson 2009, Leonard 2001, Olejniczak 2006, Rodriguez 1994, 
Uckun 1988} as well as all normal B lymphocytes in peripheral blood and spleen, but not by 
granulocytes, monocytes, platelets, erythrocytes, and T lymphocytes {Uckun 1988}. Briefly, the 


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 18
25 March 2022
anti-CD19 CAR comprises the following domains: an anti-human CD19 single-chain variable 
region fragment derived from the murine monoclonal antibody FMC63; the partial extracellular 
domain and complete transmembrane and intracellular signaling domains of human CD28, a 
lymphocyte costimulatory receptor that plays an important role in optimizing T-cell survival and 
function; and the cytoplasmic portion, including the signaling domain, of human CD3ζ, a 
component of the T-cell receptor complex {Nicholson 1997}. Following CAR engagement with 
CD19+ target cells, the CD3ζ domain activates a downstream signaling cascade that leads to 
T-cell activation, proliferation, and acquisition of effector function.
Approval was based on ZUMA-1, a single-arm multicenter trial of 101 adult patients with 
aggressive B-cell NHL. Eligible patients had refractory disease to the most recent therapy or 
relapse within 1 year after autologous hematopoietic stem cell transplantation. Patients received 
a single infusion of axicabtagene ciloleucel following completion of conditioning chemotherapy. 
Efficacy was established on the basis of an objective response rate (ORR) of 72% with a 
complete response (CR) rate of 51%, as determined by an independent review committee (IRC) 
per {Cheson 2007, YESCARTA 2019}. In addition, the median duration of response (DOR) by 
IRC assessment per {Cheson 2007} was 9.2 months. The DOR was longer in patients with a best 
overall response of CR, as compared to a best overall response of partial remission 
{YESCARTA 2019}.
The most common Grade 3 or higher adverse reactions (incidence of 10% or greater) include 
febrile neutropenia, fever, cytokine release syndrome (CRS), encephalopathy, infections-
pathogen unspecified, hypotension, hypoxia, and lung infections. Serious adverse reactions 
occurred in 52% of patients and the most common serious adverse reactions (> 2%) included 
encephalopathy, fever, lung infection, febrile neutropenia, cardiac arrhythmia, cardiac failure, 
urinary tract infection, renal insufficiency, aphasia, cardiac arrest, Clostridium difficile infection, 
delirium, hypotension, and hypoxia. Fatal cases of CRS and neurologic toxicity occurred. The 
FDA approved axicabtagene ciloleucel with a Risk Evaluation and Mitigation Strategy 
{YESCARTA 2019}.
The dose of axicabtagene ciloleucel is a single intravenous (IV) infusion with a target of 
2 x 106 CAR-positive viable T cells per kg body weight (maximum 2 x 108 CAR-positive viable 
T cells per kg body weight), preceded by fludarabine and cyclophosphamide conditioning 
chemotherapy. Axicabtagene ciloleucel is not indicated for the treatment of patients with primary 
CNS lymphoma. Additional details regarding the mechanism of action and clinical results of 
axicabtagene ciloleucel can be found in the Investigator’s Brochure (IB).
2.4.
Prior Anti-CD19 CAR T-cell Study Designs and Results
Refer to the current axicabtagene ciloleucel IB for the most current anti-CD19 CAR T-cell 
nonclinical and clinical information.


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 19
25 March 2022
3.
STUDY DESIGN AND RATIONALE
3.1.
General Study Design
Study KTE-C19-112 (ZUMA-12) is a Phase 2 multicenter, open-label study evaluating the 
efficacy and safety of axicabtagene ciloleucel as first-line therapy in adult subjects with high-risk 
large B-cell lymphoma, including either HGBL with MYC and BCL2 and/or BCL6 translocations 
(double-/triple-hit lymphomas) or large B-cell lymphomas with high-intermediate-/high-risk IPI 
scores (≥ 3). Approximately 40 subjects will be enrolled upon a positive interim PET per the 
Lugano Classification {Cheson 2014} (Deauville 5-point scale [5PS] PET score of 4 or 5) after 
2 cycles (PET2+) of standard-of-care chemoimmunotherapy.
Subjects will proceed through the following study periods:

Screening

Enrollment/Leukapheresis

Conditioning chemotherapy period

Investigational product treatment period

Post-treatment assessment period

Long-term follow-up (LTFU) period
At the end of ZUMA-12, subjects who received an infusion of axicabtagene ciloleucel will 
complete the remainder of the 15-year follow-up assessments in a separate LTFU study, 
KT-US-982-5968.
An independent Data Safety Monitoring Board (DSMB) will be chartered to meet and review the 
serious adverse events (SAEs) and suspected unexpected serious adverse reactions (SUSARs) on 
a semi-annual basis after the first subject has been treated with axicabtagene ciloleucel up 
through the primary analysis. Kite Pharma, Inc. (hereafter referred to as Kite or Kite Pharma), or 
delegate, will submit SAEs and SUSARs to the DSMB on a regular basis throughout the study 
up through the primary analysis. The DSMB will also meet to review safety data after 
15 subjects have been enrolled and treated with axicabtagene ciloleucel and have had an 
opportunity to be followed for 3 months after axicabtagene ciloleucel infusion. The DSMB will 
make trial conduct recommendations on an ongoing basis based on an analysis of risk versus 
benefit. The DSMB may request additional safety data for review or recommend modifications 
to the study conduct if safety concerns are identified. Refer to Section 9.10 for further details. 
For study requirements assigned to each study period, refer to the schedule of assessments 
(SOA) (Table 3) and Section 7 for details.
CCI


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 20
25 March 2022
A study schema is described in Figure 1.
3.2.
Study Design Rationale
ZUMA-12 is an open-label, single-arm study evaluating the efficacy and safety of axicabtagene 
ciloleucel as first-line therapy in adult subjects with high-risk large B-cell lymphoma (ie, 
double-/triple-hit lymphomas or large B-cell lymphoma with IPI scores ≥ 3).
Patients with high-risk large B-cell lymphoma have an increased risk of relapse and death due to 
disease progression after first-line rituximab-based chemoimmunotherapy. This was recently 
demonstrated in a randomized study in high-risk DLBCL patients who had a change of therapy 
based on interim PET results {Casasnovas 2017}. LNH 2007-3B was a GELA randomized 
Phase 2 study that evaluated the efficacy of either R-ACVBP or R-CHOP-14 induction and a 
PET-driven autologous stem cell transplant (auto-SCT) or standard chemoimmunotherapy 
consolidation in young patients (18 to 59 years old) with high-risk DLBCL and 2 or 3 risk 
factors (age-adjusted IPI 2 or 3). PET was performed at baseline, after 2 (PET2) and 4 (PET4) 
induction cycles, with central review. At the end of induction treatment, the CR rate according to 
IWG 2007 criteria {Cheson 2014} was 47% (51 of 109 subjects) with R-ACVBP (95% CI, 38% 
to 67%) and 39% (40 of 102 subjects) with R-CHOP-14 (95% CI, 28% to 54%; P = 0.76). The 
primary objective of achieving a higher than 50% CR rate after 4 cycles of induction was not met 
in either randomization group. In this study, PET2 was positive in 66% (72 of 109 subjects) and 
71% (72 of 102 subjects) in the R-ACVBP and the R-CHOP-14 groups, respectively 
{Casasnovas 2017}. Based on the results of the LNH 2007-3B study, as well as several earlier 
studies which assessed the role of early PET-CT {de Oliveira Costa 2016, Itti 2013, Mamot 
2015, Zhu 2015}, patients with high-risk large B-cell lymphoma who also have not achieved CR 
based on dynamic PET-CT assessment may have a worse prognosis and represent a subgroup 
with a high unmet medical need. Because these patients are at higher risk of becoming resistant 
to chemoimmunotherapy, they may benefit from therapies with different mechanisms of action.
Immunotherapy, which is based on the enhancement of an immune response against the tumor, is 
a promising approach to treating many cancer types. T cells play an important role in destroying 
diseased cells throughout the body. Studies with immune checkpoint inhibitors and bi-specific 
T-cell engagers have demonstrated the potential of T cells to treat cancer. T cells need to possess 
the appropriate specificity for a tumor, be present in sufficient numbers, and overcome any local 
immunosuppressive factors to be effective. CAR-engineered T cells may address these issues 
and are an approach for cancer therapy.
Axicabtagene ciloleucel is an engineered autologous T-cell immunotherapy in which a patient’s 
own T cells are collected and subsequently genetically altered to recognize CD19. CD19 is 
expressed on the cell surface of B-cell malignancies and normal B cells. In the pivotal ZUMA-1 
Phase 1/2 trial, the safety and efficacy of axicabtagene ciloleucel were evaluated in patients with 
refractory DLBCL, primary mediastinal B-cell lymphoma (PMBCL), and transformed follicular 
lymphoma. In ZUMA-1, the ORR was 72% with a CR rate of 51%, as determined by an IRC per 
IWG 2007 criteria {Cheson 2007} and met the primary endpoint {YESCARTA 2019}. Further, 
in ZUMA-1, the ongoing durable remissions have been comparable across key covariates 
including IPI and gene expression profiling of ABC and GCB subtypes {Neelapu 2017}. Similar 


Axicabtagene Ciloleucel 
Clinical Protocol 
KTE-C19-l 12 (ZUMA-12) 
Kite Phruma, Inc. 
improved outcomes might be expected in double-/triple-hit lymphoma and in high and 
high-inte1mediate risk IPL 
Axicabtagene ciloleucel may also have improved efficacy and tolerabili 
chemo-refracto1 disease or in atients with lower disease burden 
follow-up, 67% ongoing response was observed in the first quaii ile compai·ed to 27% for the 
fomth quaitile. On the other hand, Grade 3 or higher CRS and neurologic events occmTed less 
frequently in patients with lower quaitiles of tumor burden: 4% and 7%, respectively, for the first 
quaiiile compared to 12% and 31%, respectively, for the fomth quaiiile {Locke 2018}. 
Patients with double-/triple-hit lymphoma or high-inte1mediate-/high-risk IPI (IPI score ~ 3) 
have a high unmet medical need. Therefore, axicabtagene ciloleucel will be assessed as first-line 
treatment in these high-risk lai·ge B-cell lymphoma patients who are also PET positive after 
2 cycles (PET2+) of standard-of-care chemoimmunotherapy. 
3.2.1. 
Rationale for Conditioning Chemotherapy 
Increasing levels of conditioning chemotherapy coITelates with clinical responses to adoptive cell 
therapy {Dudley 2008}. Specifically, there appeai·s to be a link between adequate lymphodepletion 
and adoptively transfeITed T-cell expansion and function in preclinical models, which 
demonstrate that the depth and duration of lymphodepletion coITelates with antitumor activity of 
the adoptively transfeITed tumor-specific CD8+T cells {Gattinoni 2005}. Lymphodepletion may 
function by eradicating cytokine sinks for the transfeITed cells, eliminating T regulato1y cells, or 
enhancing antigen presenting cell activation {Klebanoff 2005}. The cyclophosphainide and 
fludai·abine combination is a potent conditioning chemotherapy regimen. Cyclophosphainide 
(500 mg/m2/day) and fludarabine (30 mg/m2/day) are both given for 3 consecutive days. This 
combination has been studied in subjects with B-cell malignancies and was tolerated by this 
population {Kochenderfer 2017, O'Brien 2001}. The low-dose conditioning chemotherapy 
regimens used in these studies could not directly induce durable remissions. Low-dose 
cyclophosphainide and fludai·abine alone increases interleukin (IL )-15, IL-7 and monocyte 
chemoattractant protein (MCP)-1 sernm levels, which increased IL-15 senun levels is associated 
with efficacy of anti-CD19 CART cells {Kochenderfer 2017}. This low-dose cyclophosphamide 
and fludai·abine conditioning chemotherapy was also used in the pivotal ZUMA-I {Locke 2017, 
Neelapu 2017} 
3.2.2. 
Rationale for Axicabtagene Ciloleucel Dose 
The rationale for the axicabtagene ciloleucel dose in this study is based on the aggregate safety 
and efficacy data compiled from ZUMA-I as outlined in the IB. Based on the favorable 
benefit/risk ratio seen in ZUMA-I and FDA approval for the treatment of adult patients with 
relapsed or refracto1y lai·ge B-cell lymphoma after 2 or more lines of systemic therapy, 
axicabtagene ciloleucel will be administered at a tai·get dose of 2 x 106 anti-CD19 
CART cells/kg but subjects may be dosed at a minimum of 1 x 106 anti-CD19 CART cells/kg. 
For subjects weighing~ 100 kg, a maximum flat dose of axicabtagene ciloleucel at 
2 x 108 anti-CD19 CART cells will be administered. 
CONFIDENTIAL 
Page 21 
25 Mru·ch 2022 


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 22
25 March 2022
A positive risk benefit ratio is further supported by the expectation that subjects in this study will 
have a lower disease burden at the time of axicabtagene ciloleucel administration as they are 
receiving the dose earlier in their disease course compared to subjects in ZUMA-1 {Locke 
2018}. In ZUMA-1, the observed response rates were consistent when comparing subsets with 
high versus lower tumor burden based on medians (ZUMA-1 clinical study report [CSR]; 
Section 11.1.1.3).
3.3.
Participating Sites
Approximately 10 centers located in North America and the European Union will participate in 
this study and other regions may be considered. During the conduct of the study, additional 
regions, countries, or sites may be added as necessary.
3.4.
Number of Subjects
Participants in this trial will be referred to as “subjects.” It is anticipated that approximately 
40 subjects will be enrolled and treated into this study.
3.5.
Replacement of Subjects
Subjects may continue to be enrolled until the specified number of subjects are dosed with 
axicabtagene ciloleucel. Subjects who have not received axicabtagene ciloleucel will be retained 
in the analyses of disposition and safety, where appropriate (see Section 10.6).
3.6.
Study Duration
3.6.1.
Study Duration for Individual Subjects
The duration of the study for individual subjects will be up to approximately 15 years. The 
duration of participation for individual subjects will vary depending on a subject’s screening 
requirements, response to treatment, survival, and timing of transition to the separate Kite LTFU 
study, KT-US-982-5968 (discussed in Section 7.13).
Following at least 36 months of assessments in the ZUMA-12 protocol, subjects who received an 
infusion of axicabtagene ciloleucel will complete the remainder of the 15-year follow-up 
assessments in the separate LTFU study, KT-US-982-5968. 
For a subject who completes participation in this study and also completes the LTFU period in 
the separate LTFU study, the entire duration of a subject’s participation in both studies will be up 
to approximately 15 years after the initial infusion of axicabtagene ciloleucel. The need for 
prolonged follow-up is based on the potential persistence of gene transfer vectors in treated 
subjects and need to understand and mitigate the potential risks of delayed onset adverse events 
(AEs) that could be the potential consequence of this emerging technology.


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 23
25 March 2022
3.6.2.
Completion of Study
Completion of the study is defined as the time at which the last subject completes at least 
36 months of assessments, is lost to follow-up, withdraws consent, or dies. Upon activation of 
the LTFU study, KT-US-982-5968 at the subject’s study site, the subject will be offered the 
opportunity to complete LTFU assessments under the KT-US-982-5968 protocol.


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 24
25 March 2022
4.
SUBJECT IDENTIFICATION ASSIGNMENT
Each subject who enters the screening period, which starts when the subject signs the informed 
consent form (ICF), will receive a unique subject identification (ID) number. This number will 
be used to identify the subject throughout the study and must be used on all study documentation 
related to the subject. The subject identification number will never be changed even if the subject 
is rescreened.


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 25
25 March 2022
5.
SUBJECT ELIGIBILITY
5.1.
Inclusion Criteria
101.
Large B-cell lymphoma with one or more of the following features:

HGBL with MYC and BCL2 and/or BCL6 translocations (double-hit or triple-hit) as 
determined by investigator by fluorescent in situ hybridization 
OR

Other histologically confirmed large B-cell lymphoma defined by WHO 2016 
{Swerdlow 2016} with an IPI score of ≥ 3 at initial diagnosis or anytime between 
initial diagnosis and enrollment, including the following lymphoma types:
DLBCL-NOS, including GCB type and ABC type
Intravascular large B-cell lymphoma
T-cell/histiocyte-rich large B-cell lymphoma
DLBCL associated with chronic inflammation
Epstein-Barr virus + DLBCL-NOS
HGBL-NOS
102.
Subjects must have a positive interim PET per the Lugano Classification {Cheson 
2014}(Deauville PET score of 4 or 5) after 2 cycles (PET2+) of chemoimmunotherapy as 
follows:

2 cycles of an anti-CD20 monoclonal antibody (unless investigator determines that 
tumor is CD20 negative) and anthracycline-containing regimen (eg, DA-EPOCH-R), 
with or without intrathecal chemotherapy, at the discretion of the investigator per 
local standard of care for double-hit or triple-hit lymphoma
OR

2 cycles of an anti-CD20 monoclonal antibody (unless investigator determines that 
tumor is CD20 negative) and anthracycline-containing regimen (eg, R-CHOP) at the 
discretion of the investigator per local standard of care for large B-cell lymphoma 
with IPI score of ≥ 3
103.
At least 2 weeks must have elapsed since any prior systemic therapy at the time the 
subject is planned for leukapheresis


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 26
25 March 2022
104.
No evidence, suspicion, and/or history of CNS involvement of lymphoma
105.
Toxicities due to prior therapy must be stable and recovered to Grade 1 or less (except for 
clinically nonsignificant toxicities such as alopecia)
106.
Age 18 or older
107.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
108.
Adequate bone marrow, renal, hepatic, pulmonary, and cardiac function defined as:

Absolute neutrophil count ≥ 1000/μL

Platelet count ≥ 75,000/μL

Absolute lymphocyte count ≥ 100/μL

Creatinine clearance (as estimated by Cockcroft Gault) ≥ 60 mL/min

Serum alanine aminotransferase and aspartate aminotransferase ≤ 2.5 upper limit of 
normal (ULN)

Total bilirubin ≤ 1.5 mg/dL, except in subjects with Gilbert’s syndrome

Cardiac ejection fraction ≥ 50%, no evidence of pericardial effusion (except trace or 
physiological) as determined by an echocardiogram (ECHO), and no clinically 
significant electrocardiogram findings 

No clinically significant pleural effusion

Baseline oxygen saturation > 92% on room air
109.
Females of childbearing potential must have a negative serum or urine pregnancy test 
(females who have undergone surgical sterilization or who have been postmenopausal for 
at least 2 years are not considered to be of childbearing potential).
5.2.
Exclusion Criteria
201.
History of malignancy other than nonmelanoma skin cancer or carcinoma in situ 
(eg, cervix, bladder, breast) unless disease free for at least 3 years
202.
History of Richter’s transformation of chronic lymphocytic leukemia or PMBCL
203.
History of autologous or allogeneic SCT
204.
Prior CD19-targeted therapy


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 27
25 March 2022
205.
Prior CAR therapy or other genetically modified T-cell therapy
206.
History of severe, immediate hypersensitivity reaction attributed to aminoglycosides
207.
Presence or suspicion of fungal, bacterial, viral, or other infection that is uncontrolled or 
requiring IV antimicrobials for management; simple urinary tract infection and 
uncomplicated bacterial pharyngitis are permitted if responding to active treatment and 
after consultation with the sponsor’s medical monitor
208.
History of human immunodeficiency virus (HIV) infection or acute or chronic active 
hepatitis B or C infection; subjects with history of hepatitis infection must have cleared 
their infection as determined by standard serological and genetic testing per current 
Infectious Diseases Society of America guidelines or applicable country guidelines
209.
Presence of any indwelling line or drain (eg, percutaneous nephrostomy tube, indwelling 
Foley catheter, biliary drain, or pleural/peritoneal/pericardial catheter); dedicated central 
venous access catheters, such as a Port-A-Cath® or Hickman® catheter, are permitted
210.
Subjects with detectable cerebrospinal fluid malignant cells, brain metastases, or active 
CNS lymphoma
211.
History or presence of CNS disorder, such as seizure disorder, cerebrovascular 
ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS 
involvement
212.
Subjects with cardiac atrial or cardiac ventricular lymphoma involvement
213.
History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or 
other clinically significant cardiac disease within 12 months of enrollment
214.
Requirement for urgent therapy due to tumor mass effects (eg, blood vessel compression, 
bowel obstruction, or transmural gastric involvement)
215.
Primary immunodeficiency
216.
History of autoimmune disease (eg, Crohns, rheumatoid arthritis, systemic lupus) 
resulting in end organ injury or requiring systemic immunosuppression/systemic disease 
modifying agents within the last 2 years
217.
History of symptomatic deep vein thrombosis or pulmonary embolism within 6 months of 
enrollment
218.
Any medical condition likely to interfere with assessment of safety or efficacy of study 
treatment
219.
History of severe immediate hypersensitivity reaction to any of the agents used in this 
study


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 28
25 March 2022
220.
Live vaccine ≤ 6 weeks prior to planned start of conditioning regimen
221.
Women of childbearing potential who are pregnant or breastfeeding because of the 
potentially dangerous effects of the preparative chemotherapy on the fetus or infant. 
Females who have undergone surgical sterilization or who have been postmenopausal for 
at least 2 years are not considered to be of childbearing potential
222.
Subjects of either sex who are not willing to practice birth control from the time of 
consent through 6 months after the completion of conditioning chemotherapy or 
axicabtagene ciloleucel infusion, whichever is longer
223.
In the investigator’s judgment, the subject is unlikely to complete all protocol-required 
study visits or procedures, including follow-up visits, or comply with the study 
requirements for participation


Axicabtagene Ciloleucel 
Clinical Protocol 
KTE-C19-l 12 (ZUMA-12) 
6_ 
6.1. 
6.1.1. 
PROTOCOL TREATMENT 
Study Treatment 
Leukapheresis 
Kite Phruma, Inc. 
Leukapheresis refers to the procedure for collecting peripheral blood mononuclear cells 
(PBMCs) that are used to manufacture axicabtagene ciloleucel. 
Subjects will undergo leukapheresis to obtain T cells for the manufacturing of axicabtagene 
ciloleucel. Leukapheresed cells obtained at paiiicipating centers will be shipped to the sponsor's 
manufacturing facility as described in the Investigational Product Manual (1PM). 
At least 2 weeks must have elapsed since any prior systemic therapy at the time the subject is 
planned for leukapheresis. 
-
CONFIDENTIAL 
Page 29 
25 Mru·ch 2022 


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 30
25 March 2022
6.1.3.
Conditioning Chemotherapy
Conditioning chemotherapy refers to fludarabine and cyclophosphamide used for 
lymphodepletion prior to administration of axicabtagene ciloleucel.
Conditioning chemotherapy will be supplied by the investigative site unless otherwise noted.
Refer to the current product label for guidance on packaging, storage, preparation, administration, 
and toxicity management associated with the administration of chemotherapy agents.
6.1.3.1.
Fludarabine
Fludarabine phosphate is a synthetic purine nucleoside that differs from physiologic nucleosides 
in that the sugar moiety is arabinose instead of ribose or deoxyribose. Fludarabine is a purine 
antagonist antimetabolite.
Refer to the most recent version of the package insert for specific details surrounding the 
administration of fludarabine.
6.1.3.2.
Cyclophosphamide
Cyclophosphamide is a nitrogen mustard-derivative that acts as an alkylating agent following 
conversion to active metabolites in the liver and has potent immunosuppressive activity. The 
serum half-life after IV administration ranges from 3 to 12 hours; the drug and/or its metabolites 
can be detected in the serum for up to 72 hours after administration.
Refer to the most recent version of the package insert for specific details surrounding the 
administration of cyclophosphamide.
CCI


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 31
25 March 2022
6.1.3.3.
Mesna
Mesna is a detoxifying agent used to inhibit the hemorrhagic cystitis induced by chemotherapy. 
The active ingredient in mesna is a synthetic sulfhydryl compound designated as 
sodium-2-mercaptoethane sulfonate with a molecular formula of C2H5NaO3S2.
Mesna should be administered per institutional guidelines. Refer to the most recent version of the 
package insert for specific details surrounding the administration of mesna.
6.1.4.
Axicabtagene Ciloleucel
Axicabtagene ciloleucel is the investigational product for this study.
Axicabtagene ciloleucel is supplied cryopreserved in cryostorage bags. The product in the bag is 
slightly cloudy and cream to yellow color. The cryostorage bag containing axicabtagene 
ciloleucel arrives frozen in a liquid nitrogen dry shipper. The bag must be stored in vapor phase 
of liquid nitrogen and remain frozen until the subject is ready for treatment to assure that viable 
live autologous cells are administered to the subject.
Axicabtagene ciloleucel is a subject-specific product. The product is labelled per local 
regulations with the subject’s unique subject ID number assigned at the time of screening. Upon 
receipt, verification that the product and subject-specific labels match the subject’s information 
(eg, subject ID number) is essential. Do not infuse the product if the information on the 
subject-specific label does not match the intended subject. The volume of axicabtagene 
ciloleucel infused, the thaw start/stop time, and axicabtagene ciloleucel administration start/stop 
time will all be noted in the subject’s medical record. The product must not be thawed until the 
subject is ready for the infusion. Refer to the IPM for details and instruction on storage, thawing, 
and administration of axicabtagene ciloleucel.
There have been no instances of accidental overdose of subjects in this program to date. In case 
of accidental overdose, treatment should be supportive. Corticosteroid therapy may be 
considered if any dose is associated with severe toxicity.
If any problems related to the use of axicabtagene ciloleucel or any products that support the 
management of axicabtagene ciloleucel (eg, cryostorage bags, subject ID labels) are identified, 
research staff should report the problem per the instructions in the IPM.
Refer to the current version of the IB for more details regarding axicabtagene ciloleucel.
6.1.5.
Concomitant Therapy
Concomitant therapy refers to treatment that subjects receive during the conduct of the study.
During the course of the study, investigators may prescribe any concomitant therapies deemed 
necessary to provide adequate supportive care except those medications listed in Section 6.1.6.


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 32
25 March 2022
All concomitant therapies, including medications, intubation, dialysis, oxygen, and blood 
products, will be recorded.
For subjects who receive axicabtagene ciloleucel treatment:

Concomitant therapies will be recorded from the date of the informed consent until 3 months 
after completing treatment with axicabtagene ciloleucel.

After this 3-month follow-up period, targeted concomitant therapies will be recorded for 
either 24 months after axicabtagene ciloleucel infusion or until disease progression, 
whichever occurs first. Targeted concomitant therapies include gammaglobulin, 
immunosuppressive drugs, anti-infective drugs, and vaccinations.
For subjects who are enrolled, but not dosed with axicabtagene ciloleucel, concomitant therapies 
will be recorded from the date of the informed consent until 30 days after the last study-specific 
procedure has occurred (eg, leukapheresis, conditioning chemotherapy) or until the initiation of 
new antilymphoma therapy, whichever occurs first.
For subjects who are not enrolled (eg, screen failure), only concomitant therapies related to any 
SAE[s] will be recorded.
Specific concomitant therapy collection requirements and instructions are included in the case 
report form (CRF) completion guidelines.
6.1.6.
Excluded Medications
Excluded medications refer to treatment that is not to be administered, unless otherwise 
specified, during the conduct of the study.
Corticosteroid therapy at a pharmacologic dose (≥ 5 mg/day of prednisone or equivalent doses of 
other corticosteroids) and other immunosuppressive drugs must be avoided for 7 days prior to 
leukapheresis and 5 days prior to axicabtagene ciloleucel administration.
Systemic corticosteroids may not be administered as premedication to subjects for whom 
CT scans with contrast are contraindicated (ie, subjects with contrast allergy or impaired renal 
clearance). Such subjects should undergo noncontrast CT scans instead.
Corticosteroids and other immunosuppressive drugs should also be avoided for 3 months after 
axicabtagene ciloleucel administration unless used to manage axicabtagene ciloleucel-related 
toxicities. Other medications that might interfere with the evaluation of axicabtagene ciloleucel, 
such as nonsteroidal anti-inflammatory agents, should also be avoided for the same period unless 
medically necessary.
Therapeutic doses of systemic anticoagulants, such as unfractionated heparin and low-molecular 
weight heparin, should be avoided when possible anytime subjects are at risk of bleeding due to 
thrombocytopenia.


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 33
25 March 2022
Treatments for lymphoma, such as chemotherapy, immunotherapy, targeted agents, radiation, 
and high-dose corticosteroids (other than those defined/allowed in this protocol) and other 
investigational agents, are prohibited, except as needed for treatment of disease progression after 
axicabtagene ciloleucel.
If permissibility of a specific medication/treatment is in question, contact the sponsor’s medical 
monitor.
6.1.7.
Subsequent Therapy
Subsequent therapy refers to treatment administered after axicabtagene ciloleucel that is 
necessary to treat a subject’s disease.
Subsequent therapy administered after axicabtagene ciloleucel that is necessary to treat a 
subject’s disease, such as non-study specified chemotherapy, immunotherapy, targeted agents, 
SCT, or radiation therapy, will be recorded for subjects until one of the following happens: the 
subject transitions to the LTFU study KT-US-982-5968, is considered lost to follow-up, 
withdraws consent, or dies.
For subjects who are enrolled, but do not receive axicabtagene ciloleucel infusion, any additional 
anti-lymphoma therapy will also be collected until the subject completes their participation in the 
current study, is considered lost to follow-up, withdraws consent, or dies, whichever occurs first.
6.1.8.
Toxicity Management
To date, the following risks have been identified with axicabtagene ciloleucel: CRS, neurologic 
events, infections, cytopenias, and hypogammaglobulinemia. Refer to Section 6 of the current IB 
for details regarding these events and management guidance.
As the safety experience with axicabtagene ciloleucel increases, the management guidance may 
be updated. Therefore, it is important to always refer to the most current version of the 
axicabtagene ciloleucel IB for guidance regarding managing axicabtagene ciloleucel-related 
toxicities. Additional information and management recommendations can also be found in the IB 
regarding important potential risks associated with axicabtagene ciloleucel, as well as possible 
complications associated with malignancy and cancer treatment.
Refer to the SOA (Table 3) for the timing of evaluations for CRS-related symptoms.


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 34
25 March 2022
7.
STUDY PROCEDURES
Research staff should refer to the SOA (Table 3) for an outline of the procedures required.
The visit schedule is calculated from axicabtagene ciloleucel infusion on Day 0.
The visit schedule for disease assessments is also calculated from axicabtagene ciloleucel 
infusion on Day 0, including CT scans, PET scans, bone marrow biopsy, physical exams needed 
to assess disease, and collection of subsequent antilymphoma therapy.
An overview of study assessments/procedures is outlined below. Refer to the CRF completion 
guidelines for data collection requirements and best practices for documentation of study procedures.
7.1.
Informed Consent
Before a subject participates in the clinical study, the investigator is responsible for obtaining 
written informed consent from the subject after adequately explaining the study design, anticipated 
benefits, and potential risks. Subjects should sign the most current institutional Review Board 
(IRB)/Independent Ethics Committee (IEC)-approved ICF before any nonstandard-of-care 
study-specific activity or procedure is performed.
The consent process and the subject’s agreement or refusal to participate in the study must be 
documented in the subject’s medical records. If the subject agrees to participate, the ICF must be 
signed and dated by both the subject and the person who conducted the informed consent 
discussion. The original signed ICF will be retained in accordance with institution policy and 
IRB/IEC requirements, and a copy of the ICF will be provided to the subject.
All subjects who are enrolled into the study should be reconsented with any updated version of 
the IRB/IEC-approved ICF if the new version is relevant to their participation.
7.2.
Screening
Investigative sites will maintain a log of all screened subjects who were reviewed and evaluated 
for study participation. Information collected in the screening log should include limited 
information, such as the date of screening, date the subject was enrolled, or the reason for why 
the subject failed screening.
The screening period begins on the date the subject signs the IRB/IEC-approved ICF and 
continues through confirmation of eligibility into the study. Informed consent must be obtained 
before completion of any nonstandard-of-care study-specific procedures. Procedures that are part 
of standard of care are not considered study-specific and, therefore, may be performed prior to 
obtaining consent and used to confirm eligibility provided they occur within the time allowance 
outlined below and in the SOA.
After written informed consent has been obtained, Kite will assign a unique subject ID number to 
the subject.


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 35
25 March 2022
See Section 7.2.1 for the study procedures for subjects who rescreen into the study. Only subjects 
who meet the eligibility criteria listed in Section 5 will be enrolled into the study. If at any time 
prior to enrollment the subject fails to meet the eligibility criteria, the subject should be 
designated as a screen failure within the subject’s screening log, and the reasons for failing 
screening should also be recorded.
Refer to the SOA for a listing of study procedures to be completed during the screening period.
7.2.1.
Rescreening
Subjects who are unable to complete or meet the eligibility criteria during the 28-day screening 
period will be permitted to rescreen 1 time. Subjects will retain the same subject ID number 
assigned at the original screening. If rescreening occurs within 28 days of the signing of the 
original informed consent, it is only necessary to perform the procedure(s)/assessment(s) that did 
not originally meet the eligibility criteria; all other initial screening procedures/assessments do 
not need to be repeated. If rescreening occurs after more than 28 days, or leukapheresis is 
delayed more than 28 days from the signing of the original informed consent, subjects must be 
reconsented and repeat all screening procedures/assessments.
7.3.
Demographic Data
Demographic data will be collected as per country and local regulations and guidelines. Where 
applicable, demographic data will include sex, year of birth, race, ethnicity, and country of 
enrollment to study a possible association between these variables and subject safety and 
treatment effectiveness.
7.4.
Medical and Treatment History
Relevant medical history prior to the start of AE reporting will be collected. Relevant medical 
history is defined as data on the subject’s current medical condition that would be typically 
shared in a referral letter. In addition to the medical history, all history related to the subject’s 
disease, treatment, and response to treatment will be collected and must date back to the original 
diagnosis. All findings will be recorded on the CRFs.
For subjects who are being referred from another clinic or institution to the participating research 
center, copies from the subject’s chart should be obtained.
7.5.
Conditioning Chemotherapy and Axicabtagene Ciloleucel Infusion
Administration of CAR T cells to subjects with ongoing infection or inflammation, even if such 
processes are asymptomatic, increases the risk of high-grade and fatal toxicity. All efforts should 
be made to rule out such conditions prior to cell infusion. Signs, symptoms, or abnormal 
laboratory results attributed to the malignancy tumor fever and elevated C-reactive protein (CRP) 
are diagnoses of exclusion that require a documented workup to establish. Conditioning 
chemotherapy and axicabtagene ciloleucel infusion should be initiated only once it is reasonably 
assured that cell infusion can safely proceed.


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 36
25 March 2022
Refer to Section 7.5.3 for requirements for workup of potential infectious and/or inflammatory 
states.
7.5.1.
Requirements for Initiating Conditioning Chemotherapy
If any of the following criteria are met prior to the initiation of conditioning chemotherapy, then 
the workup listed in Section 7.5.3 must be performed to determine the potential cause if there is 
no identified source of infection.

Temperature > 38°C within 72 hours of conditioning chemotherapy

CRP > 100 mg/L anytime between enrollment to start of conditioning chemotherapy

White blood cell (WBC) count or WBC differential concerning for infectious process 
between enrollment to start of conditioning chemotherapy WBC > 20,000, rapidly increasing 
WBC, or differential with high percentage of segs/bands)
Additionally:

If any screening assessments or procedures are repeated between confirmation of eligibility 
and the start of conditioning chemotherapy and results are outside the eligibility criteria listed 
in Section 5, then the condition must resolve prior to proceeding with conditioning 
chemotherapy.

Complete history and physical exam including head, eyes, ears, nose, and throat (HEENT), 
and cardiac, vascular, respiratory, gastrointestinal, integumentary, and neurological systems 
must not reveal evidence of infection/inflammation.

The subject must not have received systemic antimicrobials for the treatment of a known or 
suspected infection within 48 hours before conditioning chemotherapy (prophylactic use of 
antimicrobials is allowed).

The treatment course of any antimicrobials given for known or suspected antecedent 
infection should be complete as per infectious disease consult (if applicable) 
recommendation before stopping or switching to prophylactic antimicrobials.

If a subject is confirmed to have an infectious process for which antimicrobials are not 
available (eg, viral pneumonia), the infection must be clinically resolved as determined by 
the investigator in consultation with the infectious disease service (if applicable).

Most recently collected blood, urine, or other body fluid cultures must show no growth for at 
least 48 hours, and any other infectious workup performed (bacterial, viral serologies, 
polymerase chain reaction (PCR), stool studies, imaging studies) must be negative. If clinical 
suspicion is for an infection for which cultures are unlikely to be positive within 48 hours 
(eg, fungal infection), adequate time must be allowed for cultures to become positive.
Once the above criteria are met, then the subject can proceed with conditioning chemotherapy.


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 37
25 March 2022
7.5.2.
Requirements for Initiating Axicabtagene Ciloleucel Infusion
If any of the following criteria are met prior to the initiation of axicabtagene ciloleucel infusion, 
then the workup listed in Section 7.5.3 must be performed to determine the potential cause if 
there is no identified source of infection.

Temperature > 38°C within 72 hours of axicabtagene ciloleucel infusion

CRP > 100 mg/L anytime between enrollment to start of axicabtagene ciloleucel infusion

WBC count or WBC differential concerning for infectious process between enrollment to 
start of axicabtagene ciloleucel infusion WBC > 20,000, rapidly increasing WBC, or 
differential with high percentage of segs/bands)
Additionally:

If any screening assessments or procedures are repeated between confirmation of eligibility 
and the start of axicabtagene ciloleucel infusion and results are outside the eligibility criteria 
listed in Section 5, then the condition must resolve prior to proceeding with axicabtagene 
ciloleucel infusion (except for peripheral blood cell counts that have been impacted by 
conditioning chemotherapy).

Complete history and physical exam including HEENT, and cardiac, vascular, respiratory, 
gastrointestinal, integumentary, and neurological systems must not reveal evidence of 
infection/inflammation.

The subject must not have received systemic antimicrobials for the treatment of a known or 
suspected infection within 48 hours before axicabtagene ciloleucel (prophylactic use of 
antimicrobials is allowed).

The treatment course of any antimicrobials given for known or suspected antecedent 
infection should be complete as per infectious disease consult (if applicable) 
recommendation before stopping or switching to prophylactic antimicrobials.

If a subject is confirmed to have an infectious process for which antimicrobials are not 
available (eg, viral pneumonia), the infection must be clinically resolved as determined by 
the investigator in consultation with the infectious disease service (if applicable).

Most recently collected blood, urine, or other body fluid cultures must show no growth for at 
least 48 hours, and any other infectious workup performed (bacterial, viral serologies, PCR, 
stool studies, imaging studies) must be negative. If clinical suspicion is for an infection for 
which cultures are unlikely to be positive within 48 hours (eg, fungal infection), adequate 
time must be allowed for cultures to become positive.
Once the above criteria are met, then the subject can proceed with administration of axicabtagene 
ciloleucel.
If the axicabtagene ciloleucel infusion is delayed > 2 weeks, protocol-specified conditioning 
chemotherapy must be repeated.


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 38
25 March 2022
7.5.3.
Requirements to Work-up Potential Infectious and/or Inflammatory States
In the absence of an identified source of infection (eg, line infection, pneumonia on chest x-ray), 
the minimum workup to be performed prior to administration of conditioning chemotherapy 
and/or axicabtagene ciloleucel consists of:

Call Kite medical monitor

Infectious disease service consult

CT imaging of the chest, abdomen, and pelvis with IV contrast. If there is a medical 
contraindication to contrast, then noncontrast CT is allowed.

The following must be performed (prior to the initiation of antimicrobials if clinically 
feasible):
Blood cultures (aerobic and anaerobic x 2 bottles each) and urinalysis and urine culture. 
Deep/induced sputum culture if clinically indicated
All indwelling lines, such as central venous catheters, should be examined for any signs 
of infection and additional cultures should be drawn from the line.
Nasopharyngeal-throat swab or equivalent assay for viral infection, such as influenza A/B 
(including H1N1), parainfluenza 1/2/3, adenovirus, respiratory syncytial virus, 
coronavirus, metapneumovirus
Collection of fungal cultures and markers as appropriate (galactomannan, Fungitell®)
Collection of appropriate serum viral studies (eg, cytomegalovirus)

If a CNS process is suspected, appropriate brain imaging and subsequent lumbar puncture 
with cytology, culture, Gram stain, and viral PCR should be performed.

Any additional sign or symptom-directed investigation should be performed as clinically 
indicated.
Prior to proceeding with conditioning chemotherapy or axicabtagene ciloleucel infusion, the 
above workup must not suggest the presence of an active infection and all requirements for 
conditioning chemotherapy and axicabtagene ciloleucel infusion must be satisfied.
If the above workup was triggered due to CRP > 100 mg/L, testing for CRP should be repeated, 
and if CRP continues to increase significantly, evaluation should be performed for any other 
potential infectious or inflammatory condition not previously evaluated.


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 39
25 March 2022
7.5.4.
Conditioning Chemotherapy Administration (Day –5 Through Day –3 Prior 
to Axicabtagene Ciloleucel Infusion)
Subjects will receive a conditioning chemotherapy regimen consisting of cyclophosphamide and 
fludarabine. The first dose of conditioning chemotherapy will be designated as Day –5. Subjects 
will initiate conditioning chemotherapy with cyclophosphamide and fludarabine beginning on 
Day –5 and through Day –3, with 2 rest days (Day –2 and Day –1) before receiving axicabtagene 
ciloleucel. The 3-day conditioning chemotherapy regimen will be administered in an outpatient 
setting.
The 3-day conditioning regimen of fludarabine and cyclophosphamide will be administered in 
accordance with the following daily dosing instructions:

IV hydration with a balanced crystalloid according to institutional guidelines prior to 
administration of cyclophosphamide on the day of infusion

Cyclophosphamide 500 mg/m2 IV over approximately 60 minutes or per institutional 
guidelines

Fludarabine 30 mg/m2 IV over approximately 30 minutes or per institutional guidelines

Additional IV hydration with a balanced crystalloid according to institutional guidelines to be 
administered upon completion of the cyclophosphamide infusion

Mesna to be administered per institutional guidelines
Subjects should be instructed to drink plenty of liquids during chemotherapy and throughout the 
24-hour period following chemotherapy (approximately 2 L/24 hours). In general, subjects 
should be kept well hydrated but closely monitored to prevent fluid overload. 
Refer to the SOA Table 3 for a listing of study procedures to be completed during the 
axicabtagene ciloleucel conditioning chemotherapy period.
7.6.
Physical Exam, Vital Signs, and Performance Status
Physical exams will be performed during screening and at times noted in the SOA. All physical 
exam changes noted in subsequent exams when compared to the baseline exam will be reported 
as AEs.
Vital signs, including blood pressure (BP), heart rate, respiratory rate, oxygen saturation, and 
temperature, will be monitored and recorded at screening and at times outlined in the SOA. In 
addition to the time points outlined in the SOA, it is recommended that vital signs are monitored 
during and after study treatment (see Section 6) and as clinically indicated.
Performance status as measured by the ECOG scale will be performed to quantify the subject’s 
general well-being and ability to perform activities of daily life.


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 40
25 March 2022
7.7.
Cardiac Function
Each subject’s cardiac function, as measured by left ventricular ejection fraction, will be 
assessed during the screening period to confirm study eligibility. No evidence of pericardial 
effusion will also be confirmed, per study eligibility criteria. Both the left ventricular ejection 
fraction and pericardial effusion will be assessed prior to study entrance by an ECHO. An ECHO 
that was performed after the subject’s last chemoimmunotherapy treatment may also be used to 
confirm eligibility, provided that it occurred ≤ 28 days prior to signing the consent.
To establish a baseline, a 12-lead electrocardiogram will also be performed during the screening 
period.
7.8.
Neurological Examination
A neurological examination will be performed, and any of the following abnormalities will be 
recorded: level of consciousness, orientation, vision, cranial nerves and brain stem functions, 
pyramidal and extra pyramidal motor system, reflexes, muscle tone and trophic findings, 
coordination, sensory system, and neuropsychological findings (eg, speech, cognition, and 
emotion).
A neurological examination should be done prior to axicabtagene ciloleucel infusion on 
treatment Day 0, then on Day 1, Day 3, Day 5, and Day 7 during the observation period, which 
must last a minimum of 7 days.
For new onset of neurologic symptoms suspected to be related to axicabtagene ciloleucel 
treatment, refer to Section 6.1.8. Subjects will be specifically asked about changes in 
neurological status since the previous neurological examination, as noted in the SOA 
(see Table 3).
7.9.
Disease Assessment
Subjects will be evaluated for disease response by the site investigator at times indicated in the 
SOA. Disease assessments will be evaluated per the Lugano Classification {Cheson 2014} 
(see Appendix 1). Flow cytometric, molecular, or cytogenetic studies will not be used to 
determine response.
7.9.1.
Imaging
7.9.1.1.
Pre-treatment Disease Assessment
A fluorodeoxyglucose (FDG)-PET from skull base to mid-thighs and a diagnostic quality 
contrast-enhanced (unless contraindicated) CT from skull base through lesser trochanters 
(PET-CT), along with the appropriate imaging of all other sites of disease must be performed 
within 28 days prior to enrollment/leukapheresis.


Axicabtagene Ciloleucel 
Clinical Protocol 
KTE-C19-l 12 (ZUMA-12) 
Kite Phruma, Inc. 
If a PET-CT cannot be perfonned as standard of care following 2 cycles of 
chemoimmunotherapy, a subject may have the PET-CT perfonned on study after infonned 
consent is obtained. 
7.9.1.2. 
Post-ti·eatment Response Assessment 
Post-ti·eatment PET-CT response assessments will begin at Day 28 and continue at time points 
outlined in the SOA (Table 3). If there was evidence of baseline bone maITow involvement and 
no PET-CT is available or if there are unexplained cytopenias or suspicion of bone maITow 
involvement, then a bone maiTow aspirate and biopsy will be perfo1med in subjects who are 
being assessed for CR. To confnm a CR, the bone man ow aspirate and biopsy must show no 
evidence of disease by m01phology, or, if indetenninate by mo1p hology, must be negative by 
immunohistochemistiy. 
PET-CTs will continue through Month 24 or until disease progression, whichever comes first. If 
the subject's disease has not progressed by Month 24, disease assessments can then be perfo1med 
at standai·d-of-cai·e intervals. Subjects with symptoms suggestive of disease progression should 
be evaluated for progression at the time symptoms occur even if this requires an unscheduled 
visit. If the subject has sta1ted subsequent antilymphoma therapy, then imaging assessments will 
no longer be required per protocol. PET-CT can be perfonned at any time disease progression is 
suspected. FDG-PET assessment takes precedence over CT assessment for time points when 
both are available. If only CT is available for a paiticulai· time point, then the CT assessment 
should include a comparison with and may be affected by the PET-CT assessment at the prior 
time point. Please refer to the imaging manual for finther details. 
Bone maiTow aspirate/biopsy should also be considered to evaluate hemophagocytic 
lymphohistiocytosis as indicated. Refer to the IB for additional infonnation. 
7.9.1.3. 
Response Evaluation to Reti·eatment 
For the pmpose of dete1mining response to reti·eatment with axicabtagene ciloleucel, the last 
scan prior to reu-eatment will be considered the baseline. 
7.9.2. 
Determination of Bone Marrow Involvement 
A subject's bone maiTow involvement should be confnmed by PET-CT or bone maITow biopsy 
and aspirate prior to enrollment. Confinnation of man ow involvement from dete1mination at 
initial diagnosis or between diagnosis and screening is acceptable. 
CONFIDENTIAL 
Page 41 
25 Mru·ch 2022 


Axicabtagene Ciloleucel 
Clinical Protocol 
KTE-C19-l 12 (ZUMA-12) 
Kite Phruma, Inc. 
7.10. 
Cell Collection and Axicabtagene Ciloleucel Study Treatment Schedule and 
Administration 
7.10.1. 
Leukapheresis 
Subjects must remain eligible per the eligibility criteria outlined in Section 5 prior to the sta1t of 
leukapheresis. 
If any screening assessments or procedures are repeated between confinnation of eligibility and 
the strut of leukapheresis and results m·e outside the eligibility criteria listed in Section 5, conta.ct 
the sponsor's medical monitor prior to proceeding with leukapheresis. 
Before leukapheresis commences, the following criteria must be met: 
• 
No evidence or suspicion of an infection 
• 
Co1t icosteroid therapy at a phmm acologic dose (~ 5 mg/day of prednisone or equivalent 
doses of other c01ticosteroids) and other immunosuppressive diugs must be avoided for 
7 days prior to leukapheresis 
The leukapheresis visit should occur within approximately 5 days of eligibility confnmation. 
After a subject commences leukapheresis, the subject will be considered emolled into the study. 
If criteria m·e not met, leukapheresis must be delayed until the event resolves. If leukapheresis is 
delayed more than 5 days after eligibility confnmation, baseline complete blood count (CBC) 
with differential and chemistry panel must be repeated. If results are outside the eligibility 
criteria listed in Section 5, contact the medical monitor prior to proceeding with leukapheresis. 
After the above criteria m·e met, mononuclem· cells will be obtained by leukapheresis 
(12 to 15 L) with a goal to tm·get approximately 5 to 10 x 109 mononuclem· cells. The 
leukapheresed cells m·e then packaged for expedited shipment to the manufacturing facility as 
described in the IPM. 
Refer to the SOA Table 3 for a listing of study procedures to be completed on the leukapheresis 
collection day and as outlined in the SOA. 
-
CONFIDENTIAL 
Page42 
25 Mru·ch 2022 


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 43
25 March 2022
7.10.3.
Axicabtagene Ciloleucel Treatment Period
7.10.3.1.
Axicabtagene Ciloleucel Premedication Dosing
The following pre-axicabtagene ciloleucel infusion medications should be administered 
approximately 1 hour prior to infusion:

Acetaminophen 500 to 1000 mg taken orally or equivalent

Diphenhydramine 12.5 to 25 mg administered either orally or via IV or equivalent
7.10.3.2.
Axicabtagene Ciloleucel Administration Day 0
All subjects will receive axicabtagene ciloleucel infusion at a healthcare facility, followed by 
daily monitoring at a healthcare facility for ≥ 7 days to monitor for signs and symptoms of CRS 
and neurologic events. Alternatively, subjects may be hospitalized to receive their axicabtagene 
ciloleucel infusion and be observed for CRS and neurologic events in the hospital setting, if 
deemed appropriate by the investigator. Post-infusion monitoring of subjects must be for a 
minimum of 7 days unless otherwise required by country regulatory agencies (refer to 
Appendix 3).
If subjects are hospitalized, subjects should not be discharged from the hospital until all 
axicabtagene ciloleucel-related non-hematological toxicities resolve to Grade 1 or lower, or 
return to baseline. Subjects may be discharged with noncritical and clinically stable or improving 
toxicities (eg, renal insufficiency) even if higher than Grade 1, if deemed appropriate by the 
investigator. Subjects should remain in a hospital for ongoing axicabtagene ciloleucel-related 
fever, hypotension, hypoxia, or ongoing neurologic events higher than Grade 1, or if deemed 
necessary by the investigator.
Subjects should be instructed to remain within proximity of the clinical study site for at least 
4 weeks following axicabtagene ciloleucel infusion. Subjects should be advised to refrain from 
driving and engaging in hazardous occupations or activities, such as or operating heavy or 
potentially dangerous machinery, for at least 8 weeks following axicabtagene ciloleucel infusion. 
Subjects and their family members/caregivers should be educated on potential CRS and 
neurologic symptoms, such as fever, dyspnea, confusion, aphasia, dysphasia, somnolence, 
encephalopathy, ataxia, or tremor. Subjects or their family members/caregivers should be 
instructed to immediately contact the treating investigator or seek immediate medical attention if 
any of these symptoms develop.
Refer to the SOA for a listing of study procedures to be completed during the axicabtagene 
ciloleucel treatment period.
Central venous access, such as a port or a peripherally inserted central catheter, is required for 
the administration of axicabtagene ciloleucel. Catheter care, per institutional guidelines, should 
be followed. Materials and instructions for the thawing, timing, and administering of 
axicabtagene ciloleucel are outlined in the IPM. Vital signs should be measured during and after 
axicabtagene ciloleucel treatment (see Section 7.6).
Research sites should follow institutional guidelines for the infusion of cell products.


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 44
25 March 2022
7.10.3.3.
Axicabtagene Ciloleucel Retreatment
Subjects who achieve a PR or CR and subsequently experience disease progression may have an 
option to receive a second course of conditioning chemotherapy and axicabtagene ciloleucel.
The following criteria must be met prior to being considered for a repeat course of therapy:

Subject had a PR or CR at any time after axicabtagene ciloleucel therapy and then 
subsequently progressed with CD19 tumor expression confirmed centrally by biopsy after 
disease progression and prior to retreatment

Subject continues to meet the original study eligibility criteria with the exception of prior 
axicabtagene ciloleucel use in this study; screening assessments and procedures should be 
repeated if clinically indicated (eg, ECHO)

Subject has not received subsequent therapy 10.3.for the treatment of lymphoma

Subject did not experience a life-threatening toxicity related to axicabtagene ciloleucel 
during the original course of treatment 

Toxicities related to conditioning chemotherapy (fludarabine and cyclophosphamide), with 
the exception of alopecia, have resolved to Grade 1 or lower, or returned to baseline prior to 
retreatment
Sites are required to collect a biopsy confirming disease progression and CD19 expression and to 
submit the biopsied tissue to the central laboratory before initiating retreatment.
The decision to retreat should be made in consultation with the sponsor’s medical monitor. In 
addition, before performing any study-related procedures or treatment, it is necessary to 
1) discuss the risks and benefits of retreatment with the subject, and 2) confirm with the subject 
how the second dose will be manufactured. The second dose could be manufactured at the same 
time that the first axicabtagene ciloleucel dose is made with existing cryopreserved PBMCs. 
Alternatively, the subject may need to undergo a second leukapheresis and should be informed of 
this possibility. These conversations should also be recorded in the subject’s source document.
A maximum of 1 retreatment course may occur per subject. Subjects who are retreated will 
follow the same treatment schedule and procedural requirements per the initial treatment.
Allowance for retreatment is based on clinical experience in ZUMA-1, where a total of 
10 subjects were retreated with axicabtagene ciloleucel (1 subject in Phase 1 and 9 subjects in 
Phase 2). Overall, 7 of the 10 retreated subjects responded to retreatment; of these, 2 subjects 
remained in response at the time of the 12-month follow-up from the first treatment.
After a subject is deemed eligible for retreatment and the means by which the second dose of 
axicabtagene ciloleucel has been confirmed (which will include determining whether a second 
leukapheresis is required), the subject will follow the study procedure requirements of the current 
IRB-approved protocol.


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 45
25 March 2022
In some circumstances, subjects may be eligible to receive a second course of treatment after 
enrolling in the LTFU rollover study. Retreatment eligibility criteria are described in the LTFU 
study, KT‐US‐982-5968, protocol.
7.11.
Laboratory
7.11.1.
Local Laboratory Analysis
Assessments listed in Table 2 will be performed at the local laboratory at the time points 
indicated in the SOA.
Table 2.
Clinical Laboratory Parameters
Serum Chemistries
Hematology
Other
Albumin
Alanine aminotransferase
Alkaline phosphatase
Aspartate aminotransferase
Bicarbonate total
Bilirubin total
BUN or ureaa 
Calcium total
Chloride
Creatinine
Glucose
Lactate dehydrogenase
Magnesium total
Potassium
Sodium
Uric acidb 
CBC with differentialc
C-reactive protein
Ferritin
Pregnancy test
Viral testingd
Abbreviations: BUN, blood urea nitrogen; CBC, complete blood count; EU, European Union.
a
If BUN test cannot be analyzed by the local laboratory, urea should be analyzed. 
b
Per institutional guidelines. 
C
At the following pharmacokinetic time points, CBC with differential will be analyzed centrally: prior to leukapheresis, 
Day 7, Weeks 2 and 4, and Months 3, 6, 9, 12, and 24.
d
For EU sites only, serologic tests (eg, human immunodeficiency virus, hepatitis B, hepatitis C, syphilis) may be carried out 
per institution guidelines and EU regulations
7.11.2.
Central Laboratory Analyses
Assessment of CBC with differential will be submitted for central analysis at the following 
pharmacokinetic (PK) time points: prior to leukapheresis, Day 7, Weeks 2 and 4, and Months 3, 
6, 9, 12, and 24.


Axicabtagene Ciloleucel 
Clinical Protocol 
KTE-C19-l 12 (ZUMA-12) 
Kite Phruma, Inc. 
Clinical biospecimens (eg, tumor, maiTow, blood, cerebral spinal fluid [CSF], or other tissues) 
will be sent from clinical study centers to the centrnl laborato1y for sample processing, 
accessioning, and distribution to specialty laboratories. 
• 
Biospecimens are obtained at the times indicated in the SOA and instructions regai·ding 
sample submission to centr·al laboratories ai·e provided in the Centr·al Laborato1y Manual. 
• 
Biospecimens to be collected by study sites: 
-
Archival tumor tissue (biopsy or slides) or fresh tumor sample if archive tissue is not 
available 
I 
-
Bone maiTow biopsy and aspirate, at baseline and/or post-tr·eatment as needed, for 
confmnation of diagnosis and genetic analyses related specifically to large B-cell 
lymphoma 
-
Blood for phannacokinetics (levels of anti-CD19 CART cells), replication-competent 
retl'ovirns (RCR), and minimal residual disease (MRD) testing 
-
Sernm for phan nacodynainics (levels of sennn cytokines) 
-
CSF, if applicable, for phaimacokinetics and phaimacodynainics 
Each subject will have the 
right to have the sample material destr·oyed at any time by contacting the investigator who, in 
tum, can contact the sponsor. The investigator should provide the sponsor with the study and 
subject ID number so that the sample can be located and destr·oyed. For subjects who withdraw 
consent, any samples that were not requested to be returned or destl'oyed will remain with the 
sponsor, and any data that may be generated from these samples will be entered in the study 
database. 
Multiple specialty laboratories may be employed for specific analyses. Refer to the Centi-al 
Laborato1y Manual for instructions regarding submitting such samples to the appropriate 
laborato1y . 
7.11.2.1. 
Centi-al Confmnation of Diagnosis 
Local diagnosis of large B-cell lymphoma for dete1lllination of study eligibility will be made by 
the investigator at each site. Diagnosis will be confomed retr·ospectively by a centr·alized 
specialty laborato1y (see Centr·al Laborato1y Manual) using tumor tissue in the fo1m of an 
archival fonnalin-fixed pai·affin-embedded block, unstained pre-cut slides, or fresh tumor tissue 
from an on-study baseline (prior to conditioning chemotherapy) biopsy, along with a pathology 
repo1i . 
CONFIDENTIAL 
Page46 
25 Mru·ch 2022 


Axicabtagene Ciloleucel 
Clinical Protocol 
KTE-C19-l 12 (ZUMA-12) 
This confnmation of diagnosis will include the following: 
Kite Phruma, Inc. 
• 
Assessment of expression of other indication specific markers by immunohistochemistry or 
fluorescence in situ hybridization as needed for central confnmation of disease histology 
• 
Mo1phological evaluation by hematoxylin and eosin staining 
• 
Anatomical location of the biopsy 
• 
Central review of local pathology repo1t 
If the central laborato1y pathologist's diagnosis is discordant with local laborato1y diagnosis, an 
additional pathologist will review the case for adjudication. If the inte1pretation remains 
discordant with the local laborato1y diagnosis, the sponsor will be consulted to detennine if the 
coITect tissue block or slides was received. If the coITect sample was received, the original slides 
used for local diagnosis will be requested for central review. If results are still discordant, the 
central laborato1y's pathologist and the sponsor's medical monitor will review the 
documentation and images. The central diagnosis will be used in cases where adjudication fails 
to reach a concordant result with the local diagnosis. Additional details will be specified in the 
charter for the central specialty laborato1y. 
-
I 
I 
I 
7.11.2.3. 
Phaimacokinetics and Phannacodynainics 
PK and phaimacodynamic analyses will be perfo1med on blood (levels of anti-CD19 CAR 
T cells) and sennn (cytokines) at the intervals outlined in the SOA to evaluate predictive markers 
for the efficacy and safety of axicabtagene ciloleucel. The following cytokines and chemokines 
may be included in the panel: homeostatic, pro-inflammato1y and immune modulating cytokines 
CONFIDENTIAL 
Page 47 
25 Mru·ch 2022 


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 48
25 March 2022
IL-2, IL-6, IL-10, IL-12p40/p70, IL-15, IL-17a, tumor necrosis factor-α, interferon-γ and 
granulocyte-macrophage colony-stimulating factor; acute phase reactants, such as CRP; 
chemokines IL-8, MCP-1, and macrophage inflammatory protein-1α and interferon gamma-
induced protein (IP)-10; and hemophagocytic lymphohistiocytosis-related markers ferritin and 
IL-2Rα.
CSF samples and additional subject samples (eg, pleural fluid) will be obtained when feasible 
from subjects who develop Grade 2 or higher neurologic events for evaluation of inflammatory 
cytokine and chemokine levels and presence of anti-CD19 CAR T cells. As applicable, 
lymphocyte populations residing in the CSF, or other subject samples, may also be monitored for 
the purpose of understanding the safety profile of axicabtagene ciloleucel.
7.11.2.4.
Product Characteristics
Samples of leukapheresis material or final product will be retained and tested by the sponsor or 
specialty laboratory for the purpose of understanding the mechanism of action and safety profile 
of axicabtagene ciloleucel.
7.11.2.5.
Replication-competent Retrovirus Testing
Axicabtagene ciloleucel comprises T cells transduced with a γ-retroviral vector; hence, there is a 
theoretical risk for RCR developing in exposed subjects. Additional information is provided in 
the IB. The timing of blood draws for determination of the presence of RCR is specified in the 
SOA or may be done as clinically indicated.
RCR testing will occur at leukapheresis and at Months 3, 6, and 12. If a subject tests positive for 
RCR at any time point within the first year, samples will continue to be collected and tested 
yearly for up 15 years or as clinically indicated.
7.12.
Post-treatment Assessment Period
After completing study treatment, all subjects will return to the clinic for post-treatment 
follow-up visits.
If a subject does not respond to treatment at any time during the post-treatment assessment 
period, then the subject will continue to undergo the post-treatment follow-up procedures per the 
SOA, and then be followed for survival and disease outcomes in the LTFU portion of the study 
starting with the Month 6 visit (Table 4).
Refer to the SOA (Table 3) for a listing of study procedures and disease assessments to be 
completed during the post-treatment follow-up period.


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 49
25 March 2022
7.13.
Long-term Follow-up Period
All enrolled subjects will be followed in the LTFU for safety analysis and survival and disease 
status for up to 15 years, if applicable. Subjects will begin the LTFU period beginning at the 
Month 6 visit. After completion of at least 36 months of assessments in the current protocol, 
subjects will transition to the LTFU study, KT-US-982-5968, after providing signed informed 
consent. Subjects who did not respond to treatment may receive off-protocol therapy but will 
continue to be followed for disease assessments (if progression was not documented), subsequent 
antilymphoma therapy, and survival.
Subjects may also be contacted by telephone to confirm survival status and subsequent 
antilymphoma therapy use. If the subject fails to return to the clinic for a scheduled 
protocol-specific visit, sites will need to make 2 attempts, using both the telephone and either 
mail or email to contact the subject. Sites must document both attempts to contact the subject. If 
a subject does not respond within 1 month after the second contact, then the subject will be 
considered lost to follow-up, and no additional contact will be required.
Refer to the SOA (Table 4) for a listing of study procedures and disease assessments to be 
completed during the LTFU period.
Subjects who are enrolled but did not receive the investigational product will be followed only 
until the end of this study and will undergo the following assessments at the time points outlined 
in the SOA:

Subsequent therapy for the treatment of NHL

Survival status 

Disease assessment per protocol
All subjects who received an infusion of axicabtagene ciloleucel will transition to the LTFU 
study KT-US-982-5968, where they will be monitored for occurrence of late-onset targeted 
AEs/SAEs suspected to be possibly related to axicabtagene ciloleucel as defined in Protocol 
KT-US-982-5968 and presence of RCR for up to 15 years from the time of axicabtagene 
ciloleucel infusion (also refer to Section 7.14).
In the LTFU study, KT-US-982-5968, subjects will continue assessments at timepoints 
contiguous with the LTFU timepoints in this study.
7.14.
Summary of Scheduled Assessments
The SOA and th LTFU  assessments are provided in Table 3 and Table 4, respectively.


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 50
25 March 2022
Table 3.
Schedule of Assessments
Procedure
Screening
Enrollment/ 
Leukapheresis
Conditioning Chemotherapy
Axicabtagene 
Ciloleucel 
Administration
Post-treatment Follow-up
(each visit calculated from Day 0)
Visit
Within 
28 days of 
enrollment
Within approx.  
5 days of 
eligibility 
confirmation
D-5
D-4
D-3
D-2
D-1
D0
D1 to 7a
Week 2
(± 3 
days)
Week 4
(± 3 
days)
Month 2
(± 1 
week)
Month 3
(± 1 
week)
Medical history 
X
Physical examinationb
X
X
X
X
X
X
X
X
X
Neurological examinationc
X
X
QOD
X
X
Weight (plus height at 
screening)
X
X
Vital signs (BP, HR,RR, O2 
saturation, temperature)
Xd
X
X
X
X
X
X
X
X
X
X
ECOG performance status
X
Electrocardiogram
X
X
ECHOe
X
PET-CT disease assessmentf
Xd
X
X
Archival /Fresh tumor sampleg
X
D7-14
Pregnancy test (serum or urine)
X
Xh
Xh
X
Blood draw for chemistry panel
X
X
X
X
X
X
X
X
X
X
Blood draw for CBC with 
differentiali
X
X
X
X
X
X
X
X
X
X
Blood draw for serology (EU 
sites)j
X
X
Blood draw for LDH
X
Blood draw for MRD
X
X


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 51
25 March 2022
Procedure
Screening
Enrollment/ 
Leukapheresis
Conditioning Chemotherapy
Axicabtagene 
Ciloleucel 
Administration
Post-treatment Follow-up
(each visit calculated from Day 0)
Visit
Within 
28 days of 
enrollment
Within approx.  
5 days of 
eligibility 
confirmation
D-5
D-4
D-3
D-2
D-1
D0
D1 to 7a
Week 2
(± 3 
days)
Week 4
(± 3 
days)
Month 2
(± 1 
week)
Month 3
(± 1 
week)
Lumbar puncturek
X
Blood draw for CRP/ferritin
X
X
X
Blood draw for anti-CD19 CAR 
T cells and central CBC with 
differentialm
X
D7
X
X
X
Blood draw for RCR analysisn
X
X
Blood draw for cytokineso
X
X
D1, D3, 
D7
X
X
Blood draw for lymphocyte 
subsets
X
X
X
X
Leukapheresis 
X
Fludarabine/Cyclophosphamide
X
X
X
Axicabtagene ciloleucel 
intravenous infusion
X
Adverse events/Concomitant 
therapyp 
X
X
X
X
X
X
X
X
X
X
X
X
X
Abbreviations: BP, blood pressure; CAR, chimeric antigen receptor; CBC, complete blood count; CNS, central nervous system; CRP, C-reactive protein; CRS, cytokine release 
syndrome; D, day; ECHO, echocardiogram; ECOG, Eastern Cooperative Oncology Group; EU, European Union; HR, heart rate; LDH, lactate dehydrogenase; MRD, minimal 
residual disease; MRI, magnetic resonance imaging; PET-CT, positron emission tomography–computed tomography; PK, pharmacokinetics; QOD, every other day; RCR, 
replication-competent retrovirus; RR, respiratory rate.
a
Axicabtagene ciloleucel administration period, refer to Appendix 3 for requirements by country regulatory agencies.
b
Subjects with new onset symptoms related to CRS should undergo physical examination at least daily until symptoms resolve to baseline. Subjects with symptoms of CNS 
malignancy, such as new onset severe headaches, neck stiffness, seizures, encephalopathy, cranial nerve deficits, or any focal neurologic findings on physical exam, will have 
a brain MRI and lumbar puncture for examination of cerebral spinal fluid. A physical exam is required prior to the start of conditioning chemotherapy and prior to 
axicabtagene ciloleucel infusion. 
CCI


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 52
25 March 2022
c
Neurologic assessment: A neurological assessment should be done prior to axicabtagene ciloleucel infusion on treatment Day 0, on treatment Day 1, Day 3, Day 5, and Day 7 
during the minimum 7-day observation period. For new onset of neurologic symptoms or if neurologic symptoms persist, neurologic examination will be performed at least 
daily until symptoms resolve to baseline.
d
In addition to the time points outlined in the SOA, it is recommended that vital signs are monitored during and after study treatment (see Section 6) and as clinically indicated.
e
ECHO will be performed following the subject’s last chemotherapy treatment and within 28 days prior to signing the consent may be used for confirmation of eligibility.
f
PET-CT will be performed within 28 days prior to enrollment. If bone marrow involvement was not evaluated within 28 days of enrollment, a PET-CT or a bone marrow 
biopsy will be performed to establish a baseline. PET-CT shall be performed at any time disease progression is suspected. If there is evidence of baseline bone marrow 
involvement, or if there are unexplained cytopenias, or suspicion of bone marrow involvement, a bone marrow aspirate and biopsy will be performed in subjects who are 
being assessed for CR in order to confirm complete response. 
 
g
Either formalin-fixed paraffin-embedded tumor block or 30 unstained slides will be required. If an archived tumor sample is not available, a fresh tumor sample is required 
prior to start of chemotherapy to continue on study. 
 
Archived and fresh tumor samples (if applicable) will be submitted to a central laboratory after eligibility has been confirmed and prior to start of conditioning 
chemotherapy. Slides that have been previously stained with antibodies or other reagents are not acceptable. Screen failed subjects’ archived samples should not be submitted. 
h
Pregnancy test (serum or urine): EU only: test to be completed within 7 days prior to both leukapheresis and conditioning chemotherapy for females of childbearing potential.
i
At the following time points, CBC with differential will be analyzed centrally: prior to leukapheresis, Day 7, Weeks 2 and 4, and Month 3.
j
For EU sites, serologic test (eg, HIV, hepatitis B, hepatitis C, syphilis) will be carried out per institutional guidelines and EU regulations. This may be done within 30 days 
prior to leukapheresis or on the day of leukapheresis.
k
Subjects with symptoms of CNS malignancy (eg, new onset severe headaches, neck stiffness, or focal neurological findings) will have lumbar puncture performed at 
screening to assess cerebral spinal fluid for possible CNS involvement. Subjects with new onset Grade 2 or higher neurologic symptoms after axicabtagene ciloleucel infusion 
will have lumbar puncture performed to assess cerebral spinal fluid when feasible. Measuring the opening pressure should be done, if possible, with recording of the results in 
the subject site chart.
m
Blood draws for anti-CD19 CAR T cells and central CBC with differential will be collected prior to leukapheresis and on Day 7, Weeks 2 and 4, and Month 3. If a subject 
who was admitted to the hospital within the 7-day observation period is discharged and then subsequently re-admitted to the hospital with any axicabtagene ciloleucel-related 
adverse events, blood samples for anti-CD19 CAR T cells will be collected on the day of hospital re-admission and then weekly through and including the day of discharge. 
Blood samples for anti-CD19 CAR T cells will also be collected at the time of disease progression prior to starting any subsequent antilymphoma therapy. Blood and serum 
samples may also be used for further anti-CD19 CAR T-cell evaluation as clinically indicated.
n
Blood draws for RCR will be collected prior to leukapheresis and at Months 3, 6, and 12 then collect yearly for up to 15 years. Yearly samples will only be collected/analyzed 
if positive at Month 3, 6, or 12. Blood and serum samples may also be used for further RCR evaluation as clinically indicated.
o
Blood draws for cytokines will be collected prior to leukapheresis, on Day 0 prior to administration of axicabtagene ciloleucel, on Days 1, 3, 7, and Weeks 2 and 4. If a 
subject who was admitted to the hospital within the 7-day observation period is discharged and then subsequently re-admitted to the hospital with any axicabtagene ciloleucel-
related adverse events, blood samples for cytokines will be collected on the day of hospital re-admission and then weekly through and including the day of discharge. Blood 
samples for cytokines will also be collected at the time of disease progression prior to starting any subsequent antilymphoma therapy. If the subject experiences a Grade 3 or 
higher axicabtagene ciloleucel-related toxicity, such as a Grade 3 CRS or neurologic event, 1 additional blood draw for cytokines will be taken at the time of the Grade 3 or 
higher axicabtagene ciloleucel-related toxicity and upon resolution of the event.
p
Adverse events will be recorded from the date of enrollment until 3 months after completing treatment with axicabtagene ciloleucel. Concomitant therapies will be recorded 
from the date of informed consent until 3 months after completing treatment with axicabtagene ciloleucel. 
CCI
CCI
CCI
CCI


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 53
25 March 2022
Table 4.
Long-term Follow-up Assessments
Procedure
Long-term Follow-up Period 
Each visit calculated from Day 0
(all visits have ± 28 day window)
Visit 
frequency
Month
6
Month
9
Month
12
Month
15
Month
18
Month
24
Month
30
Month
36 a
Month
42
Month
48
Month
54
Month
60
Month 72 
and 
Annually 
Thereafter
Physical 
examination 
(with 
neurological 
examination)b
X
X
X
X
X
X
PET-CT 
disease 
assessmentc
X
X
X
X
X
X
X
X
X
X
X
X
X
Survival status
X
X
X
X
X
X
X
X
X
X
X
X
X
Blood draw for 
CBC with 
differentiald
X
X
X
X
X
X
Blood draw for 
lymphocyte 
subsets
X
X
X
X
X
X
Blood draw for 
anti-CD19 
CAR T cells 
and central 
CBC with 
differentiale
X
X
X
X
Blood draw for 
RCR analysisf
X
X
X
X
X
X
X
Blood draw for 
MRD
X


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 54
25 March 2022
Procedure
Long-term Follow-up Period 
Each visit calculated from Day 0
(all visits have ± 28 day window)
Visit 
frequency
Month
6
Month
9
Month
12
Month
15
Month
18
Month
24
Month
30
Month
36 a
Month
42
Month
48
Month
54
Month
60
Month 72 
and 
Annually 
Thereafter
Targeted 
SAEsg
X
X
X
X
X
X
Targeted 
concomitant 
medicationsh
X
X
X
X
X
X
Subsequent 
therapy for 
NHLi
X
X
X
X
X
X
X
X
X
X
X
X
X
Abbreviations: CAR, chimeric antigen receptor; CBC, complete blood count; CT, computed tomography; NHL, non-Hodgkin lymphoma; PET-CT, positron emission tomography–computed 
tomography; MRD, minimal residual disease; RCR, replication-competent retrovirus; SAE, serious adverse event.
a
After completion of at least 36 months of assessments in ZUMA-12, subjects who received an infusion of axicabtagene ciloleucel will transition to the LTFU study KT-US-982-5968 
after providing signed informed consent, to complete the remainder of the 15-year LTFU period.
b
Physical exams will continue through Month 24.
c
PET-CT/disease assessments will continue through Month 24 or until disease progression, whichever comes first. If subject’s disease has not progressed by Month 24, disease 
assessments will continue to be performed per standard of care.
d
Blood draw for CBC with differentials will continue through Month 24 or until disease progression, whichever comes first. 
e
Blood draw for anti-CD19 CAR T cells and central CBC with differential will continue through Month 24. 
f
Blood draws for RCR analysis will continue through Month 12. Yearly samples will only be collected/analyzed if positive at Month 3, 6, or 12. Blood and serum samples may also be 
used for further RCR evaluation as clinically indicated. 
g
After 3 months, only targeted SAEs will be reported. Targeted SAEs are defined as infections; neurological, hematological, and autoimmune disorders; and secondary malignancies that 
occur up to 24 months after axicabtagene ciloleucel infusion or until disease progression (whichever occurs first).
h
Targeted concomitant medications will be collected for 24 months or until disease progression (whichever occurs first). 
i
Subsequent therapy refers to therapy administered after axicabtagene ciloleucel infusion for a subject’s disease, such as non-study-specified chemotherapy, immunotherapy, target 
agents, as well as stem cell transplant and radiation therapy, which must be collected until the subject completes the LTFU period, is considered lost to follow-up, withdraws consent, or 
dies. Subjects may be contacted by telephone to collect information about subsequent therapy for NHL and to assess survival status.  


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 55
25 March 2022
8.
SUBJECT WITHDRAWAL
Subjects have the right to withdraw from the study at any time and for any reason without 
prejudice to their future medical care by the physician or at the institution.
Subjects can decline to continue to receive study-required treatment and/or other 
protocol-required procedures at any time during the study while continuing to participate in the 
study. This is referred to as partial withdrawal of consent.
If partial withdrawal of consent occurs, the investigator must discuss with the subject the 
appropriate process for discontinuation from the investigational product, study treatment, or 
other protocol-required therapies and must also discuss options for continued participation, 
completion of procedures, and the associated data collection as outlined in the SOA. The level of 
follow-up and method of communication should also be discussed between the research staff and 
the subject and documented in the source documents.
Withdrawal of full consent from a study means that the subject does not wish to receive further 
protocol-required therapy, undergo procedures, and continue participating in study follow-up. 
Subject data collected up until withdrawal of consent will be retained and included in the 
analysis of the study. Publicly available data (death records) can be included after withdrawal of 
consent if local regulations permit. The investigator is to discuss with the subject appropriate 
procedures for withdrawal from the study.
As part of the study, sites may be asked to conduct searches of public records, such as those 
establishing survival status, if available, to obtain survival data for any subject for whom the 
survival status is not known. Sites may be asked to also retrieve autopsy reports to confirm status 
of disease at the time of death.
The investigator and/or sponsor can also decide to withdraw a subject from the investigational 
product and/or other protocol-required therapies, protocol procedures, or the study as a whole at 
any time prior to study completion.
8.1.
Reasons for Removal from Treatment
Reasons for removal from protocol-required investigational products or procedures include any 
of the following:

AEs

Subject request

Product not available

Lost to follow-up

Death

Decision by sponsor


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 56
25 March 2022
8.2.
Reasons for Removal from Study
Reasons for removal of a subject from the study are as follows:

Subject withdrawal of consent from further follow-up

Investigator decision

Lost to follow-up

Death


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 57
25 March 2022
9.
SAFETY REPORTING
9.1.
Adverse Events
An AE is defined as any untoward medical occurrence in a clinical trial subject. The event does 
not necessarily have a relationship with study treatment. The investigator is responsible for 
ensuring that any AEs observed by the investigator or reported by the subject are recorded in the 
subject’s medical record. The definition of AEs includes worsening of a pre-existing medical 
condition. Worsening indicates that the pre-existing medical condition has increased in severity, 
frequency, and/or duration or has an association with a worse outcome. When recording such 
events, provide descriptions that the pre-existing condition has changed (eg, more frequent 
headaches for a subject with pre-existing headaches or BP has increased in a subject with 
pre-existing hypertension).
A pre-existing condition that has not worsened during the study or involves an intervention, such 
as elective cosmetic surgery or a medical procedure while on study, is not considered an AE.
Interventions for pretreatment conditions (such as elective cosmetic surgery) or medical procedures 
that were planned before study participation are not considered AEs. Hospitalization for study-
treatment infusions or precautionary measures per institutional policy are not considered AEs.
The term “disease progression,” as assessed by measurement of malignant lesions on radiographs 
or other methods, should not be reported as AEs. Death due to disease progression in the absence 
of signs and symptoms should be reported under the primary tumor type (eg, B-cell lymphoma).
When an AE or SAE is due to the disease under investigation, it is necessary to report the signs 
and symptoms. Worsening of signs and symptoms of the malignancy under study should also be 
reported as AEs in the appropriate section of the CRF.
The investigator’s clinical judgment is used to determine whether a subject is to be removed 
from treatment due to an AE. If a subject requests to withdraw from protocol-required therapies 
or the study because of an AE, then the subject should undergo the procedures outlined in the 
Month 3 visit of the SOA.
9.2.
Reporting of Adverse Events
The investigator is responsible for reporting all AEs observed by the investigator or reported by 
the subject that occur after enrollment (ie, commencement of leukapheresis) through 3 months 
after treatment with axicabtagene ciloleucel infusion.
After 3 months, targeted AEs (eg, infections, neurological, hematological, and autoimmune 
disorders, and secondary malignancies) will be monitored and reported for 15 years after 
treatment with axicabtagene ciloleucel or until disease progression, whichever occurs first.
For subjects who are enrolled, but do not receive axicabtagene ciloleucel, the AE reporting 
period ends 30 days after the last study-specific procedure (eg, leukapheresis, conditioning 
chemotherapy).


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 58
25 March 2022
The investigator must provide the information listed below regarding the AEs being reported:

AE diagnosis or syndrome (if not known, signs or symptoms)

Dates of onset and resolution

Severity

Assessment of relatedness to axicabtagene ciloleucel, conditioning chemotherapy, or study 
procedures

Action taken
The AE grading scale used will be the National Cancer Institute (NCI) Common Terminology 
Criteria for Adverse Events (CTCAE) version 5.0. A copy of the grading scale can be 
downloaded from the Cancer Therapy Evaluation Program home page (http://ctep.cancer.gov). 
CRS events will be reported using the grading scale outlined in the IB.
In reviewing AEs, investigators must assess whether the AE is possibly related to 
1) axicabtagene ciloleucel, 2) conditioning chemotherapy, 3) any protocol-required study 
procedure or treatment, 4) disease progression, 5) concurrent disease, 6) concomitant medication, 
or 7) other. The relationship is indicated by a Yes or No response and entered into the CRF. A 
Yes response should indicate that there is evidence to suggest a causal relationship between the 
study treatment or procedure and the AE. Additional relevant data with respect to describing the 
AE will be collected in the CRFs.
The investigator is expected to follow reported AEs until stabilization or resolution. If a subject 
begins a new antilymphoma therapy, the AE reporting period for non-SAEs ends at the time the 
new treatment is started.
9.2.1.
Reporting Abnormal Laboratory Findings
The investigator is responsible for reviewing laboratory test results and determining whether an 
abnormal value in an individual study subject represents a clinically significant change from the 
subject’s baseline values. In general, abnormal laboratory findings without clinical significance 
(based on the investigator’s judgment) are not to be recorded as AEs. However, abnormal 
laboratory findings that result in new or worsening clinical sequelae, or that require therapy or 
adjustment in current therapy, are considered AEs. Where applicable, clinical sequelae (not the 
laboratory abnormality) are to be recorded as the AE.


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 59
25 March 2022
An abnormal laboratory test result must be reported as an AE if it is a change from baseline and 
meets any of the following criteria:

Is associated with clinical symptoms

Results in a medical intervention (eg, potassium supplementation for hypokalemia or iron 
replacement therapy for anemia) or a change in concomitant therapy

Is clinically significant in the investigator’s judgment
9.3.
Definition of Serious Adverse Events
An SAE is defined as an AE that meets at least 1 of the following serious criteria:

Fatal

Life-threatening (places the subject at immediate risk of death)

Requires inpatient hospitalization or prolongation of existing hospitalization

Results in persistent or significant disability/incapacity

Congenital anomaly/birth defect

Other medically important event
An AE would meet the criterion of “requires hospitalization” if the event necessitated an 
admission to a healthcare facility (eg, overnight stay).
Events that require an escalation of care when the subject is already hospitalized should be 
recorded as an SAE. Examples of such events include movement from routine care in the 
hospital to the intensive care unit or if that event resulted in a prolongation of the existing 
planned hospitalization.
If an investigator considers an event to be clinically important, but it does not meet any of the 
serious criteria, the event could be classified as an SAE with the criterion of “other medically 
important serious event.”
The terms “severe” and “serious” are not synonymous. Severity refers to the intensity of an AE 
according to NCI CTCAE criteria; the event itself may be of relatively minor medical 
significance and, therefore, may not meet the seriousness criteria. Severity and seriousness need 
to be independently assessed for each AE recorded on the electronic CRF (eCRF).


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 60
25 March 2022
9.4.
Reporting of Serious Adverse Events 
The investigator is responsible for reporting all SAEs observed by the investigator or reported by 
the subject that occur after signing of the informed consent through 3 months after the 
axicabtagene ciloleucel infusion or until the initiation of another antilymphoma therapy, 
whichever occurs first. After 3 months, only targeted SAEs will be reported. Targeted SAEs are 
defined as and include infections; neurological, hematological, and autoimmune disorders; and 
secondary malignancies that occur up to 15 years after axicabtagene ciloleucel infusion or until 
disease progression, whichever occurs first.
SAEs, which the investigator assesses as related to axicabtagene ciloleucel, should be reported 
regardless of the time period.
For subjects who screen fail or are enrolled but do not receive axicabtagene ciloleucel, the 
reporting period for SAEs ends 30 days after the last study-specific procedure (eg, screening 
procedure, leukapheresis, conditioning chemotherapy).
All SAEs must be submitted to Kite via the electronic SAE system within 24 hours of the 
investigator’s knowledge of the event. If the electronic SAE system is unavailable (eg, system 
outage), then the SAE must be submitted using the SAE Report Form and emailed to the SAE 
Reporting mailbox: 
Following completion of ZUMA-12, any relevant information on ongoing SAEs must be 
submitted to Kite Pharma within 24 hours of the investigator’s knowledge of the event using the 
paper SAE Report Form and sent via e-mail to the SAE Reporting mailbox: 
Subsequently, all SAEs will be reported to the health authorities per local reporting guidelines.
Disease progression of the malignancy is not considered an AE. However, signs and symptoms 
of disease progression may be recorded on the CRF as AEs or SAEs and indicated as being due 
to disease progression. If the malignancy has a fatal outcome before the end of the SAE reporting 
period, then the event leading to the death must be recorded as an SAE with the outcome being 
fatal.
Death must be reported if it occurs during the SAE reporting period, irrespective of any 
intervening treatment.
Any death occurring after the first dose of chemotherapy, for the purpose of pre-conditioning, 
and within 3 months of axicabtagene ciloleucel infusion, regardless of attribution to treatment, 
requires expedited reporting within 24 hours. Any death occurring after the SAE reporting period 
requires expedited reporting within 24 hours only if it is considered related to treatment.
9.5.
Reporting Deaths
Deaths that occur during the protocol-specified AE reporting period that are attributed by the 
investigator solely to progression of underlying lymphoma should be recorded as SAEs with the 
PPD
PPD


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 61
25 March 2022
preferred term “B-cell lymphoma” and must be reported immediately to the sponsor. Death is an 
outcome and not a distinct event. The event or condition that caused or contributed to the fatal 
outcome should be recorded on the AE form. However, every effort should be made to capture 
the established cause of death, which may become available later on (eg, after autopsy). Refer to 
the CRF completion guidelines for detailed instructions.
9.6.
Diagnosis Versus Signs and Symptoms
For AEs, a diagnosis (if known) rather than individual signs and symptoms should be recorded 
on the AE form. The exception is for CRS where both the diagnosis and the signs and symptoms 
will be captured on the AE form. For signs and symptoms of the underlying cancer, the signs and 
symptoms should be captured. However, on the AE form, the investigator should state that these 
signs and symptoms are due to the underlying disease.
9.7.
Pregnancy and Lactation
There is no relevant clinical experience with axicabtagene ciloleucel in pregnant or lactating 
women, and animal reproductive studies have not been performed. Women of childbearing 
potential must have a negative pregnancy test prior to enrollment because of the potentially 
dangerous effects of the preparative chemotherapy on the fetus. Women of childbearing potential 
should be monitored according to local and country-specific regulations. This experimental 
therapy should not be administered to pregnant women or women who are breastfeeding.
Female subjects and female partners of male subjects are recommended to use highly effective 
contraception (method must achieve an annual failure rate of < 1%) for at least 6 months after 
conditioning chemotherapy dosing or the administration of axicabtagene ciloleucel, whichever is 
longer. Male subjects are recommended to not father a child for at least 6 months after the 
conditioning chemotherapy dosing or the administration of axicabtagene ciloleucel, whichever is 
longer. Refer to Appendix 4 for a complete list of highly effective contraception methods.
If a pregnancy occurs in either a female subject enrolled into the study or a female partner of a 
male subject within 6 months of completing conditioning chemotherapy or the administration of 
axicabtagene ciloleucel, whichever is longer, the pregnancy must be reported to the sponsor. 
Information regarding the pregnancy and/or the outcome may be requested by the sponsor.
The pregnancy should be reported to the sponsor within 24 hours of the investigator’s knowledge 
of the pregnancy event by using the pregnancy report form and emailing it to: 
The pregnancy outcome should be reported to the sponsor using the pregnancy outcome report 
form and emailing it to: 
Lactation cases occurring in female patients taking protocol-required therapies (PRT) and up to 
6 months after PRT should be reported to 
 within 24 hours of awareness 
using the lactation reporting form.
PPD
PPD
PPD


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 62
25 March 2022
9.8.
Hospitalization and Prolonged Hospitalization
Any AE that results in hospitalization or prolonged hospitalization should be documented and 
reported as an SAE as described in Section 9.4.
The following hospitalization scenarios are not considered to be SAEs:

Hospitalization for palliative care or hospice care

Planned hospitalization required by the protocol (eg, for monitoring of the subject or to 
perform an efficacy measurement for the study)

Planned hospitalization for a pre-existing condition

Hospitalization due to progression of the underlying cancer
9.9.
Abnormal Vital Sign Values
Not all vital sign abnormalities qualify as an AE. A vital sign result must be reported as an AE if 
it is a change from baseline and meets any of the following criteria:

Accompanied by clinical symptoms

Results in a medical intervention or a change in concomitant therapy

Clinically significant in the investigator’s judgment
It is the investigator’s responsibility to review all vital sign findings. Medical and scientific 
judgment should be exercised in deciding if an isolated vital sign abnormality should be 
classified as an AE. However, if a clinically significant vital sign abnormality is a sign of a 
disease or syndrome (eg, high BP), only the diagnosis (ie, hypertension) should be recorded on 
the CRF.
9.10.
Data Safety Monitoring Board 
An independent DSMB will be chartered to meet and review the SAEs and SUSARs on a semi-
annual basis after the first subject has been treated with axicabtagene ciloleucel up through the 
primary analysis. Kite Pharma, or delegate, will submit SAEs and SUSARs to the DSMB on a 
regular basis throughout the study up through the primary analysis. The DSMB will also meet to 
review safety data after 15 subjects have been enrolled and treated with axicabtagene ciloleucel 
and have had an opportunity to be followed for 3 months after axicabtagene ciloleucel infusion. 
The DSMB will make trial conduct recommendations on an ongoing basis based on an analysis 
of risk vs benefit. The DSMB may request additional safety data for review or recommend 
modifications to the study conduct if safety concerns are identified. The DSMB may meet more 
often as needed.


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 63
25 March 2022
The sponsor may request additional reviews by the DSMB. Data submitted to the DSMB may be 
monitored or unmonitored to facilitate timely DSMB review. At the time of expedited reporting 
of SUSARs to the FDA, Kite Pharma (or designee) will concurrently submit these reports to the 
DSMB chair.


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 64
25 March 2022
10.
STATISTICAL CONSIDERATIONS
10.1.
Hypothesis
No formal hypothesis will be tested. This study is designed to estimate the CR rate in subjects 
with high-risk large B-cell lymphoma. The CR rate targeted in this study is 60%.
10.2.
Study Endpoints
10.2.1.
Primary Endpoint
CR rate is defined as the incidence of a CR per the Lugano Classification {Cheson 2014} as 
determined by study investigators. All evaluable subjects who do not meet the criteria for a CR 
by the analysis data cutoff date will be considered non-responders.
The final analysis will be performed on subjects in this study after at least 36 months of follow-
up. Subjects will be transitioned to the KT-US-982-5968 study for the remainder of the 15-year 
LTFU period. Descriptive estimates of key efficacy and safety analyses may be updated to assess 
the overall treatment profile.
10.2.2.
Secondary Endpoints
ORR is defined as the incidence of either a CR or a PR per the Lugano Classification {Cheson 
2014} as determined by the study investigators. All evaluable subjects who do not meet the 
criteria for an objective response by the analysis cutoff date will be considered non-responders.
DOR is defined only for subjects who experience an objective response after axicabtagene 
ciloleucel infusion and is the time from the first objective response to disease progression per the 
Lugano Classification {Cheson 2014} or death from any cause. Subjects not meeting the criteria 
for disease progression or death from any cause by the analysis data cutoff date will be censored 
at their last evaluable disease assessment date. Subjects who receive any subsequent new 
antilymphoma therapy, including SCT in the absence of documented disease progression or 
death, will be censored at the last evaluable disease assessment prior to the subsequent new 
antilymphoma therapy.
EFS is defined as the time from the axicabtagene ciloleucel infusion date to the earliest date of 
disease progression per the Lugano Classification {Cheson 2014}, commencement of subsequent 
new antilymphoma therapy including SCT, or death from any cause. Subjects alive, in response, 
and with no new antilymphoma therapy including SCT will be censored at the last evaluable 
disease assessment.
PFS is defined as the time from the axicabtagene ciloleucel infusion date to the date of disease 
progression per the Lugano Classification {Cheson 2014} or death from any cause. Subjects not 
meeting the criteria for disease progression or death from any cause by the analysis data cutoff 
date will be censored at the last evaluable disease assessment. Subjects who receive any 
subsequent new antilymphoma therapy including SCT in the absence of documented disease 
progression or death will be censored at the last evaluable disease assessment prior to the 
subsequent new antilymphoma therapy.


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 65
25 March 2022
OS is defined as the time from axicabtagene ciloleucel infusion to the date of death from any 
cause. Subjects who are alive will be censored at their last date known to be alive or the data 
cutoff date, whichever is earlier. Subjects who die after the data cutoff date will be censored at 
the data cutoff date.
Relapse with CNS disease is defined as the time from the axicabtagene ciloleucel infusion date 
to the earliest date of CNS involvement with lymphoma, as determined by typical symptoms, 
CSF evaluation, and/or diagnostic imaging.
Incidence of AEs (including Grade 3 or higher, serious, fatal, and AEs of interest) and clinically 
significant changes in safety laboratory values. Additional secondary endpoints include PK and 
pharmacodynamic endpoints, such as the evaluation of anti-CD19 CAR T-cell levels in the blood 
and cytokine levels in the serum in relationship with clinical outcome.
10.2.4.
Covariates and Subgroups
The following covariates at screening/baseline may be used in efficacy and safety analyses:

Age (< 65, ≥ 65 years)

Gender

Race

Ethnicity

ECOG status 

IPI score

Diagnosis category (double-hit lymphomas versus triple-hit lymphomas versus 
non-double-/triple-hit with IPI score ≥ 3)

Levels of cytokines

Levels of CAR T cells

CR achieved on the study
Additional associative analyses of covariates with subject outcomes will be specified in the 
statistical analysis plan.
CCI


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 66
25 March 2022
10.3.
Sample Size Considerations
In the GELA randomized Phase 2 study evaluating the efficacy of R-ACVBP or R-CHOP-14 
induction, using IWF 2007 criteria in young patients with high-risk DLBCL, the primary 
objective of achieving a higher than 50% CR rate after 4 cycles of induction regimen was not 
met in both randomization groups (47% in R-ACVBP and 39% in R-CHOP-14) {Casasnovas 
2017}. Accordingly, it is postulated that a CR rate of 60% would represent a clinically 
meaningful improvement over standard chemoimmunotherapy in a high-risk large B-cell 
lymphoma patient population. Although there is no formal hypothesis testing, the sample size 
has been determined in part with descriptive analysis described below.
The trial uses a single-arm design to estimate the CR rate in subjects with high-risk large B-cell 
lymphoma treated with axicabtagene ciloleucel. A CR rate of 60% with axicabtagene ciloleucel 
treatment is targeted. With a total sample size of 40 subjects, an observed CR rate of 60% will 
yield an 80% CI for the response rate with a maximum half-width of less than or equal to 11%, 
corresponding to a lower limit of at least 48.6%. This target CR rate, and the lower limit of the 
80% CI for the CR rate, is meaningful because it would represent a significant improvement in 
the response rate for the subjects with high-risk large B-cell lymphoma and would likely offer an 
improvement over existing therapies in patients with high-risk large B-cell lymphoma.
Table 5 provides the estimated CR rate and the lower and upper limits of 80%/95% CI based on 
the Clopper-Pearson method for a range of possible CR rates for a sample of 40 subjects. 
Table 5.
Lower and Upper Limits of 80%/95% CIs for CR Rates from 60% to 
100% for a Sample of 40 Subjects
Number (%) of CRs
24 (60)
28 (70)
32 (80)
36 (90)
40 (100)
Lower and upper limits 
of 80% CI (%, %)
48.6, 70.6
58.8, 79.5
69.6, 88.0
81.0, 95.6
94.4, 100
Lower and upper limits 
of 95% CI (%, %)
43.3, 75.1
53.5, 83.4
64.4, 90.9
76.3, 97.2
91.2, 100
Abbreviations: CI, confidence interval; CR, complete response.
10.4.
Access to Individual Subject Treatment Assignments
This is a single-arm, open-label study, and subjects and investigators will be aware of treatment 
received. Data-handling procedures for the study will be devised to reduce potential sources of 
bias and maintain the validity and credibility of the study. These procedures will be outlined in 
the study statistical plan, DSMB charter, and trial integrity document.
10.5.
Interim Analysis and Early Stopping Guidelines
The DSMB will meet and review SAEs and SUSARs on a semi-annual basis after the first 
subject has been dosed. The DSMB may request additional safety data.


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 67
25 March 2022
One planned interim analysis will be performed. Interim Analysis 1 will be conducted after 
15 subjects have been enrolled and treated with axicabtagene ciloleucel and have had an 
opportunity to be followed for 3 months after axicabtagene ciloleucel infusion. This analysis will 
be for efficacy and safety and will be descriptive.
10.6.
Analysis Subsets
In this study, subjects are to be dosed at a target of 2 x 106 (1.0 x 106 to 2.4 x 106) anti-CD19 
CAR T cells/kg. A minimum dose of 1 x 106 anti-CD19 CAR T cells/kg may be administered. 
For subjects weighing ≥ 100 kg, a maximum flat dose of 2 x 108 anti-CD19 CAR T cells will be 
administered. Subjects are considered to have received the target dose if they receive at least 
1 x 106 anti-CD19 CAR T cells/kg.
The safety analysis set is defined as all subjects treated with any dose of axicabtagene ciloleucel. 
This analysis set will be used for all safety data analyses.
The full analysis set will consist of all enrolled/leukapheresed subjects and will be used for the 
summary of subject disposition and the listing of deaths.
The response evaluable analysis set will consist of the subjects who are enrolled and treated with 
axicabtagene ciloleucel at a dose of at least 1 x 106 anti-CD19 CAR T cells/kg and have a 
centrally confirmed disease type (double-/triple-hit lymphomas) or large B-cell lymphoma with 
an IPI score ≥ 3. This analysis set will be used for all efficacy data analyses including CR rate, 
ORR, endpoints based on response (DOR, EFS, and PFS), relapse with CNS, and OS.
10.7.
Planned Method of Analysis
The primary analysis will occur after all treated subjects have an opportunity to be assessed for 
response 6 months after the Week 4 disease assessment. The CSR will be written based on the 
data collected and analyzed from this primary analysis. The final analysis will occur after all 
subjects complete at least 36 months of follow-up.
The primary analysis of CR rate will be based on the investigator’s review of disease 
assessments in the response evaluable analysis set.
10.7.1.
CR Rate
The subject incidence of CR will be calculated. The 2-sided 80%/90%/95% CIs will be provided 
about the CR rate, calculated with the Clopper-Pearson method.
10.7.2.
ORR
The subject incidence of objective response will be calculated. The 2-sided 80%/90%/95% CIs 
will be provided about the ORR, calculated with the Clopper-Pearson method.
The incidence of subjects with CR, PR, stable disease, PD, not done, and not evaluable, as best 
overall response to treatment, and exact 2-sided 80%/90%/95% CIs about the incidence will be 
generated.


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 68
25 March 2022
10.7.3.
DOR
Kaplan-Meier plots, estimates, and 2-sided 80%/90%/95% CIs will be generated for DOR among 
the subjects who achieve an objective response. Kaplan-Meier estimates of the proportion of 
subjects alive and PFS at 3-month intervals will be provided. The number of subjects censored or 
having events and the reasons for censoring or type of events (PD or death) will be summarized.
A sensitivity analysis of DOR will be conducted in which disease assessments obtained after 
SCT (for subjects who undergo SCT while in an axicabtagene ciloleucel-induced response) will 
be used in the derivation of DOR.
DOR may be evaluated in subgroups defined by the covariates described in Section 10.2.4.
10.7.4.
EFS
Kaplan-Meier plots, estimates, and 2-sided 80%/90%/95% CIs will be generated for EFS. 
Kaplan-Meier estimates of the proportion of subjects alive and event-free at 3-month intervals 
will be provided. The number of subjects censored or having events, and the reasons for 
censoring or type of events (PD, subsequent new antilymphoma therapy, or death) will be 
summarized.
EFS may be evaluated in subgroups defined by the covariates described in Section 10.2.4.
10.7.5.
PFS
Kaplan-Meier plots, estimates, and 2-sided 80%/90%/95% CIs will be generated for PFS. 
Kaplan-Meier estimates of the proportion of subjects alive and progression-free at 3-month 
intervals will be provided. The number of subjects censored or having events, and the reasons for 
censoring or type of events (PD or death) will be summarized. 
PFS may be evaluated in subgroups defined by the covariates described in Section 10.2.4.
10.7.6.
OS
Kaplan-Meier plots, estimates, and 2-sided 80%/90%/95% CIs will be generated for OS. 
Estimates of the proportion of subjects alive at 3-month intervals will be provided through 
2 years after the final subject has been enrolled and then annually through the completion of the 
study. The number of subjects censored or having events, and the reasons for censoring or type 
of events (death) will be summarized. 
OS may be evaluated in subgroups defined by the covariates described in Section 10.2.4.
10.7.7.
Relapse with CNS Disease
The number of subjects with CNS relapse and time to relapse with CNS disease among the 
subjects who experience CNS relapse will be summarized.
Relapse with CNS disease may be evaluated in subgroups defined by the covariates described in 
Section 10.2.4.


Axicabtagene Ciloleucel 
Clinical Protocol 
KTE-C19-l 12 (ZUMA-12) 
10.7.8. 
Safety 
Kite Phruma, Inc. 
Subject incidence rates of AEs, including all, serious, fatal, CTCAE Grade 3 or higher, 
treatment-related AEs, and AEs of interest repo1ted throughout the conduct of the study, will be 
tabulated by system organ class and prefened tenns or prefened te1ms only, coded with the 
Medical Dictiona1y for Regulato1y Activities. Changes in laborato1y values and vital signs will 
be summarized with descriptive statistics. 
The incidence of concomitant medications will be summarized. 
Tables and/or nairntives of deaths through the LTFU and treatment-related SAEs will be 
provided. 
The incidence, prevalence, duration, and reversibility of identified risks, RCR, and secondaiy 
malignancies will be summai·ized. 
10.7.9. 
Pharmacokinetic Analysis 
The levels of anti-CD19 CART cells measured in peripheral blood at Day 7 after axicabtagene 
ciloleucel infusion will be summarized with descriptive statistics. 
10.7.10. 
Pharmacodynamics Analyses 
The levels of cytokines in sernm will be summai·ized with descriptive statistics. 
-
CONFIDENTIAL 
Page 69 
25 Mru·ch 2022 


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 70
25 March 2022
11.
REGULATORY OBLIGATIONS
This study will be conducted in accordance with the protocol and with the following:

Consensus ethical principles derived from international guidelines including the Declaration 
of Helsinki

Applicable International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) 
Guidelines

Applicable local laws and regulations
11.1.
Independent Review Board/Independent Ethics Committee
A copy of the protocol, ICF, and any additional subject or trial information, such as subject 
recruitment materials, must be submitted to each site’s respective IRB/IEC for approval. After 
approval is obtained from the IRB/IEC, all documents must be provided to the key sponsor 
contact before subject recruitment can begin.
The investigator must also receive IRB/IEC approval for all protocol and ICF changes or 
amendments. Investigators must ensure that ongoing/continuous IRB/IEC approval (ie, annual 
approval) is provided throughout the conduct of the study. Copies of IRB/IEC approval are to be 
forwarded to the key sponsor contact for archiving.
During the course of the study, investigators will submit site-specific and study SAEs (provided 
to the site by the key sponsor contact) along with any protocol deviations to their IRB/IEC in 
accordance with their respective IRB/IEC policies. 
11.2.
Subject Confidentiality
Subject confidentiality must be maintained within all material that is submitted to the key 
sponsor contact. The following rules are to be applied.

Subjects will be identified by a unique ID number

Year of birth/age at time of enrollment will be reported according with local laws and 
regulations
For the reporting of SAEs, subjects will be identified by their respective subject ID number, 
initials, and year of birth (as per their local reporting requirements for both initials and year of 
birth).


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 71
25 March 2022
Per country-specific regulations and ICH/GCP guidelines, investigators and institutions are 
required to permit authorization to the sponsor, contract research organization, IRB/IEC, and 
regulatory agencies to subject’s original source documents for verification of study data. The 
investigator is responsible for informing potential subjects that such individuals will have access 
to their medical records, which includes personal information.
11.3.
Investigator Signatory Obligations
Each CSR will be signed by the coordinating investigator. The coordinating investigator will be 
identified by Kite under the following criteria:

Is a recognized expert in the disease setting

Provided significant contributions to the design or analysis of study data

Participated in the study and enrolled a high number of eligible subjects


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 72
25 March 2022
12.
PROTOCOL AMENDMENTS AND TERMINATION
If the protocol is amended, the investigator’s agreement with the amendment and the IRB/IEC 
approval of the amendment must be obtained. Documentation acknowledging approval from 
both parties are to be submitted to the key sponsor contact.
Both Kite Pharma and the investigator reserve the right to terminate the investigator’s 
participation in the study as per the terms of the agreement in the study contract. The investigator 
is to provide written communication to the IRB/IEC regarding either the trial completion or early 
termination and provide the contract research organization with a copy of the correspondence.
Kite Pharma reserves the unilateral right, at its sole discretion, to determine whether to 
manufacture axicabtagene ciloleucel and provide it to sites and subjects after the completion of 
the study.


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 73
25 March 2022
13.
STUDY DOCUMENTATION AND ARCHIVING
The investigator will maintain a list of qualified staff to whom study responsibilities have been 
delegated. The individuals authorized to fulfil these responsibilities should be outlined and 
included in the Delegation of Authority Form.
Source documents are original documents, data, and records for which the study data are 
collected and verified. Examples of such source documents may include, but are not limited to, 
hospital records and patient charts; laboratory, pharmacy, and radiology records; subject diaries; 
microfiches; correspondence; and death registries. CRF entries may be considered as source data 
if the site of the original data collection is not available. However, the use of the CRFs as source 
documentation is not recommended as a routine practice.
The investigator and study staff are responsible for maintaining a comprehensive and centralized 
filing system of all subject records that are readily retrieved to be monitored and or audited at 
any time by the key sponsor contact, health authorities, and IRB/IECs. The filing system will 
include at a minimum:

Subject content including ICFs and subject ID lists

Protocols and protocol amendments, IB, copies of pre-study documentation, and all IRB/IEC 
and sponsor communication

Proof of receipt, experimental treatment flow records, and experimental product-related 
correspondence
Original source documents supporting entries into CRFs must be maintained at the site and 
readily available upon request. No study documents should be discarded without prior written 
agreement between Kite and the investigator. If storage is no longer available to archive source 
documents, or if source documents must be moved to an alternative location, the research staff 
should notify the key sponsor contact prior to shipping the documents.


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 74
25 March 2022
14.
STUDY MONITORING AND DATA COLLECTION
The key sponsor contact, monitors, auditors, or regulatory inspectors are responsible for 
contacting, and visiting the investigator for the purpose of inspecting the facilities and verifying 
source documents and records must also assure that subject confidentially is respected.
The monitor is responsible for source document verification of CRF data at regular intervals 
during the study. Protocol adherence and accuracy and consistency of study conduct and data 
collection with respect to local regulations will be confirmed. Monitors will have access to 
subject records as identified in Section 13.
By signing the investigator’s agreement, the investigator agrees to cooperate with the monitor to 
address and resolve issues identified during monitoring visits.
In accordance with ICH/GCP and the audit plan, a site may be chosen for a site audit. A site 
audit would include, but is not limited to, an inspection of the facility(ies), review of subject- and 
study-related records, and compliance with protocol requirements as well as ICH/GCP and 
applicable regulatory policies.
All data will be collected in an electronic CRF system. All entries must be completed in English 
and concomitant therapies should be identified by tradenames. For further details surrounding 
the completion of CRFs, please refer to the CRF completion guidelines.


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 75
25 March 2022
15.
PUBLICATION
Authorship of publications from data generated in study KTE-C19-112 (ZUMA-12) will be 
determined based on the uniform requirements for manuscripts submitted to biomedical journals 
(as outlined in the International Committee of Medical Journal Editors December 2013), which 
states that authorship should be based on:

Substantial contributions to the conception or design of the work, acquisition of data, 
analysis, or interpretation of data for the work; and

Drafting the article or revising it critically for important intellectual content; and

Final approval of the version to be published; and

Agreement to be accountable for all aspects of the work in ensuring that questions related to 
the accuracy or integrity of any part of the work are appropriately investigated or resolved
When a large, multicenter group has conducted the work, the group should identify the 
individuals who accept direct responsibility for the manuscript. This individual should fully meet 
the criteria for authorship defined above.
Funding, collection of data, or general supervision of the research alone or in combination does 
not qualify an individual for authorship.
Any publication, in any form, that is derived from this study must be submitted to Kite for 
review and approval. The study contract among the institution, principal investigator, and Kite or 
its delegate will outline the requirements for publication review.


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 76
25 March 2022
16.
COMPENSATION
Kite will provide compensation for study-related illness or injury pursuant to the information 
outlined in the injury section of the ICF.


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 77
25 March 2022
17.
REFERENCES
Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Mueller SP, et al. Role 
of imaging in the staging and response assessment of lymphoma: consensus of the 
International Conference on Malignant Lymphomas Imaging Working Group. J 
Clin Oncol 2014;32 (27):3048-58.
Broyde A, Boycov O, Strenov Y, Okon E, Shpilberg O, Bairey O. Role and Prognostic 
Significance of the Ki-67 Index in Non-Hodgkin's Lymphoma. Am J Hematol 
2009;84 (6):338-43.
Casasnovas RO, Ysebaert L, Thieblemont C, Bachy E, Feugier P, Delmer A, et al. FDG-PET-
driven consolidation strategy in diffuse large B-cell lymphoma: final results of a 
randomized phase 2 study. Blood 2017;130 (11):1315-26.
Castro JE, James DF, Sandoval-Sus JD, Jain S, Bole J, Rassenti L, et al. Rituximab in 
combination with high-dose methylprednisolone for the treatment of chronic 
lymphocytic leukemia. Leukemia 2009;23 (10):1779-89.
Chaganti S, Illidge T, Barrington S, McKay P, Linton K, Cwynarski K, et al. Guidelines for the 
management of diffuse large B-cell lymphoma. Br J Haematol 2016;174 (1):43-
56.
Chen AI, Leonard JT, Okada CY, Gay ND, Chansky K, Fan G, et al. Outcomes of DA-EPOCH-
R induction plus autologous transplant consolidation for double hit lymphoma. 
Leuk Lymphoma 2017:1-6.
Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. 
Recommendations for initial evaluation, staging, and response assessment of 
Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 
2014;32 (27):3059-68.
Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised 
response criteria for malignant lymphoma. J Clin Oncol 2007;25 (5):579-86.
Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, et al. Long-term 
outcome of patients in the LNH-98.5 trial, the first randomized study comparing 
rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by 
the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 2010;116 (12):2040-5.
de Jonge AV, Roosma TJ, Houtenbos I, Vasmel WL, van de Hem K, de Boer JP, et al. Diffuse 
large B-cell lymphoma with MYC gene rearrangements: Current perspective on 
treatment of diffuse large B-cell lymphoma with MYC gene rearrangements; case 
series and review of the literature. Eur J Cancer 2016;55:140-6.


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 78
25 March 2022
de Oliveira Costa R, Hallack Neto A, Siqueira S, Lage LA, de Paula HM, Coutinho AM, et al. 
Interim Fluorine-18 Fluorodeoxyglucose PET-Computed Tomography and Cell of 
Origin By Immunohistochemistry Predicts Progression-Free and Overall Survival 
in Diffuse Large B-Cell Lymphoma Patients in the Rituximab Era. Nucl Med 
Commun 2016;37 (10):1095-101.
Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, et al. Adoptive cell therapy 
for patients with metastatic melanoma: evaluation of intensive myeloablative 
chemoradiation preparative regimens. J Clin Oncol 2008;26 (32):5233-9.
Flowers CR, Sinha R, Vose JM. Improving outcomes for patients with diffuse large B-cell 
lymphoma. CA Cancer J Clin 2010;60 (6):393-408.
Friedberg JW. How I treat double-hit lymphoma. Blood 2017;130 (5):590-6.
Gattinoni L, Finkelstein SE, Klebanoff CA, Antony PA, Palmer DC, Spiess PJ, et al. Removal of 
homeostatic cytokine sinks by lymphodepletion enhances the efficacy of 
adoptively transferred tumor-specific CD8+ T cells. J Exp Med 2005;202 (7):907-
12.
Green TM, Young KH, Visco C, Xu-Monette ZY, Orazi A, Go RS, et al. Immunohistochemical 
double-hit score is a strong predictor of outcome in patients with diffuse large B-
cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, 
vincristine, and prednisone. J Clin Oncol 2012;30 (28):3460-7.
Howlader N, Noone A, Krapcho M, Miller D, Bishop K, Altekruse S, et al. SEER Cancer 
Statistics Review, 1975-2013. National Cancer Institute. Bethesda, MD, 
http://seer.cancer.gov/csr/1975_2013/, based on November 2015 SEER data 
submission, posted to the SEER web site, April 2016. 2015.
International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for 
aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329 (14):987-94.
Itti E, Meignan M, Berriolo-Riedinger A, Biggi A, Cashen AF, Vera P, et al. An International 
Confirmatory Study of the Prognostic Value of Early PET/CT in Diffuse Large B-
cell Lymphoma: Comparison between Deauville Criteria and DeltaSUVmax. Eur 
J Nucl Med Mol Imaging 2013;40 (9):1312-20.
Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, et al. Gene therapy 
with human and mouse T-cell receptors mediates cancer regression and targets 
normal tissues expressing cognate antigen. Blood 2009;114 (3):535-46.
Klebanoff CA, Khong HT, Antony PA, Palmer DC, Restifo NP. Sinks, suppressors and antigen 
presenters: how lymphodepletion enhances T cell-mediated tumor 
immunotherapy. Trends Immunol 2005;26 (2):111-7.


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 79
25 March 2022
Kochenderfer JN, Somerville RPT, Lu T, Shi V, Bot A, Rossi J, et al. Lymphoma Remissions 
Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With 
High Serum Interleukin-15 Levels. J Clin Oncol 2017;35 (16):1803-13.
Leonard JP, Schattner EJ, Coleman M. Biology and management of mantle cell lymphoma. Curr 
Opin Oncol 2001;13 (5):342-7.
Locke F, Ghobadi A, Lekakis L, Miklos D, Jacobson C, E. J, et al. Outcomes by prior lines of 
therapy (LoT) in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel 
(Axi-Cel) in patients (Pts) with refractory large B cell lymphoma. J Clin Oncol 
2018;Abstract # 3039.
Locke FL, Neelapu SS, Bartlett NL, Lekakis LJ, Miklos D, Jacobson CA, et al. Primary Results 
From ZUMA-1: A Pivotal Trial of Axicabtagene Ciloleucel (Axi-cel; KTE-C19) 
in Patients With Refractory Aggressive Non-Hodgkin Lymphoma (NHL). 
American Association for Cancer Research (AACR) 2017;Abstract #CT019.
Mamot C, Klingbiel D, Hitz F, Renner C, Pabst T, Driessen C, et al. Final Results of a 
Prospective Evaluation of the Predictive Value of Interim Positron Emission 
Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-
CHOP-14 (SAKK 38/07). J Clin Oncol 2015;33 (23):2523-9.
Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma 
incidence patterns by WHO subtype in the United States, 1992-2001. Blood 
2006;107 (1):265-76.
NCCN. Clinical Practice Guidelines in Oncology; Non-Hodgkin's Lymphomas, Version 3. 2016.
Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene 
Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J 
Med 2017;377 (26):2531-44.
Nicholson IC, Lenton KA, Little DJ, Decorso T, Lee FT, Scott AM, et al. Construction and 
characterisation of a functional CD19 specific single chain Fv fragment for 
immunotherapy of B lineage leukaemia and lymphoma. Mol Immunol 1997;34 
(16-17):1157-65.
Nowakowski GS, Blum KA, Kahl BS, Friedberg JW, Baizer L, Little RF, et al. Beyond RCHOP: 
A Blueprint for Diffuse Large B Cell Lymphoma Research. J Natl Cancer Inst 
2016;108 (12).
O'Brien SM, Kantarjian HM, Cortes J, Beran M, Koller CA, Giles FJ, et al. Results of the 
fludarabine and cyclophosphamide combination regimen in chronic lymphocytic 
leukemia. J Clin Oncol 2001;19 (5):1414-20.


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 80
25 March 2022
Oki Y, Noorani M, Lin P, Davis RE, Neelapu SS, Ma L, et al. Double hit lymphoma: the MD 
Anderson Cancer Center clinical experience. Br J Haematol 2014;166 (6):891-
901.
Olejniczak SH, Stewart CC, Donohue K, Czuczman MS. A quantitative exploration of surface 
antigen expression in common B-cell malignancies using flow cytometry. 
Immunol Invest 2006;35 (1):93-114.
Petrich AM, Gandhi M, Jovanovic B, Castillo JJ, Rajguru S, Yang DT, et al. Impact of induction 
regimen and stem cell transplantation on outcomes in double-hit lymphoma: a 
multicenter retrospective analysis. Blood 2014;124 (15):2354-61.
Rodriguez J, Pugh WC, Romaguera JE, Cabanillas F. Primary mediastinal large cell lymphoma. 
Hematological Oncology 1994;12 (4):175-84.
Sehn LH, Gascoyne RD. Diffuse large B-cell lymphoma: optimizing outcome in the context of 
clinical and biologic heterogeneity. Blood 2015;125 (1):22-32.
Staiger AM, Ziepert M, Horn H, Scott DW, Barth TFE, Bernd HW, et al. Clinical Impact of the 
Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in 
Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of 
the German High-Grade Non-Hodgkin's Lymphoma Study Group. J Clin Oncol 
2017;35 (22):2515-26.
Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the 
World Health Organization classification of lymphoid neoplasms. Blood 
2016;127 (20):2375-90.
Tilly H, Vitolo U, Walewski J, da Silva MG, Shpilberg O, Andr  M, et al. Diffuse large B-cell 
lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment 
and follow-up. Annals of Oncology 2012;23 (Suppl 7):vii78-vii82.
Uckun FM, Jaszcz W, Ambrus JL, Fauci AS, Gajl-Peczalska K, Song CW, et al. Detailed Studies 
on Expression and Function of CD19 Surface Determinant by Using B43 
Monoclonal Antibody and the Clinical Potential of Anti-CD19 Immunotoxins. 
Blood 1988;71 (1):13-29.
Wilson WH, sin-Ho J, N. PB, Hsi ED, Friedberg J, Cheson B, et al. Phase III Randomized Study 
of R-CHOP Versus DA-EPOCH-R and Molecular Analysis of Untreated Diffuse 
Large B-Cell Lymphoma: CALGB/Alliance 50303. Blood (ASH Annual Meeting 
Abstracts) 2016:Abstract #469 
YESCARTA, Kite Pharma Inc. YESCARTA® (axicabtagene ciloleucel) Suspension for 
Intravenous Infusion. U. S. Prescribing Information. Santa Monica, CA. Revised: 
May.  2019:


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 81
25 March 2022
Zhu D, Xu XL, Fang C, Ji M, Wu J, Wu CP, et al. Prognostic Value of Interim (18)F-FDG-PET 
in Diffuse Large B Cell Lymphoma Treated with Rituximab-Based Immune-
Chemotherapy: A Systematic Review and Meta-Analysis. Int J Clin Exp Med 
2015;8 (9):15340-50.
Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, Pfreundschuh M, et al. Standard 
International prognostic index remains a valid predictor of outcome for patients 
with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol 
2010;28 (14):2373-80.


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 82
25 March 2022
18.
APPENDICES
Appendix 1.
Lugano Classification {Cheson 2014}
Appendix 2.
International Prognostic Index in Aggressive Lymphomas
Appendix 3.
Country-Specific Regulatory Agency Requirements
Appendix 4.
Birth Control Methods Which May Be Considered as Highly Effective


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 83
25 March 2022
Appendix 1.
Lugano Classification {Cheson 2014}
Please refer to {Cheson 2014} for details of assessment.
Deauville 5-Point Scale (5PS) {Barrington 2014}
Score
Description 
1 
No uptake above background 
2 
Uptake ≤ mediastinum 
3 
Uptake > mediastinum but ≤ liver 
4 
Uptake moderately higher than liver 
5 
Uptake markedly higher than liver and/or new lesions
X 
New areas of uptake unlikely to be related to lymphoma  
Complete Remission:
Complete Metabolic Response for Positron Emission Tomography–Computed Tomography-
Based Response
The designation of complete metabolic response requires all of the following:

A 5PS (5-point scale) score of 1, 2 or 3, with or without a residual mass 
In Waldeyer’s ring or extranodal sites with high physiologic uptake or with activation 
within spleen or marrow, uptake may be greater than normal in the mediastinum and/or 
liver. In this circumstance, complete metabolic response may be inferred if uptake at sites 
of initial involvement is no greater than surrounding normal tissue even if the tissue has 
high physiologic uptake.

No new sites of disease should be observed 

No evidence of fluorodeoxyglucose (FDG)-avid disease in bone marrow
Complete Radiologic Response for Computed Tomography-Based Response 
The designation of complete radiologic response requires all of the following:

Target nodes/nodal masses must regress to ≤ 1.5 cm in longest transverse diameter (LDi) of a 
lesion

No extralymphatic sites of disease

Absent nonmeasured lesion


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 84
25 March 2022

Organ enlargement regress to normal

No new sites of disease should be observed

Bone marrow normal by morphology; if indeterminate, immunohistochemistry negative
Partial Remission: 
Partial Metabolic Response for Positron Emission Tomography–Computed Tomography-Based 
Response
The designation of partial metabolic response requires all of the following:

A 5PS score of 4 or 5, with reduced uptake compared to baseline (screening), and residual 
mass(es) of any size 
Note:
At interim, these findings suggest responding disease 
At end of treatment, these findings suggest residual disease 

No new sites of disease should be observed 

Residual uptake is higher than uptake in normal bone marrow but reduced compared with 
baseline (diffuse uptake is compatible with reactive changes from chemotherapy allowed)
If there are persistent focal changes in the marrow in the context of a nodal response, 
consideration should be given to further evaluation with magnetic resonance image or biopsy or 
an interval scan.
Partial Radiologic Response for Computed Tomography-Based Response 
The designation of partial radiologic response requires all of the following:

≥ 50% decrease in sum of the product of the perpendicular diameters of up to 6 target 
measurable nodes and extranodal sites 
When a lesion is too small to measure on a computed tomography scan, assign 5 mm x 
5 mm as the default value
When no longer visible, 0 x 0 mm
For a node > 5 mm x 5 mm, but smaller than normal, use actual measurement for 
calculation 

Absent/normal, regressed, but no increase of nonmeasured lesions

Spleen must have regressed by > 50% in length beyond normal 

No new sites of disease should be observed


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 85
25 March 2022
Stable Disease:
No Metabolic Response for Positron Emission Tomography–Computed Tomography-Based 
Response 
The designation of no metabolic response requires all of the following:

A 5PS score of 4 or 5, with no significant change in FDG uptake compared to baseline 
(screening) at an interim time point or end of treatment 

No new sites of disease should be observed 

No change from baseline in bone marrow
Stable Radiologic Disease for Computed Tomography-Based Response
The designation of stable radiologic disease requires all of the following:

< 50% decrease from baseline in the sum of the product of the perpendicular diameters of up 
to 6 dominant, measurable nodes and extranodal sites; no criteria for progressive disease are 
met

No increase consistent with progression in nonmeasured lesion and organ enlargement 

No new sites of disease should be observed 
Progressive Disease:
Progressive Metabolic Disease for Positron Emission Tomography–Computed 
Tomography-Based Response 
The designation of progressive metabolic disease requires at least 1 of the following:

A 5PS score 4 or 5 with an increase in intensity of uptake from baseline and/or

New FDG-avid foci consistent with lymphoma at interim or end of treatment assessment 

New FDG-avid foci consistent with lymphoma rather than another etiology (eg, infection, 
inflammation). If uncertain regarding etiology of new lesions, biopsy or interval scan may be 
considered

New or recurrent FDG-avid foci in bone marrow 


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 86
25 March 2022
Progressive Radiologic Disease for Computed Tomography-Based Response 
The designation of progressive radiologic disease requires at least one of the following:

An individual node/lesion must be abnormal with:
LDi > 1.5 cm and 
Increase by ≥ 50% from cross product of LDi and perpendicular diameter nadir and
An increase in LDi or SDi, shortest axis perpendicular to the LDi, (SDi) from nadir 
■
0.5 cm for lesions ≤ 2 cm
■
1.0 cm for lesions > 2 cm
In the setting of splenomegaly, the splenic length must increase by > 50% of the extent of 
its prior increase beyond baseline (eg, a 15-cm spleen must increase to > 16 cm). If no 
prior splenomegaly, spleen must increase by at least 2 cm from baseline 
New or recurrent splenomegaly

New or clear progression of pre-existing nonmeasured lesions

New lesion
Regrowth of previously resolved lesions
A new node > 1.5 cm in any axis
A new extranodal site > 1.0 cm in any axis; if < 1.0 cm in any axis, its presence must be 
unequivocal and must be attributable to lymphoma
Assessable disease of any size unequivocally attributable to lymphoma

New or recurrent bone marrow involvement


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 87
25 March 2022
Appendix 2.
International Prognostic Index in Aggressive Lymphomas
The International Prognostic Index (IPI) score is calculated by adding the number of prognostic 
factors:

Age > 60 years

Performance status ≥ 2

Lactate dehydrogenase > 1 x normal

Extranodal sites > 1

Stage III or IV
The IPI risk level is determined based on the IPI score: 
Risk Level
IPI Score
Low (L)
0 or 1
Low-intermediate (LI)
2
High-intermediate (HI)
3
High (H)
4 or 5


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 88
25 March 2022
Appendix 3.
Country-Specific Regulatory Agency Requirements 
France
The post-infusion monitoring of subjects, described in Section 7.10.3.2 of this protocol, will be 
extended by monitoring on Day 8, Day 9, and Day 10, according to procedures outlined in 
Table 3, column “Axicabtagene Ciloleucel Administration Period, D1 to 7.” The subject may 
stay hospitalized or return to the clinic daily for this extended monitoring at the discretion of the 
investigator.
The daily monitoring will include vital signs (see Section 7.6), blood draw for chemistry panel 
with C-reactive protein, blood draw for complete blood count with differential, and neurological 
examination (see Section 7.8). Any observed toxicity will be managed according to Section 6.1.8 
of this protocol.


Axicabtagene Ciloleucel
Kite Pharma, Inc.
Clinical Protocol
KTE-C19-112 (ZUMA-12)
CONFIDENTIAL
Page 89
25 March 2022
Appendix 4.
Birth Control Methods Which May Be Considered as Highly Effective
For the purpose of this guidance, methods that can achieve a failure rate of < 1% per year when 
used consistently and correctly are considered as highly effective birth control methods. Such 
methods include:

Combined (estrogen and progesterone containing) hormonal contraception associated with 
inhibition of ovulation1:
Oral
Intravaginal
Transdermal

Progestogen-only hormonal contraception associated with inhibition of ovulation2:
Oral 
Injectable
Implantable2

Intrauterine device2

Intrauterine hormone-releasing system2

Bilateral tubal occlusion2

Vasectomized partner 2,3

Sexual abstinence4
1
Hormonal contraception may be susceptible to interaction with the investigational product, which may reduce the efficacy of 
the contraception method.
2
Contraception methods that in the context of this guidance are considered to have low user dependency.
3
Vasectomized partner is a highly effective birth control method provided that partner is the sole sexual partner of the woman 
of childbearing potential trial subject and that the vasectomized partner has received medical assessment of the surgical 
success.
4
In the context of this guidance sexual abstinence is considered a highly effective method only if defined as refraining from 
heterosexual intercourse during the entire period of risk associated with the study treatments. The reliability of sexual 
abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the 
subject.

SAP_001.pdf: 
Sponsor:
Kite Pharma, Inc.
2400 Broadway
Santa Monica, CA 90404
United States of America
Product Name:
Axicabtagene ciloleucel
Protocol
A Phase 2 Multicenter Study Evaluating the Efficacy and Safety of 
Axicabtagene Ciloleucel as First-Line Therapy in Subjects with High-
Risk Large B-Cell Lymphoma (ZUMA-12)
Protocol Number:
KTE-C19-112
Version Number:
2.0
Release Date:
25 SEPTEMBER 2019
Replaces Previous Version(s):
1.0 27 July 2018
CONFIDENTIALITY NOTICE
This document contains confidential information of Kite Pharma Inc, a wholly owned subsidiary of 
Gilead Sciences Inc. This document must not be disclosed to anyone other than the site research staff and 
members of the institutional review board/independent ethics committee, a scientific review board, or an 
equivalent. The information in this document cannot be used for any purpose other than the conduct of 
the clinical investigation without the prior written consent of Kite Pharma, Inc. Questions regarding how 
this document should be used or the conduct of the clinical trial should be directed to the key sponsor 
contacts.


KTE-C19-112
Statistical Analysis Plan
Kite Pharma, Inc.
CONFIDENTIAL
Page 2
25 September 2019
TABLE OF CONTENTS
TABLE OF CONTENTS ..............................................................................................................................................2
LIST OF TABLES.........................................................................................................................................................3
LIST OF FIGURES.......................................................................................................................................................3
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS................................................................................4
1.
INTRODUCTION ................................................................................................................................................6
2.
OBJECTIVES.......................................................................................................................................................7
3.
STUDY DESIGN..................................................................................................................................................8
3.1.
Overview..................................................................................................................................................8
3.2.
Hypothesis..............................................................................................................................................11
3.3.
Sample Size Consideration.....................................................................................................................11
4.
STUDY ENDPOINTS AND COVARIATES ....................................................................................................12
4.1.
Endpoints ...............................................................................................................................................12
4.1.1.
Primary Endpoint .................................................................................................................12
4.1.2.
Secondary Endpoints............................................................................................................12
4.2.
Covariates and Subgroups......................................................................................................................13
5.
DEFINITIONS....................................................................................................................................................14
5.1.
General...................................................................................................................................................14
5.2.
Safety .....................................................................................................................................................14
5.3.
Efficacy..................................................................................................................................................17
6.
ANALYSIS SUBSETS.......................................................................................................................................20
6.1.
Safety Analysis Set ................................................................................................................................20
6.2.
Full Analysis Set ....................................................................................................................................20
6.3.
Response Evaluable Analysis Set...........................................................................................................20
6.4.
Safety Retreatment Analysis set.............................................................................................................20
6.5.
Subgroup Analysis Sets..........................................................................................................................20
7.
INTERIM ANALYSIS AND EARLY STOPPING GUIDELINES...................................................................21
8.
DATA SCREENING AND ACCEPTANCE......................................................................................................22
8.1.
General Principles ..................................................................................................................................22
8.2.
Electronic Transfer and Archiving of Data ............................................................................................22
8.3.
Handling of Missing and Incomplete Data.............................................................................................22
8.3.1.
Efficacy ................................................................................................................................22
8.3.2.
Safety....................................................................................................................................22
8.4.
Detection of Bias....................................................................................................................................22
8.5.
Outliers...................................................................................................................................................23
8.6.
Distributional Characteristics.................................................................................................................23
8.7.
Validation and Configuration Management ...........................................................................................23
9.
STATISTICAL METHODS OF ANALYSIS ....................................................................................................24
9.1.
General Principles ..................................................................................................................................24
9.2.
Subject Accountability...........................................................................................................................24
9.3.
Important Protocol Deviations ...............................................................................................................24
9.4.
Demographic and Baseline Characteristics............................................................................................24
9.5.
Efficacy Analyses...................................................................................................................................25
9.5.1.
CR rate .................................................................................................................................25


KTE-C19-112
Statistical Analysis Plan
Kite Pharma, Inc.
CONFIDENTIAL
Page 3
25 September 2019
9.5.2.
ORR and Best Overall Response (BOR)..............................................................................26
9.5.3.
DOR .....................................................................................................................................26
9.5.4.
EFS.......................................................................................................................................26
9.5.5.
PFS.......................................................................................................................................26
9.5.6.
OS.........................................................................................................................................27
9.5.7.
Relapse with CNS Disease...................................................................................................27
9.5.8.
Tumor Burden ......................................................................................................................27
9.5.9.
ORR and BOR among Subjects Retreated with axicabtagene ciloleucel.............................27
9.5.10.
DORR...................................................................................................................................27
9.6.
Safety Analyses......................................................................................................................................28
9.6.1.
Adverse Events.....................................................................................................................28
9.7.
Product Characteristics...........................................................................................................................30
9.8.
Pharmacokinetics ...................................................................................................................................31
9.9.
Pharmacodynamics ................................................................................................................................31
9.10.
Subsequent Anti-Cancer Therapy and SCT ...........................................................................................31
10.
CHANGES FROM PROTOCOL-SPECIFIED ANALYSES.............................................................................32
11.
REFERENCES ...................................................................................................................................................33
12.
APPENDICES ....................................................................................................................................................34
Appendix 1.
Conventions for Clinical Data that Require Imputation for Partial or Missing Dates ............35
Appendix 2.
Derivation of Time to Event Endpoints and Last Date Known to Be Alive...........................37
LIST OF TABLES
Table 1.
Lower and upper limits of 80/95% CIs for CR rates from 60% to 100% for a sample 
of 40 subjects..........................................................................................................................11
Table 2.
Imputation Rules for Partial or Missing Start Dates...............................................................35
LIST OF FIGURES
Figure 1.
Study Schema for Study KTE-C19-112 .................................................................................10


KTE-C19-112
Statistical Analysis Plan
Kite Pharma, Inc.
CONFIDENTIAL
Page 4
25 September 2019
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS
Abbreviation
Definition
ADaM
Analysis data model
AE
Adverse event
ASCT
Autologous stem cell transplant
BOR
Best overall response
BSA
Body surface area
CAR
Chimeric antigen receptor
CI
CNS
Confidence Interval
Central nervous system
CR
Complete response
CRF
Case report form
CRS
Cytokine release syndrome
CSF
Cerebrospinal fluid
CSR
Clinical study report
CTCAE
Common terminology criteria for adverse event
DOR
Duration of response
DORR
DLBCL
Duration of response to retreatment
Diffuse large B-cell lymphoma
DSMB
Data safety monitoring board
ECOG
Eastern Cooperative Oncology Group
EFS
Event-free survival
FAS 
GVHD
IPI
MedDRA
Full Analysis Set
Graft-Versus-Host-Disease
International Prognostic Index
Medical Dictionary for Regulatory Activities
MST
NCI
MedDRA search terms 
National Cancer Institute
ND
Not done
NE
Not evaluable
ORR
Objective response rate
OS
Overall survival
PET-CT
Positron emission tomography-computed tomography


KTE-C19-112
Statistical Analysis Plan
Kite Pharma, Inc.
CONFIDENTIAL
Page 5
25 September 2019
Abbreviation
Definition
PFS 
Progression-free survival
PR
Partial response
PT
Preferred term
RCR
Replication-competent retrovirus
SAP
Statistical analysis plan
SCT
Stem cell transplant
SD
Stable disease
SDTM
Study data tabulation model 
SMQ
Standardized MedDRA query 
SOC
System organ class
SUSAR
TEAE
Suspected unexpected serious adverse reactions
Treatment-emergent adverse event
WHO
World Health Organization


KTE-C19-112
Statistical Analysis Plan
Kite Pharma, Inc.
CONFIDENTIAL
Page 6
25 September 2019
1.
INTRODUCTION
This statistical analysis plan (SAP) provides the pre-specification and details for the statistical 
analyses to support the protocol KTE-C19-112 (ZUMA-12) entitled “A Phase 2 Multicenter 
Study Evaluating the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in 
Subjects with High-Risk Large B-Cell Lymphoma”.  The scope of this document is to provide 
details on the planned interim, primary, and final analyses.


KTE-C19-112
Statistical Analysis Plan
Kite Pharma, Inc.
CONFIDENTIAL
Page 7
25 September 2019
2.
OBJECTIVES
The primary objective of the analyses outlined herein is to estimate the efficacy of axicabtagene 
ciloleucel, as measured by CR rate, in subjects with high-risk large B-cell lymphoma, as 
determined by study investigators.
Secondary objectives are to characterize the safety profile, and to further characterize efficacy 
with secondary endpoints; further secondary objectives will include 
pharmacokinetic/pharmacodynamics endpoints.


KTE-C19-112
Statistical Analysis Plan
Kite Pharma, Inc.
CONFIDENTIAL
Page 8
25 September 2019
3.
STUDY DESIGN
3.1.
Overview
Study KTE-C19-112 is a Phase 2, multicenter, single arm, open-label study evaluating the 
efficacy and safety of axicabtagene ciloleucel as first-line therapy in subjects with high-risk large 
B-cell lymphoma.
Approximately 40 subjects with high-risk large B-cell lymphoma, including either high-grade B-
cell lymphoma (HGBL) with MYC and BCL2 and/or BCL6 translocations (double-/triple-hit 
lymphomas), or large B-cell lymphoma with a high-intermediate/ high-risk International 
Prognostic Index (IPI) score ≥3, will be enrolled and treated with cyclophosphamide and 
fludarabine conditioning chemotherapy, followed by a target dose of 2 x 106 anti-CD19 chimeric 
antigen receptor (CAR) T cells/kg body weight.
Each subject with a positive interim positron emission tomography-computed tomography 
(PET-CT) per the Lugano Classification (Cheson et al, 2014) (Deauville 5-point scale PET score 
of 4 or 5) after 2 cycles (PET2+) of standard-of-care chemoimmunotherapy will proceed through 
the following study periods:

Screening

Enrollment/Leukapheresis

Conditioning chemotherapy period

Investigational Product (IP) treatment period

Post treatment assessment period

Long term follow-up period
For study requirements assigned to each study period, refer to protocol Section 7 for details.
At specific time points as outlined in the schedule of assessments, subjects will undergo the 
following assessments/procedures: collection of informed consent, general medical history 
including previous treatments for large B-cell lymphoma, physical exam including vital signs 
and performance status, neurologic assessments, blood draws for complete blood count, 
chemistry panels, cytokines, C-reactive protein, lymphocyte subsets, replication-competent 
retrovirus (RCR) and anti-CD19 CAR T cell analysis. Subjects will also undergo a baseline 
electrocardiogram, echocardiogram, PET-CT, and leukapheresis. Subjects may also need bone 
marrow aspirate/biopsy, brain magnetic resonance image, and lumbar puncture.
CCII 


KTE-C19-112
Statistical Analysis Plan
Kite Pharma, Inc.
CONFIDENTIAL
Page 9
25 September 2019
Routinely throughout the conduct of the study, subjects will be asked to report concomitant 
medications and adverse events and will have their disease assessed.
The primary endpoint is complete response (CR) rate, defined as the incidence of a CR per the 
Lugano Classification (Cheson et al, 2014), as determined by study investigators. All evaluable 
subjects who do not meet the criteria for a CR by the analysis data cutoff date will be considered 
non-complete responders.
Further details on study procedures may be found in the study protocol.  A study schema is 
present in Figure 1.


KTE-Cl9-l 12 
Statistical Analysis Plan 
Kite Pharma, Inc. 
Figure 1. 
Study Schema for Study KTE-C19-112 
OJ) 
.5 
i::: 
(I) 
(I) 
;... u 
(/) 
"'' 
rn 
·;;; 
(I) 
;... 
Cl) 
..i::: g-
_. .:.< 
;:::l 
(I) 
....:I 
i::: 
(I) a 
0 
;... 
i::: 
_. 
_. 
u;>,. 
.9 
0 a 
(I) 
..0 
_. 
u 
OJ) . e 
i::: 
0 
·.-= 
"O 
i::: 
0 u 
Treatment Period: Axicabta1:,ene Ciloleucel 
"O 
Treatment 
0 ·5 
p... .... 
Subjects will receive a single infusion of axicabtagene 
5 a 
ciloleucel administered intravenously at a target dose of 
rn 
rn 
(I) 
2 x I 06 anti-CD 19 CAR T cells/kg on treatment day 0 . 
rn 
___. 
rn 
____. 
.... 
Subjects will receive axicabtagene ciloleucel in a health 
i::: 
Cl) 
care facility followed by a minimum 7 day observation 
§ 
period. 
e<:l 
(I) 
;... 
f-, 
.... 
rn 
0 
p... 
Approximately 40 subjects who are either double hit/triple hit or have IPI 2: 3 will be enrolled and treated. 
C 
Enrollment/Leukapheresis: Subjects who have a positive interim PET per the Lugano Classification { Cheson 2014} (Deauville 
PET score of 4 or 5) after 2 cycles (PET2+) of an anti-CD20 monoclonal antibody and anthracycl ine-containing regimen per local 
standard of care (eg, DA-EPOCH-R) if double hit/triple hit, or an anti-CD20 monoclonal antibody and anthracycline-containing 
Conditioning Chemotherapy: Subjects wi ll receive a 3-day conditioning chemotherapy regimen consisting of tludarabine 
30 mg/m2/day and cyclophosphamide 500 mg/m2/day (Day 5 to Day 3) followed by 2 rest days (Day 2 and Day 1 ). 
CONFIDENTIAL 
Page 10 
"O 
0 -~ 
p... 
0.. 
;:::l 
I 
.9 
0 
a 
;... 
Cl) 
f-, 
OJ) 
i::: 
0 
....:I 
29 June 2018 


KTE-C19-112
Statistical Analysis Plan
Kite Pharma, Inc.
CONFIDENTIAL
Page 11
25 September 2019
3.2.
Hypothesis
No formal hypothesis will be tested. This study is designed to estimate the CR rate in subjects 
with high-risk large B-cell lymphoma. The CR rate targeted in this study is 60%.
3.3.
Sample Size Consideration
In the GELA randomized phase 2 study evaluating the efficacy of R-ACVBP or R-CHOP-14 
induction, using IWF 2007 criteria in young patients with high-risk DLBCL, the primary 
objective of achieving a higher than 50% CR rate after 4 cycles of induction regime was not met 
in both randomization groups (Casasnovas et al, 2017). Accordingly, it is postulated that a CR 
rate of 60% would represent a clinically meaningful improvement over standard 
chemoimmunotherapy in a high-risk large B-cell lymphoma patient population. Although there is 
no formal hypothesis testing, the sample size has been determined in part with descriptive 
analysis described below.    
The trial uses a single-arm design to estimate the CR rate in subjects with high-risk large B-cell 
lymphoma treated with axicabtagene ciloleucel. A CR rate of 60% with axicabtagene ciloleucel 
treatment is targeted. With a total sample size of 40 subjects, an observed CR rate of 60% will 
yield an 80% confidence interval (CI) for the response rate with a maximum half-width of less 
than or equal to 11%, corresponding to a lower limit of at least 48.6%. This target CR rate, and 
the lower limit of the 80% CI for the CR rate, is meaningful because it would represent a 
significant improvement in the response rate for the subjects with high-risk large B-cell 
lymphoma and would likely offer an improvement over existing therapies in patients with high-
risk large B-cell lymphoma (Table 1).
Table 1 provides the estimated CR rate, and the lower and upper limits of 80/95% CIs based on 
the Clopper-Pearson method for a range of possible CR rate for a sample of 40 subjects. 
Table 1.
Lower and upper limits of 80/95% CIs for CR rates from 60% to 100% for a 
sample of 40 subjects
Number (%) of 
CRs
24 (60)
28 (70)
32 (80)
36 (90)
40 (100)
Lower and Upper 
Limits of 80% CI 
(%, %)
48.6, 70.6
58.8, 79.5
69.6, 88.0
81.0, 95.6
94.4, 100
Lower and Upper 
Limits of 95% CI 
(%, %)
43.3, 75.1
53.5, 83.4
64.4, 90.9
76.3, 97.2
91.2, 100
One planned interim analysis will be performed. Interim Analysis 1 will be conducted after 15 
subjects have been enrolled and treated with axicabtagene ciloleucel, and have had an 
opportunity to be followed for 3 months after axicabtagene ciloleucel infusion. This analysis will 
be for efficacy and safety, and will be descriptive. 


KTE-C19-112
Statistical Analysis Plan
Kite Pharma, Inc.
CONFIDENTIAL
Page 12
25 September 2019
4.
STUDY ENDPOINTS AND COVARIATES
4.1.
Endpoints
4.1.1.
Primary Endpoint  

CR rate, defined as the incidence of a CR per the Lugano Classification (Cheson et al, 2014)
as determined by study investigators.
4.1.2.
Secondary Endpoints

Objective response rate (ORR),  defined as the incidence of either a CR or a partial response 
(PR) per the Lugano Classification (Cheson et al, 2014) as determined by the study 
investigators

Duration of response (DOR), defined only for subjects who experience an objective response 
after axicabtagene ciloleucel infusion and is the time from the first objective response to 
disease progression per the Lugano Classification (Cheson et al, 2014) or death from any 
cause. 

Event-free survival (EFS), defined as the time from the axicabtagene ciloleucel infusion date 
to the earliest date of disease progression per the Lugano Classification (Cheson et al, 2014), 
commencement of subsequent new anti-lymphoma therapy including SCT, or death from any 
cause. 

Progression-free survival (PFS), defined as the time from the axicabtagene ciloleucel 
infusion date to the date of disease progression per the Lugano Classification (Cheson et al, 
2014) or death from any cause.  

Overall survival (OS), defined as the time from axicabtagene ciloleucel infusion to the date 
of death from any cause.  

Incidence of adverse events (including grade ≥3, serious, fatal, and adverse events of interest) 
and clinically significant changes in safety lab values.

Relapse with central nervous system (CNS) disease, defined only for subjects who 
experience CNS relapse and defined as the time from the axicabtagene ciloleucel infusion 
date to the earliest date of CNS involvement with lymphoma as determined by typical 
symptoms, CSF evaluation, and/or diagnostic imaging. 
Additional secondary endpoints include pharmacokinetic/pharmacodynamic endpoints such as 
evaluation of levels of anti-CD19 CAR T cells in blood and levels of cytokines in serum in 
relationship with clinical outcome.


KTE-C19-112
Statistical Analysis Plan
Kite Pharma, Inc.
CONFIDENTIAL
Page 13
25 September 2019
4.2.
Covariates and Subgroups
The following covariates at screening/baseline or on the study may be used to examine CR, ORR 
and other efficacy and safety endpoints in covariate or subgroups analyses:  

Age (< 65, ≥ 65 years)

Gender

Race

Ethnicity

ECOG status

IPI score

Diagnosis category (double-hit lymphomas vs triple-hit lymphomas vs non double-/triple-hit 
with IPI score ≥3), by both local and central pathology

Levels of cytokines

Levels of CAR T Cells

CR achieved on the study
Covariate levels that are sparse may be collapsed for purposes of statistical modeling.
Additional associative analyses of covariates with subject outcomes may be explored. 


KTE-C19-112
Statistical Analysis Plan
Kite Pharma, Inc.
CONFIDENTIAL
Page 14
25 September 2019
5.
DEFINITIONS
5.1.
General
Study enrollment:  Study enrollment occurs at the commencement of leukapheresis.
Study Day 0:  Study Day 0 is defined as the day the subject received the first axicabtagene 
ciloleucel infusion.  The day prior to Study Day 0 will be study day -1.  The day of enrollment 
and any days after enrollment and before study day -1 will be sequential and negative integer-
valued.  
Baseline:  The baseline value is defined as the last value taken prior to first dose of conditioning 
chemotherapy; if enrolled subjects do not receive conditioning chemotherapy, the baseline value 
is defined as the last value taken prior to enrollment/leukapheresis.
Study therapy:  Study therapy is defined as conditioning chemotherapy or axicabtagene 
ciloleucel.
On-study:  Time from enrollment to the last date of contact.
End of study:  This will occur after all subjects treated with axicabtagene ciloleucel have been 
followed for 15 years post axicabtagene ciloleucel infusion, have withdrawn consent, been lost to 
follow-up, or have died.
Actual follow-up time:  Actual follow-up time among all subjects treated with axicabtagene 
ciloleucel is calculated as the time from the first dose of axicabtagene ciloleucel to the date of 
death, last date known alive, lost to follow-up, or withdrawal of consent, whichever is later.
Potential follow-up time:  Potential follow-up time is defined as the time from the axicabtagene 
ciloleucel infusion to the data cutoff date for the analysis.
Follow-up time for response:  Follow-up time for response is derived as the time from the 
axicabtagene ciloleucel infusion date to the last disease assessment or censoring date.  Follow-up 
time for response is derived using the reverse Kaplan-Meier approach in which the censoring 
times and event times are reversed to derive the median follow-up time.
5.2.
Safety
Treatment-emergent adverse event (TEAE): Any adverse event with onset on or after the 
axicabtagene ciloleucel infusion. For subjects who receive retreatment with axicabtagene 
ciloleucel, TEAEs after retreatment may be summarized separately.
Deaths:  All deaths that occur after leukapheresis up through the end of study.
Adverse events of interest:  Adverse events of interest for axicabtagene ciloleucel treatment 
include adverse events in the categories of:


KTE-C19-112
Statistical Analysis Plan
Kite Pharma, Inc.
CONFIDENTIAL
Page 15
25 September 2019
Important Identified risks:

Cytokine-release syndrome (CRS)

Neurologic toxicity

Cytopenias, including
neutropenia 
thrombocytopenia 
anemia 

Hypogammaglobulinemia

Infections
Important Potential risks:

Secondary malignancies

Tumor lysis syndrome

Bone marrow failure

Graft-Versus-Host-Disease (GVHD)

Replication competent retrovirus (RCR)

Immunogenicity (anti-axicabtagene ciloleucel antibodies)
Cytokine release syndrome (CRS):  CRS as a syndrome (i.e. a collection of individual 
symptoms) is identified via collection of the syndrome on a case report form specifically 
designed to collect CRS. Individual symptoms of CRS are separately collected on the adverse 
events log and are linked to the CRS syndrome. CRS syndrome severity is graded according to a 
modification of the grading system proposed by Lee and colleagues (Lee et al, 2014).  In the 
modified grading scale, neurologic AEs are not reported as part of the CRS syndrome; rather, 
they are reported on the AE log form separately based on specific symptoms per Common 
Terminology Criteria for Adverse Events (CTCAE).
Neurologic toxicity (Neurotoxicity):  Neurologic adverse events will be identified with Medical 
Dictionary for Regulatory Activities (MedDRA) search terms (MST) search strategy based on 
known neurologic toxicities associated with anti-CD19 immunotherapy (Topp et al, 2015). The 
search strategy focuses on central nervous system (CNS) toxicity, without regard to temporal 
relationship and concomitant conditions (e.g. CRS).  MedDRA system organ classes (SOCs) of 
Psychiatric Disorders and Nervous System Disorders will be reviewed for additional events.


KTE-C19-112
Statistical Analysis Plan
Kite Pharma, Inc.
CONFIDENTIAL
Page 16
25 September 2019
These events will then be evaluated for potential inclusion as neurologic AEs. Neurologic 
toxicity will be reported separately from CRS.
Cytopenias (including aplastic anemia): Cytopenias (neutropenia or thrombocytopenia or 
anemia including aplastic anemia and bone marrow failure) are identified as: 

Thrombocytopenia will be identified using the standardized MedDRA query (SMQ) for 
haematopoietic thrombocytopenia (narrow search)

Neutropenia will be identified using Kite-specified MedDRA search terms (MST)

Anemia (including aplastic anemia) will be identified using the SMQ haematopoietic 
erythropenia (broad search)
Subjects with cytopenias (neutropenia or thrombocytopenia or anemia) present on or after 
Day 30 post axicabtagene ciloleucel infusion will be summarized separately by cell lineage.
Hypogammaglobulinemia: Hypogammaglobulinemia will be identified using a MST search 
strategy defined by Kite.  
Infections:  Infections are identified as adverse events within the system organ class (SOC) of 
Infections and Infestations that occur after treatment with axicabtagene ciloleucel and in 
MedDRA high level group terms (HLGTs) that capture events of: 
1) Bacterial infection, encompassing PTs within the MedDRA HLGTs of 
a) bacterial infectious disorders 
b) chlamydial infectious disorders
2) Viral infection, encompassing PTs within the MedDRA HLGTs of viral infectious disorders
3) Opportunistic infections, encompassing PTs within the MedDRA HLGTs of 
a) fungal infectious disorders
b) mycobacterial infectious disorders
4) Other infections, encompassing PTs within the MedDRA HLGTs of Infections pathogen 
unspecified
Secondary malignancy:  Adverse events that are coded into the SOC of Neoplasms benign, 
malignant, and unspecified (including cysts and polyps) will be reviewed to identify potential 
events.  Additionally, adverse events that are coded into the SOC of Neoplasms benign, 
malignant, and unspecified (including cysts and polyps) will be reviewed to identify other 
potential events.  
Tumor Lysis Syndrome:  Tumor lysis syndrome will be identified as events with MedDRA PTs
in the Tumor Lysis Syndrome SMQ (MedDRA). The narrow version of this SMQ will be used.


KTE-C19-112
Statistical Analysis Plan
Kite Pharma, Inc.
CONFIDENTIAL
Page 17
25 September 2019
Bone marrow failure:  Bone marrow failure will be identified using the narrow SMQ of 
haematopoietic cytopenias affecting more than one type of blood test.
Graft-Versus-Host Disease (GVHD):  Graft-Versus-Host-Disease (GVHD) will be identified 
using a MST search strategy defined by Kite by using subsets of PT from HLGT of procedural 
related injuries and complications NEC and high level term (HLT) of immune and associated 
conditions NEC.
Immunogenicity (Anti-axicabtagene ciloleucel antibody): Immunogenicity will be identified 
for subjects who have treatment emergent anti-axicabtagene ciloleucel antibodies and have 
developed any AE belonging to the SMQ of anaphylactic reaction and the SMQ of 
hypersensitivity.  The narrow version of these two SMQs will be used.
Time to Onset of Event/Syndrome:  Time to onset of an event/syndrome is defined as the time 
from study day 0 to the day of the first occurrence of the event/syndrome.  Time to Onset of 
Grade 3 or Higher Events/Syndromes are defined in the same way, but restricted to Grade 3 or 
higher events/syndromes.
Duration of Event/Syndrome:  The duration across all events is the last day of the last event 
first day of the first event +1, regardless of whenever the events are consecutive, overlapping, or 
neither. 
Durations of events will not be calculated for events that are ongoing at the time of the data 
cutoff date or subject death.  For events defined by laboratory criteria, time to onset and duration 
will not be calculated.  For events defined by both laboratory criteria and adverse events, only 
the adverse event component will be used to define time to onset and duration.
5.3.
Efficacy
CR rate: CR rate is defined as the incidence of a CR per the Lugano Classification (Cheson et 
al, 2014) as determined by study investigators. All evaluable subjects who do not meet the 
criteria for a CR by the analysis data cutoff date will be considered non-complete responders.  
The derivation of this endpoint will only include response assessments obtained after the initial 
axicabtagene ciloleucel infusion and up to progressive disease (PD)/death due to any cause or the 
disease assessments prior to any subsequent anti-lymphoma therapy including stem cell 
transplant (SCT) or retreatment with axicabtagene ciloleucel.  
ORR: ORR is defined as the incidence of either a CR or a PR per the Lugano Classification 
(Cheson et al, 2014) as determined by the study investigators. All evaluable subjects who do not 
meet the criteria for an objective response by the analysis cutoff date will be considered non-
responders, including the subjects with nonevaluable assessment data and those without any 
assessment.  The derivation of this endpoint will only include response assessments obtained 
after the initial axicabtagene ciloleucel infusion and up to PD/death due to any cause or the 
disease assessments prior to any subsequent anti-lymphoma therapy including SCT or 
retreatment with axicabtagene ciloleucel


KTE-C19-112
Statistical Analysis Plan
Kite Pharma, Inc.
CONFIDENTIAL
Page 18
25 September 2019
DOR:  DOR is defined only for subjects who experience an objective response (CR or PR) after 
axicabtagene ciloleucel infusion and is the time from the first objective response to disease 
progression per the Lugano Classification (Cheson et al, 2014) or death due to any cause. 
Subjects not meeting the criteria for disease progression or death by the analysis data cutoff date 
will be censored at their last evaluable disease assessment date. The DOR for subjects who 
receive any subsequent anti-lymphoma therapy including SCT or retreatment with axicabtagene 
ciloleucel in the absence of documented disease progression or death due to any cause will be 
censored at the last evaluable disease assessment prior to the start date of the subsequent anti-
lymphoma therapy. Further details on the derivation of DOR are provided in Appendix 2.  
EFS: EFS is defined as the time from the axicabtagene ciloleucel infusion date to the earliest 
date of disease progression per the Lugano Classification (Cheson et al, 2014), commencement 
of subsequent anti-lymphoma therapy including SCT or retreatment with axicabtagene 
ciloleucel, or death due to any cause. Subjects alive, in response, and with no new anti-
lymphoma therapy including SCT or retreatment with axicabtagene ciloleucel will be censored at 
the last evaluable disease assessment. Further details on the derivation of EFS are provided in
Appendix 2.
PFS:  PFS is defined as the time from the axicabtagene ciloleucel infusion date to the date of 
disease progression per the Lugano Classification (Cheson et al, 2014) or death due to any cause.  
Subjects not meeting the criteria for disease progression or death from any cause by the analysis 
cutoff date will be censored at the last evaluable disease assessment.  The PFS for subjects who 
receive any subsequent anti-lymphoma therapy including SCT or retreatment with axicabtagene 
ciloleucel in the absence of documented disease progression or death due to any cause will be 
censored at the last evaluable disease assessment prior to the start date of the subsequent anti-
lymphoma therapy.  Further details on the derivation of PFS are provided in Appendix 2.
OS:  OS is defined as the time from the axicabtagene ciloleucel infusion to the date of death due 
to any cause.  Subjects who are alive by the analysis data cutoff date will be censored at their last 
date known to be alive or the data cutoff date, whichever is earlier. Subjects who die after the 
data cutoff date will be censored at the data cutoff date. Further details on the derivation of 
overall survival and the specific data modules that will be used to derive the last date known to 
be alive are provided in Appendix 2.
Relapse with CNS: relapse with CNS disease is defined only for subjects who experience CNS 
relapse. It is defined as the time from the axicabtagene ciloleucel infusion date to the earliest date 
of CNS involvement with lymphoma as determined by typical symptoms, CSF evaluation, and/or 
diagnostic imaging.
Duration of response to retreatment (DORR):  DORR is defined only for subjects who receive 
retreatment following progression of disease and then go on to experience an objective response 
to retreatment. It is defined as the time from the first objective response after retreatment to 
disease progression per the Lugano Classification (Cheson et al, 2014) or death due to any cause.  
Subjects not meeting the criteria for disease progression after retreatment or death due to any 
cause by the analysis data cutoff date will be censored at their last evaluable disease assessment 
date after retreatment.  DORR will be derived using disease assessments obtained on study prior 


KTE-C19-112
Statistical Analysis Plan
Kite Pharma, Inc.
CONFIDENTIAL
Page 19
25 September 2019
to the start date of any subsequent anti-lymphoma therapy including SCT.  Further details on the 
derivation of DORR are provided in Appendix 2.


KTE-C19-112
Statistical Analysis Plan
Kite Pharma, Inc.
CONFIDENTIAL
Page 20
25 September 2019
6.
ANALYSIS SUBSETS
In this study, subjects are to be dosed at a target of 2 x 106 (1.0 x 106 to 2.4 x106) anti-CD19 
CAR T cells/kg. A minimum dose of 1 x 106 anti-CD19 CAR T cells/kg may be administered. 
For subjects weighing ≥100 kg, a maximum flat dose of 2 x 108 anti-CD19 CAR T cells will be 
administered. Subjects are considered to have received the target dose if they receive at least 1 x 
106 anti-CD19 CAR T cells/kg.
6.1.
Safety Analysis Set
The safety set is defined as all subjects treated with any dose of axicabtagene ciloleucel. This 
analysis set will be used for all safety data analyses.
6.2.
Full Analysis Set
The full analysis set (FAS) will consist of all enrolled/leukapheresed subjects and will be used 
for the summary of subject disposition and the listing of deaths.
6.3.
Response Evaluable Analysis Set
The response evaluable analysis set will consist of the subjects who are enrolled and treated with 
axicabtagene ciloleucel at a dose of at least 1 x 106 anti-CD19 CAR T cells/kg, and centrally 
confirmed disease type (double-/triple- hit lymphomas) or IPI score ≥3. This analysis set will be 
used for all efficacy data analyses including CR rate and ORR, and endpoints based on response 
(DOR, EFS, PFS), relapse with CNS, and OS.
6.4.
Safety Retreatment Analysis set
The safety retreatment analysis set will consist of all subjects who undergo retreatment with 
axicabtagene ciloleucel. This set will be used for all retreatment safety and efficacy analyses.
6.5.
Subgroup Analysis Sets
Subgroup analyses of selected efficacy and safety endpoints may be performed for the covariates
and subgroups defined in Section 4.2.


KTE-C19-112
Statistical Analysis Plan
Kite Pharma, Inc.
CONFIDENTIAL
Page 21
25 September 2019
7.
INTERIM ANALYSIS AND EARLY STOPPING GUIDELINES
The data safety monitoring board (DSMB) will meet and review the serious adverse events 
(SAEs) and suspected unexpected serious adverse reactions (SUSARs) on at least a semi-annual 
basis after the first subject has been treated with axicabtagene ciloleucel up through the primary 
analysis of the study. The DSMB will also review SAEs and SUSARs on a regular basis up 
through the primary analysis. 
One planned interim analysis will be performed. At Interim Analysis 1, the DSMB will meet to 
review safety data after 15 subjects have been enrolled and treated with axicabtagene ciloleucel 
and have had an opportunity to be followed for 3 months after axicabtagene ciloleucel infusion.
The DSMB will make trial conduct recommendations on an ongoing basis based on an analysis 
of risk vs benefit. The DSMB may request additional safety data or may recommend modifying 
the study conduct if safety concerns are identified. Data submitted to the DSMB may be 
monitored or unmonitored to facilitate and ensure timely DSMB review.


KTE-C19-112
Statistical Analysis Plan
Kite Pharma, Inc.
CONFIDENTIAL
Page 22
25 September 2019
8.
DATA SCREENING AND ACCEPTANCE
8.1.
General Principles
The database will be subject to the edit checks outlined in the Data Management Plan and 
additional manual data reviews defined by the study team. Data inconsistencies will be reviewed 
and resolved before the database snapshot for the primary analyses and the final database lock. 
For interim analyses, snapshots may include data that has not passed all data cleaning procedures 
at the time the data are extracted for snapshot.  
8.2.
Electronic Transfer and Archiving of Data
The database for this study will be managed and maintained by Kite Pharma.  Raw data, Study 
Data Tabulation Model (SDTM) data, and Analysis Data Model (ADaM) datasets will be 
generated by Kite Pharma, Inc. and will be archived for all planned analyses. Any additional 
unplanned analyses that occur after the primary analyses and prior to the final analysis will also 
be archived. 
Data from the central pathology laboratory, the product characteristics central laboratory 
assessment of subject serum samples (CAR T cell levels in the peripheral blood, antibody assays, 
RCR testing) will be generated from contract laboratories and Kite Pharma. These data will be 
transferred to Kite held in a peripheral directory and not built into the clinical trial database. At 
the time analyses require these data, they may be merged with the SDTM and ADaM datasets.
8.3.
Handling of Missing and Incomplete Data
8.3.1.
Efficacy
The method for handling missing data is described in the definition for each efficacy endpoint.  
Every effort will be made to obtain complete dates for deaths. In the event of a partial or missing 
death date and the corresponding censoring date for survival, the algorithm in Appendix 2 will be 
used.
8.3.2.
Safety
Partial adverse event start dates will be imputed. If dates are missing or incomplete for adverse 
event start dates, the algorithm defined in Appendix 1 will be used. Completely missing death 
dates or death dates with only a year reported will not be imputed.  
8.4.
Detection of Bias
A listing of subjects with important protocol deviations will be generated. The deviations 
included in this list will include violations of eligibility criteria and use of exclusionary 
medication during the study. Lack of protocol compliance will be evaluated by summarizing the 
subject incidence of important protocol deviations. High rates of important protocol deviations 
may indicate bias.


KTE-C19-112
Statistical Analysis Plan
Kite Pharma, Inc.
CONFIDENTIAL
Page 23
25 September 2019
8.5.
Outliers
Descriptive statistics will be used to identify potential outliers in any key variables analyzed. 
Suspected outliers will be included in all analyses unless there is sufficient scientific justification 
to exclude them.
8.6.
Distributional Characteristics
The goal of the primary statistical analysis is to estimate CR rate.  All 80/90/95% confidence 
intervals will be 2-sided and calculated via the Clopper-Pearson method.  This test assumes only 
the independence of the individual subject responses.
8.7.
Validation and Configuration Management
Programs for the development of the SDTM and ADaM datasets and the generation of the tables, 
figures, and listings will be developed and maintained according to Kite Pharma Standard 
Operating Procedures. The software and version used to generate analyses will be indicated in 
the archived documentation.


KTE-C19-112
Statistical Analysis Plan
Kite Pharma, Inc.
CONFIDENTIAL
Page 24
25 September 2019
9.
STATISTICAL METHODS OF ANALYSIS
9.1.
General Principles
The primary analysis will occur after all treated subjects have an opportunity to be assessed for 
response 6 months after the Week 4 disease assessment. The clinical study report (CSR) will be 
written based on the data collected and analyzed from this primary analysis. The final analysis 
will occur after all subjects complete the study. The primary analysis of CR rate will be based on 
investigator review of disease assessments in the response evaluable analysis set.
9.2.
Subject Accountability
The number of subjects screened, enrolled, leukapheresed, treated with conditioning 
chemotherapy, treated with axicabtagene ciloleucel, and retreated with axicabtagene ciloleucel 
will be summarized.  The reasons for discontinuing treatment and the disease assessment and 
survival follow-up periods will be summarized.
Summaries of actual follow up time will be provided.
The number of subjects enrolled by country and site will be summarized.  
The number of subjects in each analysis set along with reasons for exclusion will be provided.
9.3.
Important Protocol Deviations
The clinical study team will define important protocol deviation categories and review all 
potential important protocol deviations at minimum, prior to the database snapshot for the 
primary efficacy analysis. Important protocol deviations will be categorized by deviation type 
(e.g. entry/eligibility, use of excluded medication, etc).  The subject incidence of important 
protocol deviations will be summarized overall and by deviation category.
9.4.
Demographic and Baseline Characteristics
Summary statistics and frequencies for the following demographic and baseline characteristics 
will be tabulated:

Age (< 65, ≥ 65)

Race:  white, Asian, other (categories may be collapsed or expanded based on accrual)

Ethnicity (Hispanic or Latino, Not Hispanic or Latino)

Sex (male, female)

Weight

Height


KTE-C19-112
Statistical Analysis Plan
Kite Pharma, Inc.
CONFIDENTIAL
Page 25
25 September 2019

IPI score

ECOG performance status 

Diagnosis category (double-hit lymphomas vs triple-hit lymphomas vs non double-/triple-hit 
with IPI score ≥3). Double/triple hit status will be summarized per investigator and per 
central pathology.

Disease stage

Disease extent (presence of B symptoms, splenic involvement, extranodal disease, bulky 
disease)

Bone marrow involvement
9.5.
Efficacy Analyses
For the primary analysis, the investigator assessment status per the Lugano Classification 
(Cheson et al, 2014) for CR rate will be used. The investigator reviewer will provide the 
determination of disease status (CR, PR, stable disease [SD], progressive disease [PD], not 
evaluable [NE], not done [ND]) at each time point.  SAS programs developed by Kite Pharma 
will derive the best overall response (BOR), DOR, EFS, and PFS based on these assessments.
The primary efficacy analysis will be presented in the response evaluable analysis set.
For subjects retreated with axicabtagene ciloleucel, disease assessments obtained prior to 
retreatment but not disease assessment obtained after retreatment will be included in the primary 
summaries of ORR and BOR, DOR, EFS, PFS, and summaries of change in tumor burden (if 
applicable). For such retreated subjects, disease assessments obtained after retreatment will be 
included in the summaries of ORR, BOR rate to retreatment with axicabtagene ciloleucel, and 
DOR after retreatment with axicabtagene ciloleucel.
In the event any subject undergoes any subsequent antilymphoma therapy (including SCT or 
retreatment with axicabtagene ciloleucel) while on study, the subject’s BOR and change in tumor 
burden will be derived only based on disease outcomes assessed prior to initiation of the 
subsequent anti-lymphoma therapy (including SCT or retreatment with axicabtagene ciloleucel), 
whichever is earlier. For subjects without documentation of disease progression prior to initiation 
of the subsequent anti-lymphoma therapy (including SCT or retreatment with axicabtagene 
ciloleucel), DOR, EFS, and PFS time will be censored at the last disease assessment prior to the 
initiation of subsequent anti-lymphoma therapy. 
9.5.1.
CR rate 
9.5.1.1.
Primary Analyses of CR Rate
The subject incidence of CR will be calculated. The 2-sided 80/90/95% CIs will be provided 
about the CR rate, calculated with the Clopper-Pearson method.


KTE-C19-112
Statistical Analysis Plan
Kite Pharma, Inc.
CONFIDENTIAL
Page 26
25 September 2019
9.5.1.2.
Subgroup Analyses of CR 
CR rate, and 95% CIs about CR rate will be generated for subgroups defined in Section 4.2.
A forest plot of the proportion of responders for each of these groups will be generated.  
9.5.2.
ORR and Best Overall Response (BOR) 
9.5.2.1.
Primary Analyses of ORR and BOR
The subject incidence of objective response will be calculated. The 2-sided 80/90/95% CIs will 
be provided about the ORR, calculated with the Clopper-Pearson method.
The incidence of subjects with PR, SD, PD, ND and NE, as BOR to treatment and exact 2-sided 
80/90/95% CIs about the incidence will also be generated.
9.5.2.2.
Subgroup Analyses of ORR 
ORR, and 95% CIs about ORR will be generated for subgroups defined in Section 4.2.
A forest plot of the proportion of responders for each of these groups will be generated.
9.5.3.
DOR
Kaplan-Meier plots, estimates, and 2-sided 80/90/95% CIs will be generated for DOR among the 
subjects who achieve an objective response. Kaplan-Meier estimates of the proportion of 
subjects alive and progression-free at 3-month intervals will be provided. The number of subjects 
censored or having events, and the reasons for censoring or type of events (PD or death) will be 
summarized.
A sensitivity analysis of DOR will be conducted in which disease assessments obtained after 
SCT (for subjects who undergo SCT while in an axicabtagene ciloleucel-induced response) will 
be used in the derivation of DOR.
DOR may be evaluated in subgroups defined by the covariates described in Section 4.2.
9.5.4.
EFS
Kaplan-Meier plots, estimates, and 2-sided 80/90/95% CIs will be generated for EFS. Kaplan-
Meier estimates of the proportion of subjects alive and event-free at 3-month intervals will be 
provided. The number of subjects censored or having events, and the reasons for censoring or 
type of events (PD, subsequent anti-lymphoma therapy, or death) will be summarized.
EFS may be evaluated in subgroups defined by the covariates described in Section 4.2.
9.5.5.
PFS
Kaplan-Meier plots, estimates, and 2-sided 80/90/95% CIs will be generated for PFS. Kaplan-
Meier estimates of the proportion of subjects alive and progression-free at 3-month intervals will 


KTE-C19-112
Statistical Analysis Plan
Kite Pharma, Inc.
CONFIDENTIAL
Page 27
25 September 2019
be provided. The number of subjects censored or having events, and the reasons for censoring or 
type of events (PD or death) will be summarized.
PFS may be evaluated in subgroups defined by the covariates described in Section 4.2.
9.5.6.
OS
Kaplan-Meier plots, estimates and 2-sided 80/90/95% CIs will be generated for OS. Estimates of 
the proportion of subjects alive at 3-month intervals will be provided through 2 years after the 
final subject has been enrolled and then annually through the completion of the study. The 
number of subjects censored or having events, and the reasons for censoring or type of events 
(death) will be summarized.
OS may be evaluated in subgroups defined by the covariates described in Section 4.2.
9.5.7.
Relapse with CNS Disease
The number of subjects with CNS relapse and time to relapse with CNS disease among the 
subjects who experience CNS relapse will be summarized.
Relapse with CNS disease may be evaluated in subgroups defined by the covariates described in 
Section 4.2.
9.5.8.
Tumor Burden
The change in tumor burden, as measured by the sum of the products of the diameters of the 
selected lesions, from baseline to post-baseline nadir will be summarized in absolute numbers 
(mm2) and percentage. A graphical summary of this change will be presented in a vertical bar 
chart with each subject’s change from baseline to nadir displayed as a vertical bar, with color 
coding that indicates best response attained (“waterfall” plot).  Summary statistics will be 
provided for this change. Additionally, plots over time of the percent change in tumor burden for 
each subject (superimposed on one graph) will be presented. Data collected after the subsequent 
anti-lymphoma therapy including SCT or retreatment with axicabtagene ciloleucel will not be 
included for the analyses.
9.5.9.
ORR and BOR among Subjects Retreated with axicabtagene ciloleucel
The subject incidence of objective response and BOR (CR, PR, SD, PD, NE) to the retreatment
among subjects retreated with axicabtagene ciloleucel will be calculated. Confidence intervals 
will be provided about the ORR and CR rate to the retreatment.  
9.5.10.
DORR
The analysis of DORR will use the same methods as the analysis of duration of response.


KTE-C19-112
Statistical Analysis Plan
Kite Pharma, Inc.
CONFIDENTIAL
Page 28
25 September 2019
9.6.
Safety Analyses
The primary analysis of safety data will summarize all treatment-emergent adverse events and 
laboratory values. For subjects who undergo retreatment with axicabtagene ciloleucel, adverse 
events occurring in the axicabtagene ciloleucel retreatment period may be summarized in an 
additional separate summary that presents only the AEs occurring during the axicabtagene 
ciloleucel retreatment period. 
Adverse events will be coded with MedDRA. The version of the MedDRA may vary over time 
as the current version in use is updated. The severity of adverse events will be graded using the 
National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) 
version 5.0 or above. Cytokine release syndrome (CRS) will be graded using a revised CRS 
grading scale developed by Lee et al (Lee et al, 2014). The incidence and severity of CRS will be 
reported as a syndrome with severity per Lee et al. Individual symptoms associated with CRS 
will be graded per CTCAE version 5.0 or above.
Tables and/or narratives of deaths through the long term follow-up and treatment related SAEs 
will be provided.
Subjects enrolled but not dosed with axicabtagene ciloleucel will be followed for adverse events 
for 30 days after the last study procedure. Adverse events reported in these patients will be 
archived in the study database and available in SDTM and ADaM datasets, but will not be 
tabulated in adverse event summaries.
The safety summaries by disease diagnosis type (eg, double-hit lymphomas vs triple-hit 
lymphomas vs non double-/triple-hit with IPI score ≥ 3) may be presented.
9.6.1.
Adverse Events
The subject incidence of the following treatment-emergent adverse events will be tabulated by 
SOC and PT:

Summary of adverse events (any, worst severity, serious, related)

All adverse events

All serious adverse events

All leukapheresis-related adverse events

All conditioning-chemotherapy-related adverse events

All axicabtagene ciloleucel-related adverse events

All conditioning chemotherapy-related serious adverse events

All axicabtagene ciloleucel-related serious adverse events

All Grade 3 or higher adverse events


KTE-C19-112
Statistical Analysis Plan
Kite Pharma, Inc.
CONFIDENTIAL
Page 29
25 September 2019

All Grade 3 or higher conditioning chemotherapy-related adverse events

All Grade 3 or higher axicabtagene ciloleucel-related adverse events

The most common adverse events (incidence ≥20%) 

The most common grade 3 or higher adverse events (incidence ≥10%) 

Fatal adverse events

Adverse events of interest, including important identified and important potential risks 
Summary statistics for the onset time (Kaplan-Meier estimates) and duration of adverse events of 
interest will be provided.
The subject incidence of deaths will be provided.   
A subject listing of deaths and serious adverse events (including narratives) will be provided.
Subgroup analyses of AEs may be generated using the covariates listed in Section 4.2. 
Summary of AEs during specific time periods may be conducted to support the safety 
evaluations.
9.6.1.1.
Laboratory Test Results
Laboratory results will be graded according to NCI CTCAE version 5.0 or above.  Laboratory 
data collected at baseline and throughout the axicabtagene ciloleucel treatment period will be 
summarized. Lab shift tables calculating the shift from baseline to minimum post-baseline and/or 
maximum post-baseline will be presented for select analytes. The incidence of worst CTCAE 
grade post-baseline by grade for all analytes will be provided.  Additional laboratory shift tables 
calculating the shift from the last assessment prior to axicabtagene ciloleucel infusion to the 
worst CTCAE grade post axicabtagene ciloleucel infusion may be generated.
9.6.1.2.
Replication Competent Retrovirus (RCR)
The subject incidence of replication competent retrovirus (RCR) detected in blood samples will 
be tabulated overall and by assessment time. The persistence of RCR over time will be 
summarized.
9.6.1.3.
Exposure to Study Treatment 
Summary statistics and subject listings will be provided for the following:

Total body surface area (BSA)-adjusted dose of cyclophosphamide

Total BSA-adjusted dose of fludarabine

Weight-adjusted dose of axicabtagene ciloleucel


KTE-C19-112
Statistical Analysis Plan
Kite Pharma, Inc.
CONFIDENTIAL
Page 30
25 September 2019

Number and percent of subjects who received a dose of axicabtagene ciloleucel within +/-
10% of the planned dose
The analysis by patient demographics (age, and sex etc.) as well as by tumor burden may be 
provided. 
Separate summaries will be presented for the 2nd administration of conditioning chemotherapy
and retreatment of axicabtagene ciloleucel for subjects in the Safety Retreatment Analysis Set.
9.6.1.4.
Exposure to Concomitant Medications and Procedures  
The subject incidence of concomitant medications will be provided and summarized, including 
tocilizumab, steroids, vasopressors, and IVIG.  In addition, the incidence of dialysis and 
intubation will be summarized.
9.6.1.5.
Schedule of Study Treatment
Summary statistics will be provided for the following durations:

Days from leukapheresis to commencement of conditioning chemotherapy

Days from leukapheresis to administration of axicabtagene ciloleucel

Days from leukapheresis to axicabtagene ciloleucel product release

Days from leukapheresis to receipt of axicabtagene ciloleucel at the study site

Days from conditioning chemotherapy to administration of axicabtagene ciloleucel

Duration of hospitalization for the axicabtagene ciloleucel infusion
9.7.
Product Characteristics
Summary statistics and subject listings will be provided for the following:

Total CAR T cells of the axicabtagene ciloleucel infusion

Total T cells of the axicabtagene ciloleucel infusion

Transduction ratio

Percentages of CD4 and CD8 T cells

Percentages of T cell memory phenotypes

IFN-gamma production in co-cultures of axicabtagene ciloleucel product and CD19+ target 
cells

Vector copy number of axicabtagene ciloleucel product


KTE-C19-112
Statistical Analysis Plan
Kite Pharma, Inc.
CONFIDENTIAL
Page 31
25 September 2019
9.8.
Pharmacokinetics
Summary statistics for the level of CAR T cells in serum post axicabtagene ciloleucel infusion 
will be provided for CAR T cells measured at day 7, week 2, week 4, month 3, month 6, month 
12, and month 24.  The maximum CAR T cell level attained, the time at which the maximum 
level was attained, and the time at which there were no detectable CAR T cells in the serum will 
be summarized.   The area under the curve (AUC) of CAR T cell levels from day 0 to day 28 and 
the peak value of CAR T cell levels from day 0 to day 28 will be summarized and may be used 
in subgroup analyses. Additional detail can be found in the translational research plan.
9.9.
Pharmacodynamics
Levels of cytokines in serum in relationship with clinical outcome will be detailed in the
translational research plan.
9.10.
Subsequent Anti-Cancer Therapy and SCT
The incidence and type (by WHO Drug coded term and categories) of subsequent anti-
lymphoma therapy and subsequent SCT (autologous, allogeneic) by treatment period will be 
summarized.
The subject incidence of SCT post-treatment with axicabtagene ciloleucel will be tabulated by 
occurrence of SCT post progression on axicabtagene ciloleucel or occurrence of SCT while in an 
axicabtagene ciloleucel-induced response.  


KTE-C19-112
Statistical Analysis Plan
Kite Pharma, Inc.
CONFIDENTIAL
Page 32
25 September 2019
10.
CHANGES FROM PROTOCOL-SPECIFIED ANALYSES
There is no change from protocol-specified analyses. 


KTE-C19-112
Statistical Analysis Plan
Kite Pharma, Inc.
CONFIDENTIAL
Page 33
25 September 2019
11.
REFERENCES
Casasnovas RO, Ysebaert L, Thieblemont C, Bachy E, Feugier P, Delmer A, et al. FDG-PET-
driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized 
phase 2 study. Blood. 2017;130(11):1315-26.
Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA. 
Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-
Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059-68.
Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. 
Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 
2014;124(2):188-95.
Topp MS, Gökbuget N, Stein AS, Zugmaier G, O'Brien S, Bargou RC, et al. Safety and activity 
of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic 
leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncology. 2015;16(1):57-66.


KTE-C19-112
Statistical Analysis Plan
Kite Pharma, Inc.
CONFIDENTIAL
Page 34
25 September 2019
12.
APPENDICES
Appendix 1.
Conventions for Clinical Data that Require Imputation for Partial or Missing Dates
Appendix 2.
Derivation of Time to Event Endpoints and Last Date Known to Be Alive


KTE-C19-112
Statistical Analysis Plan
Kite Pharma, Inc.
CONFIDENTIAL
Page 35
25 September 2019
Appendix 1.
Conventions for Clinical Data that Require Imputation for Partial or 
Missing Dates
The following data will be imputed using the following algorithm:

Adverse event start dates

Deaths (please see exceptions below)

Concomitant medication start dates

Subsequent anti-cancer therapy start dates
Table 2.
Imputation Rules for Partial or Missing Start Dates
Start Date
Stop Date
Complete:  
yyyymmdd
Partial:  yyyymm
Partial:  yyyy
Missing
< Study 
Day 0
≥ Study 
Day 0
< Study 
Day 0
yyyymm
≥ Study 
Day 0
yyyymm
< Study 
Day 0
yyyy
≥ Study 
Day 0
yyyy
Partial
yyyymm
= Study 
Day 0
yyyymm
2
1
2
1
n/a
1
1
≠ day 0
yyyymm
2
2
2
2
2
Partial
yyyy
= Study
Day 0
yyyy
3
1
3
1
n/a
1
1
≠ Study 
Day 0
yyyy
3
3
3
3
3
Missing
4
1
4
1
4
1
1
1  impute the date of day 1
2  impute the first of the month
3  impute January 1 of the year
4  impute January 1 of the stop year
Note:  if the start date imputation leads to a start date that is after the stop date, then do not impute the start date.


KTE-C19-112
Statistical Analysis Plan
Kite Pharma, Inc.
CONFIDENTIAL
Page 36
25 September 2019
Imputation rules for partial or missing death dates:
1) If death year and month are available but day is missing:

If yyyymm for the last contact date  yyyymm for death date, set death date to the day 
after the last date known to be alive.

If yyyymm for the last date known to be alive < yyyymm for death date, set death date to 
the first day of the death month.

If yyyymm for last date known to be alive > yyyymm for death date, data error and do 
not impute.
2) If both month and day are missing for death date or a death date is completely missing, do 
not impute and censor the subject survival time at the last date known to be alive.


KTE-C19-112
Statistical Analysis Plan
Kite Pharma, Inc.
CONFIDENTIAL
Page 37
25 September 2019
Appendix 2.
Derivation of Time to Event Endpoints and Last Date Known to Be 
Alive
Additional detail on the derivations of DOR, DORR, EFS, PFS, and OS is provided below. 
Duration of response (DOR):  DOR is defined only for subjects who experience an objective 
response (CR or PR) after axicabtagene ciloleucel infusion and is the time from the first 
objective response to disease progression per the Lugano Classification (Cheson et al, 2014) or 
death due to any cause.  Subjects not meeting the criteria for disease progression or death by the 
analysis data cutoff date will be censored at their last evaluable disease assessment date. The 
DOR for subjects who receive any subsequent anti-lymphoma therapy (including SCT or 
retreatment with axicabtagene ciloleucel) in the absence of documented disease progression or 
death due to any cause will be censored at the last evaluable disease assessment prior to the start 
date of the subsequent anti-lymphoma therapy. A sensitivity analysis will be conducted in which 
disease assessments obtained after SCT are included in the derivation of DOR.  
Primary analysis of DOR:
Circumstance
Event / Censored
Date of Event / Censoring
Disease progression prior to initiation of 
subsequent anti-lymphoma therapy (including 
SCT or retreatment with axicabtagene 
ciloleucel)
Event
Progression date
Death due to any cause without documented 
disease progression and without subsequent 
anti-lymphoma therapy (including SCT or 
retreatment with axicabtagene ciloleucel)
Event
Death date
Remain in response without any subsequent 
anti-lymphoma therapy (including SCT or 
retreatment with axicabtagene ciloleucel)
Censored
Date of last evaluable disease 
assessment 
Initiated subsequent anti-lymphoma therapy 
(including SCT or retreatment with 
axicabtagene ciloleucel) prior to documented 
progression or death due to any cause
Censored
Date of last evaluable disease 
assessment prior to initiation 
of subsequent anti-lymphoma
therapy (including SCT or 
retreatment, whichever is 
earlier)
Progression or death due to any cause
documented after data cutoff for analysis
Censored
Date of last evaluable disease 
assessment prior to data 
cutoff for analysis
No progression through discontinuation of study 
prior to the data cutoff for analysis
Censored
Date of last evaluable disease 
assessment prior to data 
cutoff for analysis


KTE-C19-112
Statistical Analysis Plan
Kite Pharma, Inc.
CONFIDENTIAL
Page 38
25 September 2019
Sensitivity analysis of DOR (including the disease assessments after SCT):
Circumstance
Event / Censored
Date of Event / Censoring
Disease progression after SCT, but prior to 
other subsequent anti-lymphoma therapy 
(including retreatment with axicabtagene 
ciloleucel)
Event
Progression date
Death due to any cause after SCT without prior 
documented disease progression and other
subsequent anti-lymphoma therapy (including 
retreatment with axicabtagene ciloleucel)
Event
Death date
Remain in response after SCT without other
subsequent anti-lymphoma therapy (including 
retreatment with axicabtagene ciloleucel)
Censored
Date of last evaluable disease 
assessment 
Remain in response after SCT prior to other
subsequent anti-lymphoma therapy (including 
retreatment with axicabtagene ciloleucel)
Censored
Date of last evaluable disease 
assessment prior to initiation 
of subsequent anti-lymphoma
therapy or retreatment, 
whichever is earlier
Progression or death due to any cause 
documented after data cutoff for analysis
Censored
Date of last evaluable disease 
assessment prior to data 
cutoff for analysis
No progression through discontinuation of study 
prior to the data cutoff for analysis
Censored
Date of last evaluable disease 
assessment prior to data 
cutoff for analysis
Duration of response to retreatment (DORR):  DORR is defined only for subjects who receive 
retreatment following progression of disease and then go on to experience an objective response 
to retreatment. It is defined as the time from the first objective response after retreatment to 
disease progression per the Lugano Classification (Cheson et al, 2014) or death due to any cause.  
Subjects not meeting the criteria for disease progression after retreatment or death due to any 
cause by the analysis data cutoff date will be censored at their last evaluable disease assessment 
date after retreatment.  The DORR for subjects who receive any subsequent anti-lymphoma
therapy (including SCT) after axicabtagene ciloleucel retreatment in the absence of prior 
documented progression will be censored at the last evaluable disease assessment prior to 
subsequent anti-lymphoma therapy. Disease assessments obtained after SCT will not be used in 
the derivation of DORR. A sensitivity analysis may be conducted in which disease assessments 
obtained after the SCT are included in the derivation of DORR. 


KTE-C19-112
Statistical Analysis Plan
Kite Pharma, Inc.
CONFIDENTIAL
Page 39
25 September 2019
Primary analysis of DORR:
Circumstance
Event / Censored
Date of Event / Censoring
Disease progression prior to initiation of 
subsequent anti-lymphoma therapy (including 
SCT)
Event
Progression date
Death due to any cause without documented 
disease progression and without subsequent 
anti-lymphoma therapy (including SCT)
Event
Death date
Remain in response without any subsequent 
anti-lymphoma therapy (including SCT)
Censored
Date of last evaluable disease 
assessment 
Initiated subsequent anti-lymphoma therapy 
(including SCT) prior to documented 
progression or death due to any cause
Censored
Date of last evaluable disease 
assessment prior to initiation 
of subsequent anti-lymphoma
therapy (including SCT)
Progression or death due to any cause 
documented after data cutoff for analysis
Censored
Date of last evaluable disease 
assessment prior to data 
cutoff for analysis
No progression through discontinuation of study 
prior to the data cutoff for analysis
Censored
Date of last evaluable disease 
assessment prior to data 
cutoff for analysis


KTE-C19-112
Statistical Analysis Plan
Kite Pharma, Inc.
CONFIDENTIAL
Page 40
25 September 2019
Sensitivity analysis of DORR (including the disease assessments after SCT):
Circumstance
Event / Censored
Date of Event / Censoring
Disease progression after SCT, but prior to 
other subsequent anti-lymphoma therapy 
Event
Progression date
Death due to any cause after SCT without prior 
documented disease progression and other 
subsequent anti-lymphoma therapy 
Event
Death date
Remain in response after SCT without other
subsequent anti-lymphoma therapy
Censored
Date of last evaluable 
disease assessment 
Remain in response after SCT prior to other 
subsequent anti-lymphoma therapy
Censored
Date of last evaluable 
disease assessment prior to 
initiation of subsequent anti-
lymphoma therapy
Progression or death due to any cause 
documented after data cutoff for analysis
Censored
Date of last evaluable 
disease assessment prior to 
data cutoff for analysis
No progression through discontinuation of 
study prior to the data cutoff for analysis
Censored
Date of last evaluable 
disease assessment prior to 
data cutoff for analysis
Event-free Survival (EFS):  EFS is defined as the time from the axicabtagene ciloleucel 
infusion date to the earliest date of disease progression per the Lugano Classification (Cheson et 
al, 2014), commencement of subsequent anti-lymphoma therapy including SCT or retreatment 
with axicabtagene ciloleucel, or death from any cause. Subjects alive, in response, and with no 
new anti-lymphoma therapy including SCT or retreatment with axicabtagene ciloleucel will be 
censored at the last evaluable disease assessment.


KTE-C19-112
Statistical Analysis Plan
Kite Pharma, Inc.
CONFIDENTIAL
Page 41
25 September 2019
Primary analysis of EFS:
Circumstance
Event / Censored
Date of Event / Censoring
Disease progression prior to initiation of 
subsequent anti-lymphoma therapy (including 
SCT or retreatment with axicabtagene 
ciloleucel)
Event
Progression date
Subject with CR or PR or a best response of SD 
and subsequently received anti-lymphoma
therapy (including SCT or retreatment with 
axicabtagene ciloleucel)
Event
Date of last evaluable disease 
assessment prior to initiation 
of subsequent anti-lymphoma
therapy (including SCT or 
retreatment)
Subsequent anti-lymphoma therapy in the 
absence of any evaluable disease assessment 
Event
Axicabtagene ciloleucel 
infusion date
Death due to any cause without documented 
disease progression (excluding the death after 
the initiation of subsequent anti-lymphoma
therapy) 
Event
Death date
Death due to any cause without documented 
disease progression and after the initiation of 
subsequent anti-lymphoma therapy (including 
SCT or retreatment with axicabtagene 
ciloleucel)
Event
Date of last evaluable disease 
assessment prior to initiation 
of subsequent anti-lymphoma
therapy (including SCT or 
retreatment)
Subsequent anti-lymphoma therapy (including 
SCT or retreatment with axicabtagene 
ciloleucel) started prior to documented 
progression or death due to any cause 
Event 
Date of last evaluable disease 
assessment prior to initiation 
of subsequent anti-lymphoma
therapy (including SCT or 
retreatment)
Remain in response without new anti-
lymphoma therapy (including SCT or 
retreatment with axicabtagene ciloleucel) 
Censored
Date of last evaluable disease 
assessment 
Progression or death documented after data 
cutoff for analysis
Censored
Date of last evaluable disease 
assessment prior to data 
cutoff for analysis
Remain event-free through the discontinuation 
of the study prior to data cutoff for analysis
Censored
Date of last evaluable disease 
assessment prior to data 
cutoff for analysis
Subjects treated but no post baseline disease 
assessment 
Censored
Axicabtagene ciloleucel 
infusion date


KTE-C19-112
Statistical Analysis Plan
Kite Pharma, Inc.
CONFIDENTIAL
Page 42
25 September 2019
Progression-free Survival (PFS):  PFS is defined as the time from the axicabtagene ciloleucel 
infusion date to the date of disease progression per the Lugano Classification (Cheson et al, 
2014) or death due to any cause.  Subjects not meeting the criteria for disease progression or 
death will be censored at the last evaluable disease assessment.  Subjects who receive any 
subsequent anti-lymphoma therapy including SCT or retreatment with axicabtagene ciloleucel in 
the absence of documented disease progression or death due to any cause will be censored at the 
last evaluable disease assessment prior to the start date of the subsequent anti-lymphoma therapy.  
Primary analysis of PFS:
Circumstance
Event / Censored
Date of Event / Censoring
Disease progression prior to initiation of 
subsequent anti-lymphoma therapy (including 
SCT or retreatment with axicabtagene 
ciloleucel)
Event
Progression date
Death due to any cause without documented 
disease progression (excluding the death after 
the initiation of subsequent anti-lymphoma
therapy (including SCT or retreatment with 
axicabtagene ciloleucel) 
Event
Death date
Remain in response without subsequent anti-
lymphoma therapy (including SCT or 
retreatment with axicabtagene ciloleucel)
Censored
Date of last evaluable disease 
assessment 
Initiated subsequent anti-lymphoma therapy 
(including SCT or retreatment with 
axicabtagene ciloleucel) prior to documented 
progression or death due to any cause 
Censored
Date of last evaluable disease 
assessment prior to initiation 
of subsequent anti-lymphoma
therapy (including SCT or 
retreatment)
Progression or death due to any cause 
documented after data cutoff for analysis
Censored
Date of last evaluable disease 
assessment prior to data 
cutoff for analysis
No progression through discontinuation of study 
prior to the data cutoff for analysis
Censored
Date of last evaluable disease 
assessment prior to data 
cutoff for analysis
Subjects treated but no post baseline disease 
assessment 
Censored
Axicabtagene ciloleucel 
infusion date
Overall Survival (OS):  OS is defined as the time from the axicabtagene ciloleucel infusion to 
the date of death due to any cause.  Subjects who have not died by the analysis data cutoff date 
will be censored at their last date known to be alive prior to the data cutoff date with the 


KTE-C19-112
Statistical Analysis Plan
Kite Pharma, Inc.
CONFIDENTIAL
Page 43
25 September 2019
exception that subjects known to be alive or determined to have died after the data cutoff date 
will be censored at the data cutoff date.
Circumstance
Event / Censored
Date of Event / Censoring
Death prior to data cutoff date for 
analysis
Event
Death date
Death after data cutoff date for analysis
Censored
Data cutoff date
Known to be alive after data cutoff date 
for analysis
Censored
Data cutoff date
Alive up through data cutoff date and no 
further information available after cutoff 
date
Censored
Last date known to be alive up 
through the data cutoff date
Alive including withdrawal of consent 
or lost to follow-up prior to data cutoff 
date
Censored
Last date known to be alive prior to 
withdrawal of consent or lost to 
follow-up
Last date known to be alive
The last date known to be alive with be derived by obtaining the maximum complete date among 
the following data modules:

Start and end dates of AE (including targeted AE) and concomitant medication

Screening dates

Leukapheresis dates

Conditioning chemo admin dates

axicabtagene ciloleucel infusion dates

CT scan dates

PET scan dates

Clinical symptoms of lymphoma assessment dates

Target lesion assessment

Non-target lesion assessment

New lesion assessment


KTE-C19-112
Statistical Analysis Plan
Kite Pharma, Inc.
CONFIDENTIAL
Page 44
25 September 2019

Disease response assessment

Long term follow up subject status date where status  ‘alive’

End of treatment disposition where status is not equal to death, lost to follow up

End of post-treatment assessment period where status is not equal to death, lost to follow up

End of study data where end of study reason is not equal to death, lost to follow up